<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Abstracts of the 9th World Research Congress of the European Association for Palliative Care, EAPC 2016</style></title><secondary-title><style face="normal" font="default" size="100%">Palliative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Palliative Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">fentanyl</style></keyword><keyword><style face="normal" font="default" size="100%">melatonin</style></keyword><keyword><style face="normal" font="default" size="100%">morphine</style></keyword><keyword><style face="normal" font="default" size="100%">opiate</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">advance care planning</style></keyword><keyword><style face="normal" font="default" size="100%">advanced cancer</style></keyword><keyword><style face="normal" font="default" size="100%">analgesia</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">cancer pain</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">consensus development</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based nursing</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">palliative therapy</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">reliability</style></keyword><keyword><style face="normal" font="default" size="100%">tablet</style></keyword><keyword><style face="normal" font="default" size="100%">validity</style></keyword><keyword><style face="normal" font="default" size="100%">visually impaired person</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1477-030X</style></isbn><abstract><style face="normal" font="default" size="100%">The proceedings contain 772 papers. The topics discussed include: developing a research agenda for palliative care: from nursing to cochrane; which outcomes best reflect patients&apos; experience of cancer pain management in clinical practice and research?; clinical challenges in cancer pain management which inform our research question; PhD and master education - an update; advance care planning in frail older people and nursing homes: results of the international PACE study (www.eupace.eu); advance care planning in Australia - evidence on effectiveness and implementation; cancer pain guidelines - an institutional approach: a cluster randomised controlled trial; fentanyl sublingual tablets versus subcutaneous morphine for the management of severe cancer pain episodes in patients on opioid treatment: a double-blind randomized non-inferiority trial (eudraCT 2013-003319-23); early palliative care for patients with advanced cancer: caregiver results from a cluster-randomised controlled trial; randomised double blind placebo controlled phase II trial of prolonged release melatonin for prevention of delirium in inpatients with advanced cancer; a brief, patient- and proxy-reported outcome measure for the adult palliative care population: validity and reliability of the integrated palliative outcome scale (IPOS); and randomised double blind placebo controlled phase II trial of prolonged release melatonin for prevention of delirium in inpatients with advanced cancer.</style></abstract><notes><style face="normal" font="default" size="100%">L614041459&#xD;2017-01-17</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L614041459&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gerety, M. B.</style></author><author><style face="normal" font="default" size="100%">Cornell, J. E.</style></author><author><style face="normal" font="default" size="100%">Plichta, D. T.</style></author><author><style face="normal" font="default" size="100%">Eimer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.B. Gerety, Audie L. Murphy Vet. Memorial Hosp., 7400 Merton Minter Blvd., San Antonio, TX 78284, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adverse events related to drugs and drug withdrawal in nursing home residents</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1326-1332</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antacid agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">captopril</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular agent</style></keyword><keyword><style face="normal" font="default" size="100%">codeine</style></keyword><keyword><style face="normal" font="default" size="100%">desipramine</style></keyword><keyword><style face="normal" font="default" size="100%">digoxin</style></keyword><keyword><style face="normal" font="default" size="100%">diltiazem</style></keyword><keyword><style face="normal" font="default" size="100%">furosemide</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal agent</style></keyword><keyword><style face="normal" font="default" size="100%">glyceryl trinitrate</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">heparin</style></keyword><keyword><style face="normal" font="default" size="100%">hydrocortisone</style></keyword><keyword><style face="normal" font="default" size="100%">ibuprofen</style></keyword><keyword><style face="normal" font="default" size="100%">isophane insulin</style></keyword><keyword><style face="normal" font="default" size="100%">ispagula</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">paracetamol</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">ranitidine</style></keyword><keyword><style face="normal" font="default" size="100%">verapamil</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">atrioventricular dissociation</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric care</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric disorder</style></keyword><keyword><style face="normal" font="default" size="100%">heart supraventricular arrhythmia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intravenous drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">musculoskeletal disease</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">orthostatic hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To (1) develop and standardize explicit criteria to link clinical adverse events to drug withdrawal, (2) determine the incidence and severity of Adverse Drug Events (ADEs) and Adverse Drug Withdrawal Events (ADWEs) in a nursing home population, and (3) establish the contribution of demographic, clinical, and functional characteristics to ADEs and ADWEs. Design: Retrospective record review of an admission cohort. Setting and Subjects: Consecutive admissions of residents of an academic Veterans Affairs nursing home with available records and lengths of stay &gt;30 days (n = 175). Subjects were 96% men, aged 70 ± 12 years, and took 7.0 ± 3.4 medications. Methods: We applied standardized algorithms to determine incidence, probability, and severity of ADEs and ADWEs. Multiple regression techniques were used to identify factors associated with frequency and risk of events. Results: Ninety five residents experienced 201 ADEs. Twelve required hospitalization or prolonged hospitalization, and one resident died. Sixty two persons had 94 ADWEs. None were associated with death and one with hospitalization. The four most commonly prescribed drug classes accounted for 72% of ADEs and 80% of ADWEs. Results of multivariate analyses showed common risk factors for both ADEs and ADWEs: number of diagnoses, number of medications, and hospitalization during the nursing home stay. Conclusions: ADEs and ADWEs were common in nursing home residents in this Veteran&apos;s Affairs setting. Explicit criteria developed and applied in this study should be applied prospectively in other settings, both to further define risk of drug discontinuation and to assist in development of specific drug discontinuation guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">L23353943&#xD;1993-12-20</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L23353943&amp;from=export</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">8227915</style></custom5></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Federico, G.</style></author><author><style face="normal" font="default" size="100%">Del Forno, A.</style></author><author><style face="normal" font="default" size="100%">Del Borgo, C.</style></author><author><style face="normal" font="default" size="100%">Lucia, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G. Federico, Ist. di Clinica della Mal. Infettive, Universita Cattolica S. Cuore, 00100 Roma, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adverse-effects of antibiotics in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Giornale di Gerontologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Giornale di Gerontologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">481-486</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cephalosporin</style></keyword><keyword><style face="normal" font="default" size="100%">chloramphenicol</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">ethambutol</style></keyword><keyword><style face="normal" font="default" size="100%">glycopeptide</style></keyword><keyword><style face="normal" font="default" size="100%">isoniazid</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">quinolone derivative</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">streptomycin</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">conference paper</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">ototoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year></dates><isbn><style face="normal" font="default" size="100%">0017-0305</style></isbn><abstract><style face="normal" font="default" size="100%">In elderly the adverse-effects of antibiotics are more relevant as a consequence of an increased frequency and severity. This can be often related to an impaired renal function and/or to an increased susceptibility of different organs and apparatus. There is an increased frequency of interactions between antibiotics and other drugs which are chronically assumed by older patients. In this paper the results of a retrospective study on adverse effects of antibiotics in 377 patients over 60 years are reported. Transient rash were observed in 7 out 170 patients treated with penicillins (4.1%), in one out of 150 treated with cephalosporins (0.7%), in one out of 87 treated with tetracyclines (1.1%), in 2 out 71 (2.8%) treated with cotrimoxazole. Ototoxicity was documented in 9 out 47 patients treated with streptomycin (19.1%) and in none of 45 patients treated with other aminoglycosides. Hepatotoxicity was present in one out of 41 patients treated with quinolones (2.4%), in one out of 29 treated with erythromicin (3.4%), in 7 out of 69 treated with the association of isoniazid with rifampin (10.1%). No adverse effect was documented in 50 patients treated with ethambutol, in 37 patients with chloramphenicol, in 8 with metronidazole, in 6 with clindamycin and in 6 with glycopreptides.</style></abstract><notes><style face="normal" font="default" size="100%">L24277313&#xD;1994-09-21</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L24277313&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Brien, K. S.</style></author><author><style face="normal" font="default" size="100%">Arzika, A. M.</style></author><author><style face="normal" font="default" size="100%">Amza, A.</style></author><author><style face="normal" font="default" size="100%">Maliki, R.</style></author><author><style face="normal" font="default" size="100%">Ousmane, S.</style></author><author><style face="normal" font="default" size="100%">Kadri, B.</style></author><author><style face="normal" font="default" size="100%">Nassirou, B.</style></author><author><style face="normal" font="default" size="100%">Mankara, A. K.</style></author><author><style face="normal" font="default" size="100%">Harouna, A. N.</style></author><author><style face="normal" font="default" size="100%">Colby, E.</style></author><author><style face="normal" font="default" size="100%">Lebas, E.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Le, V.</style></author><author><style face="normal" font="default" size="100%">Nguyen, W.</style></author><author><style face="normal" font="default" size="100%">Keenan, J. D.</style></author><author><style face="normal" font="default" size="100%">Oldenburg, C. E.</style></author><author><style face="normal" font="default" size="100%">Porco, T. C.</style></author><author><style face="normal" font="default" size="100%">Doan, T.</style></author><author><style face="normal" font="default" size="100%">Arnold, B. F.</style></author><author><style face="normal" font="default" size="100%">Lietman, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Francis I. Proctor Foundation, University of California, San Francisco, USA.&#xD;Centre de Recherche et Interventions en Santé Publique, Birni N&apos;Gaoure, Niger.&#xD;Programme Nationale de Santé Oculaire, Niamey, Niger.&#xD;Centre de Recherche Médical et Sanitaire, Niamey, Niger.&#xD;Department of Ophthalmology, University of California, 490 Illinois Street, San Francisco, CA, 94158, USA.&#xD;Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.&#xD;Institute for Global Health Sciences, University of California, San Francisco, USA.&#xD;Francis I. Proctor Foundation, University of California, San Francisco, USA. tom.lietman@ucsf.edu.&#xD;Department of Ophthalmology, University of California, 490 Illinois Street, San Francisco, CA, 94158, USA. tom.lietman@ucsf.edu.&#xD;Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. tom.lietman@ucsf.edu.&#xD;Institute for Global Health Sciences, University of California, San Francisco, USA. tom.lietman@ucsf.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">822</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Azithromycin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Macrolides</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">Niger/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Adaptive trial</style></keyword><keyword><style face="normal" font="default" size="100%">*Azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">*Cluster-randomized trial</style></keyword><keyword><style face="normal" font="default" size="100%">*Mass drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">*Mortality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2458</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Biannual distribution of azithromycin to children 1-59 months old reduced mortality by 14% in a cluster-randomized trial. The World Health Organization has proposed targeting this intervention to the subgroup of children 1-11 months old to reduce selection for antimicrobial resistance. Here, we describe a trial designed to determine the impact of age-based targeting of biannual azithromycin on mortality and antimicrobial resistance. METHODS: AVENIR is a cluster-randomized, placebo-controlled, double-masked, response-adaptive large simple trial in Niger. During the 2.5-year study period, 3350 communities are targeted for enrollment. In the first year, communities in the Dosso region will be randomized 1:1:1 to 1) azithromycin 1-11: biannual azithromycin to children 1-11 months old with placebo to children 12-59 months old, 2) azithromycin 1-59: biannual azithromycin to children 1-59 months old, or 3) placebo: biannual placebo to children 1-59 months old. Regions enrolled after the first year will be randomized with an updated allocation based on the probability of mortality in children 1-59 months in each arm during the preceding study period. A biannual door-to-door census will be conducted to enumerate the population, distribute azithromycin and placebo, and monitor vital status. Primary mortality outcomes are defined as all-cause mortality rate (deaths per 1000 person-years) after 2.5 years from the first enrollment in 1) children 1-59 months old comparing the azithromycin 1-59 and placebo arms, 2) children 1-11 months old comparing the azithromycin 1-11 and placebo arm, and 3) children 12-59 months in the azithromycin 1-11 and azithromycin 1-59 arms. In the Dosso region, 50 communities from each arm will be followed to monitor antimicrobial resistance. Primary resistance outcomes will be assessed after 2 years of distributions and include 1) prevalence of genetic determinants of macrolide resistance in nasopharyngeal samples from children 1-59 months old, and 2) load of genetic determinants of macrolide resistance in rectal samples from children 1-59 months old. DISCUSSION: As high-mortality settings consider this intervention, the results of this trial will provide evidence to support programmatic and policy decision-making on age-based strategies for azithromycin distribution to promote child survival. TRIAL REGISTRATION: This trial was registered on January 13, 2020 (clinicaltrials.gov: NCT04224987 ).</style></abstract><notes><style face="normal" font="default" size="100%">1471-2458&#xD;O&apos;Brien, Kieran S&#xD;Arzika, Ahmed M&#xD;Amza, Abdou&#xD;Maliki, Ramatou&#xD;Ousmane, Sani&#xD;Kadri, Boubacar&#xD;Nassirou, Beido&#xD;Mankara, Alio Karamba&#xD;Harouna, Abdoul Naser&#xD;Colby, Emily&#xD;Lebas, Elodie&#xD;Liu, Zijun&#xD;Le, Victoria&#xD;Nguyen, William&#xD;Keenan, Jeremy D&#xD;Oldenburg, Catherine E&#xD;Porco, Travis C&#xD;Doan, Thuy&#xD;Arnold, Benjamin F&#xD;Lietman, Thomas M&#xD;AVENIR Study Group&#xD;INV-002454/Bill and Melinda Gates Foundation/&#xD;OPP1210548/Bill and Melinda Gates Foundation/&#xD;Clinical Trial Protocol&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;BMC Public Health. 2021 Apr 29;21(1):822. doi: 10.1186/s12889-021-10824-7.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC8082631</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12889-021-10824-7</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>192</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kolbe, F.</style></author><author><style face="normal" font="default" size="100%">Sitar, D. S.</style></author><author><style face="normal" font="default" size="100%">Papaioannou, A.</style></author><author><style face="normal" font="default" size="100%">Campbell, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">City of Hamilton-Social and Public Health Services Department, Hamilton, Ontario, Canada. fkolbe@city.toronto.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients</style></title><secondary-title><style face="normal" font="default" size="100%">Can J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Can J Clin Pharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">119-22</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amantadine/*administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/*administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Institutionalization</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Fall</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1198-581X (Print)&#xD;1198-581x</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: We tested the hypothesis that individualized dosing of amantadine hydrochloride, based upon a patient&apos;s creatinine clearance, would maintain efficacy against influenza A infection while reducing adverse reactions to the drug. DESIGN: A prospective cohort study PARTICIPANTS: Residents of two nursing homes with a total population of 301 individuals INTERVENTION: Amantadine hydrochloride was administered prophylactically subsequent to a confirmed influenza A outbreak. The dose was individualized based upon the resident&apos;s calculated creatinine clearance. RESULTS: The concentration of amantadine hydrochloride in the circulation at steady-state in patients who had doses adjusted for their estimated creatinine clearance was not different by nursing home or by sex of the resident. The mean concentration was within the 95% CI for the target concentration of 1.6 micromol/L. Side effects were modest and did not require discontinuation of amantadine hydrochloride therapy. Only the presence of concurrent influenza-like illness was significantly associated with adverse events during amantadine hydrochloride therapy. CONCLUSIONS: Adjustment of doses for estimated creatinine clearance is feasible in a long term care facility when amantadine hydrochloride is indicated for influenza A prophylaxis. These data form the basis for a definitive study of amantadine hydrochloride efficacy in patients with reduced renal function. Concurrent influenza-like illness is likely to confound attempts to associate adverse reactions to the administration of amantadine hydrochloride therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Kolbe, Faron&#xD;Sitar, Daniel S&#xD;Papaioannou, Alexandra&#xD;Campbell, Glenda&#xD;Clinical Trial&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Canada&#xD;Can J Clin Pharmacol. 2003 Fall;10(3):119-22.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gharbi, M.</style></author><author><style face="normal" font="default" size="100%">Drysdale, J. H.</style></author><author><style face="normal" font="default" size="100%">Lishman, H.</style></author><author><style face="normal" font="default" size="100%">Goudie, R.</style></author><author><style face="normal" font="default" size="100%">Molokhia, M.</style></author><author><style face="normal" font="default" size="100%">Johnson, A. P.</style></author><author><style face="normal" font="default" size="100%">Holmes, A. H.</style></author><author><style face="normal" font="default" size="100%">Aylin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NIHR Health Protection Research Unit, Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.&#xD;Department of Primary Care and Public Health, Imperial College London, London, UK.&#xD;Medical School, St George&apos;s University of London, London, UK.&#xD;Nuffield Department of Population Health, University of Oxford, Oxford, UK.&#xD;Department of Primary Care and Public Health Sciences, King&apos;s College, London, UK.&#xD;Healthcare-Associated Infections and Antimicrobial Resistance Division, National Infection Service, Public Health England, London, UK.&#xD;NIHR Health Protection Research Unit, Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK p.aylin@imperial.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">l525</style></pages><volume><style face="normal" font="default" size="100%">364</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Prescriptions/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">England/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli Infections/drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Admission/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Patterns, Physicians&apos;/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Sepsis/drug therapy/microbiology/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/complications/drug therapy/*mortality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0959-8138 (Print)&#xD;0959-8138</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the association between antibiotic treatment for urinary tract infection (UTI) and severe adverse outcomes in elderly patients in primary care. DESIGN: Retrospective population based cohort study. SETTING: Clinical Practice Research Datalink (2007-15) primary care records linked to hospital episode statistics and death records in England. PARTICIPANTS: 157 264 adults aged 65 years or older presenting to a general practitioner with at least one diagnosis of suspected or confirmed lower UTI from November 2007 to May 2015. MAIN OUTCOME MEASURES: Bloodstream infection, hospital admission, and all cause mortality within 60 days after the index UTI diagnosis. RESULTS: Among 312 896 UTI episodes (157 264 unique patients), 7.2% (n=22 534) did not have a record of antibiotics being prescribed and 6.2% (n=19 292) showed a delay in antibiotic prescribing. 1539 episodes of bloodstream infection (0.5%) were recorded within 60 days after the initial UTI. The rate of bloodstream infection was significantly higher among those patients not prescribed an antibiotic (2.9%; n=647) and those recorded as revisiting the general practitioner within seven days of the initial consultation for an antibiotic prescription compared with those given a prescription for an antibiotic at the initial consultation (2.2% v 0.2%; P=0.001). After adjustment for covariates, patients were significantly more likely to experience a bloodstream infection in the deferred antibiotics group (adjusted odds ratio 7.12, 95% confidence interval 6.22 to 8.14) and no antibiotics group (8.08, 7.12 to 9.16) compared with the immediate antibiotics group. The number needed to harm (NNH) for occurrence of bloodstream infection was lower (greater risk) for the no antibiotics group (NNH=37) than for the deferred antibiotics group (NNH=51) compared with the immediate antibiotics group. The rate of hospital admissions was about double among cases with no antibiotics (27.0%) and deferred antibiotics (26.8%) compared with those prescribed immediate antibiotics (14.8%; P=0.001). The risk of all cause mortality was significantly higher with deferred antibiotics and no antibiotics than with immediate antibiotics at any time during the 60 days follow-up (adjusted hazard ratio 1.16, 95% confidence interval 1.06 to 1.27 and 2.18, 2.04 to 2.33, respectively). Men older than 85 years were particularly at risk for both bloodstream infection and 60 day all cause mortality. CONCLUSIONS: In elderly patients with a diagnosis of UTI in primary care, no antibiotics and deferred antibiotics were associated with a significant increase in bloodstream infection and all cause mortality compared with immediate antibiotics. In the context of an increase of Escherichia coli bloodstream infections in England, early initiation of recommended first line antibiotics for UTI in the older population is advocated.</style></abstract><notes><style face="normal" font="default" size="100%">1756-1833&#xD;Gharbi, Myriam&#xD;Drysdale, Joseph H&#xD;Lishman, Hannah&#xD;Goudie, Rosalind&#xD;Molokhia, Mariam&#xD;Johnson, Alan P&#xD;Holmes, Alison H&#xD;Aylin, Paul&#xD;Orcid: 0000-0003-4589-1743&#xD;Evaluation Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;BMJ. 2019 Feb 27;364:l525. doi: 10.1136/bmj.l525.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6391656 http://www.icmje.org/coi_disclosure.pdf and declare: grants support from NIHR and Dr Foster Intelligence for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work except for MG who declares working as an epidemiologist at GSK in therapeutic areas not related to the submitted work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.l525</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">96</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Buul, L. W.</style></author><author><style face="normal" font="default" size="100%">Veenhuizen, R. B.</style></author><author><style face="normal" font="default" size="100%">Achterberg, W. P.</style></author><author><style face="normal" font="default" size="100%">Schellevis, F. G.</style></author><author><style face="normal" font="default" size="100%">Essink, R. T.</style></author><author><style face="normal" font="default" size="100%">de Greeff, S. C.</style></author><author><style face="normal" font="default" size="100%">Natsch, S.</style></author><author><style face="normal" font="default" size="100%">van der Steen, J. T.</style></author><author><style face="normal" font="default" size="100%">Hertogh, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; Department of General Practice and Elderly Care Medicine, VU University Medical Center, Amsterdam, The Netherlands.&#xD;Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.&#xD;EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; Department of General Practice and Elderly Care Medicine, VU University Medical Center, Amsterdam, The Netherlands; NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands.&#xD;Dutch Institute for Rational Use of Medicine (IVM), Utrecht, The Netherlands.&#xD;Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.&#xD;Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.&#xD;EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; Department of General Practice and Elderly Care Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: J.vandersteen@vumc.nl.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic prescribing in Dutch nursing homes: how appropriate is it?</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-37</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Utilization/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Care/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Patterns, Physicians&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/diagnosis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/diagnosis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing homes</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic prescribing</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To investigate the appropriateness of decisions to prescribe or withhold antibiotics for nursing home (NH) residents with infections of the urinary tract (UTI), respiratory tract (RTI), and skin (SI). DESIGN: Prospective study. SETTING: Ten NHs in the central-west region of the Netherlands. PARTICIPANTS: Physicians providing medical care to NH residents. MEASUREMENTS: Physicians completed a registration form for any suspected infection over an 8-month period, including patient characteristics, signs and symptoms, and treatment decisions. An algorithm, developed by an expert panel and based on national and international guidelines, was used to evaluate treatment decisions for appropriateness of initiating or withholding antibiotics. RESULTS: Appropriateness of 598 treatment decisions was assessed. Overall, 76% were appropriate, with cases that were prescribed antibiotics judged less frequently &quot;appropriate&quot; (74%) compared with cases in which antibiotics were withheld (90%) (P = .003). Decisions around UTI were least often appropriate (68%, compared with 87% for RTI and 94% for SI [P &lt; .001]). The most common situations in which antibiotic prescribing was considered inappropriate were those indicative of asymptomatic bacteriuria or viral RTI. CONCLUSION: Although the rate of appropriate antibiotic prescribing in Dutch NHs is relatively high compared with previous studies in other countries, our results suggest that antibiotic consumption can be reduced by improving appropriateness of treatment decisions, especially for UTI. Given the current antibiotic resistance developments in long-term care facilities, interventions reducing antibiotic use for asymptomatic bacteriuria and viral RTI are warranted.</style></abstract><notes><style face="normal" font="default" size="100%">1538-9375&#xD;van Buul, Laura W&#xD;Veenhuizen, Ruth B&#xD;Achterberg, Wilco P&#xD;Schellevis, François G&#xD;Essink, Rob T G M&#xD;de Greeff, Sabine C&#xD;Natsch, Stephanie&#xD;van der Steen, Jenny T&#xD;Hertogh, Cees M P M&#xD;Journal Article&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Med Dir Assoc. 2015 Mar;16(3):229-37. doi: 10.1016/j.jamda.2014.10.003. Epub 2014 Nov 20.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2014.10.003</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kistler, C. E.</style></author><author><style face="normal" font="default" size="100%">Zimmerman, S.</style></author><author><style face="normal" font="default" size="100%">Scales, K.</style></author><author><style face="normal" font="default" size="100%">Ward, K.</style></author><author><style face="normal" font="default" size="100%">Weber, D.</style></author><author><style face="normal" font="default" size="100%">Reed, D.</style></author><author><style face="normal" font="default" size="100%">McClester, M.</style></author><author><style face="normal" font="default" size="100%">Sloane, P. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.E. Kistler, Department of Family Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Antibiotic Prescribing Pathway for Presumed Urinary Tract Infections in Nursing Home Residents</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1719-1725</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">cephalosporin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">nitrofurantoin</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">quinoline derived antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">assessment of humans</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial growth</style></keyword><keyword><style face="normal" font="default" size="100%">clinical decision making</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli infection</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">indwelling catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella infection</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">Loeb criteria</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">North Carolina</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus infection</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urine culture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1532-5415&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Due to the high rates of inappropriate antibiotic prescribing for presumed urinary tract infections (UTIs) in nursing home (NH) residents, we sought to examine the antibiotic prescribing pathway and the extent to which it agrees with the Loeb criteria; findings can suggest strategies for antibiotic stewardship. Methods: Chart review of 260 randomly-selected cases from 247 NH residents treated with an antibiotic for a presumed UTI in 31 NHs in North Carolina. We examined the prescribing pathway from presenting illness, to the prescribing event, illness work-up and subsequent clinical events including emergency department use, hospitalization, and death. Analyses described the decision-making processes and outcomes and compared decisions made with Loeb criteria for initiation of antibiotics. Results: Of 260 cases, 60% had documented signs/symptoms of the presenting illness and 15% met the Loeb criteria. Acute mental status change was the most commonly documented sign/symptom (24%). NH providers (81%) were the most common prescribers and ciprofloxacin (32%) was the most commonly prescribed antibiotic. Fourteen percent of presumed UTI cases included a white blood cell count, 71% included a urinalysis, and 72% had a urine culture. Seventy-five percent of cultures grew at least one organism with ≥100,000 colony-forming units/milliliter and 12% grew multi-drug resistant organisms; 28% of antibiotics were prescribed for more than 7 days, and 7% of cases had a subsequent death, emergency department visit, or hospitalization within 7 days. Discussion: Non-specific signs/symptoms appeared to influence prescribing more often than urinary tract-specific signs/symptoms. Prescribers rarely stopped antibiotics, and a minority prescribed for overly long periods. Providers may need additional support to guide the decision-making process to reduce antibiotic overuse and antibiotic resistance.</style></abstract><notes><style face="normal" font="default" size="100%">L615273823&#xD;2017-04-13&#xD;2017-08-23</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L615273823&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/jgs.14857</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28369756</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jgs.14857</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturgis, T. M.</style></author><author><style face="normal" font="default" size="100%">Yancy, W.</style></author><author><style face="normal" font="default" size="100%">Cole, J. C.</style></author><author><style face="normal" font="default" size="100%">Proctor, D. D.</style></author><author><style face="normal" font="default" size="100%">Minhas, B. S.</style></author><author><style face="normal" font="default" size="100%">Marcuard, S. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T.M. Sturgis, Medical Center Gastroenterology, 800 Moye Blvd., Greenville, NC 27858, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic prophylaxis in percutaneous endoscopic gastrostomy</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2301-2304</style></pages><volume><style face="normal" font="default" size="100%">91</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cefazolin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">sodium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">clinical protocol</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">erythema</style></keyword><keyword><style face="normal" font="default" size="100%">exudate</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intravenous drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">percutaneous endoscopic gastrostomy</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">stoma</style></keyword><keyword><style face="normal" font="default" size="100%">stomach pH</style></keyword><keyword><style face="normal" font="default" size="100%">wound infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9270</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: The benefit of antibiotic prophylaxis in percutaneous endoscopic gastrostomy is controversial. The aim of this study is to determine whether prophylactic antibiotic treatment with Cefazolin reduces the incidence of peristomal infection after percutaneous endoscopic gastrostomy. Methods: Of the 131 hospitalized or nursing home patients referred for percutaneous endoscopic gastrostomy, 115 were enrolled in a prospective randomized double-blind placebo controlled trial. Sixty-one (group 1) were randomized in a double-blind fashion and received either Cefazolin or saline pregastrostomy. Fifty-four patients (group 2) were on antibiotics for prior medical indications pregastrostomy. Patients had their peristomal area evaluated on a daily basis for 1 wk after gastrostomy. Erythema and exudate were scored on a scale from 0 to 4; induration was scored on a scale of 0 to 3; a maximum score of 8 or higher or the presence of pus was criteria for infection. Results: Wound infection occurred in 4 of 30 (13%) participants receiving Cefazolin and in 6 of 31 (19%) participants receiving saline (p &gt; 0.5). In the 54 patients on antibiotics for prior indications, wound infection was observed in 2 subjects (3%). This finding was a significant difference when compared with the placebo group (p &lt; 0.02). Conclusions: A single dose of Cefazolin prophylaxis does not reduce the overall peristomal wound infection in percutaneous endoscopic gastrostomy. Patients receiving prior extended antibiotic therapy have fewer peristomal wound infections.</style></abstract><notes><style face="normal" font="default" size="100%">L26383189&#xD;1996-11-30</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L26383189&amp;from=export</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">8931406</style></custom5></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>204</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madden, G. R.</style></author><author><style face="normal" font="default" size="100%">Argraves, S. M.</style></author><author><style face="normal" font="default" size="100%">Van Ness, P. H.</style></author><author><style face="normal" font="default" size="100%">Juthani-Mehta, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1Yale Internal Medicine Residency Program,Yale New Haven Hospital,New Haven,Connecticut.&#xD;2Yale Program on Aging,Yale University School of Medicine,New Haven,Connecticut.&#xD;4Department of Internal Medicine,Section of Infectious Diseases,Yale University School of Medicine,New Haven,Connecticut.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic susceptibility of urinary isolates in nursing home residents consuming cranberry capsules versus placebo</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">356-7</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Capsules</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Bacterial/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacteriaceae/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacteriaceae Infections/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">*Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><abstract><style face="normal" font="default" size="100%">Antimicrobial susceptibility of urinary isolates is compared amongst nursing home participants from a randomized controlled trial of cranberry capsules versus placebo. We hypothesized that cranberry spares non-Escherichia coli Enterobacteriaceae, which tend to be less susceptible to oral antibiotics. Analyses showed no differences in susceptibility or proportions of non-E. coli Enterobacteriaceae.</style></abstract><notes><style face="normal" font="default" size="100%">1559-6834&#xD;Madden, Gregory R&#xD;Argraves, Stephanie M&#xD;Van Ness, Peter H&#xD;Juthani-Mehta, Manisha&#xD;K23 AG028691/AG/NIA NIH HHS/United States&#xD;P30 AG021342/AG/NIA NIH HHS/United States&#xD;1K23AG028691/AG/NIA NIH HHS/United States&#xD;UL1 TR000142/TR/NCATS NIH HHS/United States&#xD;P30-AG21342/AG/NIA NIH HHS/United States&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Infect Control Hosp Epidemiol. 2015 Mar;36(3):356-7. doi: 10.1017/ice.2014.66.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4336946</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS654571</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/ice.2014.66</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aricò, E.</style></author><author><style face="normal" font="default" size="100%">Castiello, L.</style></author><author><style face="normal" font="default" size="100%">Bracci, L.</style></author><author><style face="normal" font="default" size="100%">Urbani, F.</style></author><author><style face="normal" font="default" size="100%">Lombardo, F.</style></author><author><style face="normal" font="default" size="100%">Bacigalupo, I.</style></author><author><style face="normal" font="default" size="100%">Ancidoni, A.</style></author><author><style face="normal" font="default" size="100%">Vanacore, N.</style></author><author><style face="normal" font="default" size="100%">Falcione, A.</style></author><author><style face="normal" font="default" size="100%">Reggiani, C.</style></author><author><style face="normal" font="default" size="100%">Dutti, G. M.</style></author><author><style face="normal" font="default" size="100%">Maglie, M. G.</style></author><author><style face="normal" font="default" size="100%">Papa, O.</style></author><author><style face="normal" font="default" size="100%">Bartoletti, P. L.</style></author><author><style face="normal" font="default" size="100%">Ozzella, G.</style></author><author><style face="normal" font="default" size="100%">Bevilacqua, N.</style></author><author><style face="normal" font="default" size="100%">Nicastri, E.</style></author><author><style face="normal" font="default" size="100%">Belardelli, F.</style></author><author><style face="normal" font="default" size="100%">Sconocchia, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">FaBioCell, Core Facilities, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy. eleonora.arico@iss.it.&#xD;FaBioCell, Core Facilities, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.&#xD;Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.&#xD;Medical Biotechnology and Translational Medicine PhD School, II University of Rome &quot;Tor Vergata&quot;, Via Montpellier 1, 00133, Rome, Italy.&#xD;National Centre for Disease Prevention and Health Promotion, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.&#xD;Special Units for Regional Continued Care (USCAR), Rome, Italy.&#xD;Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133, Rome, Italy.&#xD;National Institute for Infectious Diseases &quot;Lazzaro Spallanzani&quot;, Via Portuense 292, 00149, Rome, Italy.&#xD;Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133, Rome, Italy. filippo.belardelli@ift.cnr.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">584</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase II as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*HIV Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-beta/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-beta</style></keyword><keyword><style face="normal" font="default" size="100%">Randomised controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">non-hospitalized patients</style></keyword><keyword><style face="normal" font="default" size="100%">protocol</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 3</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The primary objective of the study is to demonstrate the efficacy of low-dose IFN-β in reducing the risk of SARS-CoV-2 recently infected elderly patients to progress towards severe COVID-19 versus control group within 28 days. Secondary objectives are: 1) To assess the reduction in Intensive Care Unit (ICU) admission in patients treated with IFN-β versus control group within 28 days of randomization 2) To assess the reduction in number of deaths in IFN- β compared to control group (day 28) 3) To evaluate the increase in proportion of participants returning to negative SARS-CoV-2 RT-PCR in IFN-β -treated versus control group at Day 14 and Day 28 4) To assess the increase in SARS-CoV-2-specific binding antibody titers in IFN-β compared to control group (day 28) 5) To assess the safety of IFN-β -treated patients versus control group TRIAL DESIGN: Randomized, Open-Label, Controlled, Superiority Phase II Study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to one of the two treatment groups in a ratio 2:1 (IFN-treated versus control patients). Randomization will be stratified by gender. Stratified randomization will balance the presence of male and female in both study arms. PARTICIPANTS: Male and female adults aged 65 years or older with newly diagnosed SARS-CoV-2 infection and mild COVID-19 symptoms are eligible for the study. The trial is being conducted in Rome. Participants will be either hospitalized or home isolated. A group of physicians belonging to the Special Unit for Regional Continued Care (USCAR), specifically trained for the study and under the supervision of the National Institute for Infectious Diseases &quot;Lazzaro Spallanzani&quot;, will be responsible for the screening, enrolment, treatment and clinical monitoring of patients, thus acting as a bridge between clinical centers and territorial health management. Inclusion criteria are as follows: ≥ 65 years of age at time of enrolment; Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, in any specimen &lt; 72 hours prior to randomization; Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures; Understands and agrees to comply with planned study procedures; Agrees to the collection of nasopharyngeal swabs and venous blood samples per protocol; Being symptomatic for less than 7 days before starting therapy; NEWS2 score ≤2. Exclusion criteria are as follows: Hospitalized patients with illness of any duration, and at least one of the following: Clinical assessment (evidence of rales/crackles on exam) and SpO2 ≤ 94% on room air at rest or after walking test, OR Acute respiratory failure requiring mechanical ventilation and/or supplemental oxygen; Patients currently using IFN-β (e.g., multiple sclerosis patients); Patients undergoing chemotherapy or other immunosuppressive treatments; Patients with chronic kidney diseases; Known allergy or hypersensitivity to IFN (including asthma); Any autoimmune disease (resulting from patient anamnesis); Patients with signs of dementia or neurocognitive disorders; Patients with current severe depression and/or suicidal ideations; Being concurrently involved in another clinical trial; HIV infection (based on the anamnesis); Use of any antiretroviral medication; Impaired renal function (eGFR calculated by CKD-EPI Creatinine equation &lt; 30 ml/min); Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition); Any physical or psychological impediment in a patient that could let the investigator to suspect his/her poor compliance; Lack or withdrawal of informed consent INTERVENTION AND COMPARATOR: Control arm: No specific antiviral treatment besides standard of care. Treatment arm: 11μg (3MIU) of IFN-β1a will be injected subcutaneously at day 1, 3, 7, and 10 in addition to standard of care. The drug solution, contained in a pre-filled cartridge, will be injected by means of the RebiSmart® electronic injection device. Interferon β1a (Rebif®, Merck KGaA, Darmstadt, Germany) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). The dose selected for this study is expected to exploit the antiviral and immunomodulatory properties of the cytokine without causing relevant toxicity or inducing refractoriness phenomena sometimes observed after high-dose and/or chronic IFNβ treatments. MAIN OUTCOMES: Primary endpoint of the study is the proportion of patients experiencing a disease progression, during at least 5 days, according to the National Early Warning Score (NEWS2). The NEWS2 score is a standardized approach aimed at promptly detecting signs of clinical deterioration in acutely ill patients and establishing the potential need for higher level of care. It is based on the evaluation of vital signs, including respiratory rate, oxygen saturation, temperature, blood pressure, pulse/heart rate, AVPU response. The resulting observations, compared to a normal range, are combined in a single composite &quot;alarm&quot; score. Any other clinical sign clearly indicating a disease worsening will be considered as disease progression. RANDOMIZATION: Sixty patients will be randomized 2:1 to receive IFN-β1a plus the standard of care or the standard of care only. Eligible patients will be randomized (no later than 36 h after enrolment) by means of a computerized central randomization system. All patients will receive a unique patient identification number at enrolling visit when signing the informed consent and before any study procedure is performed. This number remains constant throughout the entire study. The randomization of patients will be closed when 60 patients have been enrolled. The randomization will be stratified by sex; for each stratum a sequence of treatments randomly permuted in blocks of variable length (3 or 6) will be generated. BLINDING (MASKING): This is an open-label study. After the randomization, patients will be notified whether they will be in the experimental arm or in the control arm. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The study plans to enrol 60 patients: 40 in the IFN-β1a arm, 20 in the control arm, according to a 2:1 - treated: untreated ratio. TRIAL STATUS: Protocol Version: 3.0 Version Date: 18/03/2021 The study is open for recruitment since 16/04/2021.Recruitment is expected to l be completed before 15/08/2021. TRIAL REGISTRATION: EudraCT N°: 2020-003872-42, registration date: 19/10/2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.&quot;</style></abstract><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Aricò, Eleonora&#xD;Orcid: 0000-0003-4728-9246&#xD;Castiello, Luciano&#xD;Bracci, Laura&#xD;Urbani, Francesca&#xD;Lombardo, Flavia&#xD;Bacigalupo, Ilaria&#xD;Ancidoni, Antonio&#xD;Vanacore, Nicola&#xD;Falcione, Alessandro&#xD;Reggiani, Chiara&#xD;Dutti, Giovanni Marco&#xD;Maglie, Maria Grazia&#xD;Papa, Ombretta&#xD;Bartoletti, Pier Luigi&#xD;Ozzella, Giuseppina&#xD;Bevilacqua, Nazario&#xD;Nicastri, Emanuele&#xD;Belardelli, Filippo&#xD;Sconocchia, Giuseppe&#xD;Clinical Trial Protocol&#xD;Letter&#xD;Trials. 2021 Sep 3;22(1):584. doi: 10.1186/s13063-021-05367-6.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC8413691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-021-05367-6</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mintzer, J. E.</style></author><author><style face="normal" font="default" size="100%">Tune, L. E.</style></author><author><style face="normal" font="default" size="100%">Breder, C. D.</style></author><author><style face="normal" font="default" size="100%">Swanink, R.</style></author><author><style face="normal" font="default" size="100%">Marcus, R. N.</style></author><author><style face="normal" font="default" size="100%">McQuade, R. D.</style></author><author><style face="normal" font="default" size="100%">Forbes, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. E. Mintzer, Medical University of South Carolina, Alzbeimer&apos;s Research and Clinical Programs, 5900 Core Rd., N. Charlestron, SC 29406-6076</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aripiprazole for the treatment of psychoses in institutionalized patients with alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">918-931</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">benzatropine</style></keyword><keyword><style face="normal" font="default" size="100%">benzodiazepine derivative</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">mood stabilizer</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">sedative agent</style></keyword><keyword><style face="normal" font="default" size="100%">temazepam</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone</style></keyword><keyword><style face="normal" font="default" size="100%">zolpidem tartrate</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">accidental injury</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">agitated depression</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">brain edema</style></keyword><keyword><style face="normal" font="default" size="100%">brain hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">brain ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">Brief Psychiatric Rating Scale</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Global Impression scale</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">confusion</style></keyword><keyword><style face="normal" font="default" size="100%">conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">consciousness</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">ecchymosis</style></keyword><keyword><style face="normal" font="default" size="100%">edema</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiogram</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">facial nerve paralysis</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gait disorder</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">irritability</style></keyword><keyword><style face="normal" font="default" size="100%">limb pain</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">mydriasis</style></keyword><keyword><style face="normal" font="default" size="100%">neuropsychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral edema</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">salivation</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">subarachnoid hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">subdural hematoma</style></keyword><keyword><style face="normal" font="default" size="100%">symptom</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">treatment response</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urine incontinence</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1064-7481&#xD;1545-7214</style></isbn><abstract><style face="normal" font="default" size="100%">To assess the efficacy and safety of aripiprazole for psychosis associated with Alzheimer dementia (AD). Methods: In this double-blind, multlcenter study, 487 institutionalized patients with psychosis associated with AD were randomized to placebo or aripiprazole, 2,5 or 10 mg/day. Primary)&apos; efficacy assessment was the mean change from baseline to week 10 on the Neuropsychiatrie Inventory-Nursing Home (NPI-NH) version Psychosis Subscale score. Secondary measures included NPI-NH Total, Clinical Global Impression-Severity of Illness (CGI-S), Brief Psychiatric Rating Scale (BPRS) Core and Total, and the Cohen-Mansfield Agitation Inventory (CMAI) scores. Results: Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df= 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46[1.6]; F= 4.68, df=l, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F =4.72, df= 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3-07 [6.9] versus -1.74 [7.8]; F = 7.30, df= 1, 407,p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F= 5.23, df= 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; x* = 5-52, df= 1, p = 0.019 [CMH]). Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS and CMAl scores. Aripiprazole 2 mg/day was not efficacious. Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N= 1; 5 mg/day, N = 2; 10 mg/day, N = 4; placebo, N = 0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 mg/day, 2%; 10 mg/day, 7%;placebo, 3%) were considered to be treatment-related. Conclusion: Aripiprazole IO mg/day was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms, agitation, and clinical global impression. However, clinicians should be aware of the safety considerations of atypical antipsychotic uses in this population. © 2007 American Association for Geriatric Psychiatry.</style></abstract><notes><style face="normal" font="default" size="100%">L354927193&#xD;2009-08-18</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354927193&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/JGP.0b013e3181557b47</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17974864</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/JGP.0b013e3181557b47</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Putot, A.</style></author><author><style face="normal" font="default" size="100%">Bouiller, K.</style></author><author><style face="normal" font="default" size="100%">Laborde, C.</style></author><author><style face="normal" font="default" size="100%">Gilis, M.</style></author><author><style face="normal" font="default" size="100%">Févre, A.</style></author><author><style face="normal" font="default" size="100%">Hacquin, A.</style></author><author><style face="normal" font="default" size="100%">Manckoundia, P.</style></author><author><style face="normal" font="default" size="100%">Hoefler, F.</style></author><author><style face="normal" font="default" size="100%">Bermejo, M.</style></author><author><style face="normal" font="default" size="100%">Mendes, A.</style></author><author><style face="normal" font="default" size="100%">Serratrice, C.</style></author><author><style face="normal" font="default" size="100%">Prendki, V.</style></author><author><style face="normal" font="default" size="100%">Sanchez, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, France.&#xD;Department of Infectious Diseases, Besançon University Hospital, Besançon, France.&#xD;Department of Geriatric Internal Medicine, Nimes University Hospital, Nimes, France.&#xD;Department of Geriatrics, Besançon University Hospital, Besançon, France.&#xD;Department of Internal Medicine and Infectious Diseases, Troyes Hospital Centre, Troyes, France.&#xD;Division of Geriatrics, University Hospitals of Geneva, Geneva, Switzerland.&#xD;Division of Internal Medicine for the aged, University Hospitals of Geneva, Geneva, Switzerland.&#xD;Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland.&#xD;Department of Clinical Research, Troyes Hospital Centre, Troyes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">J Gerontol A Biol Sci Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Gerontol A Biol Sci Med Sci</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">bacteraemia</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">co-infection</style></keyword><keyword><style face="normal" font="default" size="100%">superinfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1079-5006 (Print)&#xD;1079-5006</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: It is uncertain whether antibiotic therapy should be started in SARS CoV-2 pneumonia. We aimed to investigate the association between early antibiotic therapy and the risk of in-hospital mortality in older patients. METHODS: We performed a retrospective international cohort study (ANTIBIOVID) in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive patients aged 75 or more hospitalised and testing positive for SARS-CoV-2, 1072 had a radiologically confirmed pneumonia, of which 914 patients were still alive and hospitalized at 48 hours. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting (SIPTW) was applied. To assess the association between early antibiotic therapy and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier and Cox proportional hazards regression analyses were performed. RESULTS: Of the 914 patients with SARS-CoV-2 pneumonia, median age of 86, 428 (46.8%) received antibiotics in the first 48 hours after diagnosis. Among these patients, 147 (34.3%) died in hospital within one month vs 118 patients (24.3%) with no early antibiotic treatment. After SIPTW, early antibiotic treatment was not significantly associated with mortality (adjusted hazard ratio, 1.23; 95% CI, 0.92-1.63; P = .160). Microbiologically confirmed superinfections occurred rarely in both groups (bacterial pneumonia: 2.5% vs 1.5%, P = .220; blood stream infection: 8.2% vs 5.2%, P = .120; Clostridioides difficile colitis: 2.4% vs 1.0%, P = .222). CONCLUSIONS: In a large multicentre cohort of older inpatients with SARS-CoV-2 pneumonia, early antibiotic treatment did not appear to be associated with an improved prognosis.</style></abstract><notes><style face="normal" font="default" size="100%">1758-535x&#xD;Putot, Alain&#xD;Orcid: 0000-0002-4408-554x&#xD;Bouiller, Kevin&#xD;Laborde, Caroline&#xD;Gilis, Marine&#xD;Févre, Amélie&#xD;Hacquin, Arthur&#xD;Manckoundia, Patrick&#xD;Hoefler, Florence&#xD;Bermejo, Messaline&#xD;Mendes, Aline&#xD;Orcid: 0000-0003-0098-6503&#xD;Serratrice, Christine&#xD;Prendki, Virginie&#xD;Sanchez, Stéphane&#xD;Journal Article&#xD;J Gerontol A Biol Sci Med Sci. 2021 Jul 17:glab209. doi: 10.1093/gerona/glab209.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC8406862</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/gerona/glab209</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, D. A.</style></author><author><style face="normal" font="default" size="100%">Beier, M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.A. Smith, Central of Texas, Box 2105, Brownwood, TX 76804, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">129-132</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aggression</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">dehydration</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug information</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">editorial</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">gynecomastia</style></keyword><keyword><style face="normal" font="default" size="100%">hemoconcentration</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperprolactinemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">Mini Mental State Examination</style></keyword><keyword><style face="normal" font="default" size="100%">motor dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">multiinfarct dementia</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">occlusive cerebrovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">orthostatic hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">osteoporosis</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">sexual dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">tachycardia</style></keyword><keyword><style face="normal" font="default" size="100%">transient ischemic attack</style></keyword><keyword><style face="normal" font="default" size="100%">venous thromboembolism</style></keyword><keyword><style face="normal" font="default" size="100%">risperdal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">1525-8610</style></isbn><notes><style face="normal" font="default" size="100%">L38380415&#xD;2004-04-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L38380415&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S1525-8610(04)70069-9</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">risperdal(Janssen,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Janssen(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">15008183</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1525-8610(04)70069-9</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortensen, E. M.</style></author><author><style face="normal" font="default" size="100%">Halm, E. A.</style></author><author><style face="normal" font="default" size="100%">Pugh, M. J.</style></author><author><style face="normal" font="default" size="100%">Copeland, L. A.</style></author><author><style face="normal" font="default" size="100%">Metersky, M.</style></author><author><style face="normal" font="default" size="100%">Fine, M. J.</style></author><author><style face="normal" font="default" size="100%">Johnson, C. S.</style></author><author><style face="normal" font="default" size="100%">Alvarez, C. A.</style></author><author><style face="normal" font="default" size="100%">Frei, C. R.</style></author><author><style face="normal" font="default" size="100%">Good, C.</style></author><author><style face="normal" font="default" size="100%">Restrepo, M. I.</style></author><author><style face="normal" font="default" size="100%">Downs, J. R.</style></author><author><style face="normal" font="default" size="100%">Anzueto, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VA North Texas Health Care System, Dallas2University of Texas Southwestern Medical Center, Dallas.&#xD;University of Texas Southwestern Medical Center, Dallas.&#xD;VERDICT Research Program, South Texas Veterans Health Care System, San Antonio5University of Texas Health Science Center at San Antonio.&#xD;Center for Applied Health Research, Central Texas Veterans Health Care System jointly with Scott and White Healthcare, Temple, Texas.&#xD;University of Connecticut Medical Center, Farmington.&#xD;VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, Pennsylvania.&#xD;VA North Texas Health Care System, Dallas2University of Texas Southwestern Medical Center, Dallas3Texas Tech University Health Sciences Center, Dallas.&#xD;University of Texas Health Science Center at San Antonio9University of Texas at Austin.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2199-208</style></pages><volume><style face="normal" font="default" size="100%">311</style></volume><number><style face="normal" font="default" size="100%">21</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Azithromycin/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/*chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, Veterans/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0098-7484 (Print)&#xD;0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">IMPORTANCE: Although clinical practice guidelines recommend combination therapy with macrolides, including azithromycin, as first-line therapy for patients hospitalized with pneumonia, recent research suggests that azithromycin may be associated with increased cardiovascular events. OBJECTIVE: To examine the association of azithromycin use with all-cause mortality and cardiovascular events for patients hospitalized with pneumonia. DESIGN: Retrospective cohort study comparing older patients hospitalized with pneumonia from fiscal years 2002 through 2012 prescribed azithromycin therapy and patients receiving other guideline-concordant antibiotic therapy. SETTING: This study was conducted using national Department of Veterans Affairs administrative data of patients hospitalized at any Veterans Administration acute care hospital. PARTICIPANTS: Patients were included if they were aged 65 years or older, were hospitalized with pneumonia, and received antibiotic therapy concordant with national clinical practice guidelines. MAIN OUTCOMES AND MEASURES: Outcomes included 30- and 90-day all-cause mortality and 90-day cardiac arrhythmias, heart failure, myocardial infarction, and any cardiac event. Propensity score matching was used to control for the possible effects of known confounders with conditional logistic regression. RESULTS: Of 73,690 patients from 118 hospitals identified, propensity-matched groups were composed of 31,863 patients exposed to azithromycin and 31,863 matched patients who were not exposed. There were no significant differences in potential confounders between groups after matching. Ninety-day mortality was significantly lower in those who received azithromycin (exposed, 17.4%, vs unexposed, 22.3%; odds ratio [OR], 0.73; 95% CI, 0.70-0.76). However, we found significantly increased odds of myocardial infarction (5.1% vs 4.4%; OR, 1.17; 95% CI, 1.08-1.25) but not any cardiac event (43.0% vs 42.7%; OR, 1.01; 95% CI, 0.98-1.05), cardiac arrhythmias (25.8% vs 26.0%; OR, 0.99; 95% CI, 0.95-1.02), or heart failure (26.3% vs 26.2%; OR, 1.01; 95% CI, 0.97-1.04). CONCLUSIONS AND RELEVANCE: Among older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a lower risk of 90-day mortality and a smaller increased risk of myocardial infarction. These findings are consistent with a net benefit associated with azithromycin use.</style></abstract><notes><style face="normal" font="default" size="100%">1538-3598&#xD;Mortensen, Eric M&#xD;Halm, Ethan A&#xD;Pugh, Mary Jo&#xD;Copeland, Laurel A&#xD;Metersky, Mark&#xD;Fine, Michael J&#xD;Johnson, Christopher S&#xD;Alvarez, Carlos A&#xD;Frei, Christopher R&#xD;Good, Chester&#xD;Restrepo, Marcos I&#xD;Downs, John R&#xD;Anzueto, Antonio&#xD;K23 HL096054/HL/NHLBI NIH HHS/United States&#xD;UL1 TR001105/TR/NCATS NIH HHS/United States&#xD;K23HL096054/HL/NHLBI NIH HHS/United States&#xD;KL2 TR001118/TR/NCATS NIH HHS/United States&#xD;UL1 TR001120/TR/NCATS NIH HHS/United States&#xD;KL2 TR001103/TR/NCATS NIH HHS/United States&#xD;R01NR010828/NR/NINR NIH HHS/United States&#xD;R01 NR010828/NR/NINR NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;JAMA. 2014 Jun 4;311(21):2199-208. doi: 10.1001/jama.2014.4304.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4109266</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS602919 contributed to this study had no conflicts of interest to report.</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2014.4304</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortensen, E.</style></author><author><style face="normal" font="default" size="100%">Halm, E.</style></author><author><style face="normal" font="default" size="100%">Fine, M. J.</style></author><author><style face="normal" font="default" size="100%">Johnson, C.</style></author><author><style face="normal" font="default" size="100%">Anuzeto, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Mortensen, VANTHCS, Dallas, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Azithromycin is associated with increased cardiac events but lower mortality for older patients hospitalized with pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S37-S38</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><keywords><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">macrolide</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">heart arrhythmia</style></keyword><keyword><style face="normal" font="default" size="100%">logistic regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">propensity score</style></keyword><keyword><style face="normal" font="default" size="100%">veteran</style></keyword><keyword><style face="normal" font="default" size="100%">implantable cardioverter defibrillator</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">government</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although clinical practice guidelines recommend combination therapy with macrolides, including azithromycin, as first line therapy for patients hospitalized with pneumonia, recent research suggests that azithromycin may be associated with increased cardiovascular events. The purpose of this study was to examine the association of azithromycin use with all-cause mortality and cardiovascular events for patients hospitalized with pneumonia. METHODS: We conducted a retrospective national study using Department of Veterans Affairs administrative data of patients hospitalized at any Veterans Administration acute care hospital. We included patients &gt;65 years hospitalized with pneumonia in fiscal years 2002-2012. We included only those who received antibiotic therapy concordant with national clinical practice guidelines. Our outcomes included all-cause mortality, cardiac arrhythmias, heart failure, myocardial infarction, and any cardiac event. We used propensity score matching to control for the possible effects of known confounders with conditional logistic regression. RESULTS: Out of the 77,972 patients identified, our propensity-matched groups were composed of 34,763 azithromycin-exposed and 34,763 matched unexposed. There were no significant differences in potential confounders between groups after matching. We found that 90-day mortality was significantly lower in those who received azithromycin (exposed-17.4 % vs. unexposed-22.8 %, odds ratio [OR] 0.71, 95 % confidence interval [CI] 0.68-0.73). However, we found significant increased odds of any cardiac event (43.2 % vs 42.2 %, OR 1.04, 95 % CI 1.01-1.07), myocardial infarctions (4.9 % vs. 4.2 %, OR 1.17, 95 % CI 1.09-1.26), and cardiac arrhythmias (26.5 % vs. 25.6 %, OR 1.04, 95 % CI 1.002-1.07) but not heart failure (26.1 % vs. 25.8 %, OR 1.02, 95 % CI 0.98-1.05). CONCLUSIONS: In patients hospitalized with pneumonia we found that although azithromycin is associated with a small increase in cardiac events it is also associated with a significant decrease in all-cause mortality. Our study supports the current clinical practice guidelines that recommend the use of azithromycin as part of empiric combination therapy.</style></abstract><notes><style face="normal" font="default" size="100%">L71494775&#xD;2014-06-17</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71494775&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ekdahl, K.</style></author><author><style face="normal" font="default" size="100%">Mårtensson, A.</style></author><author><style face="normal" font="default" size="100%">Kamme, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infectious Diseases, University Hospital of Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacteraemic pneumococcal infections in Southern Sweden 1981-96: trends in incidence, mortality, age-distribution, serogroups and penicillin-resistance</style></title><secondary-title><style face="normal" font="default" size="100%">Scand J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scand J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">257-62</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteremia/*epidemiology/microbiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumococcal Infections/*epidemiology/*microbiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Serotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">*Streptococcus pneumoniae/classification/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0036-5548 (Print)&#xD;0036-5548</style></isbn><abstract><style face="normal" font="default" size="100%">In a survey of pneumococcal blood isolates from patients in Southern Sweden, 560 isolates were found between 1981 and 1996. Between these years, the incidence of pneumococcal bacteraemia increased from 5.2 to 15.2/100,000/y. The eight most common serogroups/types (14, 7, 9, 6, 23, 3, 4 and 19) accounted for &gt; 75% of the isolates, and 96.4% of the isolates were of serogroups/types represented in the present vaccine. A male preponderance (1.17:1) was noted, and the men were younger than the women (mean 57 vs 63 y of age; p &lt; 0.05). The overall case-fatality rate during the period was 19%. Seven isolates with reduced susceptibility to penicillin were noted, all from 1991 to 1996. The increasing incidence of pneumococcal bacteraemia could not be explained by any of the following factors; age or sex of the patients, changes in prevailing serogroups/types, variations in vaccine use, emergence of penicillin-resistance, more liberal indications for blood cultures or improved culture methods.</style></abstract><notes><style face="normal" font="default" size="100%">Ekdahl, K&#xD;Mårtensson, A&#xD;Kamme, C&#xD;Journal Article&#xD;England&#xD;Scand J Infect Dis. 1998;30(3):257-62. doi: 10.1080/00365549850160891.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/00365549850160891</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>202</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, H. H.</style></author><author><style face="normal" font="default" size="100%">Yaron, D.</style></author><author><style face="normal" font="default" size="100%">Piraino, A. S.</style></author><author><style face="normal" font="default" size="100%">Kapelusznik, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H.H. Liu, 219 Garnet Lane, Bala Cynwyd, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacterial and fungal growth in sputum cultures from 165 COVID-19 pneumonia patients requiring intubation: evidence for antimicrobial resistance development and analysis of risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Clinical Microbiology and Antimicrobials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Clinical Microbiology and Antimicrobials</style></full-title></periodical><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial colonization</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial growth</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial superinfection</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">community hospital</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacter</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fungus growth</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">infectious agent</style></keyword><keyword><style face="normal" font="default" size="100%">intubation</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">mouth flora</style></keyword><keyword><style face="normal" font="default" size="100%">mycosis</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">plant growth</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas</style></keyword><keyword><style face="normal" font="default" size="100%">residential home</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">seashore</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">sputum culture</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">yeast</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">glass</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">1476-0711</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Coronavirus SARS-CoV-2 causes COVID-19 illness which can progress to severe pneumonia. Empiric antibacterials are often employed though frequency of bacterial coinfection superinfection is debated and concerns raised about selection of bacterial antimicrobial resistance. We evaluated sputum bacterial and fungal growth from 165 intubated COVID-19 pneumonia patients. Objectives were to determine frequency of culture positivity, risk factors for and outcomes of positive cultures, and timing of antimicrobial resistance development. Methods: Retrospective reviews were conducted of COVID-19 pneumonia patients requiring intubation admitted to a 1058-bed four community hospital system on the east coast United States, March 1 to May 1, 2020. Length of stay (LOS) was expressed as mean (standard deviation); 95% confidence interval (95% CI) was computed for overall mortality rate using the exact binomial method, and overall mortality was compared across each level of a potential risk factor using a Chi-Square Test of Independence. All tests were two-sided, and significance level was set to 0.05. Results: Average patient age was 68.7 years and LOS 19.9 days. Eighty-three patients (50.3% of total) originated from home, 10 from group homes (6.1% of total), and 72 from nursing facilities (43.6% of total). Mortality was 62.4%, highest for nursing home residents (80.6%). Findings from 253 sputum cultures overall did not suggest acute bacterial or fungal infection in 73 (45%) of 165 individuals sampled within 24 h of intubation. Cultures ≥ 1 week following intubation did grow potential pathogens in 72 (64.9%) of 111 cases with 70.8% consistent with late pneumonia and 29.2% suggesting colonization. Twelve (10.8% of total) of these late post-intubation cultures revealed worsened antimicrobial resistance predominantly in Pseudomonas, Enterobacter, or Staphylococcus aureus. Conclusions: In severe COVID-19 pneumonia, a radiographic ground glass interstitial pattern and lack of purulent sputum prior to/around the time of intubation correlated with no culture growth or recovery of normal oral flora ± yeast. Discontinuation of empiric antibacterials should be considered in these patients aided by other clinical findings, history of prior antimicrobials, laboratory testing, and overall clinical course. Continuing longterm hospitalisation and antibiotics are associated with sputum cultures reflective of hospital-acquired microbes and increasing antimicrobial resistance. Trial registration: Not applicable as this was a retrospective chart review study without interventional arm.</style></abstract><notes><style face="normal" font="default" size="100%">L2013788519&#xD;2021-09-30</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2013788519&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s12941-021-00472-5</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">34563202</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12941-021-00472-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>200</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">200</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Levenkrohn, S.</style></author><author><style face="normal" font="default" size="100%">Fleissig, Y.</style></author><author><style face="normal" font="default" size="100%">Kopel, B.</style></author><author><style face="normal" font="default" size="100%">Arad, M.</style></author><author><style face="normal" font="default" size="100%">Klid, R.</style></author><author><style face="normal" font="default" size="100%">Kimyagarov, S.</style></author><author><style face="normal" font="default" size="100%">Adunsky, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gilad Geriatric Center, Sheba Medical Center, Tel Hashomer, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[The bacteriological profile of bacteriuria in residents of a long-term geriatric facility]</style></title><secondary-title><style face="normal" font="default" size="100%">Harefuah</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Harefuah</style></full-title></periodical><pages><style face="normal" font="default" size="100%">340-3, 405</style></pages><volume><style face="normal" font="default" size="100%">149</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Murine-Derived</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/drug therapy/*epidemiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus mirabilis/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Rituximab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0017-7768 (Print)&#xD;0017-7768</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Little is known on the bacteriological profile of consecutive urine samples in elderly patients institutionalized in nursing homes. AIM: This retrospective study aims to characterize urinary pathogens, rates of isolation of the same pathogen in subsequent urine samples and predicting factors associated with such repeated isolations. Data were retrospectively retrieved from medical charts of nursing home patients during a four-year period. The authors looked for changes in rates of positive cultures, changes in urine flora, in rates of repeated isolation of the same pathogens and the possible interrelations with the use of antibiotics. METHODS: A total number of 3229 urine cultures were studied, 1311 of which (43%) were positive and 493 out of these positive cultures (37.6%) were treated with antibiotics. The rates of positive cultures increased consistently during the study period (p=0.003). E. coli (68.1%), Klebsiella pneumoniae and Proteus mirabilis accounted for more than 90% of positive cultures. RESULTS: There was no difference with regard to pathogen types isolated from symptomatic or asymptomatic cases. The rates of recurrent bacteriuria, by the same pathogen isolated at baseline urine culture, were similar in treated and untreated cases. A regression analysis aiming to predict factors associated with subsequent positive cultures had negative results, except for cases of untreated bacteriuria with pseudomonas (CI 1.36-7.09, O.R. 3.11, p=0.006). CONCLUSION: Our data support earlier studies underscoring the need to carefully consider the role of antibiotics and for better clinical guidelines for the treatment of bacteriuria in this population.</style></abstract><notes><style face="normal" font="default" size="100%">Levenkrohn, Shalom&#xD;Fleissig, Yudit&#xD;Kopel, Bella&#xD;Arad, Marina&#xD;Klid, Raisa&#xD;Kimyagarov, Simha&#xD;Adunsky, Abraham&#xD;Journal Article&#xD;Israel&#xD;Harefuah. 2010 Jun;149(6):340-3, 405.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cohen, M. S.</style></author><author><style face="normal" font="default" size="100%">Nirula, A.</style></author><author><style face="normal" font="default" size="100%">Mulligan, M.</style></author><author><style face="normal" font="default" size="100%">Novak, R.</style></author><author><style face="normal" font="default" size="100%">Marovich, M.</style></author><author><style face="normal" font="default" size="100%">Stemer, A.</style></author><author><style face="normal" font="default" size="100%">Adams, A. C.</style></author><author><style face="normal" font="default" size="100%">Schade, A. E.</style></author><author><style face="normal" font="default" size="100%">Knorr, J.</style></author><author><style face="normal" font="default" size="100%">Tuttle, J. L.</style></author><author><style face="normal" font="default" size="100%">Sabo, J.</style></author><author><style face="normal" font="default" size="100%">Klekotka, P.</style></author><author><style face="normal" font="default" size="100%">Shen, L.</style></author><author><style face="normal" font="default" size="100%">Skovronsky, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.S. Cohen, Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting</style></title><secondary-title><style face="normal" font="default" size="100%">Topics in Antiviral Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Topics in Antiviral Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32-33</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">bamlanivimab</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">assisted living facility</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nose smear</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">resident</style></keyword><keyword><style face="normal" font="default" size="100%">reverse transcription polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">serology</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">2161-5853</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing COVID-19. Methods: BLAZE-2 is a Phase 3, randomized, double-blind, placebo-controlled, single-dose study that enrolled residents and staff at skilled nursing and assisted living facilities reporting at least one confirmed SARS-CoV-2 case. Eligible participants received bamlanivimab (4200 mg) or placebo intravenously. Nasal swabs were collected at baseline and weekly through day 57 to determine SARS-CoV-2 infection status via reverse transcriptase polymerase chain reaction (RT-PCR). COVID-19-releated symptoms and signs were recorded daily. The primary analysis prevention population included participants negative at baseline for SARS-CoV-2 by RT-PCR and serology. The primary endpoint was incidence of mild or worse COVID-19 by day 57. Results: Of the 1175 participants dosed, 966 (82.2%) comprised the prevention population. The prevention population included 299 residents for whom the median age was 76 years (range 31-104), 234 (78.3%) were aged ≥65, and 178 (59.5%) were female. All were considered at high risk for development of severe COVID-19. The proportion of residents in the prevention population with mild or worse COVID-19 by day 57 was significantly lower in the bamlanivimab group compared with the placebo group (odds ratio [OR], 0.20; 95% confidence interval [CI], 0.08 to 0.49; p&lt;0.001)(Figure). For this same group, bamlanivimab was associated with significant reductions in the incidence of moderate or worse COVID-19 by day 57 (OR, 0.20; 95% CI, 0.08 to 0.49; p&lt;0.001) and incident SARS-CoV-2 infection by day 29 (OR, 0.23; CI, 0.11 to 0.48; p&lt;0.001) compared with placebo. Of the 16 deaths reported during the study, all 5 that were attributed to COVID-19 were in the placebo group. The incidence of both adverse events and serious adverse events were balanced between the bamlanivimab and placebo group. Conclusion: Bamlanivimab was highly effective in reducing the incidence of symptomatic COVID-19 and SARS-CoV-2 infection and was well tolerated. These findings demonstrate the potential beneficial impact of bamlanivimab use on COVID-19 morbidity and mortality among skilled nursing facility residents.</style></abstract><notes><style face="normal" font="default" size="100%">L635068292&#xD;2021-05-28</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L635068292&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>195</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Langford, B. J.</style></author><author><style face="normal" font="default" size="100%">Brown, K. A.</style></author><author><style face="normal" font="default" size="100%">Diong, C.</style></author><author><style face="normal" font="default" size="100%">Marchand-Austin, A.</style></author><author><style face="normal" font="default" size="100%">Adomako, K.</style></author><author><style face="normal" font="default" size="100%">Saedi, A.</style></author><author><style face="normal" font="default" size="100%">Schwartz, K. L.</style></author><author><style face="normal" font="default" size="100%">Johnstone, J.</style></author><author><style face="normal" font="default" size="100%">MacFadden, D. R.</style></author><author><style face="normal" font="default" size="100%">Matukas, L. M.</style></author><author><style face="normal" font="default" size="100%">Patel, S. N.</style></author><author><style face="normal" font="default" size="100%">Garber, G.</style></author><author><style face="normal" font="default" size="100%">Daneman, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Public Health Ontario, Toronto, Ontario, Canada.&#xD;Hotel Dieu Shaver Health and Rehabilitation Centre, St Catharines, Ontario, Canada.&#xD;Public Health Ontario, ICES, Dalla Lana School of Public Health, Toronto, Ontario, Canada.&#xD;ICES, Toronto, Ontario, Canada.&#xD;Public Health Ontario, Sinai Health, Dalla Lana School of Public Health, Toronto, Ontario, Canada.&#xD;Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.&#xD;Unity Health Toronto, University of Toronto Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.&#xD;Public Health Ontario, University of Toronto Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.&#xD;Public Health Ontario, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.&#xD;Public Health Ontario, Sunnybrook Health Sciences Center, ICES, Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e782-e791</style></pages><volume><style face="normal" font="default" size="100%">73</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sepsis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Urinary Tract Infections/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*antimicrobial prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*older adults</style></keyword><keyword><style face="normal" font="default" size="100%">*urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: The role of antibiotics in preventing urinary tract infection (UTI) in older adults is unknown. We sought to quantify the benefits and risks of antibiotic prophylaxis among older adults. METHODS: We conducted a matched cohort study comparing older adults (≥66 years) receiving antibiotic prophylaxis, defined as antibiotic treatment for ≥30 days starting within 30 days of a positive culture, with patients with positive urine cultures who received antibiotic treatment but did not receive prophylaxis. We matched each prophylaxis recipient to 10 nonrecipients based on organism, number of positive cultures, and propensity score. Outcomes included (1) emergency department (ED) visit or hospitalization for UTI, sepsis, or bloodstream infection within 1 year; (2) acquisition of antibiotic resistance in urinary tract pathogens; and (3) antibiotic-related complications. RESULTS: Overall, 4.7% (151/3190) of UTI prophylaxis patients and 3.6% (n = 1092/30 542) of controls required an ED visit or hospitalization for UTI, sepsis, or bloodstream infection (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.12-1.57). Acquisition of antibiotic resistance to any urinary antibiotic (HR, 1.31; 95% CI, 1.18-1.44) and to the specific prophylaxis agent (HR, 2.01; 95% CI, 1.80-2.24) was higher in patients receiving prophylaxis. While the overall risk of antibiotic-related complications was similar between groups (HR, 1.08; 95% CI, .94-1.22), the risk of Clostridioidesdifficile and general medication adverse events was higher in prophylaxis recipients (HR [95% CI], 1.56 [1.05-2.23] and 1.62 [1.11-2.29], respectively). CONCLUSIONS: Among older adults with UTI, the harms of long-term antibiotic prophylaxis may outweigh their benefits.</style></abstract><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Langford, Bradley J&#xD;Orcid: 0000-0001-5467-6776&#xD;Brown, Kevin A&#xD;Diong, Christina&#xD;Marchand-Austin, Alex&#xD;Adomako, Kwaku&#xD;Saedi, Arezou&#xD;Schwartz, Kevin L&#xD;Johnstone, Jennie&#xD;MacFadden, Derek R&#xD;Matukas, Larissa M&#xD;Patel, Samir N&#xD;Garber, Gary&#xD;Daneman, Nick&#xD;159503/CIHR/Canada&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Clin Infect Dis. 2021 Aug 2;73(3):e782-e791. doi: 10.1093/cid/ciab116.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciab116</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pollock, B. G.</style></author><author><style face="normal" font="default" size="100%">Mulsant, B. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. G. Pollock, Department of Psychiatry, Division of Geriatric Psychiatry, University of Toronto, Toronto, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Between Scylla and Charybdis: Antipsychotic and other psychotropic medications in older nursing home residents</style></title><secondary-title><style face="normal" font="default" size="100%">CMAJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CMAJ</style></full-title></periodical><pages><style face="normal" font="default" size="100%">778-779</style></pages><volume><style face="normal" font="default" size="100%">183</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">amitriptyline</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">benzodiazepine derivative</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin noradrenalin reuptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">tricyclic antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">aggression</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">restlessness</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">vocalization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0820-3946&#xD;1488-2329</style></isbn><notes><style face="normal" font="default" size="100%">L361652285&#xD;2011-05-03&#xD;2011-12-08</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L361652285&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1503/cmaj.110348</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">21444612</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1503/cmaj.110348</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Handeland, M.</style></author><author><style face="normal" font="default" size="100%">Grude, N.</style></author><author><style face="normal" font="default" size="100%">Torp, T.</style></author><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Studies, University of Stavanger, Stavanger, Norway N-4036.&#xD;Department of Microbiology, Vestfold Hospital Trust, Tønsberg, Norway N-3103.&#xD;Norwegian Institute for Agricultural and Environmental Research, Plant Health and Plant Protection Division, Høgskoleveien 7, Ås, Norway N-1432.&#xD;Norwegian Institute for Agricultural and Environmental Research-Bioforsk Vest Særheim, Postvegen 213, Klepp station, Klepp, Norway N-4353. Electronic address: Rune.Slimestad@bioforsk.no.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Black chokeberry juice (Aronia melanocarpa) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Nutr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutr Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">518-25</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages/*analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Biflavonoids/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Catechin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorogenic Acid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Photinia/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Elderly people</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Uti</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0271-5317</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is a major problem in nursing homes, and the mainstay of treatment is antibiotics. The increasing prevalence of uropathogens resistant to antimicrobial agents has stimulated interest in specific nutrients, for example, cranberries, to prevent recurring UTI. Black chokeberry (Aronia melanocarpa [Michx] Elliott) is a rich source of phenolics, and thus, dietary intake of black chokeberry juice may reduce the incidences of UTI requiring medical treatment. In this pilot study, we examined the frequency of medically treated UTI among residents in 6 nursing homes who were offered black chokeberry juice or a placebo during a 6-month crossover intervention. The residents were offered a placebo drink for a 3-month period followed by chokeberry juice for the next 3 months (group A) or vice versa (group B). The juice was characterized by a high content of total phenolics (715 mg gallic acid equivalent, 100 mL(-1)), including B-type procyanidins, anthocyanins, and chlorogenic acids. Daily intake of chokeberry juice was 156 mL per resident in group A (n = 110) and 89 mL per resident in group B (n = 126). Urinary tract infection comprised 55% of all medically treated infections during the study period. The results revealed no immediate reduction in the frequency of UTI or the total use of antibiotics; however, during the subsequent 3-month period of juice administration, a reduction in antibiotics toward UTI was observed in both groups. The incidence of UTI was reduced by 55% in group A and 38% in group B. No changes in other infections or in use of prophylactics were observed.</style></abstract><notes><style face="normal" font="default" size="100%">1879-0739&#xD;Handeland, Maria&#xD;Grude, Nils&#xD;Torp, Torfinn&#xD;Slimestad, Rune&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Nutr Res. 2014 Jun;34(6):518-25. doi: 10.1016/j.nutres.2014.05.005. Epub 2014 Jun 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nutres.2014.05.005</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crane, E. S.</style></author><author><style face="normal" font="default" size="100%">Shum, M.</style></author><author><style face="normal" font="default" size="100%">Chu, D. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E.S. Crane, Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Doctors Office Center, Suite 6100, 90 Bergen Street, Newark, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Case report: Providencia stuartii conjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Ophthalmic Inflammation and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Ophthalmic Inflammation and Infection</style></full-title></periodical><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefepime</style></keyword><keyword><style face="normal" font="default" size="100%">ceftazidime</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">ertapenem</style></keyword><keyword><style face="normal" font="default" size="100%">moxifloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">piperacillin plus tazobactam</style></keyword><keyword><style face="normal" font="default" size="100%">povidone iodine</style></keyword><keyword><style face="normal" font="default" size="100%">timolol</style></keyword><keyword><style face="normal" font="default" size="100%">tobramycin</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">closed angle glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">contact lens</style></keyword><keyword><style face="normal" font="default" size="100%">diabetic retinopathy</style></keyword><keyword><style face="normal" font="default" size="100%">disease duration</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">end stage renal disease</style></keyword><keyword><style face="normal" font="default" size="100%">eye discharge</style></keyword><keyword><style face="normal" font="default" size="100%">eye irritation</style></keyword><keyword><style face="normal" font="default" size="100%">glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">glaucoma drainage implant</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immunocompromised patient</style></keyword><keyword><style face="normal" font="default" size="100%">laser coagulation</style></keyword><keyword><style face="normal" font="default" size="100%">lens implant</style></keyword><keyword><style face="normal" font="default" size="100%">letter</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">neovascular glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">non insulin dependent diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">ocular pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">patient history of cataract surgery</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">proliferative diabetic retinopathy</style></keyword><keyword><style face="normal" font="default" size="100%">Providencia stuartii</style></keyword><keyword><style face="normal" font="default" size="100%">visual impairment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1869-5760</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose: The purpose of this study is to report a case of Providencia stuartii conjunctivitis. Methods: This study is a retrospective chart review of a patient with persistent conjunctivitis. Results: We report the first case of P. stuartii conjunctivitis. Our patient was an elderly man living in a nursing home who was likely immunocompromised from longstanding diabetes mellitus. A conjunctival swab culture was able to identify the infecting bacteria and its antibiotic susceptibility. The conjunctivitis was successfully treated with vancomycin drops and oral sulfamethoxazole and trimethoprim. Discussion: P. stuartii is an increasingly common bacterium found in the urine of immunocompromised nursing home residents with indwelling Foley catheters. While it has rarely been found to cause ocular infections, P. stuartii may be suspected in elderly, immunocompromised nursing home residents.</style></abstract><notes><style face="normal" font="default" size="100%">L611690347&#xD;2016-09-01&#xD;2016-09-13</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L611690347&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s12348-016-0097-9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12348-016-0097-9</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suri, S. S.</style></author><author><style face="normal" font="default" size="100%">Thiruvinvamalai, D. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.S. Suri, Montefiore Medical Center, Bronx, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Central fever: The parkinsonism-hyperpyrexia syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S503-S504</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">amiodarone</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">apixaban</style></keyword><keyword><style face="normal" font="default" size="100%">carbidopa plus levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">creatine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">dantrolene</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">hypertensive factor</style></keyword><keyword><style face="normal" font="default" size="100%">infusion fluid</style></keyword><keyword><style face="normal" font="default" size="100%">lactic acid</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline</style></keyword><keyword><style face="normal" font="default" size="100%">acute kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">airway</style></keyword><keyword><style face="normal" font="default" size="100%">aspiration pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">brain depth stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">consciousness</style></keyword><keyword><style face="normal" font="default" size="100%">cooling</style></keyword><keyword><style face="normal" font="default" size="100%">decubitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hydration</style></keyword><keyword><style face="normal" font="default" size="100%">hyperpyrexia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intubation</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">lung embolism</style></keyword><keyword><style face="normal" font="default" size="100%">medication therapy management</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">muscle tone</style></keyword><keyword><style face="normal" font="default" size="100%">necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic malignant syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">parkinsonism</style></keyword><keyword><style face="normal" font="default" size="100%">resuscitation</style></keyword><keyword><style face="normal" font="default" size="100%">rhabdomyolysis</style></keyword><keyword><style face="normal" font="default" size="100%">rigidity</style></keyword><keyword><style face="normal" font="default" size="100%">sensory system</style></keyword><keyword><style face="normal" font="default" size="100%">withdrawal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">wound</style></keyword><keyword><style face="normal" font="default" size="100%">X ray</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1525-1497</style></isbn><abstract><style face="normal" font="default" size="100%">Learning Objective #1: Recognize that fever can result from causes other than infection, such as central fever. Learning Objective #2: Understand the importance of home medication reconciliation, and fever resulting from not taking medications. CASE: 74 year old woman sent from nursing home with hypotension and lethargy. She could not provide a significant history due to lethargy. Initial vitals: temperature of 99.3F, BP-67/31 mm Hg. She received intravenous fluid resuscitation without appropriate response and now required pressor support. The patient had a large decubitus ulcer with necrosis and was placed on broad spectrum antibiotics. Initial labs: WBC 25,000, creatinine of 1.9 mg/dl (baseline 0.6), lactate 5.5. X-Ray chest normal. The patient had a history of Parkinson&apos;s disease, atrial fibrillation and hypertension. She was on aspirin 81 mg, apixaban, selegiline, carbidopa-levodopa, amiodarone and metoprolol. On day 2, she required intubation for airway protection. Repeat x&apos;ray chest revealed new left lower lobe opacity compatible with aspiration pneumonia. On day 3, she had sustained episodes of high grade fever (107.9 F) while on appropriate antibiotics for her wound and aspiration pneumonia. Neuroleptic malignant syndrome was less likely as she had normal muscle tone and normal creatinine kinase. She was given intravenous levodopa as she had missed 2 days of medication, and was given dantrolene following which she became afebrile within 2 hours. IMPACT/DISCUSSION: Parkinsonism-hyperpyrexia Syndrome (PHS) was first described in 1981, initially termed dopamine withdrawal syndrome. It occurs following the sudden withdrawal of levodopa/carbidopa or reduction in dose. It resembles neuroleptic malignant syndrome with rigidity, pyrexia and altered consciousness. Rare causes include deep brain stimulation. Symptoms usually present 24 hours to 7 days after missed doses. Clinical features include hyperpyrexia, altered sensorium and leukocytosis. Rhabdomyolysis may occur. Complications include acute renal failure, aspiration pneumonia, pulmonary embolism and DIC. Pathophysiology may involve sudden depletion of dopamine. Mortality may be 4% mortality if recognized early, 16% if untreated. Treatment involves intravenous hydration, supplementation of dopamine orally or intravenously and close monitoring. Physical measures such as cooling therapy are helpful. Conclusion: Hyperpyrexia(&gt; 106.7F) should prompt evaluation for central causes of fever. The case illustrates the importance of home medication reconciliation upon hospitalization; not taking medications contributed to fever in this case.</style></abstract><notes><style face="normal" font="default" size="100%">L629003405&#xD;2019-08-27</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L629003405&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/11606.1525-1497</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/11606.1525-1497</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holtzman, J.</style></author><author><style face="normal" font="default" size="100%">Pheley, A. M.</style></author><author><style face="normal" font="default" size="100%">Lurie, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, St. Paul Ramsey Medical Center, MN 55101.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Changes in orders limiting care and the use of less aggressive care in a nursing home population</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">275-9</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Advance Directives</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiopulmonary Resuscitation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Selection</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">*Resuscitation Orders</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Withholding Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Death and Euthanasia</style></keyword><keyword><style face="normal" font="default" size="100%">Empirical Approach</style></keyword><keyword><style face="normal" font="default" size="100%">*Hennepin County (MN)</style></keyword><keyword><style face="normal" font="default" size="100%">*Medicaid</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Patient Relationship</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To examine changes in the aggressiveness of care of the nursing home population and to determine the factors that predict whether care is limited. DESIGN: Retrospective chart review. SETTING: All nursing homes in Hennepin County, Minnesota that care for Medicaid patients. PATIENTS: A random sample of 1605 residents of Hennepin County, MN nursing homes from 1984 and 1988 who were also Medicaid beneficiaries. The sample was stratified by year and by whether the resident died in that year. The residents were sampled disproportionately to allow approximately 400 individuals in each stratum. A total of 1405 charts (87%) was reviewed; the remainder had either been lost or destroyed. MAIN OUTCOME MEASURE: Orders limiting care (do not resuscitate, supportive care only, etc.), care that was less aggressive than care usually given to a person of that age (eg, not using antibiotics for a clear infection or not sending a resident to the hospital for an illness for which someone would &quot;usually&quot; be sent to the hospital), determined implicitly through chart review. RESULTS: The demographic characteristics of the nursing home population did not change between 1984 and 1988, but the population had significantly greater severity of illness in 1988. The percentage of residents with &apos;do not resuscitate&apos; orders (DNR) increased from 12% to 37% (P &lt; 0.0001), and the use of other orders to limit care (do not hospitalize, supportive care only, etc.) increased from 12% to 17% (P &lt; 0.05). The use of CPR did not change between the two years but the percentage of residents who were found to receive less aggressive care through implicit chart review increased from 31% to 40% (P &lt; 0.01). The year the resident was in the nursing home, the severity of illness, functional status, and dementia were significant predictors of DNR status. Factors that predict receipt of less aggressive care were similar except that age was also a significant predictor. CONCLUSIONS: The nursing home population received less aggressive care in 1988 than in 1984. Further, there was a discrepancy between what was ordered and what was delivered in the nursing home in that residents with DNR orders had care limited beyond the withholding of CPR.</style></abstract><notes><style face="normal" font="default" size="100%">Holtzman, J&#xD;Pheley, A M&#xD;Lurie, N&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;J Am Geriatr Soc. 1994 Mar;42(3):275-9. doi: 10.1111/j.1532-5415.1994.tb01751.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.1994.tb01751.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>203</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lo, L. C.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L.-C. Lo, School of Chinese Medicine, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicine for preventing symptomatic UTI among high-risk elderly residing in nursing homes</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Integrative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advances in Integrative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S31</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">adverse event</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial infection</style></keyword><keyword><style face="normal" font="default" size="100%">catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">herbal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Rehmannia</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">single blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2212-9596&#xD;2212-9588</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infection (UTI) is the most common bacterial infection among nursing home residents. Growing concerns about antimicrobial resistance have stimulated interest in nonantibiotic prophylaxis. This study aimed to evaluate Chinese herbal medicine (CHM) for preventing symptomatic UTI among high-risk elderly residing in nursing homes. Methods: This study was a single-blind, randomized, placebo-controlled, intent-to-treat efficacy trial. 11 nursing homes around Changhua Christian Hospital (CCH) participated. 162 nursing home residents, age 65 or older, with high UTI risk (catheterization (&gt;1 m/o), or diabetes mellitus, or at least one UTI in the preceding year) were randomly assigned to take CHM (5 g Tokoro Combination extract plus 5 g Rehmannia and Akebia Formula extract) pouch or placebo pouch, twice per day, for 42 days(i.e., 6 seven-day 2 pouches per participant.) in 85 treatment and 77 control group participants. After 42 days intervention, there was a follow-up period until 6 months. Results: During the intervention period, four patients in the CHM group developed symptomatic UTI, and fifteen patients in the control group. There was a significant difference between the two groups in the incidence of symptomatic UTI (P = 0.004). In the follow-up period of 6 months, the adjusted relative risk of UTI in the CHM group compared with the control group was 0.406 (95% confidence interval 0.192–0.859, P =.018) according to the Cox proportional hazards model. No significant adverse events were observed from treatment with CHM. Conclusion: Treatment with CHM reduced the risk of UTI and UTI-related hospitalization in elderly patients high-risk elderly residing in nursing homes.</style></abstract><notes><style face="normal" font="default" size="100%">L2001763851&#xD;2019-05-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2001763851&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.aimed.2019.03.087</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.aimed.2019.03.087</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahmed, H.</style></author><author><style face="normal" font="default" size="100%">Farewell, D.</style></author><author><style face="normal" font="default" size="100%">Francis, N. A.</style></author><author><style face="normal" font="default" size="100%">Paranjothy, S.</style></author><author><style face="normal" font="default" size="100%">Butler, C. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Population Medicine, Cardiff University School of Medicine, Neuadd Meirionnydd, Heath Park, United Kingdom.&#xD;Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Choice of Empirical Antibiotic Therapy and Adverse Outcomes in Older Adults With Suspected Urinary Tract Infection: Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Open Forum Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Forum Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">ofz039</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">electronic health records</style></keyword><keyword><style face="normal" font="default" size="100%">primary care</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2328-8957 (Print)&#xD;2328-8957</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nitrofurantoin is widely recommended for empirical treatment of urinary tract infection (UTI), but primary care clinicians may prescribe alternative antibiotics to improve prognosis in older, sicker patients. We assessed whether prescribing alternative antibiotics was associated with reduced risk of adverse outcomes in older patients. METHODS: This retrospective cohort study included patients aged ≥65 years empirically treated for a UTI with nitrofurantoin, cefalexin, ciprofloxacin, or co-amoxiclav. We matched patients on their propensity to receive a nitrofurantoin prescription and used mixed-effects logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for reconsultation and represcription (proxy for treatment failure), hospitalization for UTI, sepsis, or acute kidney injury, and death. RESULTS: We identified 42 298 patients aged ≥65 years prescribed empirical nitrofurantoin, cefalexin, ciprofloxacin, or co-amoxiclav for a UTI. Compared with nitrofurantoin, patients prescribed cefalexin, ciprofloxacin, or co-amoxiclav had lower odds of reconsultation and represcription (OR for cefalexin = 0.85, 95% CI = 0.75-0.98; OR for ciprofloxacin = 0.48, 95% CI = 0.38-0.61, OR for co-amoxiclav = 0.77, 95% CI = 0.64-0.93). Patients prescribed cefalexin or ciprofloxacin had greater odds of hospitalization for sepsis (OR for cefalexin = 1.89, 95% CI = 1.03-3.47; OR for ciprofloxacin = 3.21, 95% CI = 1.59-6.50), and patients prescribed cefalexin had greater odds of death (OR = 1.44, 95% CI = 1.12-1.85). CONCLUSIONS: Compared with nitrofurantoin, prescribing of alternative antibiotics for UTI in older people may be associated with lower rates of treatment failure but was not associated with reduced risk of UTI-related hospitalization or death.</style></abstract><notes><style face="normal" font="default" size="100%">2328-8957&#xD;Ahmed, Haroon&#xD;Orcid: 0000-0002-0634-8548&#xD;Farewell, Daniel&#xD;Francis, Nick A&#xD;Paranjothy, Shantini&#xD;Butler, Christopher C&#xD;Journal Article&#xD;Open Forum Infect Dis. 2019 Jan 18;6(3):ofz039. doi: 10.1093/ofid/ofz039. eCollection 2019 Mar.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6411277</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofz039</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckner, F. S.</style></author><author><style face="normal" font="default" size="100%">McCulloch, D. J.</style></author><author><style face="normal" font="default" size="100%">Atluri, V.</style></author><author><style face="normal" font="default" size="100%">Blain, M.</style></author><author><style face="normal" font="default" size="100%">McGuffin, S. A.</style></author><author><style face="normal" font="default" size="100%">Nalla, A. K.</style></author><author><style face="normal" font="default" size="100%">Huang, M. L.</style></author><author><style face="normal" font="default" size="100%">Greninger, A. L.</style></author><author><style face="normal" font="default" size="100%">Jerome, K. R.</style></author><author><style face="normal" font="default" size="100%">Cohen, S. A.</style></author><author><style face="normal" font="default" size="100%">Neme, S.</style></author><author><style face="normal" font="default" size="100%">Green, M. L.</style></author><author><style face="normal" font="default" size="100%">Chu, H. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, H. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F.S. Buckner, University of Washington, Box 358061, 750 Republican St, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical Features and Outcomes of 105 Hospitalized Patients with COVID-19 in Seattle, Washington</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2167-2173</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">nasal cannula</style></keyword><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin receptor antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxychloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxymethylglutaryl coenzyme A reductase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">hypertensive agent</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressive agent</style></keyword><keyword><style face="normal" font="default" size="100%">nonsteroid antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">remdesivir</style></keyword><keyword><style face="normal" font="default" size="100%">acute kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adult respiratory distress syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid therapy</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">epidemic</style></keyword><keyword><style face="normal" font="default" size="100%">extracorporeal oxygenation</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">heart injury</style></keyword><keyword><style face="normal" font="default" size="100%">high flow nasal cannula therapy</style></keyword><keyword><style face="normal" font="default" size="100%">home</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">hypertensive patient</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">coinfection</style></keyword><keyword><style face="normal" font="default" size="100%">mortality rate</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nasal cannula therapy</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">obese patient</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen therapy</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">real time reverse transcription polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">shock</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Washington</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1537-6591&#xD;1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Washington State served as the initial epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the United States. An understanding of the risk factors and clinical outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) may provide guidance for management. Methods: All laboratory-confirmed COVID-19 cases in adults admitted to an academic medical center in Seattle, Washington, between 2 March and 26 March 2020 were included. We evaluated individuals with and without severe disease, defined as admission to the intensive care unit or death. Results: One hundred five COVID-19 patients were hospitalized. Thirty-five percent were admitted from a senior home or skilled nursing facility. The median age was 69 years, and half were women. Three or more comorbidities were present in 55% of patients, with hypertension (59%), obesity (47%), cardiovascular disease (38%), and diabetes (33%) being the most prevalent. Most (63%) had symptoms for ≥5 days prior to admission. Only 39% had fever in the first 24 hours, whereas 41% had hypoxia at admission. Seventy-three percent of patients had lymphopenia. Of 50 samples available for additional testing, no viral coinfections were identified. Severe disease occurred in 49%. Eighteen percent of patients were placed on mechanical ventilation, and the overall mortality rate was 33%. Conclusions: During the early days of the COVID-19 epidemic in Washington State, the disease had its greatest impact on elderly patients with medical comorbidities. We observed high rates of severe disease and mortality in our hospitalized patients.</style></abstract><notes><style face="normal" font="default" size="100%">L2010311841&#xD;2020-12-16&#xD;2021-04-19</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2010311841&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/cid/ciaa632</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aspirin</style></custom1><custom5><style face="normal" font="default" size="100%">32444880</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciaa632</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diggs, N. G.</style></author><author><style face="normal" font="default" size="100%">Surawicz, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. M. Surawicz, Division of Gastroenterology, University of Washington School of Medicine, Harborview Medical Center, 325 9th Avenue, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clostridium difficile infection: Still principally a disease of the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">295-301</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cephalosporin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">quinoline derived antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant therapy</style></keyword><keyword><style face="normal" font="default" size="100%">age distribution</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial overgrowth</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">colon resection</style></keyword><keyword><style face="normal" font="default" size="100%">disease carrier</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug approval</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypoalbuminemia</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">infection sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">intestine flora</style></keyword><keyword><style face="normal" font="default" size="100%">intestine perforation</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent infection</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">Saccharomyces boulardii</style></keyword><keyword><style face="normal" font="default" size="100%">shock</style></keyword><keyword><style face="normal" font="default" size="100%">systemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">toxic megacolon</style></keyword><keyword><style face="normal" font="default" size="100%">treatment indication</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1475-0708&#xD;1744-831X</style></isbn><abstract><style face="normal" font="default" size="100%">Despite recent concerns of Clostridium difficile infection in previously low-risk individuals, it remains a disease that disproportionately affects the elderly. Besides advancing age, persons older than 65 years have more risk factors for C. difficile infection, poorer responses to treatment, more frequent recurrences, and higher morbidity and mortality. With a rapidly aging population, the need for better diagnostic tests and therapies is crucial. Moreover, the severe consequences of infection in the elderly make prevention as important as treatment. © 2010 Future Medicine Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L358850226&#xD;2010-05-28&#xD;2011-01-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L358850226&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2217/thy.10.17</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2217/thy.10.17</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Williams-Gray, C. H.</style></author><author><style face="normal" font="default" size="100%">Foltynie, T.</style></author><author><style face="normal" font="default" size="100%">Lewis, S. J. G.</style></author><author><style face="normal" font="default" size="100%">Barker, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.H. Williams-Gray, Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cognitive deficits and psychosis in Parkinson&apos;s disease: A review of pathophysiology and therapeutic options</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">477-505</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">amantadine</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine receptor stimulating agent</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">modafinil</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">brain depth stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">confusion</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drowsiness</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">edema</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperhidrosis</style></keyword><keyword><style face="normal" font="default" size="100%">hypersalivation</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">leukopenia</style></keyword><keyword><style face="normal" font="default" size="100%">Lewy body</style></keyword><keyword><style face="normal" font="default" size="100%">memory disorder</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">morphology</style></keyword><keyword><style face="normal" font="default" size="100%">muscle cramp</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">orthostatic hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">pharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">polyuria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">sweating</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">vivid dream</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">xerostomia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1172-7047</style></isbn><abstract><style face="normal" font="default" size="100%">Parkinson&apos;s disease is a neurodegenerative disorder causing not only motor dysfunction but also cognitive, psychiatric, autonomic and sensory disturbances. Symptoms of dementia and psychosis are common: longitudinal studies suggest that up to 75% of patients with Parkinson&apos;s disease may eventually develop dementia, and the prevalence of hallucinations ranges from 16-17% in population-based surveys to 30-40% in hospital-based series. These cognitive and behavioural features are important in terms of prognosis, nursing home placement and mortality. The pattern of cognitive deficits in Parkinson&apos;s disease is variable, but often includes executive impairment similar to that seen in patients with frontal lesions, as well as episodic memory impairment, visuospatial dysfunction and impaired verbal fluency. The most common manifestation of psychosis in Parkinson&apos;s disease is visual hallucinations, but delusions, paranoid beliefs, agitation and florid psychosis can also occur. An understanding of the pathophysiology underlying these symptoms is essential to the development of targeted therapeutic strategies. Post-mortem studies suggest an association between Lewy body deposition and dementia in Parkinson&apos;s disease, and indeed Parkinson&apos;s disease and dementia with Lewy bodies may form part of the same disease spectrum. Whether Lewy bodies actually play a causative role in cognitive dysfunction, however, is unknown. Deficits in neurotransmitter systems provide more obvious therapeutic targets and dysfunction of dopaminergic, cholinergic, noradrenergic and serotonergic systems have all been implicated; these may each underlie different features of Parkinson&apos;s disease dementia, perhaps explaining some of the heterogeneity of the syndrome. Psychosis has traditionally been considered as a dopaminergic drug-induced phenomenon, but factors intrinsic to the disease process itself also cause hallucinations and delusions. These factors may include Lewy body deposition in the limbic system, cholinergic deficits and impairments of primary visual processing. Therapeutic intervention for cognitive and behavioural symptoms in Parkinson&apos;s disease currently focuses on two main groups of drugs: cholinesterase inhibitors and atypical antipsychotics. A recent large, randomised, controlled trial suggests that cholinesterase inhibitors can produce a modest improvement in cognitive function, as well as psychotic symptoms, generally without an adverse effect on motor function. Certain atypical antipsychotics allow hallucinations, delusions and behavioural problems to be brought under control with minimal deleterious effects on motor function and cognition, but their safety in elderly patients has recently been called into question. Deep brain stimulation does not appear to be a useful treatment for cognitive and psychiatric dysfunction in patients with Parkinson&apos;s disease. Modafinil improves alertness in Parkinson&apos;s disease and warrants further investigation to establish its effects on cognitive performance. © 2006 Adis Data Information BV. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L43830737&#xD;2006-07-20&#xD;jsessionid=GQpLRz0vf7YjC1Yq66vh3lTbpGnZBzn1k6XLK9cPJzPFJp26KH9m!-818462210!-949856145!8091!-1</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L43830737&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2165/00023210-200620060-00004</style></url><url><style face="normal" font="default" size="100%">http://cnsdrugs.adisonline.com/pt/re/cns/pdfhandler.00023210-200620060-00004.pdf</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">16734499</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00023210-200620060-00004</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De-la-Nogal-Fernandez, M. B.</style></author><author><style face="normal" font="default" size="100%">Soler-Bartrina, P.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Ferreiro, A. V.</style></author><author><style face="normal" font="default" size="100%">Lopez-Virtanen, B. C.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Troche, S. D. C.</style></author><author><style face="normal" font="default" size="100%">Valdueza-Beneitez, J.</style></author><author><style face="normal" font="default" size="100%">Martinez-Fernandez, V.</style></author><author><style face="normal" font="default" size="100%">Noguerol-Cal, M.</style></author><author><style face="normal" font="default" size="100%">Casas-Agudo, H.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Maria, M.</style></author><author><style face="normal" font="default" size="100%">Mitchell, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.B. De-la-Nogal-Fernandez, Hospital El Bierzo, Hospital Pharmacy, Ponferrada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Collaboration with the ophthalmology service in a public residential care home</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Hospital Pharmacy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Hospital Pharmacy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A154-A155</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><keywords><keyword><style face="normal" font="default" size="100%">alpha 1 adrenergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">alpha 2 adrenergic receptor</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">artificial tear</style></keyword><keyword><style face="normal" font="default" size="100%">beta adrenergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">carbonate dehydratase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">dexamethasone plus tobramycin</style></keyword><keyword><style face="normal" font="default" size="100%">diclofenac</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">eye drops</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxyzine</style></keyword><keyword><style face="normal" font="default" size="100%">latanoprost</style></keyword><keyword><style face="normal" font="default" size="100%">lubricating agent</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">scopolamine</style></keyword><keyword><style face="normal" font="default" size="100%">tobramycin</style></keyword><keyword><style face="normal" font="default" size="100%">tolterodine</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">cataract</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">closed angle glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intraocular pressure</style></keyword><keyword><style face="normal" font="default" size="100%">iris disease</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">ophthalmologist</style></keyword><keyword><style face="normal" font="default" size="100%">ophthalmology</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">resident</style></keyword><keyword><style face="normal" font="default" size="100%">residential care</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">suspension</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword><keyword><style face="normal" font="default" size="100%">visual acuity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-9956</style></isbn><abstract><style face="normal" font="default" size="100%">Background Due to the age and clinical situation of the residents in the nursing home, the collaboration with specialists guarantees continuing care. Purpose Describe the collaboration of the hospital ophthalmology department in resolving queries or consultations concerning the ophthalmological medication used by the residents in the public nursing home of the referential area. Material and methods A proposal was presented to the ophthalmology service in December 2017. Two doctors collaborated. A transverse study was carried out in January 2018 with residents using eye-drop treatments and their medical records were revised. Data about the use of medication of the S group (ATC codes) was collected between January 2015 and December 2017. The medications which can interact with ophthalmological diseases, e.g. glaucoma and cataracts, were revised, as were the adverse effects of the eye drops. Recommendations and improvement proposals have been sent. Results In January 2018, of the 194 residents in the care home, 23 were receiving treatment with artificial tears and seven (average age 82.7 years) were being treated, chronically, with eye drops for glaucoma. Of the seven patients, only three were being revised by the specialist. For the four residents without follow-up, the ophthalmologist suggested visiting the residence to measure ocular tension and visual acuity, and later book an outpatient appointment in 2018. Of the seven patients in treatment: one was receiving quadruple therapy (carbonic anhydrase inhibitor, alpha-2adrenergic receptor, beta-blocker and prostaglandin analogues); two received triple therapy; three double therapy; and one received monotherapy (prostaglandinanalogues). A therapeutic of betablockers and prostaglandin analogues was detected. The greatest use of ophthalmological preparations (2015- 2017) corresponded with lubricants, tobramycin-dexamethasone, tobramycin, diclofenac and latanoprost. Regarding the medication which required to be taken into account with ophthalmological diseases, these were: 1. Anticholinergic drugs which can interact in patients with acute angle-closure glaucoma: hyoscine, tolterodine, tryciclic antidepressant, typical antipsychotic, hydroxycine. Topiramate can produce glaucoma. 2. Alpha-1 adrenergic blockers. The discontinuation (or cancellation or suspension) in cataract interventions needs to be evaluated, due to the risk of inter-operative flaccid iris syndrome. Conclusion Collaboration with the ophthalmologists was found to be useful and guarantees continuing care and an efficient use of the resources, as well as the acquisition of knowledge.</style></abstract><notes><style face="normal" font="default" size="100%">L628193226&#xD;2019-06-25</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L628193226&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.332</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/ejhpharm-2019-eahpconf.332</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>196</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, C. C.</style></author><author><style face="normal" font="default" size="100%">Chang, J. C. Y.</style></author><author><style face="normal" font="default" size="100%">Mao, X. W.</style></author><author><style face="normal" font="default" size="100%">Hsu, W. T.</style></author><author><style face="normal" font="default" size="100%">Chen, S. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author><author><style face="normal" font="default" size="100%">How, C. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.-K. How, Department of Emergency Medicine, Taipei Veteran General Hospital, No. 201, Sec. 2, Shipai Rd, 112, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combining Procalcitonin and Rapid Multiplex Respiratory Virus Testing for Antibiotic Stewardship in Older Adult Patients With Severe Acute Respiratory Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-67</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">procalcitonin</style></keyword><keyword><style face="normal" font="default" size="100%">sialidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Coronavirinae</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">Enterovirus</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human parainfluenza virus 3</style></keyword><keyword><style face="normal" font="default" size="100%">Human rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza B virus</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">Metapneumovirus</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">multiplex polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">propensity score</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">protein blood level</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory virus</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">viral respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">virus detection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1538-9375&#xD;1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Virus infection is underevaluated in older adults with severe acute respiratory infections (SARIs). We aimed to evaluate the clinical impact of combining point-of-care molecular viral test and serum procalcitonin (PCT) level for antibiotic stewardship in the emergency department (ED). Design: A prospective twin-center cohort study was conducted between January 2017 and March 2018. Setting and Participants: Older adult patients who presented to the ED with SARIs received a rapid molecular test for 17 respiratory viruses and a PCT test. Measures: To evaluate the clinical impact, we compared the outcomes of SARI patients between the experimental cohort and a propensity score–matched historical cohort. The primary outcome was the proportion of antibiotics discontinuation or de-escalation in the ED. The secondary outcomes included duration of intravenous antibiotics, length of hospital stay, and mortality. Results: A total of 676 patients were included, of which 169 patients were in the experimental group and 507 patients were in the control group. More than one-fourth (27.9%) of the patients in the experimental group tested positive for virus. Compared with controls, the experimental group had a significantly higher proportion of antibiotics discontinuation or de-escalation in the ED (26.0% vs 16.1%, P = .007), neuraminidase inhibitor uses (8.9% vs 0.6%, P &lt; .001), and shorter duration of intravenous antibiotics (10.0 vs 14.5 days, P &lt; .001). Conclusions and Implications: Combining rapid viral surveillance and PCT test is a useful strategy for early detection of potential viral epidemics and antibiotic stewardship. Clustered viral respiratory infections in a nursing home is common. Patients transferred from nursing homes to ED may benefit from this approach.</style></abstract><notes><style face="normal" font="default" size="100%">L2004026060&#xD;2019-12-31&#xD;2020-01-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004026060&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jamda.2019.09.020</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31791902</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2019.09.020</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Odejide, O. O.</style></author><author><style face="normal" font="default" size="100%">Cronin, A. M.</style></author><author><style face="normal" font="default" size="100%">Davidoff, A.</style></author><author><style face="normal" font="default" size="100%">LaCasce, A. S.</style></author><author><style face="normal" font="default" size="100%">Abel, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.M. Cronin, Dana-Farber Cancer Institute, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of treatments for limited stage, non-bulky diffuse large B-cell lymphoma in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title></periodical><volume><style face="normal" font="default" size="100%">122</style></volume><number><style face="normal" font="default" size="100%">21</style></number><keywords><keyword><style face="normal" font="default" size="100%">rituximab</style></keyword><keyword><style face="normal" font="default" size="100%">cyclophosphamide</style></keyword><keyword><style face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style face="normal" font="default" size="100%">prednisone</style></keyword><keyword><style face="normal" font="default" size="100%">vincristine</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">large cell lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">hematology</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">disability</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">propensity score</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">medicare</style></keyword><keyword><style face="normal" font="default" size="100%">proportional hazards model</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">home care</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen therapy</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">overall survival</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">hazard ratio</style></keyword><keyword><style face="normal" font="default" size="100%">radiation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0006-4971</style></isbn><abstract><style face="normal" font="default" size="100%">Background The two most commonly accepted approaches for limited stage, non-bulky diffuse large B-cell lymphoma (DLBCL)-an abbreviated course of chemoimmunotherapy (CIT) with radiation (RT) or an extended course of CIT alone-are largely based on studies performed prior to the widespread use of rituximab. Little is known about the comparative effectiveness of these treatment approaches, especially for the elderly. Methods We conducted a retrospective analysis using the Surveillance Epidemiology and End Results database linked to Medicare claims (SEER-Medicare). Patients &gt; 65 years of age diagnosed with stage I or II DLBCL between January 1, 1999 and December 31, 2009 were eligible. Patients who received RT prior to CIT or 6 to 8 cycles of CIT plus RT were excluded, as we considered these to be surrogates for bulky disease. We characterized the prevalence and covariates of treatment types initiated within 180 days of diagnosis: standard treatment (3 to 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP] plus RT or 6 to 8 cycles of RCHOP), nonstandard treatment (any therapy except standard treatment), and no treatment. We also characterized disability status, defined as “poor” if there were any claims for mobility aids, oxygen therapy supplies, home care services or skilled nursing facility admissions in the 12 months prior to diagnosis. Next, using propensity-score weighted Cox regression models that included available sociodemographic and clinical characteristics (see Table), we compared treatment-free (TFS) and overall survival (OS) for patients who received one of the two standard treatments. TFS was defined as freedom from one of two events: evidence of subsequent treatment (any new claim for chemotherapy occurring &gt; 90 days after the completion of initial therapy) or death. We also assessed the odds of hospitalization and of developing poor disability status in the year following therapy for both standard treatments. Results A total of 4,035 patients were eligible: 24% received standard treatment, 66% received nonstandard treatment and 10% received no treatment. Among the patients with nonstandard treatment, 13% received RT alone, 26% received &lt; 6 cycles of RCHOP and no RT, 9% received 1, 2 or 5 cycles of RCHOP plus RT, and 52% received therapy other than RCHOP. Of those who received standard treatment, 439 received 3 to 4 cycles of RCHOP plus RT and 530 received 6 to 8 cycles of RCHOP. Characteristics of the standard treatment groups are shown below (see Table). In the propensity score analysis, TFS and OS for patients who received abbreviated CIT plus RT compared to an extended course of CIT alone were not significantly different (see Figure 1; propensity score adjusted hazard ratio [HR] for TFS 0.90, 95% CI [0.72, 1.12], p = 0.33; HR for OS 1.18, 95% CI [0.92, 1.53], p = 0.19). In addition, the odds of hospitalization was not different for patients who received abbreviated CIT plus RT compared to extended CIT (OR 0.90, 95% CI [0.70, 1.16], p = 0.43) and neither were the odds of developing poor disability status (OR 1.37, 95% CI [0.97, 1.94], p = 0.10). Conclusion In this large cohort of elderly patients with a potentially curable disease, a significant proportion received non-standard therapy or no treatment at all. For those able to complete standard treatment, there was no difference in TFS or OS comparing 3 to 4 cycles of RCHOP plus RT with 6 to 8 cycles of RCHOP, confirming clinical trial findings from the pre-rituximab era. Moreover, the lack of differences in subsequent hospitalizations or changes in disability status suggests similar tolerability, and thus similar effectiveness of both treatments.</style></abstract><notes><style face="normal" font="default" size="100%">L71265395&#xD;2013-12-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71265395&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://bloodjournal.hematologylibrary.org/content/122/21/1794.abstract?sid=2f010b22-388d-458c-b02d-49ebc59259cf</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Keyser, L. A.</style></author><author><style face="normal" font="default" size="100%">Karl, M.</style></author><author><style face="normal" font="default" size="100%">Nafziger, A. N.</style></author><author><style face="normal" font="default" size="100%">Bertino, J. S., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Colorado School of Pharmacy, Denver, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Intern Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1485-8</style></pages><volume><style face="normal" font="default" size="100%">160</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adverse Drug Reaction Reporting Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amantadine/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System Diseases/*chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Rimantadine/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-9926 (Print)&#xD;0003-9926</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Amantadine hydrochloride and rimantadine hydrochloride are recommended by the Centers for Disease Control and Prevention for prophylaxis of influenza A. While data suggest that rimantadine is better tolerated, there are no data examining the rate of adverse reactions in elderly patients who receive amantadine vs rimantadine. Our objective was to assess the adverse reaction rate in elderly nursing home patients receiving sequential amantadine and rimantadine for influenza A prophylaxis. METHODS: Data were collected in 156 nursing home patients (70% women; mean+/-SD age, 83.7+/-10.1 years) in a single care setting who received sequential therapy with amantadine and rimantadine during the 1997-1998 influenza season. Patients were assessed for central nervous system adverse effects and therapy discontinuation occurring with each agent. RESULTS: Twenty-nine (18.6%) of the 156 patients experienced an adverse effect when receiving amantadine compared with 3 patients (1.9%) when rimantadine was given (P&lt;.01). Drug use was discontinued due to adverse events in 17.3% (n = 27) of the amantadine courses and 1.9% (n=3) of the rimantadine courses (P&lt;.001). Confusion was the most frequently observed adverse event (amantadine, 10.6%; rimantadine, 0.6%; P&lt;.001). Multivariate logistic regression analysis showed that significant risk factors for central nervous system adverse events included male sex (odds ratio, 3.65), reduced calculated creatinine clearance (odds ratio, 1.78), and use of amantadine (odds ratio, 12.73). CONCLUSIONS: Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadine use in this elderly population receiving influenza prophylaxis. In addition, the discontinuation rate of amantadine was significantly higher than that with rimantadine.</style></abstract><notes><style face="normal" font="default" size="100%">Keyser, L A&#xD;Karl, M&#xD;Nafziger, A N&#xD;Bertino, J S Jr&#xD;Comparative Study&#xD;Journal Article&#xD;United States&#xD;Arch Intern Med. 2000 May 22;160(10):1485-8. doi: 10.1001/archinte.160.10.1485.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinte.160.10.1485</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Penders, Y. W. H.</style></author><author><style face="normal" font="default" size="100%">Bopp, M.</style></author><author><style face="normal" font="default" size="100%">Zellweger, U.</style></author><author><style face="normal" font="default" size="100%">Bosshard, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Bopp, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Continuing, Withdrawing, and Withholding Medical Treatment at the End of Life and Associated Characteristics: a Mortality Follow-back Study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">126-132</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">ventilator</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial feeding</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">health care availability</style></keyword><keyword><style face="normal" font="default" size="100%">home care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hydration</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical decision making</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland</style></keyword><keyword><style face="normal" font="default" size="100%">treatment withdrawal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1525-1497&#xD;0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Studies on forgoing treatment often ignore treatments that are continued until death. Objective: To investigate how often specific treatments are withdrawn or withheld before death and to describe the associated patient, physician, and care characteristics. Design: National mortality follow-back study in Switzerland in 2013/2014 using a standardized survey to collect information on the patient’s end of life and demographics on the physician. Participants: A random sample of adults who died non-suddenly without an external cause and who had met the physician completing the survey (N = 3051). Main Measures: Any of nine specific treatments was continued until death, withdrawn, or withheld. Key Results: In 2242 cases (84%), at least one treatment was either continued until death or withheld or withdrawn. The most common treatment was artificial hydration, which was continued in 23%, withdrawn in 4%, and withheld in 22% of all cases. The other eight treatments were withdrawn or withheld in 70–94% of applicable cases. The impact of physician characteristics was limited, but artificial hydration, antibiotics, artificial nutrition, and ventilator therapy were more likely to be withheld at home and in nursing homes than in the hospitals. Conclusions: Large differences exist between care settings in whether treatments are continued, withdrawn, or withheld, indicating the different availability of treatment options or different philosophies of care. While certain patient groups are more likely to have treatment withheld rather than attempted, neither patient nor physician characteristics impact the decision to continue or withdraw treatment.</style></abstract><notes><style face="normal" font="default" size="100%">L2003520759&#xD;2019-11-15&#xD;2020-01-31</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2003520759&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s11606-019-05344-5</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31654360</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11606-019-05344-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Juthani-Mehta, M.</style></author><author><style face="normal" font="default" size="100%">Van Ness, P.</style></author><author><style face="normal" font="default" size="100%">Bianco, L.</style></author><author><style face="normal" font="default" size="100%">Rink, A.</style></author><author><style face="normal" font="default" size="100%">Rubeck, S.</style></author><author><style face="normal" font="default" size="100%">Ginter, S.</style></author><author><style face="normal" font="default" size="100%">Argraves, S.</style></author><author><style face="normal" font="default" size="100%">Charpentier, P.</style></author><author><style face="normal" font="default" size="100%">Acampora, D.</style></author><author><style face="normal" font="default" size="100%">Trentalange, M.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cranberry capsules for reduction of bacteriuria plus pyuria in nursing home women: a randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></full-title></periodical><volume><style face="normal" font="default" size="100%">3</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">*cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">*microcapsule</style></keyword><keyword><style face="normal" font="default" size="100%">*nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">*pyuria</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Death</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human cell</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Stratification</style></keyword><keyword><style face="normal" font="default" size="100%">Urine culture</style></keyword><keyword><style face="normal" font="default" size="100%">Very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Bacteriuria plus pyuria is highly prevalent among female nursing home residents. Cranberry capsules are an understudied, non‐antimicrobial, prevention strategy in this population. The primary aim was to test the efficacy of two oral cranberry capsules once per day, each capsule containing 36 mg of the active ingredient proanthocyanidin (i.e. 72 mg total, equivalent to 20 ounces of cranberry juice), for reduction of bacteriuria plus pyuria among female nursing home residents. Methods. This was a double‐blind, randomized, placebo‐controlled efficacy trial of two cranberry capsules with stratification by nursing home. The primary outcome was the presence of bacteriuria (i.e. at least 105 cfu/mL of one or two organisms on urine culture) plus pyuria (i.e. any number of white blood cells on urinalysis) every two months for a total of six assessments over one year of surveillance. Secondary outcomes were symptomatic UTI, death, hospitalization, multi‐drug antibiotic resistant organisms, antibiotic prescriptions for suspected UTI, and all antimicrobial prescriptions. Results. Twenty‐one CT nursing homes participated in this clinical trial, and 185 women were randomized. The mean age of participants was 86.4 years (± 8.2) and 90.3% were white. Participants had a median of five coexisting conditions and 31.9% had bacteriuria at baseline. Overall adherence to capsule administration was 80.1%. Unadjusted results showed the presence of bacteriuria plus pyuria in 25.5% of the treatment group and 29.5% of the control group. The adjusted GEE model that accounted for missing data and covariates showed no significant difference between the treatment and control groups (29.1% versus 29.0%; OR 1.01, 95% CI 0.61, 1.66; P = 0.984). There were no significant differences in number of symptomatic UTIs, rates of death, hospitalization, multi‐drug resistant gram‐negative rod bacteriuria, antibiotics administered for suspected UTI, or overall antimicrobial utilization. Conclusion. Despite high adherence to capsule administration and a standardized dose of proanthocyanidin, cranberry capsules did not reduce bacteriuria plus pyuria among older nursing home women. Efficacy of cranberry capsules in other patient populations should be investigated.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01933993/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 627805811</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofw172.1059</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>197</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Legare, T.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Ali, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.K. Ali, Orlando VA Medical Center, 13800 Veteran Way, Orlando, FL, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cultivating Communication with Patients</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1156-1157</style></pages><volume><style face="normal" font="default" size="100%">130</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">internal defibrillator</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">lactic acid</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial growth</style></keyword><keyword><style face="normal" font="default" size="100%">blood culture</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">chill</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">conversation</style></keyword><keyword><style face="normal" font="default" size="100%">device infection</style></keyword><keyword><style face="normal" font="default" size="100%">device removal</style></keyword><keyword><style face="normal" font="default" size="100%">doctor patient relationship</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecalis</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">heart right ventricle</style></keyword><keyword><style face="normal" font="default" size="100%">hospice care</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">interpersonal communication</style></keyword><keyword><style face="normal" font="default" size="100%">laser surgery</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">palliative therapy</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">risk benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">television viewing</style></keyword><keyword><style face="normal" font="default" size="100%">transesophageal echocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">tricuspid valve</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1555-7162&#xD;0002-9343</style></isbn><notes><style face="normal" font="default" size="100%">L617758281&#xD;2017-08-17&#xD;2017-11-28</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L617758281&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.amjmed.2017.06.007</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28687267</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.amjmed.2017.06.007</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daiello, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L.A. Daiello, Pharmacotherapy Solutions, 2115 Ivanhoe Road, Orlando, FL 32804, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current issues in dementia pharmacotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S198-S202</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 8</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine</style></keyword><keyword><style face="normal" font="default" size="100%">memantine</style></keyword><keyword><style face="normal" font="default" size="100%">n methyl dextro aspartic acid receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine</style></keyword><keyword><style face="normal" font="default" size="100%">assisted living facility</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">conference paper</style></keyword><keyword><style face="normal" font="default" size="100%">confusion</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">drug approval</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Food and Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">parkinsonism</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">risk benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">symptom</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1088-0224</style></isbn><abstract><style face="normal" font="default" size="100%">Diagnosis and treatment of dementia in nursing homes and assisted living facilities remains challenging since response to treatment and disease course varies for the common degenerative dementias. Four cholinesterase inhibitors and an N-methyl-D-aspartate glutamate receptor antagonist are approved by the US Food and Drug Administration for the treatment of Alzheimer&apos;s disease (AD). Treatment with AD medications is clinically efficacious and associated with reduced caregiver burden. Some controlled trials have reported that cholinesterase inhibitors and memantine ameliorate dementia-related behavioral symptoms. Antipsychotic therapy is often used for intractable behavioral symptoms or psychosis not responding to nonpharmacologic interventions and antidementia medications; however, the risk/benefit ratio for each patient should be critically evaluated, because treatment with atypical antipsychotics has been associated with serious adverse events, including increased risk for death in older adults with dementia.</style></abstract><notes><style face="normal" font="default" size="100%">L351041985&#xD;2008-01-23</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L351041985&amp;from=export</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18095783</style></custom5></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Munoz, F. M.</style></author><author><style face="normal" font="default" size="100%">Galasso, G. J.</style></author><author><style face="normal" font="default" size="100%">Gwaltney Jr, J. M.</style></author><author><style face="normal" font="default" size="100%">Hayden, F. G.</style></author><author><style face="normal" font="default" size="100%">Murphy, B.</style></author><author><style face="normal" font="default" size="100%">Webster, R.</style></author><author><style face="normal" font="default" size="100%">Wright, P.</style></author><author><style face="normal" font="default" size="100%">Couch, R. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F.M. Munoz, Dept. of Molec. Virol./Microbiology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current Research on Influenza and other Respiratory Viruses: II International Symposium</style></title><secondary-title><style face="normal" font="default" size="100%">Antiviral Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antiviral Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">91-124</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">oseltamivir</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory syncytial virus vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">ribavirin</style></keyword><keyword><style face="normal" font="default" size="100%">sialidase</style></keyword><keyword><style face="normal" font="default" size="100%">sialidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">virus RNA</style></keyword><keyword><style face="normal" font="default" size="100%">zanamivir</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral activity</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cross reaction</style></keyword><keyword><style face="normal" font="default" size="100%">drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme immunoassay</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">genetic engineering</style></keyword><keyword><style face="normal" font="default" size="100%">HLA system</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human adenovirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Paramyxoviridae</style></keyword><keyword><style face="normal" font="default" size="100%">patient selection</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">protein structure</style></keyword><keyword><style face="normal" font="default" size="100%">Human respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">virus mutant</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">relenza</style></keyword><keyword><style face="normal" font="default" size="100%">tamiflu</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><isbn><style face="normal" font="default" size="100%">0166-3542</style></isbn><abstract><style face="normal" font="default" size="100%">Viruses are the leading cause of respiratory infections in children and adults and are a major cause of morbidity and mortality worldwide. A variety of clinical syndromes and illness severity&apos;s result from viral respiratory infections reflecting the biologic differences of the various viruses as well as differences in host resistance. Infection with one of the viruses is the principal cause of serious diseases such as sinusitis, otitis media, bronchiolitis, pneumonia and exacerbations of chronic pulmonary conditions such as asthma. Young children, older adults, and those with underlying chronic disease are at particular risk for significant morbidity with infection. Patients with underlying immunodeficiencies, such as those infected with HIV and recipients of organ transplants, may also experience serious illness. Moreover, these persons have a reduced ability to respond adequately to vaccine. The epidemiology of influenza virus is constantly undergoing change. New influenza A (H3N2) strains with the potential to infect humans were discovered in 1998 to be widespread in swine in the US. Also, for the first time, an influenza B virus was detected in harbor seals in Europe. The human outbreak of influenza A (H5N1) virus that arose from infected birds in Hong Kong in 1997 was a clear example of a potential pandemic threat. In 1999, another new influenza A virus (H9N2) emerged in China where it caused disease in chickens; and two children in Hong Kong were discovered to be infected and ill with this virus. In addition to underscoring the need for improving and enhancing global viral surveillance, recent events have indicated a need for better training of personnel, availability of adequate laboratory facilities, and development of pandemic preparedness plans in different regions of the world. In this regard, the WHO has the roles of maintaining a global influenza surveillance network during interpandemic periods and of aiding countries in pandemic preparedness. Providing effective vaccination remains the principal intervention in a pandemic plan. However, the availability of newer antiviral agents effective against both influenza A and B (in addition to the currently available antivirals), offers the possibility of treatment of selected cases and use of short-term prophylaxis during a pandemic, particularly in regions of the world where time for development and use of vaccines will not be feasible. The possibility of treating influenza has increased the demand for virologic diagnosis. Although viral culture remains essential for diagnostic and epidemiologic purposes, rapid diagnostic tests based on antigen detection that are specific and relatively sensitive for identifying both influenza A and B viruses are now available for use in the clinical setting. Genome amplification, by PCR and RT-PCR, has the greatest sensitivity but is more technically demanding than the widely available immunofluorescence and ELISA assays. A new method of diagnosis currently showing promise is TaqMan® PCR, a real time, quantitative PCR technique that offers rapid results, good sensitivity, and is less prone to contamination. Preliminary studies have shown promising results for the determination of viral loads in cystic fibrosis patients. Genome amplification methods are also useful for the study of the epidemiology of respiratory viruses. Fragments of RNA recovered from victims of the 1918 influenza pandemic with the use of RT-PCR have shown the presence of avian-like HA and NA sequences but a clear mammalian origin phylogenetically, suggesting that the 1918 influenza virus was an avian H1N1 virus that underwent mammalian adaptation. Although reported by others, pantropism and neurotropism were not confirmed by RT PCR assays of other organs at the Armed Forces Institute of Pathology in the USA. Respiratory viruses play a significant role in the pathogenesis, clinical course, and outcome of upper respiratory tract illnesses such as sinusitis and otitis media. Respiratory syncytial virus, rhinovirus, parainfluenza viruses 1, 2, and 3, and ad novirus are important causes of these illnesses in children and adults during the winter months. Adenoviruses are also notable as an important cause of disease that can affect many different organ systems. Viral replication in the respiratory tract results in the stimulation of multiple pathways for inflammation including cytokines and inflammatory mediators that lead to mucocilliary damage, dysfunction, and clinical symptoms. The use of combination anti-inflammatory and antiviral (interferon) therapy was of benefit in treatment of rhinovirus common colds. No benefit has been demonstrated with the use of steroids in viral respiratory illnesses, other than for croup in children. Pleconaril, a compound inhibiting receptor binding of picornaviruses, was beneficial in the treatment of acute rhinovirus infections in adults and adolescents and in experimental respiratory Coxsackie virus A21 infection in volunteers. AG7088, a 3C preotease inhibitor, was shown to reduce infections or severity of illness when administered before or early in the course of infection. The most significant breakthrough an antiviral treatment this past year was approval of the neuraminidase inhibitors (NI) zanamavir and oseltamivir. Both agents were approved in 1999 in the USA and many European and South American countries for the treatment of influenza A and B infections. They reduce the severity and duration of symptoms of influenza when administered within the first 2 days after illness onset. They are safe and generally well tolerated and the development of resistance is infrequent. Resistant viruses occur late in about 1% of infected subjects by either a mutation in the binding site of NA or a mutation in the HA that reduces binding affinity and the need for NA activity. Alternatively, resistance may be seen where the balance of HA binding affinity and NA eluting activity of viruses without mutations is such that sufficient NA activity remains in the presence of drug. So far, no clinical deterioration has been associated with the development of resistance, and resistant viruses appear to be less virulent in animal and models. The two potential pandemic viruses that have recently emerged, influenza A H5N1 and H9N2 are inhibited in vitro, and in animals by the NI drugs. In clinical studies, oseltamivir was shown to prevent the spread of influenza A and B to household contacts when administered after exposure to an ill family member. It also effectively prevented clinical influenza in vaccinated frail elderly populations when administered as long-term prophylaxis in the nursing home setting and, in doing so, provided additional protection to that provided by vaccination alone. Approval of these agents for prophylactic use against influenza A and B infections should occur soon. Newer but similar compounds are also under development; RWJ-270201 is a novel NI with a unique cyclopentane ring structure that shows potent activity against influenza A and B in vitro and in animal models. It has been well tolerated and shown to have an antiviral effect in human challenge studies. The most important intervention for the control of viral infections and their complications is prevention through immunization. Significant advances have occurred recently in the development and use of antiviral vaccines. The live attenuated cold-adapted influenza vaccine is now updated annually to match the FDA recommendations for the trivalent inactivated vaccine and is produced consistently to a viral titer that, when administered intranasally to children or adults, has resulted in immunity to the vaccine strain and to drift variants. An ongoing study seeks to determine whether universal immunization of young children with the cold-adapted vaccine will significantly reduce influenza in a community. Methods to improve on the currently available inactivated influenza vaccine in high risk groups such as the elderly, and for use before exposure to a pandemic virus are under investigation. The immunogenicity of the currently available trivalent inactivated vaccine was enhanced by supp ementation with recombinant NA (rNA) in animal models and in early studies of human experimental infection. The supplemented vaccine was safe, immunogenic, and followed by decreased symptomatology and viral shedding. An MF-59 adjuvanted influenza A (H5N3) vaccine was more immunogenic in naive volunteers than standard aqueous vaccine. Vaccines to augment CTL memory T cells to enhance protection against pandemic and interpandemic influenza virus infection, and production of attenuated vaccine strains via reverse genetics to modulate interferon sensitivity are other new vaccine options. Application of reverse genetics to production of vaccines for RSV and PIV is permitting genotypic and phenotypic manipulations with relative ease. Early results have provided promising new candidate vaccines. Preliminary results with cold adapted-temperature sensitive RSV and PIV live attenuated vaccines in young children indicate these vaccines are safe and immunogenic in this population. As an alternative, a novel recombinant RSV subunit vaccine, BBG2Na, was shown to be immunogenic and protective in mice, and to be safe and immunogenic in RSV seropositive healthy adults. Parallel studies to define the immune correlates of RSV disease and the factors contributing to the severity of disease in younger infants are ongoing. The identification of T-cell epitopes in RSV and clarification of their role in immunopathogenesis and as vaccine targets is an important effort.</style></abstract><notes><style face="normal" font="default" size="100%">L30348665&#xD;2000-07-02</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L30348665&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0166-3542(00)00092-9</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">relenza(Glaxo)&#xD;tamiflu(Hoffmann La Roche)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo&#xD;Hoffmann La Roche</style></custom2><custom5><style face="normal" font="default" size="100%">10854663</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0166-3542(00)00092-9</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Belisle, S. E.</style></author><author><style face="normal" font="default" size="100%">Leka, L. S.</style></author><author><style face="normal" font="default" size="100%">Dallal, G. E.</style></author><author><style face="normal" font="default" size="100%">Jacques, P. F.</style></author><author><style face="normal" font="default" size="100%">Delgado-Lista, J.</style></author><author><style face="normal" font="default" size="100%">Ordovas, J. M.</style></author><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. N. Meydani, Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, MA 02111, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cytokine response to vitamin E supplementation is dependent on pre-supplementation cytokine levels</style></title><secondary-title><style face="normal" font="default" size="100%">BioFactors</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BioFactors</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-200</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 1beta</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 6</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine production</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0951-6433</style></isbn><abstract><style face="normal" font="default" size="100%">Vitamin E supplementation has been suggested to improve immune response in the aged in part by altering cytokine production. However, there is not a consensus regarding the effect of supplemental vitamin E on cytokine production in humans. There is evidence that baseline immune health can affect immune response to supplemental vitamin E in the elderly. Thus, the effect of vitamin E on cytokines may depend on their pre-supplementation cytokine response. Using data from a vitamin E intervention in elderly nursing home residents, we examined if the effect of vitamin E on ex vivo cytokine production of IL-1β, IL-6, TNF-α, and IFN-γ depended on baseline cytokine production. We observed that the effect of vitamin E supplementation on cytokine production depended on pre-supplementation production of the respective cytokines. The interactions between vitamin E and baseline cytokine production were not explained by covariates known to impact cytokine production. Our results offer evidence that baseline cytokine production should be considered in studies that examine the effect of supplemental vitamin E on immune and inflammatory responses. Our results could have implications in designing clinical trials to determine the impact of vitamin E on conditions in which cytokines are implicated such as infections and atherosclerotic disease. © 2008 - IUBMB/IOS Press and the authors. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L354958311&#xD;2009-08-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354958311&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/biof.5520330305</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">19478423</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/biof.5520330305</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rakowsky, S. T.</style></author><author><style face="normal" font="default" size="100%">Hale, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.T. Rakowsky, Beth Israel Deaconess Medical Center, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A deadly complication of constipation-stercoral colitis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S403-S404</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">abdomen</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">cancer size</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">chronic constipation</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">colitis</style></keyword><keyword><style face="normal" font="default" size="100%">colon resection</style></keyword><keyword><style face="normal" font="default" size="100%">comfort</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">defecation</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">edema</style></keyword><keyword><style face="normal" font="default" size="100%">endoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">family study</style></keyword><keyword><style face="normal" font="default" size="100%">feces</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gender</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">lavage</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mental health</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality risk</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal dryness</style></keyword><keyword><style face="normal" font="default" size="100%">necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">palpation</style></keyword><keyword><style face="normal" font="default" size="100%">perforation</style></keyword><keyword><style face="normal" font="default" size="100%">physiology</style></keyword><keyword><style face="normal" font="default" size="100%">primary medical care</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE #1: Stercoral colitis is an important complication of chronic constipation and can result in significant morbidity and mortality LEARNING OBJECTIVE #2: Constipation and stercoral colitis should be considered in elderly patients with altered mental status or sepsis CASE: A 95 year-old woman residing in a nursing home presented with altered mental status and fevers. Per report, she had not passed a bowel movement for the preceding three days. Her physical exam was remarkable in that she was lethargic, had dry mucous membranes, and tenderness to palpation across her lower abdomen with a firm mass appreciated. She was started on intravenous fluids and broad-spectrum antibiotics. Extensive infectious work-up was negative. Due to concern for malignancy given the firm mass in her abdomen, a computed tomography scan was obtained. This revealed a massively distended rectosigmoid colon with stool impaction and perirectal stranding, consistent with severe stercoral colitis. Manual disimpaction and a bowel regimen were attempted. However, despite these interventions, she had ongoing septic physiology. Surgery was consulted and felt a hemi-colectomy may be needed given the degree of ischemia. After extensive discussions, the family opted for non-invasive management and the patient&apos;s care was transitioned to comfort focused measures. IMPACT: Constipation is a common occurrence among adults older than 50 years and is commonly encountered in both primary care and the inpatient setting. Risk factors for developing constipation in this population include female gender, increasing age, living in institutionalized setting, frequent hospitalizations, and depression. Constipation can manifest as delirium in the elderly patient and can lead to severe complications. DISCUSSION: Stercoral colitis is an important complication of constipation and can be life threatening. Stercoral colitis occurs when a large amount of stool becomes impacted in the colon, causing distention of the colonic lumen and resultant necrosis. Diagnosis can be made with computed tomography scan showing large fecal load associated with bowel wall edema or pericolonic fat stranding. Initial management includes manual disimpaction and bowel cleansing. In addition, endoscopy has a unique role to allow for direct visualization, breakdown, and lavage to encourage passage of stool. However, stercoral colitis is associated with a significant risk of mortality given the subsequent development of sepsis secondary to necrosis, ulceration or perforation. In these more severe cases, surgical intervention, such as bowel resection, is required to prevent serious consequences. Our patient presented with sepsis and alteredmental status that was found to be from stercoral colitis, related to chronic constipation. Ultimately, this was a terminal condition without surgical intervention, which was not within our patient&apos;s goals of care. This case highlights that constipation, if left untreated, can result in significant morbidity and mortality.</style></abstract><notes><style face="normal" font="default" size="100%">L615581133&#xD;2017-04-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L615581133&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahmed, A.</style></author><author><style face="normal" font="default" size="100%">Jones, L.</style></author><author><style face="normal" font="default" size="100%">Hays, C. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Ahmed, Division of Gerontology, Geriatrics and Palliative Care, Department of Medicine, School of Medicine, Birmingham, AL, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">DEFEAT Heart Failure: Assessment and Management of Heart Failure in Nursing Homes Made Easy</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">383-389</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">aldosterone antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin receptor antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">beta adrenergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">bronchodilating agent</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">carvedilol</style></keyword><keyword><style face="normal" font="default" size="100%">digitalis</style></keyword><keyword><style face="normal" font="default" size="100%">digoxin</style></keyword><keyword><style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">felodipine</style></keyword><keyword><style face="normal" font="default" size="100%">furosemide</style></keyword><keyword><style face="normal" font="default" size="100%">insulin</style></keyword><keyword><style face="normal" font="default" size="100%">lisinopril</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol succinate</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol tartrate</style></keyword><keyword><style face="normal" font="default" size="100%">nebivolol</style></keyword><keyword><style face="normal" font="default" size="100%">polystyrenesulfonate sodium</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">potassium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">spironolactone</style></keyword><keyword><style face="normal" font="default" size="100%">torasemide</style></keyword><keyword><style face="normal" font="default" size="100%">verapamil</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure measurement</style></keyword><keyword><style face="normal" font="default" size="100%">blood volume</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular risk</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug response</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte disturbance</style></keyword><keyword><style face="normal" font="default" size="100%">emphysema</style></keyword><keyword><style face="normal" font="default" size="100%">fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">heart left ventricle ejection fraction</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperkalemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">hypervolemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypokalemia</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">lung congestion</style></keyword><keyword><style face="normal" font="default" size="100%">morning dosage</style></keyword><keyword><style face="normal" font="default" size="100%">nursing care</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sodium restriction</style></keyword><keyword><style face="normal" font="default" size="100%">symptom</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">1538-9375&#xD;1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">Heart failure (HF) in older adults presents challenges that are different in many ways than those for younger adults. Diagnosis of HF in older adults can be delayed due to attributing early symptoms to normal changes of aging or, in the setting of a normal ejection fraction, failing to appreciate diastolic heart failure. Moreover, treatment of HF in the elderly is often complicated by comorbidities and polypharmacy. The long-term care setting can present even more challenges, yet can be made easy by following a simple mnemonic DEFEAT-HF. After making a clinical Diagnosis and determining the Etiology, Fluid volume must be assessed to achieve euvolemia, and Ejection frAction must be determined to guide Therapy. © 2008 American Medical Directors Association.</style></abstract><notes><style face="normal" font="default" size="100%">L50166119&#xD;2008-07-04</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L50166119&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jamda.2008.03.004</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18585640</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2008.03.004</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Durand, M.</style></author><author><style face="normal" font="default" size="100%">Forestier, E.</style></author><author><style face="normal" font="default" size="100%">Gras Aygon, C.</style></author><author><style face="normal" font="default" size="100%">Sirvain, S.</style></author><author><style face="normal" font="default" size="100%">de Wazières, B.</style></author><author><style face="normal" font="default" size="100%">Bernard, L.</style></author><author><style face="normal" font="default" size="100%">Paccalin, M.</style></author><author><style face="normal" font="default" size="100%">Legout, L.</style></author><author><style face="normal" font="default" size="100%">Roubaud Baudron, C.</style></author><author><style face="normal" font="default" size="100%">Gavazzi, G.</style></author><author><style face="normal" font="default" size="100%">Fraisse, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Court séjour gériatrique, CH Alès Cévennes, Avenue du Docteur Jean Goubert, 30100 Alès, France.&#xD;Service de maladies infectieuses, Centre Hospitalier Métropole Savoie, 73000 Chambéry, France.&#xD;Département de médecine générale, UFR médecine Montpellier-Nîmes, 34000 Montpellier, France.&#xD;Service de médecine gériatrique, CHU de Nîmes, Place du Pr R Debré, 30000 Nîmes, France.&#xD;Service de Maladies Infectieuses, CHU Hôpitaux de Tours, 37000 Tours, France.&#xD;Pôle de Gériatrie, CHU La Milétrie, 86000 Poitiers, France.&#xD;Service des maladies infectieuses et tropicales, CH Alpes Léman, Contamine sur Arve, France.&#xD;Pôle de Gérontologie Clinique, Université de Bordeaux, CHU Hôpitaux de Bordeaux, 33000 Bordeaux, France.&#xD;Service Universitaire de Gériatrie Clinique, CHU de Grenoble, 38000 Grenoble, France.&#xD;Court séjour gériatrique, CH Alès Cévennes, Avenue du Docteur Jean Goubert, 30100 Alès, France. Electronic address: dr.fraisse@ch-ales.fr.&#xD;Court séjour gériatrique, CH Alès Cévennes, Avenue du Docteur Jean Goubert, 30100 Alès, France; Service de maladies infectieuses, Centre Hospitalier Métropole Savoie, 73000 Chambéry, France; Service de médecine gériatrique, CHU de Nîmes, Place du Pr R Debré, 30000 Nîmes, France; Service de Maladies Infectieuses, CHU Hôpitaux de Tours, 37000 Tours, France; Pôle de Gériatrie, CHU La Milétrie, 86000 Poitiers, France; Service des maladies infectieuses et tropicales, CH Alpes Léman, Contamine sur Arve, France; Pôle de Gérontologie Clinique, Université de Bordeaux, CHU Hôpitaux de Bordeaux, 33000 Bordeaux, France; Service Universitaire de Gériatrie Clinique, CHU de Grenoble, 38000 Grenoble, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determinants of doctors&apos; antibiotic prescriptions for patients over 75 years old in the terminal stage of palliative care</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Dis Now</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Dis Now</style></full-title></periodical><pages><style face="normal" font="default" size="100%">340-345</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Prescriptions/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">France/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Palliative Care/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Patterns, Physicians&apos;/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Terminal Care/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Aged/Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-bacterial agent</style></keyword><keyword><style face="normal" font="default" size="100%">Palliative care-Terminal care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2666-9919</style></isbn><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Notwithstanding high prevalence of presumably bacterial infections in elderly persons (EP) in palliative care (PC), there exists no recommendation on the role of antibiotic therapy (ABP) in this type of situation. OBJECTIVE: To describe the determinants of antibiotic prescription by general practitioners (GP) and by doctors practicing in institutions (DPI) for patients&gt;75 years, in end-of-life situations in PC. METHOD: Descriptive investigation by anonymous self-administered questionnaire disseminated in France by e-mail. RESULTS: A total of 301 questionnaires analyzed: 113 GP, 188 DPIs. The latter were mainly geriatricians (69, 36.6%) and infectologists/internists (41, 21.8%). Sixty-three (55,75%) GPs and 144 (78.7%) DPIs stated that they had prescribed antibiotics. Practice in &quot;EHPAD&quot; retirement homes or intensive care was often associated with non-prescription of antibiotics. Age, PC training and number of patients monitored bore no influence. Family involvement in decision-making was more frequent for GPs than for DPIs. The main purpose of antibiotic therapy was to relieve different symptoms (fever, respiratory congestion, functional urinary signs). Most of the doctors (81%) had previously encountered complications (allergy, adverse effect), which represented the main causes of treatment discontinuation. CONCLUSION: Antibiotic use in end-of-life EPs in PC seems frequent. In accordance with the principle of beneficence, its goal of often symptom-related; that said, in the absence of scientific data, antibiotic prescription in end-of-life situations should be individualized in view of observing the other ethical caregiving principles (beneficence, non-maleficence, justice, patient autonomy) and re-evaluated daily.</style></abstract><notes><style face="normal" font="default" size="100%">2666-9919&#xD;Durand, M&#xD;Forestier, E&#xD;Gras Aygon, C&#xD;Sirvain, S&#xD;de Wazières, B&#xD;Bernard, L&#xD;Paccalin, M&#xD;Legout, L&#xD;Roubaud Baudron, C&#xD;Gavazzi, G&#xD;Fraisse, T&#xD;L’intergroupe GInGer (SPILF SFGG)&#xD;Journal Article&#xD;France&#xD;Infect Dis Now. 2021 Jun;51(4):340-345. doi: 10.1016/j.medmal.2020.10.013. Epub 2020 Oct 16.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.medmal.2020.10.013</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Durand, M.</style></author><author><style face="normal" font="default" size="100%">Forestier, E.</style></author><author><style face="normal" font="default" size="100%">Gras Aygon, C.</style></author><author><style face="normal" font="default" size="100%">Sirvain, S.</style></author><author><style face="normal" font="default" size="100%">de Wazières, B.</style></author><author><style face="normal" font="default" size="100%">Bernard, L.</style></author><author><style face="normal" font="default" size="100%">Paccalin, M.</style></author><author><style face="normal" font="default" size="100%">Legout, L.</style></author><author><style face="normal" font="default" size="100%">Roubaud Baudron, C.</style></author><author><style face="normal" font="default" size="100%">Gavazzi, G.</style></author><author><style face="normal" font="default" size="100%">Fraisse, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Fraisse, Court séjour gériatrique, CH Alès Cévennes, Avenue du Docteur Jean Goubert, Alès, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determinants of doctors’ antibiotic prescriptions for patients over 75 years old in the terminal stage of palliative care</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">beneficence</style></keyword><keyword><style face="normal" font="default" size="100%">care behavior</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">decision making</style></keyword><keyword><style face="normal" font="default" size="100%">e-mail</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">France</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrician</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">internist</style></keyword><keyword><style face="normal" font="default" size="100%">justice</style></keyword><keyword><style face="normal" font="default" size="100%">palliative therapy</style></keyword><keyword><style face="normal" font="default" size="100%">patient autonomy</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">retirement</style></keyword><keyword><style face="normal" font="default" size="100%">terminal care</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1769-6690&#xD;0399-077X</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Notwithstanding high prevalence of presumably bacterial infections in elderly persons (EP) in palliative care (PC), there exists no recommendation on the role of antibiotic therapy (ABP) in this type of situation. Objective: To describe the determinants of antibiotic prescription by general practitioners (GP) and by doctors practicing in institutions (DPI) for patients &gt; 75 years, in end-of-life situations in PC. Method: Descriptive investigation by anonymous self-administered questionnaire disseminated in France by e-mail. Results: A total of 301 questionnaires analyzed: 113 GP, 188 DPIs. The latter were mainly geriatricians (69, 36.6%) and infectologists/internists (41, 21.8%). Sixty-three (55,75%) GPs and 144 (78.7%) DPIs stated that they had prescribed antibiotics. Practice in “EHPAD” retirement homes or intensive care was often associated with non-prescription of antibiotics. Age, PC training and number of patients monitored bore no influence. Family involvement in decision-making was more frequent for GPs than for DPIs. The main purpose of antibiotic therapy was to relieve different symptoms (fever, respiratory congestion, functional urinary signs). Most of the doctors (81%) had previously encountered complications (allergy, adverse effect), which represented the main causes of treatment discontinuation. Conclusion: Antibiotic use in end-of-life EPs in PC seems frequent. In accordance with the principle of beneficence, its goal of often symptom-related; that said, in the absence of scientific data, antibiotic prescription in end-of-life situations should be individualized in view of observing the other ethical caregiving principles (beneficence, non-maleficence, justice, patient autonomy) and re-evaluated daily.</style></abstract><notes><style face="normal" font="default" size="100%">L2008466506&#xD;2021-03-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2008466506&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.medmal.2020.10.013</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">33075403</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.medmal.2020.10.013</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taylor Iii, J. A.</style></author><author><style face="normal" font="default" size="100%">Kuchel, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.A. Kuchel, UConn Center on Aging, University of Connecticut Health Center, MC-5215, 263 Farmington Avenue, Farmington, CT 06030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1920-1932</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">midomafetamine</style></keyword><keyword><style face="normal" font="default" size="100%">antihistaminic agent</style></keyword><keyword><style face="normal" font="default" size="100%">atropine</style></keyword><keyword><style face="normal" font="default" size="100%">bethanechol</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">fluoxetine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypericum perforatum extract</style></keyword><keyword><style face="normal" font="default" size="100%">methamphetamine</style></keyword><keyword><style face="normal" font="default" size="100%">nonsteroid antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">oxybutynin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">propantheline bromide</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">spasmolytic agent</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">bladder dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">bladder neck stenosis</style></keyword><keyword><style face="normal" font="default" size="100%">catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">detrusor muscle</style></keyword><keyword><style face="normal" font="default" size="100%">hypotonic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic accuracy</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">impaired bladder emptying</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">muscle biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">muscle contractility</style></keyword><keyword><style face="normal" font="default" size="100%">myofibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">nerve fiber degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">non invasive procedure</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">postvoid residual urine volume</style></keyword><keyword><style face="normal" font="default" size="100%">prostate hypertrophy</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urine incontinence</style></keyword><keyword><style face="normal" font="default" size="100%">urine retention</style></keyword><keyword><style face="normal" font="default" size="100%">urodynamics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614&#xD;1532-5415</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary incontinence and other lower urinary tract symptoms exert a major influence on the health and independence of frail older people. Detrusor underactivity (DU) is defined as a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span. DU may influence the clinical presentation and impede the therapy of disorders as common and as disparate as detrusor overactivity, urinary retention, and benign prostatic hyperplasia. Urodynamically, nearly two-thirds of incontinent nursing home residents exhibit DU. The clinical diagnosis of DU when present alone or in association with other bladder conditions such as detrusor overactivity (detrusor hyperactivity with impaired contractility (DHIC)) is challenging, because symptoms lack adequate precision. A catheterized and increasingly noninvasive ultrasound-based postvoid residual assessment allows a bedside diagnosis of retention and may suggest the presence of DU in individuals (mostly women) with a low likelihood of bladder outlet obstruction (BOO). Nevertheless, it cannot differentiate primary DU from retention secondary to BOO. The management of individuals with DHIC remains unsatisfactory, because antispasmodic anticholinergic medications may worsen retention, whereas bethanechol does not improve bladder emptying. Human detrusor biopsies reveal axonal degeneration, muscle loss, and fibrosis in DU. Animal studies suggest that multiple risk factors, including retention itself, lack of estrogen, infection, inflammation, and aging, may contribute to DU. Priority areas for future research include efforts to facilitate clinical nonurodynamic diagnosis of probable DU plus translational research designed to address the pathogenesis of this complex multifactorial geriatric syndrome. © 2006, Copyright the Authors.</style></abstract><notes><style face="normal" font="default" size="100%">L44915838&#xD;2007-01-25</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L44915838&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1532-5415.2006.00917.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17198500</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2006.00917.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>194</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuttner, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Discontinuation of Antipsychotic Medication in Two Nursing Home Patients with Diagnosis of Schizophrenia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">B5</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">lipid</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">sertraline</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">aphasia</style></keyword><keyword><style face="normal" font="default" size="100%">aspiration pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">blood glucose monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">brain injury</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">community living</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">conversation</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gait</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis C</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperlipidemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">percutaneous endoscopic gastrostomy tube</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">rigidity</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">subdural hematoma</style></keyword><keyword><style face="normal" font="default" size="100%">substance abuse</style></keyword><keyword><style face="normal" font="default" size="100%">veteran</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1538-9375&#xD;1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Antipsychotic medications are a vital part of controlling psychosis in schizophrenic patients. However, when those patients live in nursing facilities, we are obligated by CMS to undertake gradual dose reductions of antipsychotic medication if possible. Sometimes, these efforts are successful and sometimes they fail. Antipsychotic medications have many side effects, including sedation, diabetes, hyperlipidemia, weight gain, motor rigidity, impaired gait, and falls. Monitoring of blood glucose, lipids, and extrapyramidal symptoms is mandatory. As patients with schizophrenia age, many develop cognitive impairment as well as other comorbidities. These factors may affect how antipsychotic medications are metabolized and whether side effects become problematic and burdensome. Case Description: Two veterans residing at the Chillicothe VA Community Living Center with a history of schizophrenia were successfully tapered off of their antipsychotic medication without any recurrence of delusions or hallucinations. Patient A is an older veteran with a history of schizophrenia, hypertension, chronic kidney disease stage III, cognitive impairment, hepatitis C related to a distant history of IV drug use, falls with prior subdural hematoma, and dysphagia. He was on a low dose of Risperidone but was very subdued and rarely made any conversation. After taper of his antipsychotic medication, he became much more alert and verbal. He stated that he was depressed and missed his sister. He was started on sertraline and has done very well. Family noted major improvement in his ability to interact with them. Patient 2 was a 79-year-old veteran with a history of alcoholism, schizophrenia, stroke resulting in aphasia, dysphagia, and PEG tube placement. He was on aripiprazole, which was successfully tapered off without any agitation or recurrent psychosis. He passed away from sepsis several months later related to ongoing aspiration pneumonitis. Discussion: Carefully selected and monitored geriatric patients with a history of schizophrenia may be able to taper off of antipsychotic medication successfully. Factors that may have impacted our patients&apos; cases were prior substance abuse, which could have lead to a mistaken diagnosis of schizophrenia. Another possibility is that the brain injury that both suffered could have altered their cognition and psychiatric state so that psychosis was no longer present. More studies are needed to see which patients with a distant history of schizophrenia are candidates for discontinuation and deprescribing of their antipsychotic. Disclosures: All authors have stated there are no financial disclosures to be made that are pertinent to this abstract.</style></abstract><notes><style face="normal" font="default" size="100%">L2005062431&#xD;2020-03-04</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005062431&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jamda.2020.01.023</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2020.01.023</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abrutyn, E.</style></author><author><style face="normal" font="default" size="100%">Mossey, J.</style></author><author><style face="normal" font="default" size="100%">Berlin, J. A.</style></author><author><style face="normal" font="default" size="100%">Boscia, J.</style></author><author><style face="normal" font="default" size="100%">Levison, M.</style></author><author><style face="normal" font="default" size="100%">Pitsakis, P.</style></author><author><style face="normal" font="default" size="100%">Kaye, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical College of Pennsylvania, Philadelphia Department of Veterans Affairs Medical Center.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women?</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Intern Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">827-33</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-4819 (Print)&#xD;0003-4819</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine whether asymptomatic bacteriuria in elderly ambulatory women is a marker of increased mortality and, if so, whether it is because of an association with other determinants of mortality or because asymptomatic bacteriuria is itself an independent cause, the removal of which might improve longevity. DESIGN: A cohort study and a controlled clinical trial of the effect of antimicrobial treatment. SETTING: A geriatric center and 21 continuing care retirement communities. PARTICIPANTS: Women without urinary tract catheters. MEASUREMENTS: Urine cultures every 6 months (the same organism at 10(5) colony-forming units or more per mL on two midstream urine specimens defined asymptomatic bacteriuria), comorbidity, and mortality. RESULTS: In the observational study, infected residents (n = 318) were older, and sicker, and had higher mortality (18.7 per 100,000 resident-days) than uninfected residents (n = 1173; 10.1 per 100,000 resident-days). However, in a multivariate Cox analysis, infection was not related to mortality (relative risk, 1.1; P &gt; 0.2), whereas age at entry and self-rated health (score 1 [excellent] to 4 [bad or poor]) were strong predictors. In the clinical trial, mortality in 166 treated residents (13.8 per 100,000 resident-days) was comparable to that of 192 untreated residents (15.1 per 100,000 resident-days); the relative rate was 0.92 (95% CI, 0.57 to 1.47). The cure rates among treated and untreated residents were 82.9% and 15.6%, respectively. CONCLUSION: Urinary tract infection was not an independent risk factor for mortality, and its treatment did not lower the mortality rate. Screening and treatment of asymptomatic bacteriuria in ambulatory elderly women to decrease mortality do not appear warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Abrutyn, E&#xD;Mossey, J&#xD;Berlin, J A&#xD;Boscia, J&#xD;Levison, M&#xD;Pitsakis, P&#xD;Kaye, D&#xD;AG03934/AG/NIA NIH HHS/United States&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Ann Intern Med. 1994 May 15;120(10):827-33. doi: 10.7326/0003-4819-120-10-199405150-00003.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7326/0003-4819-120-10-199405150-00003</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Winblad, B.</style></author><author><style face="normal" font="default" size="100%">Kilander, L.</style></author><author><style face="normal" font="default" size="100%">Eriksson, S.</style></author><author><style face="normal" font="default" size="100%">Minthon, L.</style></author><author><style face="normal" font="default" size="100%">Båtsman, S.</style></author><author><style face="normal" font="default" size="100%">Wetterholm, A. L.</style></author><author><style face="normal" font="default" size="100%">Jansson-Blixt, C.</style></author><author><style face="normal" font="default" size="100%">Haglund, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. Winblad, Karolinska Institutet, Alzheimer&apos;s Disease Research Center, Department of Neurotec, Huddinge, 14186 Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Donepezil in patients with severe Alzheimer&apos;s disease: double-blind, parallel-group, placebo-controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1057-1065</style></pages><volume><style face="normal" font="default" size="100%">367</style></volume><number><style face="normal" font="default" size="100%">9516</style></number><keywords><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antianemic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">antigout agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">antirheumatic agent</style></keyword><keyword><style face="normal" font="default" size="100%">anxiolytic agent</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">hypnotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">laxative</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">sedative agent</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">daily life activity</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gout</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical staff</style></keyword><keyword><style face="normal" font="default" size="100%">Mini Mental State Examination</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatoid arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">0140-6736</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer&apos;s disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer&apos;s disease, by focusing primarily on cognition and activities of daily living. Methods: We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer&apos;s disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer&apos;s Disease Cooperative Study activities of daily living inventory for severe Alzheimer&apos;s disease (ADCS-ADL-severe). We analysed outcomes for patients with data at baseline and at one or more other timepoints (modified intent-to-treat population) with last observation carried forward used to replace missing data. Findings: 95 patients assigned donepezil and 99 patients assigned placebo completed the study. Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5·7, 95% CI 1·5-9·8; p=0·008, and 1·7, 0·2-3·2; p=0·03, respectively). The incidence of adverse events was comparable between groups (donepezil 82% [n=105] vs placebo 76% [n=91]), with most being transient and mild or moderate in severity. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8). Interpretation: Donepezil improves cognition and preserves function in individuals with severe Alzheimer&apos;s disease who live in nursing homes. © 2006 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L43696440&#xD;2006-05-30</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L43696440&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0140-6736(06)68350-5</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">16581404</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(06)68350-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yates, P. A.</style></author><author><style face="normal" font="default" size="100%">Newman, S. A.</style></author><author><style face="normal" font="default" size="100%">Oshry, L. J.</style></author><author><style face="normal" font="default" size="100%">Glassman, R. H.</style></author><author><style face="normal" font="default" size="100%">Leone, A. M.</style></author><author><style face="normal" font="default" size="100%">Reichel, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Reichel, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutic Advances in Respiratory Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutic Advances in Respiratory Disease</style></full-title></periodical><volume><style face="normal" font="default" size="100%">14</style></volume><keywords><keyword><style face="normal" font="default" size="100%">indwelling urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">loperamide</style></keyword><keyword><style face="normal" font="default" size="100%">osimertinib</style></keyword><keyword><style face="normal" font="default" size="100%">steroid</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">African American</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">anosmia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Asian</style></keyword><keyword><style face="normal" font="default" size="100%">asymptomatic infection</style></keyword><keyword><style face="normal" font="default" size="100%">body temperature measurement</style></keyword><keyword><style face="normal" font="default" size="100%">cancer staging</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">Caucasian</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">dyspnea</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">high risk patient</style></keyword><keyword><style face="normal" font="default" size="100%">home for the aged</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">hospital discharge</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">lacunar stroke</style></keyword><keyword><style face="normal" font="default" size="100%">lung adenocarcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">lung infiltrate</style></keyword><keyword><style face="normal" font="default" size="100%">lung sarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">never smoker</style></keyword><keyword><style face="normal" font="default" size="100%">nursing assistant</style></keyword><keyword><style face="normal" font="default" size="100%">pleura effusion</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">return to work</style></keyword><keyword><style face="normal" font="default" size="100%">self monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">sick sinus syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">stereotactic body radiation therapy</style></keyword><keyword><style face="normal" font="default" size="100%">thorax radiography</style></keyword><keyword><style face="normal" font="default" size="100%">throat culture</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment refusal</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword><keyword><style face="normal" font="default" size="100%">weakness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1753-4666&#xD;1753-4658</style></isbn><abstract><style face="normal" font="default" size="100%">Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive. Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19+ patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline. Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here. The reviews of this paper are available via the supplemental material section.</style></abstract><notes><style face="normal" font="default" size="100%">L2006065481&#xD;2020-09-08&#xD;2020-09-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2006065481&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/1753466620951053</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32873175</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1753466620951053</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moore, A. R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Keeffe, S. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Geriatric Medicine, St. Vincent&apos;s Hospital, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug-induced cognitive impairment in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs Aging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-28</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinergic Antagonists/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Delirium/*chemically induced/*prevention &amp; control/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/*chemically induced/*prevention &amp; control/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine H2 Antagonists/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotropic Drugs/*adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1170-229X (Print)&#xD;1170-229x</style></isbn><abstract><style face="normal" font="default" size="100%">Elderly people are more likely than younger patients to develop cognitive impairment as a result of taking medications. This reflects age- and disease-associated changes in brain neurochemistry and drug handling. Delirium (acute confusional state) is the cognitive disturbance most clearly associated with drug toxicity, but dementia has also been reported. The aetiology of cognitive impairment is commonly multifactorial, and it may be difficult to firmly establish a causal role for an individual medication. In studies of elderly hospital patients, drugs have been reported as the cause of delirium in 11 to 30% of cases. Medication toxicity occurs in 2 to 12% of patients presenting with suspected dementia. In some cases CNS toxicity occurs in a dose-dependent manner, often as a result of interference with neurotransmitter function. Drug-induced delirium can also occur as an idiosyncratic complication. Finally, delirium may occur secondary to iatrogenic complications of drug use. Almost any drug can cause delirium, especially in a vulnerable patient. Impaired cholinergic neurotransmission has been implicated in the pathogenesis of delirium and of Alzheimer&apos;s disease. Anticholinergic medications are important causes of acute and chronic confusional states. Nevertheless, polypharmacy with anticholinergic compounds is common, especially in nursing home residents. Recent studies have suggested that the total burden of anticholinergic drugs may determine development of delirium rather than any single agent. Also, anticholinergic effects have been identified in many drugs other than those classically thought of as having major anticholinergic effects. Psychoactive drugs are important causes of delirium. Narcotic agents are among the most important causes of delirium in postoperative patients. Long-acting benzodiazepines are the commonest drugs to cause or exacerbate dementia. Delirium was a major complication of treatment with tricyclic antidepressants but seems less common with newer agents. Anticonvulsants can cause delirium and dementia. Drug-induced confusion with nonpsychoactive drugs is often idiosyncratic in nature, and the diagnosis is easily missed unless clinicians maintain a high index of suspicion. Histamine H2 receptor antagonists, cardiac medications such as digoxin and beta-blockers, corticosteroids, non-steroidal anti-inflammatory agents and antibiotics can all cause acute, and, less commonly, chronic confusion. Drug-induced confusion can be prevented by avoiding polypharmacy and adhering to the saying &apos;start low and go slow&apos;. Special care is needed when prescribing for people with cognitive impairment. Early diagnosis of drug-induced confusion, and withdrawal of the offending agent or agents is essential.</style></abstract><notes><style face="normal" font="default" size="100%">Moore, A R&#xD;O&apos;Keeffe, S T&#xD;Journal Article&#xD;Review&#xD;New Zealand&#xD;Drugs Aging. 1999 Jul;15(1):15-28. doi: 10.2165/00002512-199915010-00002.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00002512-199915010-00002</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brown, L. K.</style></author><author><style face="normal" font="default" size="100%">Freemantle, N.</style></author><author><style face="normal" font="default" size="100%">Breuer, J.</style></author><author><style face="normal" font="default" size="100%">Dehbi, H. M.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, K.</style></author><author><style face="normal" font="default" size="100%">Jones, G.</style></author><author><style face="normal" font="default" size="100%">Ikeji, F.</style></author><author><style face="normal" font="default" size="100%">Ndoutoumou, A.</style></author><author><style face="normal" font="default" size="100%">Santhirakumar, K.</style></author><author><style face="normal" font="default" size="100%">Longley, N.</style></author><author><style face="normal" font="default" size="100%">Checkley, A. M.</style></author><author><style face="normal" font="default" size="100%">Standing, J. F.</style></author><author><style face="normal" font="default" size="100%">Lowe, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UCL Institute of Immunity and Transplantation, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.&#xD;Comprehensive Clinical Trials Unit, University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, UK. nicholas.freemantle@ucl.ac.uk.&#xD;Division of Infection and Immunity, University College London, London, UK.&#xD;Comprehensive Clinical Trials Unit, University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, UK.&#xD;Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, UK.&#xD;London School of Hygiene and Tropical Medicine, London, UK.&#xD;Infection, Inflammation, Immunity Section, UCL Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">193</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Amides/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase II as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Early Medical Intervention</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lopinavir/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Ritonavir/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">*Viral Load</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">antivirals</style></keyword><keyword><style face="normal" font="default" size="100%">combination therapy</style></keyword><keyword><style face="normal" font="default" size="100%">early treatment</style></keyword><keyword><style face="normal" font="default" size="100%">factorial design</style></keyword><keyword><style face="normal" font="default" size="100%">favipiravir</style></keyword><keyword><style face="normal" font="default" size="100%">lopinavir/ritonavir</style></keyword><keyword><style face="normal" font="default" size="100%">placebo-controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">protocol</style></keyword><keyword><style face="normal" font="default" size="100%">randomised controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo. TRIAL DESIGN: FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial. PARTICIPANTS: This trial is being conducted in the United Kingdom, with Royal Free Hospital, London as the lead site. Participants are non-hospitalised adults with highly suspected COVID-19 within the first 5 days of symptom onset, or who have tested positive with SARS-CoV-2 causing COVID-19 within the first 7 days of symptom onset, or who are asymptomatic but tested positive for SARS-CoV-2 for the first time within the last 48 hours. Inclusion criteria are as follows: 1. Any adult with the following: Symptoms compatible with COVID-19 disease (Fever &gt;37.8°C on at least one occasion AND either cough and/ or anosmia) within the first 5 days of symptom onset (date/time of enrolment must be within the first 5 days of symptom onset) OR ANY symptoms compatible with COVID-19 disease (may include, but are not limited to fever, cough, shortness of breath, malaise, myalgia, headache, coryza) and tested positive for SARS-CoV-2 within the first 7 days of symptom onset) (date/time of enrolment must be within the first 7 days of symptom onset) OR no symptoms but tested positive for SARS-CoV-2 within the last 48 hours (date/time of test must be within 48 hours of enrolment) 2. Male or female aged 18 years to 70 years old inclusive at screening 3. Willing and able to take daily saliva samples 4. Able to provide full informed consent and willing to comply with trial-related procedures Exclusion criteria are as follows: 1. Known hypersensitivity to any of the active ingredients or excipients in favipiravir and matched placebo, and in lopinavir/ritonavir and matched placebo (See Appendix 2) 2. Chronic liver disease at screening (known cirrhosis of any aetiology, chronic hepatitis (e.g. autoimmune, viral, steatohepatitis), cholangitis or any known elevation of liver aminotransferases with AST or ALT &gt; 3 X ULN)* 3. Chronic kidney disease (stage 3 or beyond) at screening: eGFR &lt; 60 ml/min/1.73m(2) * 4. HIV infection, if untreated, detectable viral load or on protease inhibitor therapy 5. Any clinical condition which the investigator considers would make the participant unsuitable for the trial 6. Concomitant medications known to interact with favipiravir and matched placebo, and with lopinavir/ritonavir and matched placebo, and carry risk of toxicity for the participant 7. Current severe illness requiring hospitalisation 8. Pregnancy and/ or breastfeeding 9. Eligible female participants of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraceptive measures during the trial and within the time point specified following last trial treatment dose. 10. Participants enrolled in any other interventional drug or vaccine trial (co-enrolment in observational studies is acceptable) 11. Participants who have received the COVID-19 vaccine *Considering the importance of early treatment of COVID-19 to impact viral load, the absence of known chronic liver/ kidney disease will be confirmed verbally by the participant during pre-screening and Screening/Baseline visit. Safety blood samples will be collected at Screening/Baseline visit (Day 1) and test results will be examined as soon as they become available and within 24 hours. INTERVENTION AND COMPARATOR: Participants will be randomised 1:1:1:1 using a concealed online minimisation process into one of the following four arms: Arm 1: Favipiravir + Lopinavir/ritonavir Oral favipiravir at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7. Arm 2: Favipiravir + Lopinavir/ritonavir placebo Oral favipiravir at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7. Arm 3: Favipiravir placebo + Lopinavir/ritonavir Oral favipiravir matched placebo at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7. Arm 4: Favipiravir placebo + Lopinavir/ritonavir placebo Oral favipiravir matched placebo at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7. MAIN OUTCOMES: The primary outcome is upper respiratory tract viral load at Day 5. SECONDARY OUTCOMES: Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy Proportion of participants with undetectable stool viral load after 7 days of therapy Rate of decrease in upper respiratory tract viral load during 7 days of therapy Duration of fever following commencement of trial medications Proportion of participants with hepatotoxicity after 7 days of therapy Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation Proportion of participants admitted to hospital with COVID-19 related illness Proportion of participants admitted to ICU with COVID-19 related illness Proportion of participants who have died with COVID-19 related illness Pharmacokinetic and pharmacodynamic analysis of favipiravir Exploratory: Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 RANDOMISATION: Participants will be randomised 1:1:1:1 using a concealed online minimisation process, with the following factors: trial site, age (≤ 55 vs &gt; 55 years old), gender, obesity (BMI &lt;30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease). BLINDING (MASKING): Participants and investigators will both be blinded to treatment allocation (double-blind). NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 240 participants, 60 in each arm. TRIAL STATUS: Protocol version 4.0 dated 7(th) January 2021. Date of first enrolment: October 2020. Recruitment is ongoing, with anticipated finish date of 31(st) March 2021. TRIAL REGISTRATION: The FLARE trial is registered with Clinicaltrials.gov, trial identifying number NCT04499677 , date of registration 4(th) August 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</style></abstract><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Brown, Li-An K&#xD;Freemantle, Nick&#xD;Breuer, Judy&#xD;Dehbi, Hakim-Moulay&#xD;Chowdhury, Kashfia&#xD;Jones, Gemma&#xD;Ikeji, Felicia&#xD;Ndoutoumou, Amalia&#xD;Santhirakumar, Krishneya&#xD;Longley, Nicky&#xD;Checkley, Anna M&#xD;Standing, Joseph F&#xD;Lowe, David M&#xD;COVID0005/LifeArc/&#xD;Clinical Trial Protocol&#xD;Letter&#xD;Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7938371</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-021-05139-2</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chibnall, J. T.</style></author><author><style face="normal" font="default" size="100%">Tait, R. C.</style></author><author><style face="normal" font="default" size="100%">Harman, B.</style></author><author><style face="normal" font="default" size="100%">Luebbert, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.T. Chibnall, Saint Louis University, School of Medicine, Department of Psychiatry, 1221 S. Grand Blvd., St. Louis, MO 63104, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1921-1929</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">gabapentin</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxyzine</style></keyword><keyword><style face="normal" font="default" size="100%">ibuprofen</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">memantine</style></keyword><keyword><style face="normal" font="default" size="100%">mirtazapine</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">paracetamol</style></keyword><keyword><style face="normal" font="default" size="100%">paroxetine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine</style></keyword><keyword><style face="normal" font="default" size="100%">rofecoxib</style></keyword><keyword><style face="normal" font="default" size="100%">sertraline</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">venlafaxine</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">analgesia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">crossover procedure</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">emotion</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">pain assessment</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">restlessness</style></keyword><keyword><style face="normal" font="default" size="100%">self care</style></keyword><keyword><style face="normal" font="default" size="100%">social interaction</style></keyword><keyword><style face="normal" font="default" size="100%">wellbeing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614&#xD;1532-5415</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To evaluate the effect of regularly scheduled administration of analgesic medication on behavior, emotional well-being, and use of as-needed psychotropic medications in nursing home residents with moderate-to-severe dementia. DESIGN: Randomized, double-blind, placebo-controlled, crossover trial. SETTING: Nursing-home based. PARTICIPANTS: Twenty-five nursing home residents with moderate-to-severe dementia. INTERVENTION: Participants received 4 weeks of acetaminophen (3,000 mg/d) and 4 weeks of placebo. MEASUREMENTS: Behavior and emotional well-being were assessed using Dementia Care Mapping, an observational method that quantifies time spent in behaviors across 26 domains (e.g., social interaction, unattended distress) and assesses emotional state while behaviors are being observed. Agitation was measured using the Cohen-Mansfield Agitation Inventory. As-needed psychotropic medication use was aggregated from medication logs. RESULTS: Participants spent more time in social interaction, engaged with media, talking to themselves, engaged in work-like activity, and experiencing unattended distress when they received acetaminophen than they did when they received placebo. Participants also spent less time in their rooms, less time removed from the nursing home unit, and less time performing personal care activities when they received acetaminophen. There were no effects on agitation, emotional well-being, or as-needed psychotropic medication use. CONCLUSION: Untreated pain inhibits activity in nursing home residents with moderate-to-severe dementia. Pain treatment in this group may facilitate engagement with the environment. © 2005 by the American Geriatrics Society.</style></abstract><notes><style face="normal" font="default" size="100%">L41826069&#xD;2006-01-13</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L41826069&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1532-5415.2005.53572.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">16274373</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2005.53572.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meurman, J. H.</style></author><author><style face="normal" font="default" size="100%">Pärnänen, P.</style></author><author><style face="normal" font="default" size="100%">Kari, K.</style></author><author><style face="normal" font="default" size="100%">Samaranayake, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, Helsinki, Finland. jukka.meurman@helsinki.fi</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of amine fluoride-stannous fluoride preparations on oral yeasts in the elderly: a randomised placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Gerodontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gerodontology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">202-9</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antifungal Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Candida/classification/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Candidiasis, Oral/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Care for Aged/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorides, Topical/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mouth/drug effects/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mouthwashes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Oral Hygiene/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Tin Fluorides/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Toothpastes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0734-0664</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Oral yeast infections are an emerging problem among medically compromised and frail elderly. Antifungal drug resistance is also increasing because of an increase in non-albicans Candida strains in these populations. We therefore set out to study, in the randomised-controlled trial setting if the use of a topical amine fluoride-stannous fluoride combination (AmF-SnF2) could control oral Candida growth in the elderly. The hypothesis was based on earlier findings showing that in vitro this combination had antifungal efficacy. METHODS: A total of 194 nursing home residents were randomised to receive either the test mouth rinse and toothpaste or a placebo twice daily for 8 months. Of these, 136 completed the trial. Saliva samples were taken using the oral rinse method, cultivated and the strain level identified with routine microbial methods. Compliance and use of preparations was assessed by a nurse. RESULTS: Significantly at the end of the trial, less mucosal lesions were observed in the test group in comparison to controls. Total bacterial count decreased in both the groups during the trial. Candida albicans was the most prevalent strain detected both at baseline and 8 months later. Only a few subjects carried non-albicans strains. The AmF-SnF2 did not significantly affect mean oral Candida counts, but median Candida counts were reduced in the AmF-SnF2 group while an increase was seen in the placebo group. However, the differences observed were not statistically significant. Compliance among the regular elderly users slightly increased during the trial for both the groups. CONCLUSION: The number of subjects with high Candida counts decreased in the AmF-SnF2 group. Hence, the fluoride combination might be useful as a support therapy for oral candidiasis. Prevalence of non-albicans Candida strains was low in this population.</style></abstract><notes><style face="normal" font="default" size="100%">1741-2358&#xD;Meurman, Jukka H&#xD;Pärnänen, Pirjo&#xD;Kari, Kirsti&#xD;Samaranayake, Lakshman&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Gerodontology. 2009 Sep;26(3):202-9. doi: 10.1111/j.1741-2358.2008.00246.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1741-2358.2008.00246.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gottlieb, R. L.</style></author><author><style face="normal" font="default" size="100%">Nirula, A.</style></author><author><style face="normal" font="default" size="100%">Chen, P.</style></author><author><style face="normal" font="default" size="100%">Boscia, J.</style></author><author><style face="normal" font="default" size="100%">Heller, B.</style></author><author><style face="normal" font="default" size="100%">Morris, J.</style></author><author><style face="normal" font="default" size="100%">Huhn, G.</style></author><author><style face="normal" font="default" size="100%">Cardona, J.</style></author><author><style face="normal" font="default" size="100%">Mocherla, B.</style></author><author><style face="normal" font="default" size="100%">Stosor, V.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: a Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">632‐644</style></pages><volume><style face="normal" font="default" size="100%">325</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">*coronavirus disease 2019 /diagnosis /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">*drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">*monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*virus load</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">COVID‐19 [*drug therapy, mortality, virology]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Dizziness /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Drug hypersensitivity /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">Faintness /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Headache /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infusions, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Nose obstruction /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Rash /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">SARS‐CoV‐2 [drug effects, *isolation &amp; purification]</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Viral Load [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Vomiting /side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><abstract><style face="normal" font="default" size="100%">Importance: Coronavirus disease 2019 (COVID‐19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID‐19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral load in mild to moderate COVID‐19. Design, Setting, and Participants: The BLAZE‐1 study is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N?=?613) who tested positive for SARS‐CoV‐2 infection and had 1 or more mild to moderate symptoms. Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17‐August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22‐September 3). These are the final analyses and represent findings through October 6, 2020. Interventions: Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n?=?101], 2800 mg [n?=?107], or 7000 mg [n?=?101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n?=?112]), or placebo (n?=?156). Main Outcomes and Measures: The primary end point was change in SARS‐CoV‐2 log viral load at day 11 (±4 days). Nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome (the proportion of patients with a COVID‐19‐related hospitalization, an emergency department [ED] visit, or death at day 29). Results: Among the 577 patients who were randomized and received an infusion (mean age, 44.7 [SD, 15.7] years; 315 [54.6%] women), 533 (92.4%) completed the efficacy evaluation period (day 29). The change in log viral load from baseline at day 11 was ‐3.72 for 700 mg, ‐4.08 for 2800 mg, ‐3.49 for 7000 mg, ‐4.37 for combination treatment, and ‐3.80 for placebo. Compared with placebo, the differences in the change in log viral load at day 11 were 0.09 (95% CI, ‐0.35 to 0.52; P?=?.69) for 700 mg, ‐0.27 (95% CI, ‐0.71 to 0.16; P?=?.21) for 2800 mg, 0.31 (95% CI, ‐0.13 to 0.76; P?=?.16) for 7000 mg, and ‐0.57 (95% CI, ‐1.00 to ‐0.14; P?=?.01) for combination treatment. Among the secondary outcome measures, differences between each treatment group vs the placebo group were statistically significant for 10 of 84 end points. The proportion of patients with COVID‐19‐related hospitalizations or ED visits was 5.8% (9 events) for placebo, 1.0% (1 event) for 700 mg, 1.9% (2 events) for 2800 mg, 2.0% (2 events) for 7000 mg, and 0.9% (1 event) for combination treatment. Immediate hypersensitivity reactions were reported in 9 patients (6 bamlanivimab, 2 combination treatment, and 1 placebo). No deaths occurred during the study treatment. Conclusions and Relevance: Among nonhospitalized patients with mild to moderate COVID‐19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS‐CoV‐2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy. Further ongoing clinical trials will focus on assessing the clinical benefit of antispike neutralizing antibodies in patients with COVID‐19 as a primary end point. Trial Registration: ClinicalTrials.gov Identifier: NCT04427501.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02246160/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 33475701,EMBASE 634003727</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2021.0202</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cohen, M. S.</style></author><author><style face="normal" font="default" size="100%">Nirula, A.</style></author><author><style face="normal" font="default" size="100%">Mulligan, M. J.</style></author><author><style face="normal" font="default" size="100%">Novak, R. M.</style></author><author><style face="normal" font="default" size="100%">Marovich, M.</style></author><author><style face="normal" font="default" size="100%">Yen, C.</style></author><author><style face="normal" font="default" size="100%">Stemer, A.</style></author><author><style face="normal" font="default" size="100%">Mayer, S. M.</style></author><author><style face="normal" font="default" size="100%">Wohl, D.</style></author><author><style face="normal" font="default" size="100%">Brengle, B.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: a Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">46‐55</style></pages><volume><style face="normal" font="default" size="100%">326</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*assisted living facility</style></keyword><keyword><style face="normal" font="default" size="100%">*coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">*incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*nursing</style></keyword><keyword><style face="normal" font="default" size="100%">*resident</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized [adverse effects, immunology, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents [adverse effects, immunology, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Assisted Living Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Attributable risk</style></keyword><keyword><style face="normal" font="default" size="100%">COVID‐19 [epidemiology, *prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization, Passive</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infusions, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Intravenous drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Monoclonal antibody therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Randomization</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse transcription polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">SARS‐CoV‐2 [isolation &amp; purification]</style></keyword><keyword><style face="normal" font="default" size="100%">Serology</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Skilled Nursing Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Virus strain</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><abstract><style face="normal" font="default" size="100%">Importance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID‐19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS‐CoV‐2, may confer rapid protection from SARS‐CoV‐2 infection and COVID‐19. Objective: To determine the effect of bamlanivimab on the incidence of COVID‐19 among residents and staff of skilled nursing and assisted living facilities. Design, Setting, and Participants: Randomized, double‐blind, single‐dose, phase 3 trial that enrolled residents and staff of 74 skilled nursing and assisted living facilities in the United States with at least 1 confirmed SARS‐CoV‐2 index case. A total of 1175 participants enrolled in the study from August 2 to November 20, 2020. Database lock was triggered on January 13, 2021, when all participants reached study day 57. Interventions: Participants were randomized to receive a single intravenous infusion of bamlanivimab, 4200 mg (n?=?588), or placebo (n?=?587). Main Outcomes and Measures: The primary outcome was incidence of COVID‐19, defined as the detection of SARS‐CoV‐2 by reverse transcriptase‐polymerase chain reaction and mild or worse disease severity within 21 days of detection, within 8 weeks of randomization. Key secondary outcomes included incidence of moderate or worse COVID‐19 severity and incidence of SARS‐CoV‐2 infection. Results: The prevention population comprised a total of 966 participants (666 staff and 300 residents) who were negative at baseline for SARS‐CoV‐2 infection and serology (mean age, 53.0 [range, 18‐104] years; 722 [74.7%] women). Bamlanivimab significantly reduced the incidence of COVID‐19 in the prevention population compared with placebo (8.5% vs 15.2%; odds ratio, 0.43 [95% CI, 0.28‐0.68]; P?&lt;?.001; absolute risk difference, ‐6.6 [95% CI, ‐10.7 to ‐2.6] percentage points). Five deaths attributed to COVID‐19 were reported by day 57; all occurred in the placebo group. Among 1175 participants who received study product (safety population), the rate of participants with adverse events was 20.1% in the bamlanivimab group and 18.9% in the placebo group. The most common adverse events were urinary tract infection (reported by 12 participants [2%] who received bamlanivimab and 14 [2.4%] who received placebo) and hypertension (reported by 7 participants [1.2%] who received bamlanivimab and 10 [1.7%] who received placebo). Conclusions and Relevance: Among residents and staff in skilled nursing and assisted living facilities, treatment during August‐November 2020 with bamlanivimab monotherapy reduced the incidence of COVID‐19 infection. Further research is needed to assess preventive efficacy with current patterns of viral strains with combination monoclonal antibody therapy. Trial Registration: ClinicalTrials.gov Identifier: NCT04497987.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02283743/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 34081073,EMBASE 635264912</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2021.8828</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Juthani-Mehta, M.</style></author><author><style face="normal" font="default" size="100%">Van Ness, P. H.</style></author><author><style face="normal" font="default" size="100%">Bianco, L.</style></author><author><style face="normal" font="default" size="100%">Rink, A.</style></author><author><style face="normal" font="default" size="100%">Rubeck, S.</style></author><author><style face="normal" font="default" size="100%">Ginter, S.</style></author><author><style face="normal" font="default" size="100%">Argraves, S.</style></author><author><style face="normal" font="default" size="100%">Charpentier, P.</style></author><author><style face="normal" font="default" size="100%">Acampora, D.</style></author><author><style face="normal" font="default" size="100%">Trentalange, M.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes: a Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1879‐1887</style></pages><volume><style face="normal" font="default" size="100%">316</style></volume><number><style face="normal" font="default" size="100%">18</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti‐Bacterial Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria [*drug therapy, mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Capsules</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy [*methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pyuria [*drug therapy, mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Importance: Bacteriuria plus pyuria is highly prevalent among older women living in nursing homes. Cranberry capsules are an understudied, nonantimicrobial prevention strategy used in this population. Objective: To test the effect of 2 oral cranberry capsules once a day on presence of bacteriuria plus pyuria among women residing in nursing homes. Design, Setting, and Participants: Double‐blind, randomized, placebo‐controlled efficacy trial with stratification by nursing home and involving 185 English‐speaking women aged 65 years or older, with or without bacteriuria plus pyuria at baseline, residing in 21 nursing homes located within 50 miles (80 km) of New Haven, Connecticut (August 24, 2012‐October 26, 2015). Interventions: Two oral cranberry capsules, each capsule containing 36 mg of the active ingredient proanthocyanidin (ie, 72 mg total, equivalent to 20 ounces of cranberry juice) vs placebo administered once a day in 92 treatment and 93 control group participants. Main Outcomes and Measures: Presence of bacteriuria (ie, at least 105 colony‐forming units [CFUs] per milliliter of 1 or 2 microorganisms in urine culture) plus pyuria (ie, any number of white blood cells on urinalysis) assessed every 2 months over the 1‐year study surveillance; any positive finding was considered to meet the primary outcome. Secondary outcomes were symptomatic urinary tract infection (UTI), all‐cause death, all‐cause hospitalization, all multidrug antibiotic‐resistant organisms, antibiotics administered for suspected UTI, and total antimicrobial administration. Results: Of the 185 randomized study participants (mean age, 86.4 years [SD, 8.2], 90.3% white, 31.4% with bacteriuria plus pyuria at baseline), 147 completed the study. Overall adherence was 80.1%. Unadjusted results showed the presence of bacteriuria plus pyuria in 25.5% (95% CI, 18.6%‐33.9%) of the treatment group and in 29.5% (95% CI, 22.2%‐37.9%) of the control group. The adjusted generalized estimating equations model that accounted for missing data and covariates showed no significant difference in the presence of bacteriuria plus pyuria between the treatment group vs the control group (29.1% vs 29.0%; OR, 1.01; 95% CI, 0.61‐1.66; P = .98). There were no significant differences in number of symptomatic UTIs (10 episodes in the treatment group vs 12 in the control group), rates of death (17 vs 16 deaths; 20.4 vs 19.1 deaths/100 person‐years; rate ratio [RR], 1.07; 95% CI, 0.54‐2.12), hospitalization (33 vs 50 admissions; 39.7 vs 59.6 hospitalizations/100 person‐years; RR, 0.67; 95% CI, 0.32‐1.40), bacteriuria associated with multidrug‐resistant gram‐negative bacilli (9 vs 24 episodes; 10.8 vs 28.6 episodes/100 person‐years; RR, 0.38; 95% CI, 0.10‐1.46), antibiotics administered for suspected UTIs (692 vs 909 antibiotic days; 8.3 vs 10.8 antibiotic days/person‐year; RR, 0.77; 95% CI, 0.44‐1.33), or total antimicrobial utilization (1415 vs 1883 antimicrobial days; 17.0 vs 22.4 antimicrobial days/person‐year; RR, 0.76; 95% CI, 0.46‐1.25). Conclusions and Relevance: Among older women residing in nursing homes, administration of cranberry capsules vs placebo resulted in no significant difference in presence of bacteriuria plus pyuria over 1 year. Trial Registration: clinicaltrials.gov Identifier: NCT01691430.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01260869/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 27787564</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2016.16141</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>201</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, B. A.</style></author><author><style face="normal" font="default" size="100%">McGeer, A.</style></author><author><style face="normal" font="default" size="100%">McArthur, M. A.</style></author><author><style face="normal" font="default" size="100%">Simor, A. E.</style></author><author><style face="normal" font="default" size="100%">Aghdassi, E.</style></author><author><style face="normal" font="default" size="100%">Davis, L.</style></author><author><style face="normal" font="default" size="100%">Allard, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Regional Geriatric Program of Toronto, Toronto, ON, Canada. barbara.liu@sunnybrook.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of multivitamin and mineral supplementation on episodes of infection in nursing home residents: a randomized, placebo-controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-42</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infections/drug therapy/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Minerals/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To evaluate the effect of vitamin and mineral supplementation on infections in an elderly institutionalized population. DESIGN: Eighteen-month, randomized, placebo-controlled trial. SETTING: Twenty-one long-term care facilities. PARTICIPANTS: Seven hundred sixty-three subjects from 21 long-term care facilities. INTERVENTION: Participants were randomized to receive one multivitamin and mineral supplementation daily or placebo. MEASUREMENTS: The primary outcome was number of infections per subject. Secondary outcomes were antibiotic use and hospitalization rates. Infection control surveillance was conducted over 18 months using standardized criteria. RESULTS: Outcome data from 748 subjects, mean age 85, were included in the intention-to-treat analysis. Using univariate analyses, there was no difference in infectious episodes between the supplemented and placebo groups (3.5 infections per 1,000 resident-days vs 3.8 infections per 1,000 resident-days, odds ratio (OR)=0.92, 95% confidence interval (CI)=0.82-1.03, P=.12). There was a reduction in antibiotic usage in the supplementation group, but this was not significant in the multivariate model. There was no difference in the number of hospital visits. In the multivariate analysis, the effect of multivitamin use on total number of infections was not significant (OR=0.77, 95% CI=0.54-1.1). Subjects without dementia had a greater rate of infections than those with dementia (OR=1.44, 95% CI=1.19-1.76). In post hoc subgroup analysis, subjects without dementia who received supplementation had a significantly lower rate of infections than those who received placebo (relative risk=0.81, 95% CI=0.66-0.99). CONCLUSION: Overall, multivitamin and mineral supplementation does not have a significant effect on the incidence of infections in institutionalized seniors, although the subgroup of residents in long-term care without dementia may benefit from supplementation. Further research is needed to determine its effect in high-risk subgroups within the nursing home population.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Barbara A&#xD;McGeer, Allison&#xD;McArthur, Margaret A&#xD;Simor, Andrew E&#xD;Aghdassi, Elaheh&#xD;Davis, Lori&#xD;Allard, Johane P&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Geriatr Soc. 2007 Jan;55(1):35-42. doi: 10.1111/j.1532-5415.2006.01033.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2006.01033.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Butler, C. C.</style></author><author><style face="normal" font="default" size="100%">Lau, M.</style></author><author><style face="normal" font="default" size="100%">Gillespie, D.</style></author><author><style face="normal" font="default" size="100%">Owen-Jones, E.</style></author><author><style face="normal" font="default" size="100%">Lown, M.</style></author><author><style face="normal" font="default" size="100%">Wootton, M.</style></author><author><style face="normal" font="default" size="100%">Calder, P. C.</style></author><author><style face="normal" font="default" size="100%">Bayer, A. J.</style></author><author><style face="normal" font="default" size="100%">Moore, M.</style></author><author><style face="normal" font="default" size="100%">Little, P.</style></author><author><style face="normal" font="default" size="100%">Davies, J.</style></author><author><style face="normal" font="default" size="100%">Edwards, A.</style></author><author><style face="normal" font="default" size="100%">Shepherd, V.</style></author><author><style face="normal" font="default" size="100%">Hood, K.</style></author><author><style face="normal" font="default" size="100%">Hobbs, F. D. R.</style></author><author><style face="normal" font="default" size="100%">Davoudianfar, M.</style></author><author><style face="normal" font="default" size="100%">Rutter, H.</style></author><author><style face="normal" font="default" size="100%">Stanton, H.</style></author><author><style face="normal" font="default" size="100%">Lowe, R.</style></author><author><style face="normal" font="default" size="100%">Fuller, R.</style></author><author><style face="normal" font="default" size="100%">Francis, N. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Bldg, University of Oxford, Oxford, United Kingdom.&#xD;Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.&#xD;Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.&#xD;Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom.&#xD;Division of Population Medicine, School of Medicine, Neuadd Meirionnydd, Cardiff University, Cardiff, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">47-56</style></pages><volume><style face="normal" font="default" size="100%">324</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Assisted Living Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Bifidobacterium animalis/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Utilization/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Feces/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactobacillus rhamnosus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 7</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0098-7484 (Print)&#xD;0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">IMPORTANCE: Probiotics are frequently used by residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care), although the evidence on whether probiotics prevent infections and reduce antibiotic use in these settings is limited. OBJECTIVE: To determine whether a daily oral probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 compared with placebo reduces antibiotic administration in care home residents. DESIGN, SETTING, AND PARTICIPANTS: Placebo-controlled randomized clinical trial of 310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018. INTERVENTIONS: Study participants were randomized to receive a daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 × 1010 to 1.6 × 1010) (n = 155), or daily matched placebo (n = 155), for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary outcome was cumulative antibiotic administration days for all-cause infections measured from randomization for up to 1 year. RESULTS: Among 310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily data including study product use, antibiotic administration, and signs of infection) were available for 98.7% randomized to the probiotic group and 97.4% randomized to placebo. Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50). A total of 120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group). Hospitalizations accounted for 94 of the events in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events in the probiotic group and 32 of the events in the placebo group. CONCLUSIONS AND RELEVANCE: Among care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic administration for all-cause infections. These findings do not support the use of probiotics in this setting. TRIAL REGISTRATION: ISRCTN Identifier:16392920.</style></abstract><notes><style face="normal" font="default" size="100%">1538-3598&#xD;Butler, Christopher C&#xD;Lau, Mandy&#xD;Gillespie, David&#xD;Owen-Jones, Eleri&#xD;Lown, Mark&#xD;Wootton, Mandy&#xD;Calder, Philip C&#xD;Bayer, Antony J&#xD;Moore, Michael&#xD;Little, Paul&#xD;Davies, Jane&#xD;Edwards, Alison&#xD;Shepherd, Victoria&#xD;Hood, Kerenza&#xD;Hobbs, F D Richard&#xD;Davoudianfar, Mina&#xD;Rutter, Heather&#xD;Stanton, Helen&#xD;Lowe, Rachel&#xD;Fuller, Richard&#xD;Francis, Nick A&#xD;13/95/10/DH_/Department of Health/United Kingdom&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;JAMA. 2020 Jul 7;324(1):47-56. doi: 10.1001/jama.2020.8556.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7341173 Mechanism Evaluation (EME) program, which is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), being part of a publicly funded research consortia that includes industrial partners, and funding from the NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK, in partnership with Public Health England during the conduct of the study; grants from NIHR Health, the NIHR Health Technology Assessment Programme, Roche Molecular Diagnostics, NIHR Health Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance; and personal fees from Pfizer, Roche Molecular Diagnostics (advisory board participation), and Janssen Pharmaceuticals (advisory board participation) outside the submitted work; and being a salaried general medical practitioner in the Cwm Taf Morgannwg University Health Board, an NIHR senior investigator, and clinical director of the University of Oxford Primary Care and Vaccines Clinical Trials Collaboration and the NIHR Oxford Community Medical Technology and Invitro Diagnostics Co-operative. Dr Hobbs reported partial funding from the NIHR School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care Oxford, the NIHR Oxford Biomedical Research Centre, and the NIHR Oxford MedTech and In-Vitro Diagnostics Co-operative. Dr Gillespie reported grants from NIHR/MRC EME during the conduct of the study. Dr Owen-Jones reported grants from NIHR EME during the conduct of the study. Dr Lown reported grants from NIHR during the conduct of the study. Dr Calder reported grants from NIHR during the conduct of the study; personal fees from Chr Hansen, and nonfinancial support from Chr Hansen outside the submitted work. Dr Bayer reported grants from NIHR during the conduct of the study. Dr Moore reported grants from NIHR during the conduct of the study. Dr Shepherd reported grants from NIHR EME during the conduct of the study. Dr Hood reported grants from NIHR EME during the conduct of the study. Dr Lowe reported grants from NIHR EME and nonfinancial support from Chr Hansen during the conduct of the study. Dr Francis reported grants from NIHR/MRC EME during the conduct of the study. No other disclosures were reported.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2020.8556</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stanton, A. L.</style></author><author><style face="normal" font="default" size="100%">Kelton, D. F.</style></author><author><style face="normal" font="default" size="100%">LeBlanc, S. J.</style></author><author><style face="normal" font="default" size="100%">Wormuth, J.</style></author><author><style face="normal" font="default" size="100%">Leslie, K. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1. Electronic address: astanton@uoguelph.ca.&#xD;Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1.&#xD;CY Heifer Farm, Batavia, NY 14020.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of respiratory disease and a preventative antibiotic treatment on growth, survival, age at first calving, and milk production of dairy heifers</style></title><secondary-title><style face="normal" font="default" size="100%">J Dairy Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Dairy Sci</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4950-4960</style></pages><volume><style face="normal" font="default" size="100%">95</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bovine Respiratory Disease Complex/mortality/*physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Disaccharides/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Heterocyclic Compounds/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Lactation/drug effects/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxytetracycline/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Infectious/veterinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-0302</style></isbn><abstract><style face="normal" font="default" size="100%">Bovine respiratory disease complex (BRD) is a common disease in weaned dairy calves that incurs economic and welfare costs. This study was an extension of a randomized clinical trial in which a single injection of tulathromycin (TUL) or oxytetracycline (TET) was administered at first movement to group housing for the prevention of BRD in the 60 d following antimicrobial treatment (BRD60). Calves treated with TUL were 0.5 times [95% confidence interval (CI): 0.4 to 0.7] as likely to be treated for BRD60 as calves treated with TET. The objectives of the current study were to evaluate the long-term effects of BRD and antibiotic treatment on growth of heifers until breeding age, age at first calving, incidence of dystocia, milk production, and mortality before first calving and mortality before 120 d in milk. At entry to the breeding barn (382 d of age), calves that experienced BRD60 weighed 16.0±2.3 kg less than calves that did not. Survival to first calving was recorded for 98% (1,343/1,392) of the heifers on this trial. For TET and TUL heifers with BRD60, 63% (94/150) and 73% (64/88) survived to first lactation, respectively. For TET and TUL calves without BRD60, 84% (436/517) and 84% (494/588) survived to first lactation, respectively. The median age at first calving for heifers with and without BRD60 was 714 (95% CI: 705-723) and 702 (95% CI: 699-705) days, respectively. Heifers with BRD60 were 1.5 (95% CI: 1.1-2.2) times more likely to have a calving ease score ≥2 at their first calving compared with heifers without BRD60. The administration of TUL at movement to group housing may have a role in the prevention of BRD and in mitigating some of the long-term effects of this disease.</style></abstract><notes><style face="normal" font="default" size="100%">1525-3198&#xD;Stanton, A L&#xD;Kelton, D F&#xD;LeBlanc, S J&#xD;Wormuth, J&#xD;Leslie, K E&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Dairy Sci. 2012 Sep;95(9):4950-4960. doi: 10.3168/jds.2011-5067.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3168/jds.2011-5067</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanroma, P.</style></author><author><style face="normal" font="default" size="100%">Muñoz, P.</style></author><author><style face="normal" font="default" size="100%">Mirón-Rubio, M.</style></author><author><style face="normal" font="default" size="100%">Aguilera, A.</style></author><author><style face="normal" font="default" size="100%">Estrada, O.</style></author><author><style face="normal" font="default" size="100%">García, D.</style></author><author><style face="normal" font="default" size="100%">González-Ramallo, V. J.</style></author><author><style face="normal" font="default" size="100%">Pajarón, M.</style></author><author><style face="normal" font="default" size="100%">Sgaramella, G. A.</style></author><author><style face="normal" font="default" size="100%">González, C. R.</style></author><author><style face="normal" font="default" size="100%">Mujal, A.</style></author><author><style face="normal" font="default" size="100%">Abad, A.</style></author><author><style face="normal" font="default" size="100%">Solé, A.</style></author><author><style face="normal" font="default" size="100%">González, S.</style></author><author><style face="normal" font="default" size="100%">Escalada, C.</style></author><author><style face="normal" font="default" size="100%">Vitoria, I.</style></author><author><style face="normal" font="default" size="100%">Gómez, M. J.</style></author><author><style face="normal" font="default" size="100%">Parra, J. J.</style></author><author><style face="normal" font="default" size="100%">Sampedro, I.</style></author><author><style face="normal" font="default" size="100%">Pereda, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Muñoz, Teaching Unit, Cantabria Health Care Service, Santander, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness and safety of ertapenem used in hospital-at-home units: Data from Spanish Outpatient Parenteral Antimicrobial Therapy Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Future Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Future Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1363-1373</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">balloon pump</style></keyword><keyword><style face="normal" font="default" size="100%">implantable port system</style></keyword><keyword><style face="normal" font="default" size="100%">peripherally inserted central venous catheter</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">daptomycin</style></keyword><keyword><style face="normal" font="default" size="100%">ertapenem</style></keyword><keyword><style face="normal" font="default" size="100%">piperacillin plus tazobactam</style></keyword><keyword><style face="normal" font="default" size="100%">teicoplanin</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal infection</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacteremia</style></keyword><keyword><style face="normal" font="default" size="100%">bone infection</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">Charlson Comorbidity Index</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired infection</style></keyword><keyword><style face="normal" font="default" size="100%">consciousness disorder</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug self administration</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">fatality</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal infection</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Gram positive bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">home care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital readmission</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperkalemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypernatremia</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">infectious arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">neutropenia</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">patient referral</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract disease</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">Spaniard</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1746-0921&#xD;1746-0913</style></isbn><abstract><style face="normal" font="default" size="100%">Aim: To evaluate the effectiveness and safety of ertapenem in patients hospitalized at home. Patients &amp; methods: Retrospective analysis of data from Spanish Outpatient Parenteral Antimicrobial Therapy (OPAT) registry. Results: Data from 1428 patients (median age 70 years; 5.4% institutionalized) and 1547 infectious processes (24% self-administration) were analyzed. Clinical cure or improvement was achieved in 93.8% of cases. Rate of related readmissions was 4.2%, of clinically important complications -3.9%, and of adverse drug reactions -3.2%. High comorbidity burden, contagion in nursing home and certain types of infection were associated with worse prognosis. Self-administration was effective and safe, except in case of nursing home-acquired infections. Conclusion: Ertapenem OPAT was effective and safe. Caregivers in nursing homes should be better trained in OPAT-related procedures.</style></abstract><notes><style face="normal" font="default" size="100%">L624231285&#xD;2018-10-15&#xD;2019-01-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L624231285&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2217/fmb-2018-0065</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">30238769</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2217/fmb-2018-0065</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">46</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nagata, S.</style></author><author><style face="normal" font="default" size="100%">Asahara, T.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Suyama, Y.</style></author><author><style face="normal" font="default" size="100%">Chonan, O.</style></author><author><style face="normal" font="default" size="100%">Takano, K.</style></author><author><style face="normal" font="default" size="100%">Daibou, M.</style></author><author><style face="normal" font="default" size="100%">Takahashi, T.</style></author><author><style face="normal" font="default" size="100%">Nomoto, K.</style></author><author><style face="normal" font="default" size="100%">Yamashiro, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Nagata, Department of Pediatrics, School of Medicine, Tokyo Women&apos;s Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Effectiveness of Lactobacillus Beverages in Controlling Infections among the Residents of an Aged Care Facility: A Randomized Placebo-Controlled Double-Blind Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Nutrition and Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Nutrition and Metabolism</style></full-title></periodical><pages><style face="normal" font="default" size="100%">51-59</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetic acid</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">laxative</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">acidity</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">beverage</style></keyword><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">intestine flora</style></keyword><keyword><style face="normal" font="default" size="100%">intestine motility</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus casei</style></keyword><keyword><style face="normal" font="default" size="100%">lactobacillus casei strain shirota fermented milk</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical staff</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">resident</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9697&#xD;0250-6807</style></isbn><abstract><style face="normal" font="default" size="100%">Backgrounds/Aims: To clarify the usefulness of Lactobacillus casei strain Shirota (LcS)-fermented milk in the normalization of bowel movements and improvement of infection control for the elderly residents and staff of facilities for the elderly. Methods: A randomized placebo-controlled double-blind test was performed among the elderly residents (average age, 85) and staff members (average age, 37) of facilities for the elderly. The participants randomly received either LcS-fermented milk or a placebo beverage once daily for 6 months. Clinical data and enteric conditions were compared between the 2 groups. Results: A significantly lower incidence of fever and improved bowel movements were seen in the LcS-fermented milk group (n = 36) in comparison to the placebo group (n = 36). The numbers of Bifidobacterium and Lactobacillus were significantly higher (p &lt; 0.01), the numbers of destructive bacteria such as Clostridium difficile were significantly lower (p &lt; 0.05), and the fecal acetic acid concentration and total acidity were significantly higher in the LcS group. A significant difference in the intestinal microbiota, fecal acetic acid, and pH was also observed between the LcS and placebo groups among the facility&apos;s staff members. Conclusions: The long-term consumption of LcSfermented milk may be useful for decreasing the daily risk of infection and improving the quality of life among the residents and staff of facilities for the elderly.</style></abstract><notes><style face="normal" font="default" size="100%">L607116079&#xD;2015-12-08&#xD;2016-02-11</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L607116079&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1159/000442305</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">26599038</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000442305</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">97</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Van Der Sande, M. A. B.</style></author><author><style face="normal" font="default" size="100%">Meijer, A.</style></author><author><style face="normal" font="default" size="100%">Şen-Kerpiclik, F.</style></author><author><style face="normal" font="default" size="100%">Enserink, R.</style></author><author><style face="normal" font="default" size="100%">Cools, H. J. M.</style></author><author><style face="normal" font="default" size="100%">Overduin, P.</style></author><author><style face="normal" font="default" size="100%">Ferreira, J. M.</style></author><author><style face="normal" font="default" size="100%">Veldman-Ariessen, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.A.B. Van Der Sande, Centre Infectious Disease Control, RIVM, PO Box 1-pb75, Bilthoven, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of post-exposition prophylaxis with oseltamivir in nursing homes: A randomised controlled trial over four seasons</style></title><secondary-title><style face="normal" font="default" size="100%">Emerging Themes in Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Emerging Themes in Epidemiology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">oseltamivir</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">influenza A (H3N2)</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza virus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza B virus</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">post exposure prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">virus detection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1742-7622</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Oseltamivir has been registered for use as post-exposition prophylaxis (PEP) following exposure to influenza, based on studies among healthy adults. Effectiveness among frail elderly nursing home populations still needs to be properly assessed. Methods. We conducted a randomised double-blind placebo-controlled trial of PEP with either oseltamivir (75 mg once daily) or placebo among nursing home units where influenza virus was detected; analysis was unblinded. The primary outcome was laboratory-confirmed influenza among residents in units on PEP; the secondary outcome was clinical diagnosis of influenza-like illness (ILI). Results: 42 nursing homes were recruited, in which 17 outbreaks occurred from 2009 through 2013, two caused by influenza virus B, the others caused by influenza virus A(H3N2). Randomisation was successful in 15 outbreaks, with a few chance differences in baseline indicators. Six outbreaks were assigned to oseltamivir and nine to placebo. Influenza virus positive secondary ILI cases were detected in 2/6 and 2/9 units respectively (ns); secondary ILI cases occurred in 2/6 units on oseltamivir, and 5/9 units on placebo (ns). Logistical challenges in ensuring timely administration were considerable. Conclusion: We did not find statistical evidence that PEP with oseltamivir given to nursing home residents in routine operational settings exposed to influenza reduced the risk of new influenza infections within a unit nor that of developing ILI. Power however was limited due to far fewer outbreaks in nursing homes than expected since the 2009 pandemic. (RCT nr NL92738).</style></abstract><notes><style face="normal" font="default" size="100%">L600286616&#xD;2014-11-11&#xD;2014-11-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L600286616&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/1742-7622-11-13</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1742-7622-11-13</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">95</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turnbull, I. R.</style></author><author><style face="normal" font="default" size="100%">Wlzorek, J. J.</style></author><author><style face="normal" font="default" size="100%">Osborne, D.</style></author><author><style face="normal" font="default" size="100%">Hotchkiss, R. S.</style></author><author><style face="normal" font="default" size="100%">Coopersmith, C. M.</style></author><author><style face="normal" font="default" size="100%">Buchman, T. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of age on mortality and antibiotic efficacy in cecal ligation and puncture</style></title><secondary-title><style face="normal" font="default" size="100%">Shock</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Shock</style></full-title></periodical><pages><style face="normal" font="default" size="100%">310-3</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cecum/injuries/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ceftriaxone/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Perforation/complications/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Metronidazole/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Sepsis/*drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Wounds, Penetrating/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1073-2322 (Print)&#xD;1073-2322</style></isbn><abstract><style face="normal" font="default" size="100%">The incidence and mortality of sepsis increase with age, consequently, 80% of the clinical mortality from sepsis occurs in patients over age 65. Despite this aged clinical population, most research models of sepsis use 6- to 16-week-old mice as patient surrogates. This age range of mice corresponds to human ages 10 to 17 years. To assess the influence of age on rodent CLP and on antibiotic therapy, we studied young (4 month), mature (12 month), and aged (24 month) mice. Male C57BL/6 mice (n = 27-30 in each age group) were subjected to cecal ligation and puncture (CLP), two punctures with a 25-gauge needle. Mice were observed untreated for 10 days. Young mice had 20% mortality, mature mice had 70% mortality (P = 0.0013 vs. young), and aged mice had 75% mortality (P = 0.0001 vs. young). To assess the effects of age on antibiotic therapy, mice were subjected to CLP as above (n = 38-40 in each age group). Mice were then randomized to treatment with intraperitoneal injections of ceftriaxone and metronidazole or normal saline. Therapy was initiated 12 h after CLP, and injections were repeated every 12 h for 7 days. Young mice saw a 56% decrease in mortality from CLP with antibiotic therapy (P = 0.001), and mature mice had a 30% decrease in mortality (P = 0.06). Aged mice saw no benefit from antibiotic therapy. We also compared plasma cytokine levels between young and aged mice after CLP. When compared with young mice, aged mice had higher levels of IL-6 and TNF-alpha 24 h after CLP. However, high IL-6 was predictive of mortality at any age. Mice appear to have age-dependent responses to intra-abdominal sepsis and to appropriate therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Turnbull, Isaiah R&#xD;Wlzorek, Joseph J&#xD;Osborne, Dale&#xD;Hotchkiss, Richard S&#xD;Coopersmith, Craig M&#xD;Buchman, Timothy G&#xD;GM 48095/GM/NIGMS NIH HHS/United States&#xD;GM00709/GM/NIGMS NIH HHS/United States&#xD;GM44118/GM/NIGMS NIH HHS/United States&#xD;GM55194/GM/NIGMS NIH HHS/United States&#xD;GM66202/GM/NIGMS NIH HHS/United States&#xD;P30 DK52574/DK/NIDDK NIH HHS/United States&#xD;T32 DK07130/DK/NIDDK NIH HHS/United States&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Shock. 2003 Apr;19(4):310-3. doi: 10.1097/00024382-200304000-00003.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00024382-200304000-00003</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fonollá, J.</style></author><author><style face="normal" font="default" size="100%">Gracián, C.</style></author><author><style face="normal" font="default" size="100%">Maldonado-Lobón, J. A.</style></author><author><style face="normal" font="default" size="100%">Romero, C.</style></author><author><style face="normal" font="default" size="100%">Bédmar, A.</style></author><author><style face="normal" font="default" size="100%">Carrillo, J. C.</style></author><author><style face="normal" font="default" size="100%">Martín-Castro, C.</style></author><author><style face="normal" font="default" size="100%">Cabrera, A. L.</style></author><author><style face="normal" font="default" size="100%">García-Curiel, J. M.</style></author><author><style face="normal" font="default" size="100%">Rodríguez, C.</style></author><author><style face="normal" font="default" size="100%">Sanbonmatsu, S.</style></author><author><style face="normal" font="default" size="100%">Pérez-Ruiz, M.</style></author><author><style face="normal" font="default" size="100%">Navarro, J. M.</style></author><author><style face="normal" font="default" size="100%">Olivares, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Olivares, Biosearch Life, Camino de Purchil 66, Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of Lactobacillus coryniformis K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">83-90</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT03167593</style></keyword><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 10</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 4</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antibody titer</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bone pain</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">decreased appetite</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">flu like syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemagglutination inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus coryniformis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">nose obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">protein blood level</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract disease</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">seroconversion</style></keyword><keyword><style face="normal" font="default" size="100%">sore throat</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1436-6215&#xD;1436-6207</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose: Elderly people are particularly vulnerable to seasonal influenza. Therefore, vaccination is strongly recommended. However, the vaccine efficacy is lower in the elderly, owing to immunosenescence. The objective of the present study was to evaluate the ability of the probiotic strain Lactobacillus coryniformis K8 CECT5711 to enhance the immune response to the influenza vaccine in the elderly and to assess the effects on symptoms related to respiratory infections. Methods: A randomized, double-blind, placebo-controlled trial was conducted between November 2015 and April 2016. A total of 98 nursing home residents, more than 65 years of age were randomly assigned to receive L. coryniformis K8 CECT5711 (3 × 109 CFU/day) or a placebo for 2 weeks before influenza vaccination. The primary outcome was the percentage of seroconversion. The secondary outcomes were the incidence of influenza-like illness (ILI) and respiratory symptoms associated with respiratory infections during the 5-month follow-up period. The serum cytokine and immunoglobulin levels were also evaluated. Results: The percentage of responders to vaccination was higher in the probiotic group than in the control group (p = 0.036). L. coryniformis ingestion was associated with a significantly lower incidence of respiratory symptoms commonly associated with respiratory infections (p = 0.007) and lower consumption of analgesics (p = 0.008). Conclusion: The administration of L. coryniformis K8 CECT5711 to an elderly population increased the immune response against the influenza vaccine and decreased symptoms associated with respiratory infections. Probiotic administration may be a natural and safe strategy to improve the efficacy of vaccines and to protect against common respiratory infections in susceptible populations.</style></abstract><notes><style face="normal" font="default" size="100%">L619200056&#xD;2017-11-16&#xD;2019-03-29</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L619200056&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s00394-017-1573-1</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">29124387</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00394-017-1573-1</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morita, Y.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, K.</style></author><author><style face="normal" font="default" size="100%">Nakano, M.</style></author><author><style face="normal" font="default" size="100%">Wakabayashi, H.</style></author><author><style face="normal" font="default" size="100%">Yamauchi, K.</style></author><author><style face="normal" font="default" size="100%">Abe, F.</style></author><author><style face="normal" font="default" size="100%">Ooka, T.</style></author><author><style face="normal" font="default" size="100%">Hironaka, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Special Needs Dentistry, Division of Hygiene and Oral Health, Showa University School of Dentistry, Tokyo, Japan.&#xD;Food Ingredients &amp; Technology Institute, Morinaga Milk Industry, Saitama, Japan.&#xD;Division of feeding and swallowing rehabilitation, Department of Restorative and Biomaterials Sciences, Meikai University School of Dentistry, Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: A randomized, double blinded, placebo-controlled clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Geriatr Gerontol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Geriatr Gerontol Int</style></full-title></periodical><pages><style face="normal" font="default" size="100%">714-721</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Food</style></keyword><keyword><style face="normal" font="default" size="100%">Food Analysis/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Gingivitis/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lactoferrin/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Lactoperoxidase/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mouth Mucosa/drug effects/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Oral Hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">lactoferrin</style></keyword><keyword><style face="normal" font="default" size="100%">lactoperoxidase</style></keyword><keyword><style face="normal" font="default" size="100%">older individuals</style></keyword><keyword><style face="normal" font="default" size="100%">periodontal bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">randomized clinical trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1447-0594</style></isbn><abstract><style face="normal" font="default" size="100%">AIM: Lactoferrin and lactoperoxidase have antimicrobial effects against oral pathogens. This randomized, double-blinded, placebo-controlled parallel group study tested the efficacy of a lactoferrin and lactoperoxidase-containing tablet (LF + LPO tablet) in improving the oral hygiene status of older individuals. METHODS: A total of 46 participants (31 nursing home residents and 15 healthy older individuals) were randomly assigned to receive either lactoferrin and lactoperoxidase-containing tablets or placebo tablets, and were asked to suck on a tablet after every meal for 8 weeks. Oral and bacteriological assessments were carried out at baseline, 4 weeks and 8 weeks. RESULTS: A total of 47 participants (test group n = 20; mean age 80.4 ± 6.4 years; placebo group n = 17; mean age 85.9 ± 6.7 years) were included in the efficacy analysis. In the test group, the total number of bacteria in the tongue coating was significantly reduced at 4 and 8 weeks compared with that at baseline, and the number of Porphyromonas gingivalis and Fusobacterium nucleatum was significantly reduced at 8 weeks. The total number of bacteria and the number of P. gingivalis in the supragingival plaque were significantly reduced at 8 weeks. Furthermore, there was a significant difference in the change in the number of P. gingivalis in supragingival plaque at 8 weeks between the two groups. CONCLUSIONS: Lactoferrin and lactoperoxidase-containing tablet ingestion showed antibacterial effects on periodontal bacteria present in the tongue coating and supragingival plaque, indicating that long-term ingestion could improve the oral hygiene of older individuals. Geriatr Gerontol Int 2017; 17: 714-721.</style></abstract><notes><style face="normal" font="default" size="100%">1447-0594&#xD;Morita, Yu&#xD;Ishikawa, Kentaro&#xD;Nakano, Manabu&#xD;Wakabayashi, Hiroyuki&#xD;Yamauchi, Koji&#xD;Abe, Fumiaki&#xD;Ooka, Takafumi&#xD;Hironaka, Shouji&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Japan&#xD;Geriatr Gerontol Int. 2017 May;17(5):714-721. doi: 10.1111/ggi.12776. Epub 2016 May 6.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ggi.12776</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gomolin, I. H.</style></author><author><style face="normal" font="default" size="100%">Siami, P. F.</style></author><author><style face="normal" font="default" size="100%">Reuning-Scherer, J.</style></author><author><style face="normal" font="default" size="100%">Haverstock, D. C.</style></author><author><style face="normal" font="default" size="100%">Heyd, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gurwin Jewish Geriatric Center, Commack, New York 11725, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1606-13</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Ciprofloxacin/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Suspensions</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Trimethoprim, Sulfamethoxazole Drug Combination/*administration &amp; dosage/therapeutic</style></keyword><keyword><style face="normal" font="default" size="100%">use</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To compare the efficacy and safety of ciprofloxacin (CIP) oral suspension to trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension among older women with acute urinary tract infections (UTIs). DESIGN: Prospective, randomized, open-label, multicenter study of older women (age 65 and older). SETTING: Community and nursing home. PARTICIPANTS: A total of 261 older women were evaluable for safety. Of these, 172 (86 community, 86 nursing home) were evaluable for clinical and bacteriological efficacy. INTERVENTION: Patients were randomized to a 10-day regimen of either CIP (250 mg/5 mL twice daily) or TMP/SMX (160/800 mg/20 mL twice daily). MEASUREMENTS: Clinical response 4 to 10 days posttherapy. RESULTS: For the efficacy-valid population, posttherapy clinical resolution was statistically superior following CIP (97%) versus TMP/SMX (85%) (95% CI=2.0-21.3; P= .009). Eradication of pretreatment bacterial isolates posttherapy was also higher following CIP (95%) versus TMP/SMX (84%) (95% CI=2.7-21.3; P= .019). For the intent-to-treat population, posttherapy clinical resolution was significantly higher in the CIP group (96%) than in the TMP/SMX group (87%) (95% CI=0.2-16.7; P= .025). Safety was assessed in the intent-to-treat population and the incidence of drug-related adverse events were significantly lower following CIP (17%) than following TMP/SMX (27%) (P= .047). Premature discontinuation due to these events was also less prevalent with CIP than with TMP/SMX (2% vs 11%, respectively) (P= .004). CONCLUSION: CIP suspension showed higher clinical success and bacteriological eradication rates than did TMP/SMX for both community-based and nursing home-residing older women with acute UTIs. Furthermore, CIP suspension was associated with significantly lower rates of adverse events and premature discontinuations compared with TMP/SMX suspension.</style></abstract><notes><style face="normal" font="default" size="100%">Gomolin, I H&#xD;Siami, P F&#xD;Reuning-Scherer, J&#xD;Haverstock, D C&#xD;Heyd, A&#xD;Oral Suspension Study Group&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Geriatr Soc. 2001 Dec;49(12):1606-13. doi: 10.1046/j.1532-5415.2001.t01-1-49268.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1532-5415.2001.t01-1-49268.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Brien, C.</style></author><author><style face="normal" font="default" size="100%">Ning, N.</style></author><author><style face="normal" font="default" size="100%">McAvoy, J.</style></author><author><style face="normal" font="default" size="100%">Mitchell, J. E.</style></author><author><style face="normal" font="default" size="100%">Kalwani, N.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Nguyen, D.</style></author><author><style face="normal" font="default" size="100%">Reejhsinghani, R.</style></author><author><style face="normal" font="default" size="100%">Rogers, A.</style></author><author><style face="normal" font="default" size="100%">Lorenzo, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. O&apos;Brien, Stanford Hospital and Clinics, Department of Pulmonology, Allergy, and Critical Care Medicine, 300 Pasteur Drive, Room H3143, Stanford, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Electrical Storm in COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">JACC: Case Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JACC: Case Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1256-1260</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">amiodarone</style></keyword><keyword><style face="normal" font="default" size="100%">cefepime</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">noradrenalin</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen</style></keyword><keyword><style face="normal" font="default" size="100%">piperacillin plus tazobactam</style></keyword><keyword><style face="normal" font="default" size="100%">remdesivir</style></keyword><keyword><style face="normal" font="default" size="100%">troponin</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">vasopressin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">autopsy</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">blood culture</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">cardioversion</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">coronary artery disease</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">dyspnea</style></keyword><keyword><style face="normal" font="default" size="100%">electrical storm (heart)</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure with preserved ejection fraction</style></keyword><keyword><style face="normal" font="default" size="100%">heart muscle injury</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">lung compliance</style></keyword><keyword><style face="normal" font="default" size="100%">lung embolism</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">multiple organ failure</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen saturation</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">percutaneous coronary intervention</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">polymorphic ventricular tachycardia</style></keyword><keyword><style face="normal" font="default" size="100%">positive end expiratory pressure ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas infection</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">thorax radiography</style></keyword><keyword><style face="normal" font="default" size="100%">throat culture</style></keyword><keyword><style face="normal" font="default" size="100%">total hip replacement</style></keyword><keyword><style face="normal" font="default" size="100%">treatment withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword><keyword><style face="normal" font="default" size="100%">virus pneumonia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">2666-0849</style></isbn><abstract><style face="normal" font="default" size="100%">COVID-19 is a global pandemic caused by SARS-CoV-2. Infection is associated with significant morbidity and mortality. Individuals with pre-existing cardiovascular disease or evidence of myocardial injury are at risk for severe disease and death. Little is understood about the mechanisms of myocardial injury or life-threatening cardiovascular sequelae. (Level of Difficulty: Intermediate.) COVID-19 is a global pandemic caused by SARS-CoV-2. Infection is associated with significant morbidity and mortality. Individuals with pre-existing…</style></abstract><notes><style face="normal" font="default" size="100%">L2006961168&#xD;2020-07-15&#xD;2020-07-16</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2006961168&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jaccas.2020.05.032</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jaccas.2020.05.032</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saxena, A. K.</style></author><author><style face="normal" font="default" size="100%">Panhotra, B. R.</style></author><author><style face="normal" font="default" size="100%">Sundaram, D. S.</style></author><author><style face="normal" font="default" size="100%">Morsy, M. N. F.</style></author><author><style face="normal" font="default" size="100%">Al-Ghamdi, A. M. A. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.K. Saxena, Nephrology Division, Department of Medicine, Sheikh Khalifa Medical City, PO Box-51900, Abu Dhabi, United Arab Emirates</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: A randomised, double-blind clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">299-305</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cefotaxime</style></keyword><keyword><style face="normal" font="default" size="100%">heparin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood clot lysis</style></keyword><keyword><style face="normal" font="default" size="100%">catheter</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">catheter thrombosis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan Meier method</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">log rank test</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">statistical analysis</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1320-5358&#xD;1440-1797</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Tunneled-cuffed catheters (TCC) are often used among the elderly to commence and carry out haemodialysis (HD). Complications like infection and thrombosis frequently reduce the lifespan of TCC. The role of an antibiotic heparin &apos;lock&apos; in the prevention of thrombotic and infectious complications and enhancement of TCC survival in the elderly has not been investigated previously. Methods: In this prospective, double-blind clinical trial, TCC (n = 119, placed among 113 elderly patients requiring HD during March 2002 - February 2003) were randomised to either group I having TCC (n = 59, placed in 58 elderly patients) locked with cefotaxime (10 mg/mL) and heparin (5000 U/mL), or group II with TCC (n = 60, placed in 55 elderly patients) having catheter-restricted filling of heparin (5000 U/mL) alone. Symptomatic catheter-related blood stream infections (CRBSI) and catheter thrombosis were the primary end points in this study. Thrombosis was defined as an inability to use the catheter at a blood flow of 200 mL/min that did not respond to catheter repositioning and/or intraluminal thrombolysis. The incidence of catheter thrombosis, CRBSI and percentage of catheter survival were estimated and statistically compared between the two groups. Results: Kaplan-Meier survival analysis using log rank test showed higher thrombosis-free TCC survival (84.7% vs 63.3%, P = 0.021), infection-free survival (68.7% vs 31.3%, P &lt; 0.001) and infection and thrombosis-free survival (65.0% vs 35.0%, P = 0.006) at 365 days in group I compared with group II. Conclusion: Cefotaxime and heparin locks safely and effectively enhance the lifespan of TCC by lowering the incidence of thrombotic and infectious complications among elderly end-stage renal failure (ESRD) patients. © 2006 The Authors.</style></abstract><notes><style face="normal" font="default" size="100%">L44086874&#xD;2006-07-30</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L44086874&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1440-1797.2006.00563.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">16889569</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1440-1797.2006.00563.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crusio, R.</style></author><author><style face="normal" font="default" size="100%">Rao, S.</style></author><author><style face="normal" font="default" size="100%">Changawala, N.</style></author><author><style face="normal" font="default" size="100%">Paul, V.</style></author><author><style face="normal" font="default" size="100%">Tiu, C.</style></author><author><style face="normal" font="default" size="100%">Van Ginkel, J.</style></author><author><style face="normal" font="default" size="100%">Chapnick, E.</style></author><author><style face="normal" font="default" size="100%">Kupfer, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Crusio, 7600 Carroll Ave, Takoma Park, MD 20912, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-8</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">carbapenem</style></keyword><keyword><style face="normal" font="default" size="100%">polymyxin B</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">sultamicillin</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter infection</style></keyword><keyword><style face="normal" font="default" size="100%">acute heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">acute kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">acute respiratory failure</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">brain disease</style></keyword><keyword><style face="normal" font="default" size="100%">carbapenem resistant Gram negative bacteria infection</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">disseminated intravascular clotting</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperbilirubinemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyperglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae infection</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas infection</style></keyword><keyword><style face="normal" font="default" size="100%">reinfection</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0036-5548&#xD;1651-1980</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Infections with carbapenem-resistant Gram-negative bacteria (CRGNB) are increasing and are associated with a high mortality. Synergistic effects of combination therapy with a polymyxin, carbapenem, and rifampin have been observed in in vitro studies. Clinical data are limited to retrospective studies. Methods: We performed an observational cohort study of patients over 18 y of age who were treated with polymyxin B combination therapy. Results: One hundred and four patients were studied. The mean age was 77 y; 73% had recently received antibiotics, 67% had recently been hospitalized, and 47% lived in a nursing facility. The most common infections were pneumonia and urinary tract infection due to Acinetobacter baumannii (33%), Klebsiella pneumoniae (24%), and Pseudomonas aeruginosa (11%). Treatment regimens included polymyxin B with a carbapenem in 48%, with additional rifampin in 23%. Clinical success was achieved in 50% and reinfection occurred in 25%. Treatment-related acute renal failure occurred in 14.4%. No treatment-related hemodialysis was needed. All-cause hospital mortality was 47% and mortality after 6 months was 77%. No significant difference was found between treatment regimens. Age (odds ratio (OR) 10.4 per 10 y, p = 0.04), severity of acute illness (OR 2.2 per point, p &lt; 0.001), and Charlson score (OR 1.12 per point, p = 0.04) were associated with hospital mortality. K. pneumoniae was associated with increased hospital survival compared to other CRGNB (p = 0.03). Conclusion: CRGNB infections are associated with previous antibiotic and health care exposure. Mortality is related to age and the severity of chronic and acute illness. © 2013 Informa Healthcare.</style></abstract><notes><style face="normal" font="default" size="100%">L370556171&#xD;2014-01-02&#xD;2014-01-08</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L370556171&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3109/00365548.2013.844350</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24206450</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/00365548.2013.844350</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Handler, S. M.</style></author><author><style face="normal" font="default" size="100%">Wright, R. M.</style></author><author><style face="normal" font="default" size="100%">Ruby, C. M.</style></author><author><style face="normal" font="default" size="100%">Hanlon, J. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.M. Handler, Division of Geriatric Medicine, Department of Medicine, School of Medicine, Pittsburgh, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology of medication-related adverse events in nursing homes</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal Geriatric Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal Geriatric Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">264-272</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">anxiolytic agent</style></keyword><keyword><style face="normal" font="default" size="100%">digoxin</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">hypnotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">sedative agent</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced disease</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte disturbance</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">medication error</style></keyword><keyword><style face="normal" font="default" size="100%">Medline</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent disease</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1543-5946</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Nursing home residents are prescribed more medications than patients in any other clinical setting. Although pharmacotherapy for older nursing home residents is usually safe and effective, it can lead to medication-related adverse events such as adverse drug reactions (ADRs), adverse drug withdrawal events (ADWEs), and therapeutic failures (TFs). Objective: This article reviews the descriptive (incidence) and analytic (risk factor) epidemiology of medication-related adverse events occurring in nursing home residents as reported in the literature during the last 2 decades. Methods: A search of MEDLINE and International Pharmaceutical Abstracts was conducted for articles published in English between January 1986 and July 2006 using the following terms: adverse drug events, adverse drug reactions, adverse drug withdrawal events, aged, drug therapy, drug-related problems, medication-related problems, nursing homes, therapeutic failures, and treatment failures. The reference lists of identified articles, recent review articles, book chapters, and the authors&apos; reference library were also searched manually. Results: Seven studies met the inclusion and exclusion criteria and were included in this review. Five studies described ADRs, 1 described ADWEs, and 1 described TFs. The studies of ADRs used different methods of detecting ADRs, resulting in incidence rates ranging from 1.19 to 7.26 per 100 resident-months. The single study of ADWEs reported an incidence of 2.60 per 100 resident-months. An incidence rate for the single study describing TFs could not be calculated. Conclusions: Medication-related adverse events are common in the nursing home setting. Additional studies are needed to enhance the detection and prevention of medication-related adverse events and to reduce their impact on residents&apos; outcomes and health care costs. © 2006 Excerpta Medica, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L44575967&#xD;2006-11-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L44575967&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.amjopharm.2006.09.011</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17062328</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.amjopharm.2006.09.011</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>199</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">199</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leppik, I. E.</style></author><author><style face="normal" font="default" size="100%">Birnbaum, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">I. E. Leppik, 7500 Western Ave, Golden Valley, MN 55427, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epilepsy in the elderly</style></title></titles><pages><style face="normal" font="default" size="100%">208-224</style></pages><volume><style face="normal" font="default" size="100%">1184</style></volume><number><style face="normal" font="default" size="100%">(Leppik I.E., leppi001@umn.edu) Department of Neurology, University of Minnesota, Minneapolis, MN, United States</style></number><keywords><keyword><style face="normal" font="default" size="100%">antacid agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">benzodiazepine</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">cimetidine</style></keyword><keyword><style face="normal" font="default" size="100%">dextropropoxyphene</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">etiracetam</style></keyword><keyword><style face="normal" font="default" size="100%">felbamate</style></keyword><keyword><style face="normal" font="default" size="100%">fluoxetine</style></keyword><keyword><style face="normal" font="default" size="100%">gabapentin</style></keyword><keyword><style face="normal" font="default" size="100%">ketoconazole</style></keyword><keyword><style face="normal" font="default" size="100%">lamotrigine</style></keyword><keyword><style face="normal" font="default" size="100%">norfluoxetine</style></keyword><keyword><style face="normal" font="default" size="100%">oxcarbazepine</style></keyword><keyword><style face="normal" font="default" size="100%">paroxetine</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">primidone</style></keyword><keyword><style face="normal" font="default" size="100%">psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">sertraline</style></keyword><keyword><style face="normal" font="default" size="100%">thyroid hormone derivative</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin</style></keyword><keyword><style face="normal" font="default" size="100%">zonisamide</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">balance impairment</style></keyword><keyword><style face="normal" font="default" size="100%">brain tumor</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">complex partial seizure</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electroencephalography</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">epileptogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">falling</style></keyword><keyword><style face="normal" font="default" size="100%">fracture</style></keyword><keyword><style face="normal" font="default" size="100%">head injury</style></keyword><keyword><style face="normal" font="default" size="100%">heart conduction</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyponatremia</style></keyword><keyword><style face="normal" font="default" size="100%">renal clearance</style></keyword><keyword><style face="normal" font="default" size="100%">liver metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">neurobiology</style></keyword><keyword><style face="normal" font="default" size="100%">neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">neutropenia</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">nystagmus</style></keyword><keyword><style face="normal" font="default" size="100%">osteoporosis</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacoepidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">protein binding</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">seizure susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">time to maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">transgenic mouse</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">darvon</style></keyword><keyword><style face="normal" font="default" size="100%">tagamet</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1749-6632&#xD;0077-8923&#xD;9781573317801</style></isbn><abstract><style face="normal" font="default" size="100%">The elderly, often defined as those 65 years or older, are the most rapidly growing segment of the population, and onset of epilepsy is higher in this age group than in any other. This paper reviews recent developments, including a new proposed definition of epilepsy, a transgenic mouse model of Alzheimer&apos;s disease that exhibits complex partial seizures, evidence that the highest incidence of epilepsy may occur after admission to a nursing home, a challenge to the vitamin D hypothesis of osteoporosis associated with antiepileptic drugs (AEDs), evidence that the genetic complement of hepatic isoenzymes is more predictive of metabolic rate than age, and data showing that there is considerable variability in serum levels of AEDs in many nursing home residents during constant dosing conditions. © 2009 New York Academy of Sciences.</style></abstract><notes><style face="normal" font="default" size="100%">L358948776&#xD;2010-06-14&#xD;2010-06-25</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L358948776&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1749-6632.2009.05113.x</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">darvon&#xD;tagamet</style></custom1><custom5><style face="normal" font="default" size="100%">20146700</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1749-6632.2009.05113.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Persson, B.</style></author><author><style face="normal" font="default" size="100%">Stimpel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Sahlgren&apos;s Hospital, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Clin Pharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-64</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Isoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prodrugs/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Tetrahydroisoquinolines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year></dates><isbn><style face="normal" font="default" size="100%">0031-6970 (Print)&#xD;0031-6970</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare the antihypertensive efficacy of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, to treatment with hydrochlorothiazide (HCTZ). PATIENTS: Two hundred and one non-hospitalized male and female patients between 65 and 80 years of age with essential hypertension. METHODS: This was a multicentre, placebo-controlled, double-blind study with a parallel group design. Subjects with a sitting diastolic blood pressure (DBP) &gt; or = 95 mmHg were randomized to monotherapy with placebo, moexipiril 7.5 mg o.d., moexipril 15 mg o.d. or HCTZ 25 mg o.d. for 8 weeks. RESULTS: Throughout the study period treatment with moexipril and HCTZ resulted in significant reductions of DBP compared with placebo, but there were no significant differences between the active treatment groups. At end point the adjusted mean reductions were 10.5, 8.7 and 10.1 mmHg in the HCTZ, moexipril 7.5 mg and moexipril 15 mg groups, respectively, compared to 3.9 mmHg in the placebo group. Treatment with moexipril was associated with two cases of first dose hypotension and two cases of moderate and reversible increases in serum creatinine levels. Otherwise, both dosages of moexipril were well tolerated and the overall percentages of patients who had adverse experiences were smaller than in the placebo group. CONCLUSION: Moexipril is well tolerated and is at least as effective as HCTZ in elderly patients with essential hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Persson, B&#xD;Stimpel, M&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Germany&#xD;Eur J Clin Pharmacol. 1996;50(4):259-64. doi: 10.1007/s002280050104.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s002280050104</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garfinkel, D.</style></author><author><style face="normal" font="default" size="100%">Mangin, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. Garfinkel, Geriatric-Palliative Department, Shoham Geriatric Medical Center, Pardes Hana, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1648-1654</style></pages><volume><style face="normal" font="default" size="100%">170</style></volume><number><style face="normal" font="default" size="100%">18</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">antihypertensive agent</style></keyword><keyword><style face="normal" font="default" size="100%">antilipemic agent</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">benzodiazepine derivative</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">carbidopa plus levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">digoxin</style></keyword><keyword><style face="normal" font="default" size="100%">dipyridamole</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">furosemide</style></keyword><keyword><style face="normal" font="default" size="100%">histamine H2 receptor antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxymethylglutaryl coenzyme A reductase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">metformin</style></keyword><keyword><style face="normal" font="default" size="100%">nitrate</style></keyword><keyword><style face="normal" font="default" size="100%">nonsteroid antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">omeprazole</style></keyword><keyword><style face="normal" font="default" size="100%">oral antidiabetic agent</style></keyword><keyword><style face="normal" font="default" size="100%">pentoxifylline</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">proton pump inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">sulfonylurea</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric care</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric disorder</style></keyword><keyword><style face="normal" font="default" size="100%">health status</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">palliative therapy</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0003-9926&#xD;1538-3679</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Polypharmacy and inappropriate medication use is a problem in elderly patients, who are more likely to experience adverse effects from multiple treatments and less likely to obtain the same therapeutic benefit as younger populations. The Good Palliative-Geriatric Practice algorithm for drug discontinuation has been shown to be effective in reducing polypharmacy and improving mortality and morbidity in nursing home in-patients. This study reports the feasibility of this approach in community-dwelling older patients. Methods: The Good Palliative-Geriatric Practice algorithm was applied to a cohort of 70 community-dwelling older patients to recommend drug discontinuations. Success rates of discontinuation, morbidity, mortality, and changes in health status were recorded. Results: The mean (SD) age of the 70 patients was 82.8 (6.9) years. Forty-three patients (61%) had 3 or more and 26% had 5 or more comorbidities. The mean follow-up was 19 months. Participants used a mean (SD) of 7.7 (3.7) medications. Protocol indicated that discontinuation was recommended for 311 medications in 64 patients (58% of drugs; mean [SD], 4.4 [2.5] drugs per patient overall, 4.9 per patient who had discontinuation). Of the discontinued drug therapies, 2% were restarted because of recurrence of the original indication. Taking nonconsent and failures together, successful discontinuation was achieved in 81%. Ten elderly patients (14%) died after a mean follow-up of 13 months, with the mean age at death of 89 years. No significant adverse events or deaths were attributable to discontinuation, and 88% of patients reported global improvement in health. Conclusions: It is feasible to decrease medication burden in community-dwelling elderly patients. This tool would be suitable for larger randomized controlled trials in different clinical settings. ©2010 American Medical Association. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L359770062&#xD;2010-10-25&#xD;2010-11-02</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L359770062&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1001/archinternmed.2010.355</style></url><url><style face="normal" font="default" size="100%">http://archinte.ama-assn.org/cgi/reprint/170/18/1648</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aspirin</style></custom1><custom5><style face="normal" font="default" size="100%">20937924</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinternmed.2010.355</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tesfaye, H.</style></author><author><style face="normal" font="default" size="100%">Prusa, R.</style></author><author><style face="normal" font="default" size="100%">Jedlickova, B.</style></author><author><style face="normal" font="default" size="100%">Lukaskova, J.</style></author><author><style face="normal" font="default" size="100%">Palivoda, M.</style></author><author><style face="normal" font="default" size="100%">Pavelkova, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. Tesfaye, Faculty Hospital Motol, Division of Clinical Pharmacology, Department of Clinical Biochemistry and Pathobiochemistry, Prague, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Focused Conference Group: P13 - Maximising benefits and minimizing harms from drugs delay of monitoring may add to pre-existing toxicity risk in elderly patients treated with potentially nephrotoxic antibiotics: Case series study</style></title><secondary-title><style face="normal" font="default" size="100%">Basic and Clinical Pharmacology and Toxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Basic and Clinical Pharmacology and Toxicology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">614-615</style></pages><volume><style face="normal" font="default" size="100%">107</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">aminoglycoside</style></keyword><keyword><style face="normal" font="default" size="100%">polypeptide antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">amikacin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">case study</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">clinical pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">kidney function</style></keyword><keyword><style face="normal" font="default" size="100%">deterioration</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">cost control</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">drug toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">drug overdose</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">polarization</style></keyword><keyword><style face="normal" font="default" size="100%">immunoassay</style></keyword><keyword><style face="normal" font="default" size="100%">intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">ischemic heart disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1742-7835</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Elderly patients are prone to drug toxicity due to existing physiologic organ function deterioration and polymorbidity. Thus, drug overdose may be fatal particularly in this population. Aminoglycoside and glycopeptide antibiotics are known nephrotoxins.We describe clinical case series of elderly patients on amikain and vancomycin therapy, who developed renal function impairment in association with toxic drug levels revealed after delayed monitoring and its consequences. Patients and methods:Data of seven patients (66-80 years old), one male and two females treated with amikacin and four females on vancomycin therapy were included in the study. Serum drugs&apos; levels determined by fluorescent polarization immunoassay (FPIA) were used to guide dose adjustment. Results: The patients in the case series demonstrated evident renal function impairment manifested by 2.5-10 fold serum creatinine elevation. Trough levels of the drugs were 2 -15 fold above the recommended range. In one case of amikacin overdose, haemodialysis was required. Underlying ischemic heart disease and sepsis were characteristic for these patients with abnormal drug levels. In conclusion, these cases illustrate that elderly patients on aminoglycoside or glycopeptide antibiotics doses are at increased risk of suddenly renal function deterioration, unless timely monitored regardless of initially normal serum creatinine. In cases, where aminoglycoside or glycopetide antibiotics are indicated in elderly patients, obtaining serum levels immediately before the second dose and accordingly dosing regimen adjustment is warranted as the therapeutic drug monitoring provided without delay may ensure safer and more effectively cost-saving therapy leading to favourable outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">L70224201&#xD;2010-08-11</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L70224201&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1742-7843.2010.00600.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1742-7843.2010.00600.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duvignaud, A.</style></author><author><style face="normal" font="default" size="100%">Lhomme, E.</style></author><author><style face="normal" font="default" size="100%">Pistone, T.</style></author><author><style face="normal" font="default" size="100%">Onaisi, R.</style></author><author><style face="normal" font="default" size="100%">Sitta, R.</style></author><author><style face="normal" font="default" size="100%">Journot, V.</style></author><author><style face="normal" font="default" size="100%">Nguyen, D.</style></author><author><style face="normal" font="default" size="100%">Peiffer-Smadja, N.</style></author><author><style face="normal" font="default" size="100%">Crémer, A.</style></author><author><style face="normal" font="default" size="100%">Bouchet, S.</style></author><author><style face="normal" font="default" size="100%">Darnaud, T.</style></author><author><style face="normal" font="default" size="100%">Poitrenaud, D.</style></author><author><style face="normal" font="default" size="100%">Piroth, L.</style></author><author><style face="normal" font="default" size="100%">Binquet, C.</style></author><author><style face="normal" font="default" size="100%">Michel, J. F.</style></author><author><style face="normal" font="default" size="100%">Lefèvre, B.</style></author><author><style face="normal" font="default" size="100%">Lebeaux, D.</style></author><author><style face="normal" font="default" size="100%">Lebel, J.</style></author><author><style face="normal" font="default" size="100%">Dupouy, J.</style></author><author><style face="normal" font="default" size="100%">Roussillon, C.</style></author><author><style face="normal" font="default" size="100%">Gimbert, A.</style></author><author><style face="normal" font="default" size="100%">Wittkop, L.</style></author><author><style face="normal" font="default" size="100%">Thiébaut, R.</style></author><author><style face="normal" font="default" size="100%">Orne-Gliemann, J.</style></author><author><style face="normal" font="default" size="100%">Joseph, J. P.</style></author><author><style face="normal" font="default" size="100%">Richert, L.</style></author><author><style face="normal" font="default" size="100%">Anglaret, X.</style></author><author><style face="normal" font="default" size="100%">Malvy, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, F-33000, Bordeaux, France. alexandre.duvignaud@chu-bordeaux.fr.&#xD;Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France. alexandre.duvignaud@chu-bordeaux.fr.&#xD;Univ. Bordeaux, Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.&#xD;Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health Research Centre, Inria SISTM, F-33000, Bordeaux, France.&#xD;CHU Bordeaux, Pôle de Santé Publique, F-33000, Bordeaux, France.&#xD;CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, F-33000, Bordeaux, France.&#xD;Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.&#xD;Department of General Practice, Univ. Bordeaux, F-33000, Bordeaux, France.&#xD;CHU Bichat Claude Bernard, Department of Infectious Diseases and Tropical Medicine, APHP, F-75000, Paris, France.&#xD;Université de Paris, IAME, INSERM, F-75018, Paris, France.&#xD;National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.&#xD;Department of Cardiology - Hypertension, CHU Bordeaux, F-33000, Bordeaux, France.&#xD;Inserm U1219, Univ. Bordeaux, F-33000, Bordeaux, France.&#xD;Department of Pharmacology and Toxicology, CHU Bordeaux, F-33000, Bordeaux, France.&#xD;Centre Hospitalier de Bastia, Service de Chirurgie Spécialisée &amp; Unité de Recherche Clinique, F-20200, Bastia, France.&#xD;Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier d&apos;Ajaccio, F-20090, Ajaccio, France.&#xD;Department of Infectious Diseases and Tropical Medicine, CHU Dijon, F-21079, Dijon, France.&#xD;Inserm U1432, Univ. Bourgogne, F-21000, Dijon, France.&#xD;Inserm, CHU Dijon, CIC-EC 1432, F-21000, Dijon, France.&#xD;Centre Medical de Steinsel, Steinsel, Luxembourg.&#xD;Formation Spécialisée en Medecine Generale (FSMG), Université de Luxembourg, Luxembourg City, Luxembourg.&#xD;Department of Infectious Diseases and Tropical Medicine, CHU Nancy, F-54000, Nancy, France.&#xD;Department of Infectious Diseases and Tropical Medicine, Hôpital Européen Georges Pompidou, APHP, F-75000, Paris, France.&#xD;Department of General Practice, Université de Paris, F-75018, Paris, France.&#xD;UMR 1137, INSERM, IAME, F-75018, Paris, France.&#xD;MSPU Pins Justaret, F-31860, Pins Justaret, France.&#xD;Department of General Practice, Univ. Paul Sabatier, F-31000, Toulouse, France.&#xD;UMR 1027 Inserm Univ. Paul Sabatier, F-31000, Toulouse, France.&#xD;CHU Toulouse, CIC, F-31000, Toulouse, France.&#xD;Clinical Research and Innovation Department, Safety and vigilance, CHU Bordeaux, F-33000, Bordeaux, France.&#xD;Clinical Research and Innovation Department, CHU Bordeaux, F-33000, Bordeaux, France.&#xD;Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health Research Centre, MORPH3EUS, F-33000, Bordeaux, France.&#xD;Department of General Practice, CIC 1401, Univ. Bordeaux, F-33000, Bordeaux, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">846</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amides/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Betacoronavirus/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Coronavirus Infections/*drug therapy/epidemiology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">France/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxychloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Imatinib Mesylate/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Luxembourg/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Viral/*drug therapy/epidemiology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Telmisartan/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Therapies, Investigational/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation. TRIAL DESIGN: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial. Participants will be randomly allocated 1:1:1:1:1 to the following strategies: Arm 1: Control arm Arms 2 to 5: Experimental treatment arms Planned interim analyses will be conducted at regular intervals. Their results will be reviewed by an Independent Data and Safety Monitoring Board. Experimental arms may be terminated for futility, efficacy or toxicity before the end of the trial. New experimental arms may be added if new evidence suggests that other treatments should be tested. A feasibility and acceptability substudy as well as an immunological substudy will be conducted alongside the trial. PARTICIPANTS: Inclusion criteria are: 65-year-old or more; Positive test for SARS-CoV-2 on a nasopharyngeal swab; Symptoms onset within 3 days before diagnosis; No hospitalisation criteria; Signed informed consent; Health insurance. Exclusion criteria are: Inability to make an informed decision to participate (e.g.: dementia, guardianship); Rockwood Clinical Frailty Scale ≥7; Long QT syndrome; QTc interval &gt; 500 ms; Heart rate &lt;50/min; Kalaemia &gt;5.5 mmol/L or &lt;3.5 mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib, nilotinib, hydroxyzine, domperidone, citalopram, escitalopram, potent inhibitors or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6-mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to any of the trial drugs or to chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic porphyria; Liver failure (Child-Pugh stage ≥B); Stage 4 or 5 chronic kidney disease (GFR &lt;30 mL/min/1.73 m²); Dialysis; Hypersentivity to lactose; Lactase deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome; Glucose-6-phosphate dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus; Colitis; Enterocolitis; Chronic hepatitis B virus disease. The trial is being conducted in France in the Bordeaux, Corse, Dijon, Nancy, Paris and Toulouse areas as well as in the Grand Duchy of Luxembourg. Participants are recruited either at home, nursing homes, general practices, primary care centres or hospital outpatient consultations. INTERVENTION AND COMPARATOR: The four experimental treatments planned in protocol version 1.2 (April 8(th), 2020) are: (1) Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9; (2) Imatinib 400 mg, 1 tablet QD from day 0 to 9; (3) Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9; (4) Telmisartan 20 mg, 1 tablet QD from day 0 to 9. The comparator is a complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days, for which there is no reason to believe that they are active on the virus. In protocol version 1.2 (April 8th, 2020): People in the control arm will receive a combination of vitamins and trace elements; people in the experimental arms will receive hydroxychloroquine, or favipiravir, or imatinib, or telmisartan. MAIN OUTCOME: The primary outcome is the proportion of participants with an incidence of hospitalisation and/or death between inclusion and day 14 in each arm. RANDOMISATION: Participants are randomized in a 1:1:1:1:1 ratio to each arm using a web-based randomisation tool. Participants not treated with an ARB or ACEI prior to enrolment are randomized to receive the comparator or one of the four experimental drugs. Participants already treated with an ARB or ACEI are randomized to receive the comparator or one of the experimental drugs except telmisartan (i.e.: hydroxychloroquine, imatinib, or favipiravir). Randomisation is stratified on ACEI or ARBs treatment at inclusion and on the type of residence (personal home vs. nursing home). BLINDING (MASKING): This is an open-label trial. Participants, caregivers, investigators and statisticians are not blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 1057 participants will be enrolled if all arms are maintained until the final analysis and no additional arm is added. Three successive futility interim analyses are planned, when the number of participants reaches 30, 60 and 102 in the control arm. Two efficacy analyses (interim n°3 and final) will be performed successively. TRIAL STATUS: This describes the Version 1.2 (April 8(th), 2020) of the COVERAGE protocol that was approved by the French regulatory authority and ethics committee. The trial was opened for enrolment on April 15(th), 2020 in the Nouvelle Aquitaine region (South-West France). Given the current decline of the COVID-19 pandemic in France and its unforeseeable dynamic in the coming months, new trial sites in 5 other French regions and in Luxembourg are currently being opened. A revised version of the protocol was submitted to the regulatory authority and ethics committee on June 15(th), 2020. It contains the following amendments: (i) Inclusion criteria: age ≥65 replaced by age ≥60; time since first symptoms &lt;3 days replaced by time since first symptoms &lt;5 days; (ii) Withdrawal of the hydroxychloroquine arm (due to external data); (iii) increase in the number of trial sites. TRIAL REGISTRATION: The trial was registered on Clinical Trials.gov on April 22(nd), 2020 (Identifier: NCT04356495): and on EudraCT on April 10(th), 2020 (Identifier: 2020-001435-27). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).</style></abstract><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Duvignaud, Alexandre&#xD;Orcid: 0000-0001-7139-2687&#xD;Lhomme, Edouard&#xD;Pistone, Thierry&#xD;Onaisi, Racha&#xD;Sitta, Rémi&#xD;Journot, Valérie&#xD;Nguyen, Duc&#xD;Peiffer-Smadja, Nathan&#xD;Crémer, Antoine&#xD;Bouchet, Stéphane&#xD;Darnaud, Thomas&#xD;Poitrenaud, Delphine&#xD;Piroth, Lionel&#xD;Binquet, Christine&#xD;Michel, Jean-François&#xD;Lefèvre, Benjamin&#xD;Lebeaux, David&#xD;Lebel, Josselin&#xD;Dupouy, Julie&#xD;Roussillon, Caroline&#xD;Gimbert, Anne&#xD;Wittkop, Linda&#xD;Thiébaut, Rodolphe&#xD;Orne-Gliemann, Joanna&#xD;Joseph, Jean-Philippe&#xD;Richert, Laura&#xD;Anglaret, Xavier&#xD;Malvy, Denis&#xD;COVERAGE study group&#xD;NA/Université de Bordeaux/&#xD;Na/inserm/&#xD;NA/Agence Nationale de la Recherche/&#xD;NA/Ministère de la Santé/&#xD;NA/EIT Health/&#xD;Clinical Trial, Phase III&#xD;Letter&#xD;Randomized Controlled Trial&#xD;Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7552584</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-020-04619-1</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Belisle, S. E.</style></author><author><style face="normal" font="default" size="100%">Hamer, D. H.</style></author><author><style face="normal" font="default" size="100%">Leka, L. S.</style></author><author><style face="normal" font="default" size="100%">Dallal, G. E.</style></author><author><style face="normal" font="default" size="100%">Delgado-Lista, J.</style></author><author><style face="normal" font="default" size="100%">Fine, B. C.</style></author><author><style face="normal" font="default" size="100%">Jacques, P. F.</style></author><author><style face="normal" font="default" size="100%">Ordovas, J. M.</style></author><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. N. Meydani, Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, MA 02111, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-2 and IL-10 gene polymorphisms are associated with respiratory tract infection and may modulate the effect of vitamin E on lower respiratory tract infections in elderly nursing home residents</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">106-114</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT00758914</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 10</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 1beta</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 2</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 6</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gene interaction</style></keyword><keyword><style face="normal" font="default" size="100%">genetic association</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9165&#xD;1938-3207</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Vitamin E supplementation may be a potential strategy to prevent respiratory tract infections (RIs) in the elderly. The efficacy of vitamin E supplementation may depend on individual factors including specific single nucleotide polymorphisms (SNPs) at immunoregulatory genes. Objective: We examined whether the effect of vitamin E on RIs in the elderly was dependent on genetic backgrounds as indicated by SNPs at cytokine genes. Design: We used data and DNA from a previous vitamin E intervention study (200 IU vitamin E or a placebo daily for 1 y) in elderly nursing home residents to examine vitamin E-gene interactions for incidence of RI. We determined the genotypes of common SNPs at IL-1β, IL-2, IL-6, IL-10, TNF-α, and IFN-γ in 500 participants. We used negative binomial regression to analyze the association between genotype and incidence of infection. Results: The effect of vitamin E on lower RI depended on sex and the SNP at IL-10 -819G→A (P = 0.03 for interaction for lower RI). Furthermore, we observed that subjects with the least prevalent genotypes at IL-2 -330A→C (P = 0.02 for upper RI), IL-10 -819G→A (P = 0.08 for upper RI), and IL-10 -1082C→T (P &lt; 0.001 for lower RI in men) had a lower incidence of RI independent of vitamin E supplementation. Conclusions: Studies that evaluate the effect of vitamin E on RIs should consider both genetic factors and sex because our results suggest that both may have a significant bearing on the efficacy of vitamin E. Furthermore, common SNPs at cytokine genes may contribute to the individual risk of RIs in the elderly. This trial was registered at clinicaltrials.gov as NCT00758914. © 2010 American Society for Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">L361080074&#xD;2011-01-19&#xD;2011-01-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L361080074&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3945/ajcn.2010.29207</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20484443</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/ajcn.2010.29207</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bariola, J. R.</style></author><author><style face="normal" font="default" size="100%">McCreary, E. K.</style></author><author><style face="normal" font="default" size="100%">Wadas, R. J.</style></author><author><style face="normal" font="default" size="100%">Kip, K. E.</style></author><author><style face="normal" font="default" size="100%">Marroquin, O. C.</style></author><author><style face="normal" font="default" size="100%">Minnier, T.</style></author><author><style face="normal" font="default" size="100%">Koscumb, S.</style></author><author><style face="normal" font="default" size="100%">Collins, K.</style></author><author><style face="normal" font="default" size="100%">Schmidhofer, M.</style></author><author><style face="normal" font="default" size="100%">Shovel, J. A.</style></author><author><style face="normal" font="default" size="100%">Wisniewski, M. K.</style></author><author><style face="normal" font="default" size="100%">Sullivan, C.</style></author><author><style face="normal" font="default" size="100%">Yealy, D. M.</style></author><author><style face="normal" font="default" size="100%">Nace, D. A.</style></author><author><style face="normal" font="default" size="100%">Huang, D. T.</style></author><author><style face="normal" font="default" size="100%">Haidar, G.</style></author><author><style face="normal" font="default" size="100%">Khadem, T.</style></author><author><style face="normal" font="default" size="100%">Linstrum, K.</style></author><author><style face="normal" font="default" size="100%">Seymour, C. W.</style></author><author><style face="normal" font="default" size="100%">Montgomery, S. K.</style></author><author><style face="normal" font="default" size="100%">Angus, D. C.</style></author><author><style face="normal" font="default" size="100%">Snyder, G. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.R. Bariola, 3601 Fifth Avenue, Suite 3A, Pittsburgh, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality among Nonhospitalized Adults with Severe Acute Respiratory Syndrome Coronavirus 2 Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></full-title></periodical><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">antigen</style></keyword><keyword><style face="normal" font="default" size="100%">bamlanivimab</style></keyword><keyword><style face="normal" font="default" size="100%">beta adrenergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">biological product</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxychloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxymethylglutaryl coenzyme A reductase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">illicit drug</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulating agent</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">prednisone</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">adrenal insufficiency</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol consumption</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Charlson Comorbidity Index</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">congestive heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">coronary artery disease</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">electronic medical record</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">end stage renal disease</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gastroesophageal reflux</style></keyword><keyword><style face="normal" font="default" size="100%">health care system</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperlipidemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">irritable colon</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">malignant neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">morbid obesity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">race</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">sickle cell anemia</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disordered breathing</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco use</style></keyword><keyword><style face="normal" font="default" size="100%">vascular disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">2328-8957</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications. Methods: In this observational study we compared outpatients who received bamlanivimab monoclonal antibody from December 9, 2020 to March 3, 2021 to nontreated patients with a positive polymerase chain reaction or antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the same period who were eligible for monoclonal antibody treatment. The primary outcome was 28-day hospitalization or all-cause mortality, and the secondary outcome was hospitalization or emergency department visit without hospitalization. The risk-adjusted odds of study outcomes comparing bamlanivimab treated and untreated patients was determined using 1:5 propensity matching and multivariable logistic regression. Results: Among 232 patients receiving bamlanivimab matched with 1160 comparator patients, the mean age was 67 years, 56% were female, and 196 (14%) of patients experienced hospitalization or mortality. After adjustment for propensity to receive treatment, bamlanivimab treatment was associated with a significantly reduced risk-adjusted odds of hospitalization or mortality within 28 days (odds ratio [OR], 0.40; 95% confidence interval [95% CI], 0.24-0.69; P &lt;. 001). Bamlanivimab treatment was also associated with a significantly lower risk adjusted odds of hospitalization or emergency department visit without hospitalization (OR, 0.54; 95% CI, 0.35-0.82; P =. 004). The results were most strongly associated with patients age 65 years and older. Conclusions: Bamlanivimab monoclonal antibody monotherapy was associated with reduced hospitalizations and mortality within 28 days among outpatients with mild to moderate COVID-19. Use of bamlanivimab monotherapy for outpatients with mild to moderate COVID-19 infection was associated with reductions in hospitalizations and mortality within 28 days. Benefit was strongest in those age 65 years or older</style></abstract><notes><style face="normal" font="default" size="100%">L2013684428&#xD;2021-07-27&#xD;2021-09-27</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2013684428&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/ofid/ofab254</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofab254</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukhopadhyay, S.</style></author><author><style face="normal" font="default" size="100%">Puopolo, K. M.</style></author><author><style face="normal" font="default" size="100%">Hansen, N. I.</style></author><author><style face="normal" font="default" size="100%">Lorch, S. A.</style></author><author><style face="normal" font="default" size="100%">DeMauro, S. B.</style></author><author><style face="normal" font="default" size="100%">Greenberg, R. G.</style></author><author><style face="normal" font="default" size="100%">Cotten, C. M.</style></author><author><style face="normal" font="default" size="100%">Sánchez, P. J.</style></author><author><style face="normal" font="default" size="100%">Bell, E. F.</style></author><author><style face="normal" font="default" size="100%">Eichenwald, E. C.</style></author><author><style face="normal" font="default" size="100%">Stoll, B. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neonatology, Department of Pediatrics, Children&apos;s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: mukhopadhs@email.chop.edu.&#xD;Division of Neonatology, Department of Pediatrics, Children&apos;s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.&#xD;Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, NC.&#xD;Department of Pediatrics, Duke University, Durham, NC.&#xD;Neonatology and Pediatric Infectious Diseases, Department of Pediatrics, Nationwide Children&apos;s Hospital, The Ohio State University College of Medicine, The Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children&apos;s Hospital, Columbus, OH.&#xD;Department of Pediatrics, University of Iowa, Iowa City, IA.&#xD;Department of Pediatrics, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants</style></title><secondary-title><style face="normal" font="default" size="100%">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Pediatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">39-46.e5</style></pages><volume><style face="normal" font="default" size="100%">221</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Extremely Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurodevelopmental Disorders/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Sepsis/complications/*drug therapy/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*culture-negative infection</style></keyword><keyword><style face="normal" font="default" size="100%">*prolonged early antibiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-3476 (Print)&#xD;0022-3476</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the hypothesis that early-onset sepsis increases risk of death or neurodevelopmental impairment (NDI) among preterm infants; and that among infants without early-onset sepsis, prolonged early antibiotics alters risk of death/NDI. STUDY DESIGN: Retrospective cohort study of infants born at the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network centers (2006-2014) at 22-26 weeks of gestation and birth weight 401-1000 g. Early-onset sepsis defined as growth of a pathogen from blood or cerebrospinal fluid culture ≤72 hours after birth. Prolonged early antibiotics was defined as antibiotics initiated ≤72 hours and continued ≥5 days without culture-confirmed infection, necrotizing enterocolitis, or spontaneous perforation. Primary outcome was death before follow-up or NDI assessed at 18-26 months corrected age. Poisson regression was used to estimate adjusted relative risk (aRR) and CI for early-onset sepsis outcomes. A propensity score for receiving prolonged antibiotics was derived from early clinical factors and used to match infants (1:1) with and without prolonged antibiotic exposure. Log binomial models were used to estimate aRR for outcomes in matched infants. RESULTS: Among 6565 infants, those with early-onset sepsis had higher aRR (95% CI) for death/NDI compared with infants managed with prolonged antibiotics (1.18 [1.06-1.32]) and to infants without prolonged antibiotics (1.23 [1.10-1.37]). Propensity score matching was achieved for 4362 infants. No significant difference in death/NDI (1.04 [0.98-1.11]) was observed with or without prolonged antibiotics among the matched cohort. CONCLUSIONS: Early-onset sepsis was associated with increased risk of death/NDI among extremely preterm infants. Among matched infants without culture-confirmed infection, prolonged early antibiotic administration was not associated with death/NDI.</style></abstract><notes><style face="normal" font="default" size="100%">1097-6833&#xD;Mukhopadhyay, Sagori&#xD;Puopolo, Karen M&#xD;Hansen, Nellie I&#xD;Lorch, Scott A&#xD;DeMauro, Sara B&#xD;Greenberg, Rachel G&#xD;Cotten, C Michael&#xD;Sánchez, Pablo J&#xD;Bell, Edward F&#xD;Eichenwald, Eric C&#xD;Stoll, Barbara J&#xD;Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network&#xD;UG1 HD068263/HD/NICHD NIH HHS/United States&#xD;U10 HD021373/HD/NICHD NIH HHS/United States&#xD;UL1 RR025764/RR/NCRR NIH HHS/United States&#xD;U10 HD053119/HD/NICHD NIH HHS/United States&#xD;UG1 HD068270/HD/NICHD NIH HHS/United States&#xD;UG1 HD027856/HD/NICHD NIH HHS/United States&#xD;UG1 HD034216/HD/NICHD NIH HHS/United States&#xD;U10 HD027871/HD/NICHD NIH HHS/United States&#xD;UG1 HD027880/HD/NICHD NIH HHS/United States&#xD;M01 RR000997/RR/NCRR NIH HHS/United States&#xD;UG1 HD053109/HD/NICHD NIH HHS/United States&#xD;UG1 HD027851/HD/NICHD NIH HHS/United States&#xD;U10 HD036790/HD/NICHD NIH HHS/United States&#xD;UG1 HD087226/HD/NICHD NIH HHS/United States&#xD;U10 HD053124/HD/NICHD NIH HHS/United States&#xD;UG1 HD068244/HD/NICHD NIH HHS/United States&#xD;UG1 HD027853/HD/NICHD NIH HHS/United States&#xD;U10 HD040521/HD/NICHD NIH HHS/United States&#xD;UG1 HD040689/HD/NICHD NIH HHS/United States&#xD;M01 RR000039/RR/NCRR NIH HHS/United States&#xD;UG1 HD087229/HD/NICHD NIH HHS/United States&#xD;M01 RR008084/RR/NCRR NIH HHS/United States&#xD;UG1 HD053089/HD/NICHD NIH HHS/United States&#xD;U10 HD040461/HD/NICHD NIH HHS/United States&#xD;M01 RR000044/RR/NCRR NIH HHS/United States&#xD;M01 RR016587/RR/NCRR NIH HHS/United States&#xD;M01 RR000750/RR/NCRR NIH HHS/United States&#xD;M01 RR000059/RR/NCRR NIH HHS/United States&#xD;K23 HD088753/HD/NICHD NIH HHS/United States&#xD;M01 RR000054/RR/NCRR NIH HHS/United States&#xD;U10 HD021397/HD/NICHD NIH HHS/United States&#xD;UG1 HD027904/HD/NICHD NIH HHS/United States&#xD;UL1 TR000142/TR/NCATS NIH HHS/United States&#xD;M01 RR007122/RR/NCRR NIH HHS/United States&#xD;M01 RR000032/RR/NCRR NIH HHS/United States&#xD;UG1 HD068284/HD/NICHD NIH HHS/United States&#xD;UG1 HD021385/HD/NICHD NIH HHS/United States&#xD;UG1 HD040492/HD/NICHD NIH HHS/United States&#xD;UG1 HD021364/HD/NICHD NIH HHS/United States&#xD;M01 RR000070/RR/NCRR NIH HHS/United States&#xD;M01 RR000080/RR/NCRR NIH HHS/United States&#xD;U10 HD040498/HD/NICHD NIH HHS/United States&#xD;UG1 HD068278/HD/NICHD NIH HHS/United States&#xD;U24 HD095254/HD/NICHD NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;J Pediatr. 2020 Jun;221:39-46.e5. doi: 10.1016/j.jpeds.2020.02.038.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7248124</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS1588607</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpeds.2020.02.038</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Falandry, C.</style></author><author><style face="normal" font="default" size="100%">Brain, E.</style></author><author><style face="normal" font="default" size="100%">Bonnefoy, M.</style></author><author><style face="normal" font="default" size="100%">Mefti, F.</style></author><author><style face="normal" font="default" size="100%">Savoye, A.</style></author><author><style face="normal" font="default" size="100%">Rigal, O.</style></author><author><style face="normal" font="default" size="100%">Oddou-Lagranière, S.</style></author><author><style face="normal" font="default" size="100%">El Kouri, C.</style></author><author><style face="normal" font="default" size="100%">Uwer, L.</style></author><author><style face="normal" font="default" size="100%">Abadie-Lacourtoisie, S.</style></author><author><style face="normal" font="default" size="100%">Cretin, J.</style></author><author><style face="normal" font="default" size="100%">Jacquin, J.</style></author><author><style face="normal" font="default" size="100%">Freyer, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Falandry, Centre Hospitalier Lyon Sud, Lyon, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">15</style></number><keywords><keyword><style face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style face="normal" font="default" size="100%">hormone</style></keyword><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">parameters</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">home care</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">pathologic fracture</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">therapy delay</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">progression free survival</style></keyword><keyword><style face="normal" font="default" size="100%">overall survival</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">cardiotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">visceral metastasis</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">fracture</style></keyword><keyword><style face="normal" font="default" size="100%">hand foot syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0732-183X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Few trials have prospectively evaluated MBC chemotherapy tolerance and outcomes in the elderly. Due to its decreased cardiotoxicity, PLD appears to be an interesting option. Methods: This trial was designed to evaluate tumour response (primary endpoint), feasibility and outcomes after 6 courses of an adapted dose of PLD (40mg/m2/4 wks) in first line hormone-resistant MBC. Results: Out of 60 patients (median age 77, range 70-88), 15% had performance status≥2, 13% initially HR-negative tumours and 70% visceral metastases. Geriatric risk factors included: medical: ≥2 co morbidities: 42%; functional: ≥1 ADL deficit: 10%, ≥1 IADL deficit: 82%, nursing home care: 12%; nutritional: albumin ≤35G/L: 26,7%, BMI&lt;21: 20%; psychological: depression 17%; biological: lymphocytes ≤ 1G/L: 23%. Thus, 23% and 58% reached Fried criteria for frailty and prefrailty. Response rates were respectively 5%, 15% and 60% for complete, partial and stable disease (clinical benefit 80%) but only 48% completed 6 cycles. Causes of premature discontinuation included progression: 18%, severe toxicities: 22%, death: 10% and fracture: 2%. Despite a manageable hamatological (H) profile, many patients presented severe (gr 3-4) non-hematological (NH) toxicities: hand foot syndromes 14%, fatigue 22%, anorexia 9%, infection 19%, pain 17% and non-pathological fractures 7%. Thus, 15% of the patients needed dose reductions and 17% treatment delays≥7 d. Six patients died during treatment (3 possibly related to PLD) and 15 had unplanned hospital admissions. H and NH severe toxicities were differently correlated with geriatric covariates: H was significantly correlated to lymphocytes≤1G/L and NH to age≥80 and nursing home care. Considering outcomes, progression free survival (median: 6.1 months) was negatively correlated with initially HR-negative tumours and increasing age and overall survival (median: 15.7 months) with nursing home care. Conclusions: Despite manageable hematological toxicities and expected response rates, PLD tolerability was poor in light of non-hematological toxicities and geriatric outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">L70712071&#xD;2012-04-10</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L70712071&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://meeting.ascopubs.org/cgi/content/abstract/29/15-suppl/9122?sid=63413269-0fde-4c09-8ce8-ff5c058d16d4</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">El-Solh, A. A.</style></author><author><style face="normal" font="default" size="100%">Aquilina, A. T.</style></author><author><style face="normal" font="default" size="100%">Dhillon, R. S.</style></author><author><style face="normal" font="default" size="100%">Ramadan, F.</style></author><author><style face="normal" font="default" size="100%">Nowak, P.</style></author><author><style face="normal" font="default" size="100%">Davies, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Critical Care, and Sleep Medicine, James P. Nolan Clinical Research Center, Department of Medicine, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York 14215, USA. solh@buffalo.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Respir Crit Care Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1038-43</style></pages><volume><style face="normal" font="default" size="100%">166</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/diagnosis/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care Units</style></keyword><keyword><style face="normal" font="default" size="100%">Length of Stay</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Bacterial/diagnosis/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration, Artificial</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1073-449X (Print)&#xD;1073-449x</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of the study was to investigate the etiology and the impact of invasive quantitative sampling on the management of severe pneumonia in institutionalized older people with antimicrobial treatment failure. Fifty-two institutionalized patients aged 70 years and older hospitalized with a presumptive diagnosis of severe pneumonia and failure to respond to treatment after 72 hours of initiation of outpatient antimicrobial therapy were enrolled. Microbial investigation included blood culture, serology, pleural fluid, and bronchoalveolar samples. A definite etiology could be established in 24 of 52 (46%) patients. Methicillin-resistant Staphylococcus aureus (33%), enteric Gram-negative bacilli (24%), and Pseudomonas aeruginosa (14%) accounted for most isolates. Atypical infections (2%) were uncommon. Invasive bronchial sampling directed a change of microbial therapy in 8 (40%) and discontinuation of antibiotics in 2 of 20 cases (10%) of definite pneumonia. Overall hospital mortality was 42%. There was no difference in mortality among definite or unverified cases or those who had invasive bronchial sampling-guided change in therapy. We conclude that antimicrobial therapy should be targeted toward &quot;nosocomial&quot; pathogens in those institutionalized patients who received prior antibiotic treatment. When combined with microbial investigation, direct visualization of the tracheobronchial tree might be useful in determining the presence of bacterial pneumonia.</style></abstract><notes><style face="normal" font="default" size="100%">El-Solh, Ali A&#xD;Aquilina, Alan T&#xD;Dhillon, Rajwinder S&#xD;Ramadan, Fadi&#xD;Nowak, Patricia&#xD;Davies, Joan&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Respir Crit Care Med. 2002 Oct 15;166(8):1038-43. doi: 10.1164/rccm.200202-123OC.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1164/rccm.200202-123OC</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murphy, S.</style></author><author><style face="normal" font="default" size="100%">West, K. P., Jr.</style></author><author><style face="normal" font="default" size="100%">Greenough, W. B., 3rd</style></author><author><style face="normal" font="default" size="100%">Cherot, E.</style></author><author><style face="normal" font="default" size="100%">Katz, J.</style></author><author><style face="normal" font="default" size="100%">Clement, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Geriatric Medicine and Gerontology, Johns Hopkins Geriatrics Centre, Baltimore, Maryland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of vitamin A supplementation on the incidence of infection in elderly nursing-home residents: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Age Ageing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Age Ageing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">435-9</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Frail Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A Deficiency/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1992</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-0729 (Print)&#xD;0002-0729</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of this study was to determine if vitamin A supplementation reduces the incidence of bacterial infections among elderly nursing-home residents. One hundred and nine patients were enrolled into a double-masked, placebo-controlled trial at an academically affiliated nursing home. Fifty-six patients received a single capsule containing 1,000 IU of vitamin A (placebo) and 53 received a single capsule containing 200,000 IU of vitamin A. Antibiotic-treated infections were enumerated for 90 days after dosing and infection rates were expressed per 1000 days of follow-up. There were 42 antibiotic-treated infections altogether, 21 in each group. The infection rates in the vitamin A and placebo groups were 4.7 and 4.3 per 1,000 days of follow-up, respectively (relative risk 1.1; 95% CI 0.6, 2.0). The findings of this study do not support a role for vitamin A supplements for the prevention of infections among frail elderly nursing-home patients.</style></abstract><notes><style face="normal" font="default" size="100%">Murphy, S&#xD;West, K P Jr&#xD;Greenough, W B 3rd&#xD;Cherot, E&#xD;Katz, J&#xD;Clement, L&#xD;S10-RR04060/RR/NCRR NIH HHS/United States&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;England&#xD;Age Ageing. 1992 Nov;21(6):435-9. doi: 10.1093/ageing/21.6.435.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ageing/21.6.435</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moon, K. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. T. Moon</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improving insomnia with melatonin, magnesium, and zinc</style></title><secondary-title><style face="normal" font="default" size="100%">American Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1293</style></pages><volume><style face="normal" font="default" size="100%">84</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">melatonin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">alertness</style></keyword><keyword><style face="normal" font="default" size="100%">arousal</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bedtime dosage</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">daytime somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">Pittsburgh Sleep Quality Index</style></keyword><keyword><style face="normal" font="default" size="100%">questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-838X&#xD;1532-0650</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Insomnia affects up to 50 percent of older adults, and has been correlated with morbidity and mortality in this population, as well as poorer quality of life. Melatonin supplementation may improve total sleep time because of its effect on regulating the sleep-wake cycle. This may be particularly useful in older patients, because of an age-related decline in melatonin production and because melatonin levels are lower in adults with insomnia than in those who report getting good sleep. Other micronutrients such as zinc and magnesium may also play a role in facilitating sleep because they are important in the endogenous synthesis of melatonin. Rondanelli and colleagues conducted a double-blind, placebo-controlled clinical trial to determine whether melatonin, magnesium, and zinc would improve symptoms of insomnia among older adults living in a long-term care facility. The Study: The authors recruited 43 adults 70 years and older living in a long-term care facility who had been diagnosed with primary insomnia, defined as difficulty in initiating or maintaining sleep for at least one month with no sign of any other contributing sleep or mental disorder, drug use, or other general medical condition. Exclusion criteria included anxiety, depression, psychosis, or the use of beta blockers or other medications that affect the central nervous system, such as benzodiazepines and other sleep-inducing agents. Patients were randomized to treatment with placebo or a combination of melatonin (5 mg), magnesium (225 mg), and zinc (11.25 mg) administered one hour before bedtime daily for eight weeks. The primary outcome was sleep quality as defined by the Pittsburgh Sleep Quality Index (PSQI), which was measured at baseline and again at the end of the study. Secondary outcomes were changes in sleep quality and daily activity according to other questionnaires, including the Leeds Sleep Evaluation Questionnaire (LSEQ). Results: The treatment group reported more significantly improved sleep quality (mean PSQI improvement of -7.1 points from baseline versus -0.3 points for the placebo group; P&lt;.001). Significantly more patients in the treatment group had a final PSQI score of 5 or less, a cutoff that is 89.6 percent sensitive and 86.5 percent specific in differentiating good sleepers from poor sleepers (59 percent in the treatment group versus 14 percent in the placebo group; P =.004). The treatment group also had significantly better scores in all four components of the LSEQ, including getting to sleep, sleep quality, hangover on awakening from sleep, and alertness the following morning. No differences were noted in daytime sleepiness between groups. Conclusion: Sleep quality was significantly improved among older adults living in a long-term care facility who received a nightly dose of melatonin, magnesium, and zinc, as was morning alertness. The authors suggest that this may also be a helpful sleep aid for the general older population. © 2011 by the American Academy of Family Physicians.</style></abstract><notes><style face="normal" font="default" size="100%">L363066274&#xD;2011-12-16&#xD;2011-12-27</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L363066274&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://www.aafp.org/afp/2011/1201/p1293.html</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Increased risk of mortality associated with the use of haloperidol in older people</style></title><secondary-title><style face="normal" font="default" size="100%">Drug and Therapeutics Bulletin</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug and Therapeutics Bulletin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">65</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">hazard ratio</style></keyword><keyword><style face="normal" font="default" size="100%">health service</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">predictive value</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">psychopharmacotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0012-6543&#xD;1755-5248</style></isbn><notes><style face="normal" font="default" size="100%">L365297958&#xD;2012-07-31&#xD;2012-08-06</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L365297958&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/dtb.2012.06.0107</style></url><url><style face="normal" font="default" size="100%">http://dtb.bmj.com/content/50/6/62.full.pdf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/dtb.2012.06.0107</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McKean, A.</style></author><author><style face="normal" font="default" size="100%">Monasterio, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. McKean, Hillmorton Hospital, Christchurch, New Zealand</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indications of atypical antipsychotics in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-7</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug industry</style></keyword><keyword><style face="normal" font="default" size="100%">effect size</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">hip fracture</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">off label drug use</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">publication</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">sudden cardiac death</style></keyword><keyword><style face="normal" font="default" size="100%">treatment indication</style></keyword><keyword><style face="normal" font="default" size="100%">whistleblowing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1751-2441&#xD;1751-2433</style></isbn><abstract><style face="normal" font="default" size="100%">Atypical antipsychotics (AAP) have become some of the most commonly prescribed medications in primary and specialist care settings. Off-label prescribing accounts for much of the expanded use of AAPs. This has become common in the elderly. Marketing by pharmaceutical companies appears to have contributed to the off-label use of AAPs, in situations where their safety and efficacy is far from established. Although evidence provides varying degrees of support for their use for behavioural and psychological symptoms of dementia, augmentation of antidepressants in depression, anxiety, insomnia and in the management of psychosis in Parkinson&apos;s Disease, there are a number of potential problems with their expanded use in the elderly. These include weight gain, type two diabetes mellitus, sudden cardiac death and increased mortality rates in the elderly with dementia. It is recommended that whenever AAPs are used off-label, a review date is identified, informed consent is obtained and treatment and side-effects are closely monitored.</style></abstract><notes><style face="normal" font="default" size="100%">L600772256&#xD;2014-12-19&#xD;2020-02-21</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L600772256&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1586/17512433.2015.974557</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">25354148</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/17512433.2015.974557</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dorfman, R.</style></author><author><style face="normal" font="default" size="100%">London, Z.</style></author><author><style face="normal" font="default" size="100%">Metias, M.</style></author><author><style face="normal" font="default" size="100%">Kabakchiev, B.</style></author><author><style face="normal" font="default" size="100%">Mukerjee, G.</style></author><author><style face="normal" font="default" size="100%">Moser, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Moser, C/O Baycrest Centre for Geriatric Care, 3560 Bathurst Street, Room 1C26, North York, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Individualized Medication Management in Ontario Long-Term Care Clinical Impact on Management of Depression, Pain, and Dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">823-829.e5</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">alprazolam</style></keyword><keyword><style face="normal" font="default" size="100%">amitriptyline</style></keyword><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">atorvastatin</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular agent</style></keyword><keyword><style face="normal" font="default" size="100%">celecoxib</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram</style></keyword><keyword><style face="normal" font="default" size="100%">clopidogrel</style></keyword><keyword><style face="normal" font="default" size="100%">codeine</style></keyword><keyword><style face="normal" font="default" size="100%">diclofenac</style></keyword><keyword><style face="normal" font="default" size="100%">dihydropyrimidine dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">duloxetine</style></keyword><keyword><style face="normal" font="default" size="100%">efavirenz</style></keyword><keyword><style face="normal" font="default" size="100%">escitalopram</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal agent</style></keyword><keyword><style face="normal" font="default" size="100%">hydromorphone</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">metoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">midazolam</style></keyword><keyword><style face="normal" font="default" size="100%">mirtazapine</style></keyword><keyword><style face="normal" font="default" size="100%">oxazepam</style></keyword><keyword><style face="normal" font="default" size="100%">oxycodone</style></keyword><keyword><style face="normal" font="default" size="100%">pantoprazole</style></keyword><keyword><style face="normal" font="default" size="100%">prescription drug</style></keyword><keyword><style face="normal" font="default" size="100%">psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">rosuvastatin</style></keyword><keyword><style face="normal" font="default" size="100%">sertraline</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">allele</style></keyword><keyword><style face="normal" font="default" size="100%">analgesia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">chronic pain</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cost control</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">decision support system</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">DNA extraction</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug identification</style></keyword><keyword><style face="normal" font="default" size="100%">drug incompatibility</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug information</style></keyword><keyword><style face="normal" font="default" size="100%">drug labeling</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug response</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug utilization</style></keyword><keyword><style face="normal" font="default" size="100%">drug utilization review</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electronic medical record</style></keyword><keyword><style face="normal" font="default" size="100%">functional status</style></keyword><keyword><style face="normal" font="default" size="100%">gastroesophageal reflux</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">gene identification</style></keyword><keyword><style face="normal" font="default" size="100%">gene interaction</style></keyword><keyword><style face="normal" font="default" size="100%">genetic variation</style></keyword><keyword><style face="normal" font="default" size="100%">heart disease</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">medication therapy management</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">Ontario</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenetic testing</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">psychopharmacotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment response</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1538-9375&#xD;1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Assess the potential benefits of identifying drug-gene interactions in nursing home (NH) residents on multiple medications. Reduce the use of high-risk medications for residents with reduced drug metabolism. Design: Open-label, nonrandomized, mixed methods study. Setting: Four NHs in Ontario. Measurements: Potential drug therapy problems (DTPs) for study cohort were identified during a medication review by a pharmacist using pharmacogenetic (PGx) clinical decision support to identify medication change opportunities. The number of DTPs identified during a standard medication review was compared with the number of DTPs identified with a PGx clinical decision support. Analysis of medication dispensing data at enrollment compared with dispensing in a 60-day window following medication review were compared for the PGx-tested study cohort with controls. Results: Prescription patterns of 90 study participants were compared with 895 controls for the same time period. Study participants were on 7 to 47 drugs, of which drugs with PGx indications ranged from 1 to 17 medications. The average medication load was 4.6 medications with PGx indications per person, whereas the controls were on 3.5 PGx drugs. Furthermore, 94% of cases and 84% of controls were on 2 or more drugs with PGx indication during the study period. Pharmacogenetic analysis identified 114 distinct DTPs in the 90 study participants, of which 29 were classified as serious. In this study, over 35% of residents were treated with antidepressants; of these, 64% have altered CYP2C19 or CYP2D6 metabolism and could benefit from drug dose adjustment or from a switch to alternative antidepressants. Twenty percent of residents were treated with hydromorphone, of which 30% have reduced response to opioids because of variations in the OPRM1 gene. Conclusions and Implications: This study demonstrated the clinical potential of PGx-based medication optimization for NH residents, impacting the management of depression, chronic pain, heart disease, and gastrointestinal symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">L2006168402&#xD;2020-07-03&#xD;2020-07-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2006168402&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jamda.2020.04.009</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32536434</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2020.04.009</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ambrozaitis, A.</style></author><author><style face="normal" font="default" size="100%">Gravenstein, S.</style></author><author><style face="normal" font="default" size="100%">van Essen, G. A.</style></author><author><style face="normal" font="default" size="100%">Rubinstein, E.</style></author><author><style face="normal" font="default" size="100%">Balciuniene, L.</style></author><author><style face="normal" font="default" size="100%">Stikleryte, A.</style></author><author><style face="normal" font="default" size="100%">Crawford, C.</style></author><author><style face="normal" font="default" size="100%">Elliott, M.</style></author><author><style face="normal" font="default" size="100%">Shult, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vilnius University, Vilnius, Lithuania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">367-74</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*drug therapy/*epidemiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Zanamivir/*administration &amp; dosage/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Antiviral chemoprophylaxis effectiveness for influenza control has not been prospectively established for unvaccinated residents of long-term care facilities. This study evaluated the efficacy and tolerability of zanamivir against the standard of care (no intervention, ie, placebo) for influenza outbreak control in a largely unvaccinated institutionalized population. OBJECTIVE: To evaluate the efficacy and tolerability of zanamivir versus placebo for influenza outbreak control in long-term care facilities. METHODS: This double-blind, randomized, placebo-controlled study prospectively enrolled/followed residents of long-term care facilities (LTCF) at 12 centers for 1 to 3 influenza seasons (1997 to 2000). Following influenza outbreak declaration, asymptomatic subjects were randomized for prophylaxis to inhaled zanamivir 10 mg or inhaled placebo given once daily for 14 days. The proportion of randomized subjects who during prophylaxis developed symptomatic, laboratory-confirmed influenza (SLCI) was the primary end point. RESULTS: Influenza outbreaks were explosive. The attack rates varied from 9.5 to 14.8 per 100 residents. Of 1763 consents given and resulting in 494 randomizations, 49% received zanamivir and 51% placebo; 66% were elderly and 9% were vaccinated. SLCI occurred in 6% of zanamivir and 9% of placebo subjects (P = .355; protective efficacy for zanamivir = 29%, 95% confidence interval 31% to 62%), and symptomatic influenza confirmed by culture in 2% and 6%, respectively (P = .052; protective efficacy = 65%, 95% confidence interval 8.5% to 86%). Zanamivir use was also associated with a 70% (95% confidence interval 13% to 89%) reduction in laboratory-confirmed influenza with fever (2% vs 6%, P = .043). Influenza B was not detected. Zanamivir was well tolerated. No virus isolate demonstrated zanamivir resistance. CONCLUSIONS: The protective efficacy of zanamivir versus placebo for SLCI was marginal, for all laboratory confirmed illnesses, but significant against culture proven and febrile influenza, suggesting zanamivir can be effective for outbreak control and symptom reduction of unvaccinated institutionalized residents. Zanamivir had an acceptable safety profile in elderly, high-risk LTCF residents and was not associated with the emergence of resistant strains.</style></abstract><notes><style face="normal" font="default" size="100%">1538-9375&#xD;Ambrozaitis, Arvydas&#xD;Gravenstein, Stefan&#xD;van Essen, Gerrit A&#xD;Rubinstein, Ethan&#xD;Balciuniene, Ligita&#xD;Stikleryte, Ausra&#xD;Crawford, Catriona&#xD;Elliott, Michael&#xD;Shult, Peter&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Med Dir Assoc. 2005 Nov-Dec;6(6):367-74. doi: 10.1016/j.jamda.2005.08.007.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2005.08.007</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gravenstein, S.</style></author><author><style face="normal" font="default" size="100%">Drinka, P.</style></author><author><style face="normal" font="default" size="100%">Osterweil, D.</style></author><author><style face="normal" font="default" size="100%">Schilling, M.</style></author><author><style face="normal" font="default" size="100%">Krause, P.</style></author><author><style face="normal" font="default" size="100%">Elliott, M.</style></author><author><style face="normal" font="default" size="100%">Shult, P.</style></author><author><style face="normal" font="default" size="100%">Ambrozaitis, A.</style></author><author><style face="normal" font="default" size="100%">Kandel, R.</style></author><author><style face="normal" font="default" size="100%">Binder, E.</style></author><author><style face="normal" font="default" size="100%">Hammond, J.</style></author><author><style face="normal" font="default" size="100%">McElhaney, J.</style></author><author><style face="normal" font="default" size="100%">Flack, N.</style></author><author><style face="normal" font="default" size="100%">Daly, J.</style></author><author><style face="normal" font="default" size="100%">Keene, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eastern Virginia Medical School, Norfolk, VA 23507, USA. gravens@evms.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Med Dir Assoc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">359-66</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Geriatric Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza Vaccines/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*drug therapy/*epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Rimantadine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Zanamivir/*administration &amp; dosage/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Despite vaccination, influenza commonly causes morbidity and mortality in institutional settings. Influenza control with rimantadine and amantadine is limited by emergence and transmission of drug-resistant influenza A variants, ineffectiveness against influenza B, and toxicity. This study evaluated the efficacy and tolerability of zanamivir versus rimantadine for influenza outbreak control in long-term care facilities. METHODS: This double-blind, randomized, controlled study prospectively enrolled nursing home residents for 3 influenza seasons (1997 to 2000). Vaccine was offered to all subjects. Following influenza outbreak declaration, subjects were randomized to inhaled zanamivir 10 mg or standard of care (rimantadine 100 mg for influenza A or placebo for influenza B) once daily for 14 days. The proportion of randomized subjects developing symptomatic, laboratory-confirmed influenza during prophylaxis was the primary endpoint. RESULTS: Of 482 randomizations (238 zanamivir, 231 rimantadine, 13 placebo), 96% of subjects were elderly or had high-risk conditions; over 90% were vaccinated. Symptomatic, laboratory-confirmed influenza occurred in 3% of zanamivir subjects and 8% of rimantadine subjects during chemoprophylaxis (P = .038; additional protective efficacy for zanamivir over rimantadine = 61%). Since only 25 subjects were randomized during 2 influenza B outbreaks and none developed influenza, the influenza B data were excluded from further analysis. Zanamivir was well tolerated and unassociated with emergence of resistant virus; rimantadine-resistant variants were common. CONCLUSIONS: This is the first prospective, controlled study demonstrating effectiveness of chemoprophylaxis for influenza outbreak control. Zanamivir prevents symptomatic, laboratory-confirmed influenza more effectively than rimantadine, is unassociated with resistant virus, and has a favorable safety profile. Zanamivir is an appropriate alternative for influenza outbreak control among institutionalized vaccinated elderly.</style></abstract><notes><style face="normal" font="default" size="100%">1538-9375&#xD;Gravenstein, Stefan&#xD;Drinka, Paul&#xD;Osterweil, Dan&#xD;Schilling, Margo&#xD;Krause, Peggy&#xD;Elliott, Michael&#xD;Shult, Peter&#xD;Ambrozaitis, Arvydas&#xD;Kandel, Ruth&#xD;Binder, Ellen&#xD;Hammond, Janet&#xD;McElhaney, Janet&#xD;Flack, Nancy&#xD;Daly, Janet&#xD;Keene, Oliver&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Med Dir Assoc. 2005 Nov-Dec;6(6):359-66. doi: 10.1016/j.jamda.2005.08.006.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2005.08.006</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knorr, J.</style></author><author><style face="normal" font="default" size="100%">Tuttle, J. L.</style></author><author><style face="normal" font="default" size="100%">Sabo, J. A.</style></author><author><style face="normal" font="default" size="100%">East, D. H.</style></author><author><style face="normal" font="default" size="100%">Price, K. L.</style></author><author><style face="normal" font="default" size="100%">Shen, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Knorr, Eli Lilly and Company, Indianapolis, IN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title></periodical><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">assisted living facility</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">letter</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">national health organization</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">post exposure prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomization</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">resident</style></keyword><keyword><style face="normal" font="default" size="100%">Severe acute respiratory syndrome coronavirus 2</style></keyword><keyword><style face="normal" font="default" size="100%">travel restriction</style></keyword><keyword><style face="normal" font="default" size="100%">bamlanivimab</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><abstract><style face="normal" font="default" size="100%">The efficient community spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the current pandemic of coronavirus disease-2019 (COVID-19), which in severe and critical cases results in progressive pulmonary infection, complicated by respiratory failure, with a high prevalence of acute respiratory distress syndrome. Of all age groups, older adults have the greatest risk of severe COVID-19 and the associated complications. Globally, there are many reports of the rapid spread of COVID-19 among residents of skilled nursing facilities, with high associated rates of morbidity and mortality. With over 1.3 million residents in nursing home care in the USA, there is an urgent need for therapeutic strategies to prevent COVID-19 in these populations. Lilly, in collaboration with the National Institute of Allergy and Infectious Diseases, conducted the BLAZE-2 trial to evaluate the efficacy and safety of the monoclonal antibody bamlanivimab (LY3819253) in preventing SARS-CoV-2 infection and COVID-19, defined as symptomatic infection, in skilled nursing and assisted living facilities. It is a phase 3 randomized, double-blind, placebo-controlled trial, where participants were randomized to bamlanivimab (4200 mg) or placebo and then followed up for 24 weeks. Conducting a trial in the midst of a pandemic in these facilities poses several challenges, including a vulnerable elderly population, travel restrictions, supply chain interruptions, and defining the target population. The operational challenges were addressed by the innovative use of mobile research units which are customized, equipped, and staffed to support BLAZE-2 randomization and participant dosing within the skilled nursing and assisted living facilities. Herein, we describe the design of the study, the analytics behind facility selection, and an innovative operational model.</style></abstract><notes><style face="normal" font="default" size="100%">L2013993740&#xD;2021-10-28</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2013993740&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s13063-021-05699-3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13063-021-05699-3</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kennedy, V. E.</style></author><author><style face="normal" font="default" size="100%">Keegan, T.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Maguire, F.</style></author><author><style face="normal" font="default" size="100%">Muffly, L. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intensity of Front-Line Regimen Is Associated with Admissions, in-Hospital Days, and Discharge Destination in Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title></periodical><pages><style face="normal" font="default" size="100%">29</style></pages><volume><style face="normal" font="default" size="100%">136</style></volume><keywords><keyword><style face="normal" font="default" size="100%">anthracycline</style></keyword><keyword><style face="normal" font="default" size="100%">cytarabine</style></keyword><keyword><style face="normal" font="default" size="100%">venetoclax</style></keyword><keyword><style face="normal" font="default" size="100%">acute myeloid leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">California</style></keyword><keyword><style face="normal" font="default" size="100%">cancer chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">cancer registry</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">funding</style></keyword><keyword><style face="normal" font="default" size="100%">hospice</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">hospital discharge</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">in-hospital mortality</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">patient transport</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">self care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1528-0020&#xD;0006-4971</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction Acute myeloid leukemia (AML) is predominantly a cancer of older adults, with median age at diagnosis of 68 years. Traditionally, AML is treated with intensive induction chemotherapy; however, older adults with AML are often poor chemotherapy candidates due to reduced performance status and multiple comorbidities. Recently, several non-traditional treatment regimens for AML have emerged that may offer less intense toxicity profiles compared to traditional chemotherapy, can be administered in the outpatient setting, and provide new front-line options for older or frailer adults with AML. We hypothesized that relative to traditional cytotoxic chemotherapy, these non-traditional options would be associated with fewer hospital admissions, fewer days in-hospital, and more frequent discharges to home rather than skilled nursing facilities among newly diagnosed older AML patients. Methods Patients ≥ 60 years with a first diagnosis of AML in the California Cancer Registry (CCR) between 2014-2017 were included. Front-line treatment regimen was manually abstracted from unstructured free-text fields in the CCR and categorized as no treatment, traditional cytotoxic chemotherapy, or non-traditional therapy. Non-traditional therapy was defined as a hypomethylating agent and venetoclax in monotherapy or combination, liposomal cytarabine and anthracycline, or non-cytotoxic targeted agents. The CCR was linked with statewide hospitalization data to obtain number of in-hospital days and number of admissions during the first 100 days following diagnosis as well as discharge destination (home/usual care vs non-home location). Results Of the 4,086 patients identified, 3,068 (75.1%) had available treatment data and are included in the current analysis. Thirty-four percent of patients were 60-69 years at diagnosis, 39.0% were 70-90 years, and 27.1% were ³ 80 years. Nearly one-third (28.5%) had ≥ 2 comorbidities. During the study period, 36.3% received traditional cytotoxic chemotherapy, 41.6% received non-traditional therapy, and 22.0% received no treatment. WAcross the full cohort, during the first 100 days following diagnosis, the median number of in-hospital days was 22, and 79.8% of patients had at least one hospitalization. Compared to patients receiving traditional chemotherapy, patients receiving non-traditional therapy spent less time in the hospital (42 vs 15 days, p &lt; 0.001). Patients receiving traditional chemotherapy also had more hospital admissions, with 63.4% having ≥ 2 admissions compared with 46.8% of patients receiving non-traditional therapy (p &lt; 0.001) (Table 1). Of the 2,443 patients with at least one hospitalization, 2,046 (83.7%) were discharged alive to either a home or non-home location; of these, 68.4% were discharged to home and/or usual self-care, 8.6% to a non-home location, such as acute rehabilitation or a skilled nursing facility, and 6.7% to hospice. The remaining patients either died in the hospital (13.5%) or had an alternate discharge destination, such as intrahospital transfer (2.7%) WCompared to patients receiving traditional chemotherapy, a lower proportion of patients receiving non-traditional therapies died in the hospital (11.0% vs 6.4% p &lt;0.001) and a greater proportion were discharged to hospice (1.6% vs 3.3%, p = 0.009). Although patients receiving non-traditional therapies were less commonly hospitalized, if hospitalized, these patients were more likely to require skilled care upon discharge. Of the patients receiving non-traditional therapy discharged alive and without hospice, 11.5% were discharged to a non-home location compared to only 5.8% of patients receiving traditional chemotherapy. Conclusions Using a population-based approach, we demonstrate that older adults with AML receiving non-traditional induction therapies have fewer admissions, in-hospital days, and in-hospital deaths, but did not have a decreased need for skilled services upon hospital discharge. At the population level, non-traditional therapies offer new treatment opportunities for older and frailer adu ts with AML. Additional studies evaluating health-related quality of life among older adults treated with these approaches are needed to delineate the patient-centered benefit of these therapies relative to traditional chemotherapy. [Formula presented] Disclosures: Muffly: Adaptive: Research Funding; Amgen: Consultancy; Servier: Research Funding.</style></abstract><notes><style face="normal" font="default" size="100%">L2013853924&#xD;2021-08-06</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2013853924&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1182/blood-2020-141344</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1182/blood-2020-141344</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klomstad, K.</style></author><author><style face="normal" font="default" size="100%">Pedersen, R.</style></author><author><style face="normal" font="default" size="100%">Førde, R.</style></author><author><style face="normal" font="default" size="100%">Romøren, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Medical Ethics, Institute of Health and Society, Faculty of Medicine, University of Oslo, P.O box 1130 Blindern, 0318, Oslo, Norway.&#xD;Centre for Medical Ethics, Institute of Health and Society, Faculty of Medicine, University of Oslo, P.O box 1130 Blindern, 0318, Oslo, Norway. maria.romoren@medisin.uio.no.&#xD;Antibiotic centre for primary care, Department of General Practice, Institute of Health and Society, Faculty of Medicine, University of Oslo, P.O box 1130 Blindern, 0318, Oslo, Norway. maria.romoren@medisin.uio.no.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Involvement in decisions about intravenous treatment for nursing home patients: nursing homes versus hospital wards</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Med Ethics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Med Ethics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">34</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Advance Care Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Attitude of Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Communication</style></keyword><keyword><style face="normal" font="default" size="100%">*Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Family</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Life Support Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Competency</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Participation</style></keyword><keyword><style face="normal" font="default" size="100%">Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative Research</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">*Decision making capacity</style></keyword><keyword><style face="normal" font="default" size="100%">*Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">*End-of-life decisions</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">*Life prolonging treatment</style></keyword><keyword><style face="normal" font="default" size="100%">*Next of kin</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient autonomy</style></keyword><keyword><style face="normal" font="default" size="100%">Committees for Medical and Health Research Ethics (No. 2009/1584a-1). The patients</style></keyword><keyword><style face="normal" font="default" size="100%">received oral and written information about the study, including the voluntariness</style></keyword><keyword><style face="normal" font="default" size="100%">of participation, the option to withdraw, and guarantees of full anonymity. All</style></keyword><keyword><style face="normal" font="default" size="100%">competent patients gave written consent, while non-competent patients’ next of kin</style></keyword><keyword><style face="normal" font="default" size="100%">were responsible for their consent, also in written form. CONSENT FOR PUBLICATION:</style></keyword><keyword><style face="normal" font="default" size="100%">Not applicable. COMPETING INTERESTS: The authors declare that they have no competing</style></keyword><keyword><style face="normal" font="default" size="100%">interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to</style></keyword><keyword><style face="normal" font="default" size="100%">jurisdictional claims in published maps and institutional affiliations.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1472-6939</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many of the elderly in nursing homes are very ill and have a reduced quality of life. Life expectancy is often hard to predict. Decisions about life-prolonging treatment should be based on a professional assessment of the patient&apos;s best interest, assessment of capacity to consent, and on the patient&apos;s own wishes. The purpose of this study was to investigate and compare how these types of decisions were made in nursing homes and in hospital wards. METHODS: Using a questionnaire, we studied the decision-making process for 299 nursing home patients who were treated for dehydration using intravenous fluids, or for bacterial infections using intravenous antibiotics. We compared the 215 (72%) patients treated in nursing homes to the 84 (28%) nursing home patients treated in the hospital. RESULTS: The patients&apos; capacity to consent was considered prior to treatment in 197 (92%) of the patients treated in nursing homes and 56 (67%) of the patients treated in hospitals (p &lt; 0.001). The answers indicate that capacity to consent can be difficult to assess. Patients that were considered capable to consent, were more often involved in the decision-making in nursing homes than in hospital (90% vs. 52%). Next of kin and other health personnel were also more rarely involved when the nursing home patient was treated in hospital. Whether advance care planning had been carried out, was more often unknown in the hospital (69% vs. 17% in nursing homes). Hospital doctors expressed more doubt about the decision to admit the patient to the hospital than about the treatment itself. CONCLUSIONS: This study indicates a potential for improvement in decision-making processes in general, and in particular when nursing home patients are treated in a hospital ward. The findings corroborate that nursing home patients should be treated locally if adequate health care and treatment is available. The communication between the different levels of health care when hospitalization is necessary, must be better. TRIAL REGISTRATION: ClinicalTrials.gov NCT01023763 (12/1/09) [The registration was delayed one month after study onset due to practical reasons].</style></abstract><notes><style face="normal" font="default" size="100%">1472-6939&#xD;Klomstad, Kristin&#xD;Pedersen, Reidar&#xD;Førde, Reidun&#xD;Romøren, Maria&#xD;Orcid: 0000-0003-3923-0025&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;BMC Med Ethics. 2018 May 8;19(1):34. doi: 10.1186/s12910-018-0258-5.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5941318</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12910-018-0258-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boddu, P.</style></author><author><style face="normal" font="default" size="100%">Shah, A. R.</style></author><author><style face="normal" font="default" size="100%">Borthakur, G.</style></author><author><style face="normal" font="default" size="100%">Verstovsek, S.</style></author><author><style face="normal" font="default" size="100%">Garcia-Manero, G.</style></author><author><style face="normal" font="default" size="100%">Daver, N.</style></author><author><style face="normal" font="default" size="100%">Kadia, T.</style></author><author><style face="normal" font="default" size="100%">Ravandi, F.</style></author><author><style face="normal" font="default" size="100%">Jain, N.</style></author><author><style face="normal" font="default" size="100%">Alhuraiji, A.</style></author><author><style face="normal" font="default" size="100%">Burger, J.</style></author><author><style face="normal" font="default" size="100%">Kornblau, S.</style></author><author><style face="normal" font="default" size="100%">Pierce, S.</style></author><author><style face="normal" font="default" size="100%">Dellasala, S.</style></author><author><style face="normal" font="default" size="100%">Jabbour, E.</style></author><author><style face="normal" font="default" size="100%">Kantarjian, H.</style></author><author><style face="normal" font="default" size="100%">Cortes, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Cortes, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting</style></title><secondary-title><style face="normal" font="default" size="100%">Leukemia and Lymphoma</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Leukemia and Lymphoma</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1312-1322</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">bosutinib</style></keyword><keyword><style face="normal" font="default" size="100%">cytarabine</style></keyword><keyword><style face="normal" font="default" size="100%">dasatinib</style></keyword><keyword><style face="normal" font="default" size="100%">decitabine</style></keyword><keyword><style face="normal" font="default" size="100%">etoposide</style></keyword><keyword><style face="normal" font="default" size="100%">fludarabine</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">homoharringtonine</style></keyword><keyword><style face="normal" font="default" size="100%">imatinib</style></keyword><keyword><style face="normal" font="default" size="100%">lactate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">mitoxantrone</style></keyword><keyword><style face="normal" font="default" size="100%">nilotinib</style></keyword><keyword><style face="normal" font="default" size="100%">ponatinib</style></keyword><keyword><style face="normal" font="default" size="100%">acute heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">allogeneic stem cell transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood vessel shunt</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">cancer survival</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">chromosome aberration</style></keyword><keyword><style face="normal" font="default" size="100%">chronic myeloid leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">clonal evolution</style></keyword><keyword><style face="normal" font="default" size="100%">complete cytogenetic response</style></keyword><keyword><style face="normal" font="default" size="100%">cytogenetic response</style></keyword><keyword><style face="normal" font="default" size="100%">disease duration</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">event free survival</style></keyword><keyword><style face="normal" font="default" size="100%">failure free survival</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gene mutation</style></keyword><keyword><style face="normal" font="default" size="100%">giant cell arteritis</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">lactate dehydrogenase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">leukemia relapse</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">lung pressure</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">ocular ischemic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">overall survival</style></keyword><keyword><style face="normal" font="default" size="100%">pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral vascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">salvage therapy</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">splenomegaly</style></keyword><keyword><style face="normal" font="default" size="100%">stem cell transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">survival rate</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocyte</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment response</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1029-2403&#xD;1042-8194</style></isbn><abstract><style face="normal" font="default" size="100%">Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractory to prior TKI who discontinued ponatinib for resistance or intolerance. Nineteen CP patients, discontinued due to resistance (n = 13), toxicity (n = 5) and to pursue stem cell transplantation (n = 1). At discontinuation, 14 were still in CP, three had progressed to AP and two to blast phase (BP). Three CP patients improved their cytogenetic response (CyR) to complete CyR (CCyR), two after SCT and one on omacetaxine. None of the 12 patients, without a major cytogenetic response at ponatinib discontinuation, including all patients treated with subsequent TKIs, responded to therapy. Seventeen AP patients, stopped ponatinib due to resistance (n = 15) or intolerance (n = 2). At discontinuation, 14 were still in AP and three had progressed to BP. Four patients were treated with SCT and one achieved major molecular response. None of the 12 patients treated with non-SCT approaches responded to subsequent therapy. Median survival for all patients was 16.6 months after ponatinib discontinuation (31, 9 and 13 months for patients in CP, AP and BP, respectively). Median survival was 60 months for patients who discontinued ponatinib for toxicity and 11 months for those who discontinued for resistance. Long-term outcome of patients with ponatinib failure are poor with estimated one-year OS and EFS rates of 54% and 40%, respectively. New treatment options are required for this subset of patients.</style></abstract><notes><style face="normal" font="default" size="100%">L618603814&#xD;2017-10-11&#xD;2018-12-28</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L618603814&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1080/10428194.2017.1379076</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28972430</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10428194.2017.1379076</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghusn, H. F.</style></author><author><style face="normal" font="default" size="100%">Teasdale, T. A.</style></author><author><style face="normal" font="default" size="100%">Skelly, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Baylor College of Medicine, Houston, TX, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Limiting treatment in nursing homes: knowledge and attitudes of nursing home medical directors</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1131-4</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">*Cardiopulmonary Resuscitation/mortality/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Coma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Knowledge, Attitudes, Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Physician Executives/education/psychology/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">*Resuscitation Orders</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Terminal Care</style></keyword><keyword><style face="normal" font="default" size="100%">Texas</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Withholding Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Death and Euthanasia</style></keyword><keyword><style face="normal" font="default" size="100%">Empirical Approach</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine nursing home medical directors&apos; knowledge about cardiopulmonary resuscitation outcome and their support of treatment limitation requests and policies. DESIGN: Mailed questionnaire, followed by telephone interview. PARTICIPANTS: Forty-six medical directors of 70 community nursing homes in Harris County, Texas. MEASUREMENTS: Medical directors were asked to estimate the CPR survival rate to discharge of all nursing home residents and that of two case scenarios. They were asked to indicate on a Likert scale their support for mandatory Do-Not-Resuscitate orders and for requests by nursing home patients to withhold other life support measures. RESULTS: Responses were received from 33 directors. Overall CPR survival rate of older nursing home residents after cardiac arrest was thought to be 10.7%. The average CPR survival rate for healthy older people with witnessed arrests was believed to be 13.8%. The perceived rate for unwitnessed arrests in terminal patients was 4.6%, significantly lower than estimates for healthy older people (P = .003) and estimates of the overall survival rate (P = .02). Medical directors were split regarding mandatory Do-Not-Resuscitate orders for patients in vegetative states, with terminal illness, with an unwitnessed arrest, or in those older than 90 years of age. Mandatory use of Do-Not-Resuscitate orders for all nursing home residents was strongly opposed. Assuming a 2% survival rate did not significantly influence medical directors&apos; opinions about mandatory DNR orders in these groups. Medical directors were more willing to support requests by stable nursing home residents to withhold resuscitation, mechanical ventilation, or hospitalization than requests to withhold antibiotics, intravenous fluids, or tube feedings (P &lt; .005). The majority of medical directors were willing to withhold all such measures for terminal patients. CONCLUSIONS: Health care professionals who are responsible for educating patients about the efficacy of cardiopulmonary resuscitation in nursing homes overestimate its benefit and may benefit from further education about its outcome. Although mandatory Do-Not-Resuscitate orders were favored for terminal or vegetative patients, medical directors are not supportive of such orders across the board. Medical directors are more willing to honor requests for treatment limitation by terminal patients than others.</style></abstract><notes><style face="normal" font="default" size="100%">Ghusn, H F&#xD;Teasdale, T A&#xD;Skelly, J R&#xD;Journal Article&#xD;United States&#xD;J Am Geriatr Soc. 1995 Oct;43(10):1131-4. doi: 10.1111/j.1532-5415.1995.tb07014.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.1995.tb07014.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>191</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kobayashi, T.</style></author><author><style face="normal" font="default" size="100%">Lau, M. J.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, A.</style></author><author><style face="normal" font="default" size="100%">Chakravarti, A.</style></author><author><style face="normal" font="default" size="100%">Astua, A. J.</style></author><author><style face="normal" font="default" size="100%">Cortes, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Kobayashi, Mount Sinai Beth Israel, New York, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Linezolid-induced lactic acidosis and thrombocytopenia in a patient with osteomyelitis: A case report</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S664-S665</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">linezolid</style></keyword><keyword><style face="normal" font="default" size="100%">cefepime</style></keyword><keyword><style face="normal" font="default" size="100%">lactic acid</style></keyword><keyword><style face="normal" font="default" size="100%">propofol</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">bicarbonate</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial protein</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial protein</style></keyword><keyword><style face="normal" font="default" size="100%">RNA 23S</style></keyword><keyword><style face="normal" font="default" size="100%">RNA</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">lactic acidosis</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">osteomyelitis</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">toe</style></keyword><keyword><style face="normal" font="default" size="100%">protein synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">dyspnea</style></keyword><keyword><style face="normal" font="default" size="100%">platelet count</style></keyword><keyword><style face="normal" font="default" size="100%">oxygenation</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">bone</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">erythema</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">body temperature</style></keyword><keyword><style face="normal" font="default" size="100%">hypoglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">ambient air</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen saturation</style></keyword><keyword><style face="normal" font="default" size="100%">non insulin dependent diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">breathing rate</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">pulse rate</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial myopathy</style></keyword><keyword><style face="normal" font="default" size="100%">lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">Gram positive infection</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">lactate blood level</style></keyword><keyword><style face="normal" font="default" size="100%">vital sign</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus mirabilis</style></keyword><keyword><style face="normal" font="default" size="100%">systolic heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic acidosis</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas</style></keyword><keyword><style face="normal" font="default" size="100%">organ perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">hypovolemia</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">systemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">case study</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">coronary artery disease</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">genetic disorder</style></keyword><keyword><style face="normal" font="default" size="100%">pleura effusion</style></keyword><keyword><style face="normal" font="default" size="100%">biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">pathology</style></keyword><keyword><style face="normal" font="default" size="100%">anion gap</style></keyword><keyword><style face="normal" font="default" size="100%">neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">ribosome</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">bone resection</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">thorax radiography</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1525-1497</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE #1: Describe differential diagnosis of lactic acidosis LEARNING OBJECTIVE #2: Identify the potential side effects of linezolid CASE: A 77 year-old male with a past medical history of coronary artery disease, systolic heart failure, lymphoma, type 2 diabetes mellitus, with a recent admission for right toe osteomyelitis actively on treatment with linezolid and cefepime, presented with a 2-day history of shortness of breath and several episodes of hypoglycemia. He had a metatarsal head resection for acute osteomyelitis of his first toe 6 weeks prior. The pathology of the metatarsal head proximal margin was initially negative for osteomyelitis, but the surgical site eventually became infected. A repeat biopsy 1 week later was positive for acute osteomyelitis, and the bone culture grew vancomycin resistant enterococci and proteus mirabilis. The patient was subsequently discharged to a nursing home to complete a 6- week regimen consisting of linezolid and cefepime. During his treatment he became increasingly lethargic and developed shortness of breath 2 days prior to admission and was subsequently brought to the hospital. His initial vital signs showed a blood pressure of 115/80mmHg, pulse rate of 72/min, respiratory rate of 18/min, oxygen saturation of 99% on room air and a body temperature of 98 °F. On physical examination, the surgical site of the right foot was clean, with no erythema, discharge or tenderness noted. Blood work revealed a white blood cell count of 5.9 K/uL, platelet count of 17 K/uL, lactic acid of 15 mmol/L, and an elevated anion gap of 29. A chest x-ray showed a mildly worsening pleural effusion. A critical care medicine consult was requested from the ED, and he was admitted to the MICU for sepsis, and severe lactic acidosis. Ongoing linezolid administrations were continued empirically, and an infectious disease consult was requested. The lactate failed to clear with adequate supportive care, and a Type B lactic acidosis secondary to Linezolid was suspected. After discontinuing linezolid, the lactic acid gradually decreased to 0.6 mmol/L, and his platelet count increased to 166 K/uL by hospital day 17. Additional bone resection was performed, however, the proximal margin was positive again. Another bone culture grew pseudomonas resistant to cefepime, and he was discharged with oral ciprofloxacin. DISCUSSION: Lactic acidosis is a condition characterized by &gt; 4-5mmol/L serum lactic acid and is the most common cause of metabolic acidosis in hospitalized patients. It is often associated with poor clinical prognosis, and sepsis is a well-known primary cause of lactic acidosis. Type A lactic acidosis occurs by decreased end-organ perfusion or oxygenation secondary to hypovolemia, cardiac failure, and sepsis. Type B lactic acidosis occurs with no clinical evidence of hypoperfusion or oxygenation. Type B1 occurs by systemic diseases such as diabetes, renal failure and malignancy. Type B2 is caused by drug intoxication. Type B3 is caused by inborn errors of metabolism. Some common causes of Type B lactic acidosis include DKA, ethanol intoxication, drug use, malignancy, alcoholism, HIV, thiamine deficiency, mitochondrial myopathy, trauma, genetic diseases, among other causes of which the mechanism is not entirely clear. Drugs such as linezolid, antiretroviral drugs, and propofol that can impair mitochondrial protein synthesis and reproduction can lead to type B lactic acidosis. Linezolid is an antibiotic of the oxazolidinone class, and is often used to manage drug-resistant gram-positive bacterial infections. This inhibits bacterial protein synthesis by binding to residues within the 23S ribosomal RNA of the 50S large subunit of bacterial ribosomes. Linezolid use can be associated with some adverse effect including thrombocytopenia, neuropathy, serotonin syndrome, and lactic acidosis. A longer duration of linezolid leads to greater exposure to mitochondrial damage, therefore we expect that the duration of linezolid use is an important risk factor for those adverse reaction. The primary tre tment for linezolidinduced lactic acidosis is discontinuation of linezolid, and most of previous reports demonstrated the recovery within 1-15 days. Although some other treatments such as hemodialysis or bicarbonate have been reported, there is still limited evidence to support their clinical utility. The prognosis of linezolid-induced lactic acidosis is poor, and one case series revealed 26 % of mortality. Sepsis is often considered a major cause of lactic acidosis. However, less common causes of lactic acidosis, such as drug adverse effects, should also be considered. Clinicians should consider these causes when lactate trends are inconsistent with other clinical data.</style></abstract><notes><style face="normal" font="default" size="100%">L72289215&#xD;2016-05-31</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L72289215&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peters, P. H., Jr.</style></author><author><style face="normal" font="default" size="100%">Gravenstein, S.</style></author><author><style face="normal" font="default" size="100%">Norwood, P.</style></author><author><style face="normal" font="default" size="100%">De Bock, V.</style></author><author><style face="normal" font="default" size="100%">Van Couter, A.</style></author><author><style face="normal" font="default" size="100%">Gibbens, M.</style></author><author><style face="normal" font="default" size="100%">von Planta, T. A.</style></author><author><style face="normal" font="default" size="100%">Ward, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Protocare Trials at the San Antonio Center for Clinical Research, San Antonio, Texas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1025-31</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acetamides/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Frail Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuraminidase/*antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Oseltamivir</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To investigate the efficacy of once-daily oral oseltamivir for 6 weeks (Tamiflu) in prophylaxis against laboratory-confirmed clinical influenza in frail older subjects living in homes for seniors and to determine the safety and tolerability of long-term oseltamivir. DESIGN: Double-blind, placebo-controlled, parallel-group, randomized, multicenter study. SETTING: Thirty-one residential homes for seniors across United States and Europe. PARTICIPANTS: Five hundred forty-eight frail older occupants (mean age 81 years, &gt;80% vaccinated). INTERVENTION: Prophylaxis with oseltamivir 75 mg or placebo once daily for 6 weeks, beginning when influenza was detected locally. MEASUREMENTS: The primary efficacy endpoint was laboratory-confirmed clinical influenza. RESULTS: Oseltamivir administration resulted in a 92% reduction in the incidence of laboratory-confirmed clinical influenza compared with placebo (placebo 12/272 (4.4%), oseltamivir 1/276 (0.4%); P = .002). Of subjects vaccinated against influenza, oseltamivir was 91% effective in preventing laboratory-confirmed clinical influenza (placebo 11/218 (5.0%), oseltamivir 1/222 (0.5%); P = .003). Oseltamivir use was associated with a significant reduction in the incidence of secondary complications (placebo 7/272 (2.6%), oseltamivir 1/276 (0.4%); P = .037). Although nearly all subjects were taking concomitant medication both before and during the study, oseltamivir was well tolerated. A similar incidence of adverse events, including gastrointestinal effects, occurred in both groups. There was no suppression of antibody response in oseltamivir recipients. CONCLUSION: Oral oseltamivir 75 mg once daily for 6 weeks effectively prevented clinical influenza in vaccinated frail older subjects using significant concomitant medications in a residential care setting. The treatment was well tolerated and provided additional protection to that afforded by vaccination.</style></abstract><notes><style face="normal" font="default" size="100%">Peters, P H Jr&#xD;Gravenstein, S&#xD;Norwood, P&#xD;De Bock, V&#xD;Van Couter, A&#xD;Gibbens, M&#xD;von Planta, T A&#xD;Ward, P&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Geriatr Soc. 2001 Aug;49(8):1025-31. doi: 10.1046/j.1532-5415.2001.49204.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1532-5415.2001.49204.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Factor, S. A.</style></author><author><style face="normal" font="default" size="100%">Feustel, P. J.</style></author><author><style face="normal" font="default" size="100%">Friedman, J. H.</style></author><author><style face="normal" font="default" size="100%">Comella, C. L.</style></author><author><style face="normal" font="default" size="100%">Goetz, C. G.</style></author><author><style face="normal" font="default" size="100%">Kurlan, R.</style></author><author><style face="normal" font="default" size="100%">Parsa, M.</style></author><author><style face="normal" font="default" size="100%">Pfeiffer, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.A. Factor, Parkinson&apos;s Dis./Movement Disord. C., Albany Medical Center, 215 Washington Ave. Ext., Albany, NY 12205, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal outcome of Parkinson&apos;s disease patients with psychosis</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1756-1761</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">amantadine</style></keyword><keyword><style face="normal" font="default" size="100%">benzatropine</style></keyword><keyword><style face="normal" font="default" size="100%">bromocriptine</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">pergolide</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline</style></keyword><keyword><style face="normal" font="default" size="100%">trihexyphenidyl</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">age</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">correlation analysis</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">disease duration</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal study</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">Mini Mental State Examination</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">onset age</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">paranoia</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rating scale</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">0028-3878</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: To examine the long-term outcome of PD patients with psychosis requiring antipsychotic therapy; to explore predictors of mortality, nursing home placement, dementia, and persistent psychosis; and to compare outcomes of those with persistent psychosis vs those whose psychosis resolved. Methods: Baseline data available from 59 patients enrolled in the PSYCLOPS (PSychosis and CLOzapine in PD Study) trial included age, age at onset of PD, duration of PD and psychosis, character of psychosis, medications, living setting, and scores for Mini-Mental State Examination (MMSE), Unified Parkinson&apos;s Disease Rating Scale, Hoehn and Yahr Scale, and Clinical Global Impression Scale. Longitudinal data were collected 26 months later regarding four outcomes: death, nursing home placement, diagnosis of dementia, and persistence of psychosis. Logistic regression was used to explore whether any baseline characteristics were associated with an increased likelihood of one of these outcomes. Results: At baseline, 56% of patients had an MMSE score of &lt;25, 12% were in a nursing home, 95% had hallucinations, and 60% had paranoia. On follow-up, 25% were dead, nursing home placement occurred in 42%, psychosis was persistent in 69%, and dementia was diagnosed in 68%. Select baseline characteristics predicted individual outcomes: Nursing home placement was associated with the presence of paranoia and older age; persistent psychosis was associated with younger age at onset of PD and longer disease duration; dementia was associated with older age at PD onset and lower initial MMSE score; no characteristics predicted death. Whether psychosis persisted or not had no significant effect on the development of the other three outcomes. The prevalence of hallucinations at follow-up was not different between groups currently receiving antipsychotics vs those on no treatment. Conclusions: Psychosis in PD requiring antipsychotic therapy is frequently associated with death, nursing home placement, development and progression of dementia, and persistence of psychosis. Still, it appears the prognosis has improved with atypical antipsychotic therapy based on the finding that 28% of NH patients died within 2 years compared with 100% in a previous study done prior to availability of this treatment.</style></abstract><notes><style face="normal" font="default" size="100%">L36737069&#xD;2003-07-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L36737069&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1212/01.WNL.0000068010.82167.CF</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">12796526</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1212/01.WNL.0000068010.82167.CF</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raveh, D.</style></author><author><style face="normal" font="default" size="100%">Levy, Y.</style></author><author><style face="normal" font="default" size="100%">Schlesinger, Y.</style></author><author><style face="normal" font="default" size="100%">Greenberg, A.</style></author><author><style face="normal" font="default" size="100%">Rudensky, B.</style></author><author><style face="normal" font="default" size="100%">Yinnon, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal surveillance of antibiotic use in the hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Qjm</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Qjm</style></full-title></periodical><pages><style face="normal" font="default" size="100%">141-52</style></pages><volume><style face="normal" font="default" size="100%">94</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/economics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Protocols</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Utilization Review</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Guideline Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, General</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infusions, Intravenous/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Israel</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Practice Patterns, Physicians&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2725 (Print)&#xD;1460-2393</style></isbn><abstract><style face="normal" font="default" size="100%">We evaluated antimicrobial use in our hospital by department, including indications for use, source of infections, use of the microbiology laboratory, and appropriateness of prescribing, in a prospective, comparative, non-interventional study of all patients receiving antimicrobial agents. We excluded departments where antimicrobial use was negligible. The other 19 departments were followed for 3 (n=4) or 4 (n=15) months, including 2 consecutive months in the spring-summer and either 1 or 2 in the autumn-winter. Antimicrobial therapy was followed from initiation, through possible adaptations, and possible change from intravenous to oral therapy, until discontinuation of treatment. Overall, 6376 antibiotics were given to 2306 patients. Of the surveyed hospitalized patients, 62%+/-22% received antibiotics, with a range of 4-100% per department. Antibiotics were prescribed for infections acquired in the community (3037 instances, 47%), in the hospital (2182, 34%), in a nursing home (575, 9%), and for prophylaxis continued post-operatively (582, 9%). The most common indications for antimicrobial use were: respiratory tract infection (1729, 27%), urinary tract infection (955, 15%), sepsis (701, 11%), intra-abdominal infections (663, 10%), prophylaxis 582 (9%), soft-tissue infection (572, 9%), and surgical site infection (319, 5%). Univariate indicators for appropriateness of treatment were: age, department, site of infection, source of infection, antimicrobial drug and serum creatinine (all p&lt;0.001). Forty-nine antimicrobials were prescribed in 279 combinations, 58% as single agent and 42% as drug combinations. Half of all antimicrobial use consisted of four agents: cefuroxime (19.1%), metronidazole (11.3%), gentamicin (10.6%) and ampicillin (10.2%), which together accounted for 20% of expenditure on antibiotics. Although use of as many as 53% of antimicrobials (26/49) surveyed was restricted, use in this category accounted for only 29% of all antimicrobial courses. Of 6376 antibiotic courses, 4101 (64%) were given intravenously and 2275 (36%) orally. Appropriateness of use of restricted drugs was lower (70%) than of unrestricted ones (84%, p&lt;0.001). Of 24571 defined daily doses (DDD) given orally, 4587 (19%) were restricted, compared to 7264 (34%) of 21602 DDDs given intravenously (p&lt;0.001). Antibiotic treatment in our hospital appears to be substantial and increasing, justifying efforts to improve appropriateness of therapy and improve clinical and financial results.</style></abstract><notes><style face="normal" font="default" size="100%">Raveh, D&#xD;Levy, Y&#xD;Schlesinger, Y&#xD;Greenberg, A&#xD;Rudensky, B&#xD;Yinnon, A M&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;QJM. 2001 Mar;94(3):141-52. doi: 10.1093/qjmed/94.3.141.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/qjmed/94.3.141</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ramírez-Ronda, C. H.</style></author><author><style face="normal" font="default" size="100%">Ballesté, C. R.</style></author><author><style face="normal" font="default" size="100%">Meléndez, B.</style></author><author><style face="normal" font="default" size="100%">Vélez, M.</style></author><author><style face="normal" font="default" size="100%">Fontán, L.</style></author><author><style face="normal" font="default" size="100%">Saavedra, S.</style></author><author><style face="normal" font="default" size="100%">González, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Program, Department of Medicine, San Juan VAMC and University Hospital, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of urinary tract infections, decubitus ulcer and pneumonia in the aging person</style></title><secondary-title><style face="normal" font="default" size="100%">Bol Asoc Med P R</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bol Asoc Med P R</style></full-title></periodical><pages><style face="normal" font="default" size="100%">42-50</style></pages><volume><style face="normal" font="default" size="100%">95</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/diagnosis/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pressure Ulcer/diagnosis/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Infectious/diagnosis/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/*drug therapy/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0004-4849 (Print)&#xD;0004-4849</style></isbn><abstract><style face="normal" font="default" size="100%">Infections in the older person are common and a significant cause of morbidity and mortality. Infections of the urinary tract, skin and soft tissue infections including decubitus ulcers, antibiotics associated diarrhea and lower respiratory tract infections are particularly important in the elderly because of their frequency. While most initial antibiotic therapy is empiric, its important before treatment to try to document the etiology for better use of antibiotics. Infections of the urinary tract are frequently and potentially serious in the elderly, they must be separated from asymptomatic bacteriuria that requires no therapy. Upper and lower urinary tract infections are frequently caused by aerobic gram negative bacilli and or enterococci. Most authors prefer the use of fluoroquinolones to manage such infections. The elderly with decubitus ulcer presents a problem in management, since these are frequent polymicrobic infections in which anaerobes play an important role. The initial therapy usually involves the combination of a fluoroquinolone plus an antianaerobic agent like clindamycin. C. difficile diarrhea as frequent in nursing home residents as well as the older person with prior antibiotics. The treatment should be with metronidazole and avoid the use of vancomycin. Pneumonias in the elderly can be acquired in the community, the nursing home or during a hospitalization. The etiologic agents that predominate change from S. pneumoniae and atypicals in those from the community to an increase in gram negative pneumonia. The initial treatment as started by most authors as well as guidelines include the use of a new fluoroquinolone like gatifloxacin alone or in combination with a beta-lactamic agent like ceftriaxone. For those infections acquired in the hospital therapy with third or fourth generation cephalosporins, carbapenems, beta-lactams with betalactamase inhibitors alone or in combination with an aminoglucoside and or vancomycin if MRSA is suspected is accepted therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Ramírez-Ronda, Carlos H&#xD;Ballesté, Carmen R&#xD;Meléndez, Bebelín&#xD;Vélez, Mayra&#xD;Fontán, Luis&#xD;Saavedra, Sonia&#xD;González, Glenda&#xD;Journal Article&#xD;Puerto Rico&#xD;Bol Asoc Med P R. 2003 Nov-Dec;95(6):42-50.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marasco, R. A.</style></author><author><style face="normal" font="default" size="100%">Ramsay, R. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. A. Marasco, Pharmaceutical Care and Management Services, 3982 Kindcrlou Forest, Valdosta, GA 31601</style></auth-address><titles><title><style face="normal" font="default" size="100%">Managing epilepsy: Issues in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Consultant Pharmacist</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Consultant Pharmacist</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-22</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">SUPPL. A</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">allopurinol</style></keyword><keyword><style face="normal" font="default" size="100%">amiodarone</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">chloramphenicol</style></keyword><keyword><style face="normal" font="default" size="100%">cimetidine</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">dextropropoxyphene</style></keyword><keyword><style face="normal" font="default" size="100%">diltiazem</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">fluconazole</style></keyword><keyword><style face="normal" font="default" size="100%">fluoxetine</style></keyword><keyword><style face="normal" font="default" size="100%">gabapentin</style></keyword><keyword><style face="normal" font="default" size="100%">Hypericum perforatum extract</style></keyword><keyword><style face="normal" font="default" size="100%">ibuprofen</style></keyword><keyword><style face="normal" font="default" size="100%">imipramine</style></keyword><keyword><style face="normal" font="default" size="100%">isoniazid</style></keyword><keyword><style face="normal" font="default" size="100%">lamotrigine</style></keyword><keyword><style face="normal" font="default" size="100%">methylphenidate</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">oxcarbazepine</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">pregabalin</style></keyword><keyword><style face="normal" font="default" size="100%">sertraline</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">verapamil</style></keyword><keyword><style face="normal" font="default" size="100%">zonisamide</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">treatment planning</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0888-5109</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: To describe key factors that can affect treatment of epilepsy in the elderly. To outline steps to reduce or discontinue antiepileptic drug therapy in those who have been seizure-free. To design a care plan for a resident with a diagnosis of epilepsy. Data Sources: Live symposium presentation based on clinical practice and research. Conclusions: Treating and managing epilepsy in the elderly may be complicated by confounding factors, including comorbidities and polypharmacy. Special attention must be paid to reduce drug interactions and monitor for effectiveness and toxicity. Consultant pharmacists play a key role in managing patients with epilepsy, and nursing facilities should strive to integrate consultant pharmacists into all stages of care plan development and revision. © 2009 American Society of Consultant Pharmacists, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L354700701&#xD;2009-07-02</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354700701&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aspirin</style></custom1><custom5><style face="normal" font="default" size="100%">19555151</style></custom5></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>47</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">47</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Neal, E.</style></author><author><style face="normal" font="default" size="100%">Myers, A.</style></author><author><style face="normal" font="default" size="100%">Miller, P. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Neal, Vanderbilt University Medical Center, Nashville, TN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medication management to improve post acute care transfer</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e244</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">insulin</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">college</style></keyword><keyword><style face="normal" font="default" size="100%">clinical pharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">medication therapy management</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">medicare</style></keyword><keyword><style face="normal" font="default" size="100%">nurse</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based practice</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">thromboembolism</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulation</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0277-0008</style></isbn><abstract><style face="normal" font="default" size="100%">PURPOSE: Patients discharged from Vanderbilt University Hospital (VUH) to post-acute care (PAC) facilities typically have multiple co-morbidities, are older, and experience 30-day re-hospitalization rates up to 25%. Improve post acute care transfer (IMPACT) aims to improve outcomes and quality of care across acute and PAC facilities. Pharmacists are creating medication management plans as part of the IMPACT transition bundle. METHODS: Pharmacists create medication management plans for all Medicare patients discharged from VUH to partner skilled nursing facilities (SNF). The medication management plan includes the pre-hospital medication list, changes made to the regimen with rationale, and monitoring recommendations. Pharmacists review the regimen for appropriateness and recommend discontinuation of potentially inappropriate medications or initiation of additional therapy according to evidence-based guidelines and core measures. Pharmacists also provide a prospective monitoring plan particularly for high-risk medications such as diuretics, insulin, and anticoagulation. Pharmacists ensure that there are stop dates for short courses of therapy like antibiotics, thromboembolism prophylaxis, and post-surgical pain medications. The medication management plan is a component of a standardized discharge bundle compiled by nurse transition advocates and sent with the patient to the SNF. Nurse transition advocates also attempt to provide a “warm hand-off” and verbally highlight any important medications issues to a SNF representative. RESULTS: Three pharmacists have provided this service for all Medicare patients discharged to partner SNFs since April 2013. Medication management plans have been completed for over 100 patients. The SNF reports that the medication management plans have helped them scrutinize multiple contradictory medication lists, and highlight important clinical issues. CONCLUSION: This project highlights pharmacists&apos; role in improving care transitions. Data is being collected to demonstrate pharmacists&apos; impact on transitions of care to post acute care facilities.</style></abstract><notes><style face="normal" font="default" size="100%">L71764278&#xD;2015-02-03</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71764278&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/phar.1356</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/phar.1356</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boockvar, K. S.</style></author><author><style face="normal" font="default" size="100%">Carlson LaCorte, H.</style></author><author><style face="normal" font="default" size="100%">Giambanco, V.</style></author><author><style face="normal" font="default" size="100%">Fridman, B.</style></author><author><style face="normal" font="default" size="100%">Siu, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.S. Boockvar, Geriatric Research, Education, Clinical Center, James J. Peters VA Medical Center, Bronx, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medication reconciliation for reducing drug-discrepancy adverse events</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal Geriatric Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal Geriatric Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-243</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">enalapril</style></keyword><keyword><style face="normal" font="default" size="100%">lansoprazole</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">tegaserod</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">hospital bed capacity</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">medication error</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">patient referral</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">patient transport</style></keyword><keyword><style face="normal" font="default" size="100%">pharmaceutical care</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary health care</style></keyword><keyword><style face="normal" font="default" size="100%">urban population</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1543-5946</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Medication reconciliation is a technique for identifying discrepancies in drug regimens prescribed in different care settings or at different time points to inform prescribing decisions and prevent medication errors. Objective: This study examined the effect of pharmacist-conducted medication reconciliation on the occurrence of discrepancy-related adverse drug events (ADEs) associated with drugs ordered at the time of a resident&apos;s return from the hospital to the nursing home. Methods: This was a preintervention/postintervention study conducted in a consecutive sample of residents of a 514-bed, urban, not-for-profit nursing home who were hospitalized in its primary referral hospital, an 1171-bed academic tertiary care hospital, and returned to the nursing home between December 2002 and January 2005. In the intervention phase, a pharmacist conducted a reconciliation of drugs ordered on return to the nursing home with those received before hospitalization, and communicated prescribing discrepancies to the physician. The primary outcome was the occurrence of discrepancy-related ADEs, as ascertained by a review of the medical records performed by 2 independent physician raters. Results: During the study period, 168 nursing home residents had 259 hospital stays. The reconciliation intervention identified 696 total prescribing discrepancies, of which physicians responded to 598 (85.9%). Among the 112 cases selected for ADE ascertainment, 11 discrepancy-related ADEs were identified, 1 in the postintervention group and 10 in the preintervention group, for an incidence of 2.3% and 14.5%, respectively (relative risk, 0.16; 95% CI, 0.02-1.2; P = NS). After adjustment for baseline ADE risk, the odds of having a discrepancy-related ADE were significantly lower in the postintervention group compared with the preintervention group (odds ratio, 0.11; 95% CI, 0.01-1.0; P = 0.05). The most commonly identified discrepancy-related ADE was pain from the omission of an analgesic (3/11 [27.3%]), and antibiotics and analgesics were the most common causes of discrepancy-related ADEs (each, 3/11 [27.3%]). Conclusions: Pharmacist medication reconciliation and communication with the physician reduced discrepancy-related ADEs in these patients transferred between the hospital and nursing home. Studies are needed to identify the most efficient ways of carrying out this task and to adapt the reconciliation process to all care settings. © 2006 Excerpta Medica, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L44575962&#xD;2006-11-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L44575962&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.amjopharm.2006.09.003</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17062324</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.amjopharm.2006.09.003</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Drastrup, A. M.</style></author><author><style face="normal" font="default" size="100%">Jakobsen, H. N.</style></author><author><style face="normal" font="default" size="100%">Madsen, G. K.</style></author><author><style face="normal" font="default" size="100%">Trærup Andersen, J. P.</style></author><author><style face="normal" font="default" size="100%">Vermehren, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.M. Drastrup, Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medication review in elderly</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A51</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">nootropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">access to information</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">clinical pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">informed consent</style></keyword><keyword><style face="normal" font="default" size="100%">intervention study</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical information</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">2515-4478</style></isbn><abstract><style face="normal" font="default" size="100%">#Objectives The number of elderly is increasing in our society. This population group suffers from more chronic diseases and is therefore taking more medications. Polypharmacy and inappro¬priate use of medication increase the risk of adverse drug reac¬tions and is a contributor to unplanned hospitalization. Therefore, it is important to focus on inappropriate use of medi¬cation and to promote rational pharmacotherapy and thereby prevent hospitalization among the elderly. The objective of this pilot study was to develop a medication review model with spe¬cial focus on the medication taken by elderly living in nursing homes and to investigate and measure the degree of implementa¬tion of potential medication changes. The main focus of the medication reviews was on four medications; antibiotic, pain patches, antipsychotics and anti-dementia drugs. Method This study was an intervention study in which medica-tion reviews were performed in corporation between a pharma¬cist and a consulting physician from the Department of Clinical Pharmacology at Copenhagen University Hospital Bispebjerg in the Capital Region of Denmark and the patientś general practi¬tioner. Only participants living in nursing homes in the Capital Region of Denmark and in treatment with antibiotic, pain patches, antipsychotics or anti-dementia drugs were included. The intervention consisted of two parts. First the pharmacist and the consulting physician performed a medication review with access to information about the patient&apos;s medication, diagnosis, laboratory result and health information. This was followed by a meeting between the pharmacist, the consulting physician and the patient&apos;s general practitioner in order to discuss the potential changes in the patient&apos;s medication. Finally, a four month fol-low-up to evaluate the degree of implementation of the accepted medication changes was performed. Results 100 patients were included and 49 informed consents were collected. 30 (61.2%) were females and the average age of the participants was 85.3 years (SD ±9.5). Medication reviews were performed and in total 530 prescriptions were reviewed. In average, the participants were treated with 10.8 medications. 109 interventions were suggested and qualified by the patient&apos;s general practitioner. 99% of the proposed changes were approved by the general practitioner and the most frequent type of intervention was discontinuation (43.5%) followed by dose reduction (23.5%) and reassessment of the treatment (22.6%). Among the 109 interventions only 18.3% were concerning the four medications in focus (antibiotic 4.3%, pain patches 1.7%, antipsychotics 11.3% and anti-dementia drugs 0.9%). After four months 34.3% interventions had been implemented and 2.8% had been partly implemented. Conclusions The type of medication review performed here showed a high degree of approved proposals which can be due to the structure of the medication review. The preliminary result showed that the medications in focus were not among the most frequent interventions indicating that the reassessment of high risk medication is complex and that irrational pharmacotherapy concerns a wide variety of medications. Therefore the four med¬ications in focus were not suited as inclusion criteria for this type of study identifying patients in high risk of adverse drug reaction.</style></abstract><notes><style face="normal" font="default" size="100%">L625368836&#xD;2018-12-11</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L625368836&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/bmjebm-2018-111070.108</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjebm-2018-111070.108</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dowling, G. A.</style></author><author><style face="normal" font="default" size="100%">Burr, R. L.</style></author><author><style face="normal" font="default" size="100%">Van Someren, E. J. W.</style></author><author><style face="normal" font="default" size="100%">Hubbard, E. M.</style></author><author><style face="normal" font="default" size="100%">Luxenberg, J. S.</style></author><author><style face="normal" font="default" size="100%">Mastick, J.</style></author><author><style face="normal" font="default" size="100%">Cooper, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.A. Dowling, Department of Physiological Nursing, University of California, San Francisco, 2 Koret Way, San Francisco, CA 94143, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">239-246</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">melatonin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">actimetry</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">phototherapy</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">sleep</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">wakefulness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614&#xD;1532-5415</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To test whether the addition of melatonin to bright-light therapy enhances the efficacy in treating rest-activity (circadian) disruption in institutionalized patients with Alzheimer&apos;s disease (AD). DESIGN: Randomized, controlled trial. SETTING: Two nursing homes in San Francisco, California. PARTICIPANTS: Fifty subjects (mean age 86) with AD. INTERVENTION: Experimental subjects received 1 hour of morning light exposure (≥2,500 lux in gaze direction) Monday to Friday for 10 weeks and 5 mg melatonin (LM, n=16) or placebo (LP, n=17) in the evening. Control subjects (n=17) received usual indoor light (150-200 lux). MEASUREMENTS: Nighttime sleep variables, day sleep time, day activity, day:night sleep ratio, and rest-activity parameters were determined using actigraphy. RESULTS: Linear mixed models were employed to test the primary study hypotheses. No significant differences in nighttime sleep variables were found between groups. At the end of the intervention, the LM group showed significant improvement in daytime somnolence as indicated by a reduction in the duration of daytime sleep, an increase in daytime activity, and an improvement in day:night sleep ratio. The LM group also evidenced a significant increase in rest-activity rhythm amplitude and goodness of fit to the cosinor model. CONCLUSION: Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. Light treatment plus melatonin increased daytime wake time and activity levels and strengthened the rest-activity rhythm. Future studies should resolve the question of whether these improvements can be attributed to melatonin or whether the two zeitgebers interact to amplify efficacy. © 2008, The American Geriatrics Society.</style></abstract><notes><style face="normal" font="default" size="100%">L351160692&#xD;2008-02-06</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L351160692&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1532-5415.2007.01543.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18070004</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2007.01543.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jafar, N.</style></author><author><style face="normal" font="default" size="100%">McGee, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">MIDODRINE-INDUCED BRADYCARDIA IN CRITICALLY ILL PATIENT</style></title><secondary-title><style face="normal" font="default" size="100%">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chest</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A1884</style></pages><volume><style face="normal" font="default" size="100%">156</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antihypertensive agent</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">hypertensive factor</style></keyword><keyword><style face="normal" font="default" size="100%">midodrine</style></keyword><keyword><style face="normal" font="default" size="100%">nitric acid derivative</style></keyword><keyword><style face="normal" font="default" size="100%">noradrenalin</style></keyword><keyword><style face="normal" font="default" size="100%">phenylephrine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">abdomen</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">anesthesiology</style></keyword><keyword><style face="normal" font="default" size="100%">autonomic dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">chill</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">dialysis</style></keyword><keyword><style face="normal" font="default" size="100%">drug overdose</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dysuria</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">hepatorenal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hydronephrosis</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">induced hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">lower abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">nephrostomy tube</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">baroreceptor</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">reflex</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">sinus bradycardia</style></keyword><keyword><style face="normal" font="default" size="100%">therapeutic dose</style></keyword><keyword><style face="normal" font="default" size="100%">ureteropelvic junction</style></keyword><keyword><style face="normal" font="default" size="100%">weaning</style></keyword><keyword><style face="normal" font="default" size="100%">x-ray computed tomography</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1931-3543&#xD;0012-3692</style></isbn><abstract><style face="normal" font="default" size="100%">SESSION TITLE: Wednesday Fellows Case Report Posters SESSION TYPE: Fellow Case Report Posters PRESENTED ON: 10/23/2019 09:45 AM - 10:45 AM INTRODUCTION: Midodrine is alpha-1 agonist agent, which is used in the ICU to accelerate weaning off IV pressors. Midodrine may cause bradycardia which can worsen hypotension and increase the requirement for vasopressors. CASE PRESENTATION: A 67 years old female with a past medical history of Multiple Sclerosis and recurrent UTI, was admitted from a nursing home complaining of lower abdominal pain, dysuria, fever and chills for two days. She had a temperature of 101 F, Heart rate of 110 bpm and her BP was 90/60 mmHg. Her physical exam was remarkable for suprapubic and right costophrenic angle tenderness. Her UA was positive for bacteria and nitrates and a CT scan of the abdomen showed a 7 mm stone in the right ureteropelvic junction with hydronephrosis. The patient was treated with broad-spectrum antibiotics and a percutaneous right nephrostomy tube. However, the patient remained hypotensive requiring pressors. After 2 days the patient continued to be Norepinephrine dependent. She received 2 doses of Midodrine 5mg, 8 hours apart, shortly after the second dose the patient developed sinus bradycardia with HR of 40 bpm, and her vasopressor requirement increased. She was switched from Norepinephrine to Dopamine and Midodrine was stopped. The patient was off Dopamine within 18 hours and her heart rate stabilized in the 70s. DISCUSSION: Midodrine is an oral agent with alpha 1-agonist properties with the same mechanism of action as phenylephrine. The drug is indicated in hepatorenal syndrome, autonomic dysfunction, and dialysis-induced hypotension. Recently, Midodrine use in the ICU has been increasing as a way to liberate the patient from Intravenous vasopressors and shorten the ICU length of stay. Reflex bradycardia, is an uncommon side effect of Midodrine use through its effect on the baroreceptors, it‘s usually transient and uncommon at therapeutic doses, however in our patient the bradycardia was prolonged and required the use of Dopamine. CONCLUSIONS: Midodrine can facilitate weaning from IV vasopressors; however bradycardia is a potential side effect that requires discontinuation of the drug and may prolong the need for vasopressors. Reference #1: L. Y. Wong. Severe Hypertension and Bradycardia Secondary to Midodrine Overdose. J Med Toxicol. 2017 Mar; 13(1): 88–90. Reference #2: Anstey et al Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo-controlled trial (the MIDAS trial BMC Anesthesiology March 2017. Reference #3: Levine AR et al, Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013 Oct;28(5):756-62. DISCLOSURES: No relevant relationships by nagham jafar, source=Web Response No relevant relationships by William McGee, source=Web Response</style></abstract><notes><style face="normal" font="default" size="100%">L2002984337&#xD;2019-10-02</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002984337&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.chest.2019.08.1627</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.chest.2019.08.1627</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chow, A. L.</style></author><author><style face="normal" font="default" size="100%">Lye, D. C.</style></author><author><style face="normal" font="default" size="100%">Arah, O. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Epidemiology, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore.&#xD;Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, United States.&#xD;Department of Infectious Diseases, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore.&#xD;Yong Loo Lin School of Medicine, National University of Singapore, Singapore.&#xD;Center for Health Policy Research, University of California, Los Angeles (UCLA), Los Angeles, United States.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mortality Benefits of Antibiotic Computerised Decision Support System: Modifying Effects of Age</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17346</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Academic Medical Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">*Clostridioides difficile/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">*Cross Infection</style></keyword><keyword><style face="normal" font="default" size="100%">*Decision Support Systems, Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Prescriptions</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis, Pseudomembranous/drug therapy/microbiology/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Readmission</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tertiary Care Centers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322</style></isbn><abstract><style face="normal" font="default" size="100%">Antibiotic computerised decision support systems (CDSSs) are shown to improve antibiotic prescribing, but evidence of beneficial patient outcomes is limited. We conducted a prospective cohort study in a 1500-bed tertiary-care hospital in Singapore, to evaluate the effectiveness of the hospital&apos;s antibiotic CDSS on patients&apos; clinical outcomes, and the modification of these effects by patient factors. To account for clustering, we used multilevel logistic regression models. One-quarter of 1886 eligible inpatients received CDSS-recommended antibiotics. Receipt of antibiotics according to CDSS&apos;s recommendations seemed to halve mortality risk of patients (OR 0.54, 95% CI 0.26-1.10, P = 0.09). Patients aged ≤65 years had greater mortality benefit (OR 0.45, 95% CI 0.20-1.00, P = 0.05) than patients that were older than 65 (OR 1.28, 95% CI 0.91-1.82, P = 0.16). No effect was observed on incidence of Clostridium difficile (OR 1.02, 95% CI 0.34-3.01), and multidrug-resistant organism (OR 1.06, 95% CI 0.42-2.71) infections. No increase in infection-related readmission (OR 1.16, 95% CI 0.48-2.79) was found in survivors. Receipt of CDSS-recommended antibiotics reduced mortality risk in patients aged 65 years or younger and did not increase the risk in older patients. Physicians should be informed of the benefits to increase their acceptance of CDSS recommendations.</style></abstract><notes><style face="normal" font="default" size="100%">2045-2322&#xD;Chow, Angela L P&#xD;Lye, David C&#xD;Arah, Onyebuchi A&#xD;Journal Article&#xD;Sci Rep. 2015 Nov 30;5:17346. doi: 10.1038/srep17346.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4663624</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep17346</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martelli, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Mortality rate in the principal infectious diseases under the action of antibiotics (penicillin and streptomycin) and its effect on composition of the Italian population by age]</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Sanita Pubblica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Sanita Pubblica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1465-91</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibiotics, Antitubercular</style></keyword><keyword><style face="normal" font="default" size="100%">*Communicable Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatologic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Penicillins</style></keyword><keyword><style face="normal" font="default" size="100%">*Streptomycin</style></keyword><keyword><style face="normal" font="default" size="100%">*Vital Statistics</style></keyword><keyword><style face="normal" font="default" size="100%">*penicillin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1950</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep-Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0021-3071 (Print)&#xD;0021-3071</style></isbn><notes><style face="normal" font="default" size="100%">Martelli, t&#xD;Journal Article&#xD;Italy&#xD;Ann Sanita Pubblica. 1950 Sep-Oct;11(5):1465-91.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hutt, E.</style></author><author><style face="normal" font="default" size="100%">Ruscin, J. M.</style></author><author><style face="normal" font="default" size="100%">Corbett, K.</style></author><author><style face="normal" font="default" size="100%">Radcliff, T. A.</style></author><author><style face="normal" font="default" size="100%">Kramer, A. M.</style></author><author><style face="normal" font="default" size="100%">Williams, E. M.</style></author><author><style face="normal" font="default" size="100%">Liebrecht, D.</style></author><author><style face="normal" font="default" size="100%">Klenke, W.</style></author><author><style face="normal" font="default" size="100%">Hartmann, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Denver Veterans Affairs Medical Center, Denver, Colorado 80220, USA. Evelyn.Hutt@uchsc.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">A multifaceted intervention to implement guidelines improved treatment of nursing home-acquired pneumonia in a state veterans home</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1694-700</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*nursing</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Guideline Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/etiology/*nursing</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To assess the feasibility of a multifaceted strategy to translate evidence-based guidelines for treating nursing home-acquired pneumonia (NHAP) into practice using a small intervention trial. DESIGN: Pre-posttest with untreated control group. SETTING: Two Colorado State Veterans Homes (SVHs) during two influenza seasons. PARTICIPANTS: Eighty-six residents with two or more signs of lower respiratory tract infection. INTERVENTION: Multifaceted, including a formative phase to modify the intervention, institutional-level change emphasizing immunization, and availability of appropriate antibiotics; interactive educational sessions for nurses; and academic detailing. MEASUREMENTS: Subjects&apos; SVH medical records were reviewed for guideline compliance retrospectively for the influenza season before the intervention and prospectively during the intervention. Bivariate comparisons-of-care processes between the intervention and control facility before and after the intervention were made using the Fischer exact test. RESULTS: At the intervention facility, compliance with five of the guidelines improved: influenza vaccination, timely physician response to illness onset, x-ray for patients not being hospitalized, use of appropriate antibiotics, and timely antibiotic initiation for unstable patients. Chest x-ray and appropriate and timely antibiotics were significantly better at the intervention than at the control facility during the intervention year but not during the control year. CONCLUSION: Multifaceted, evidence-based, NHAP guideline implementation improved care processes in a SVH. Guideline implementation should be studied in a national sample of nursing homes to determine whether it improves quality of life and functional outcomes of this debilitating illness for long-term care residents.</style></abstract><notes><style face="normal" font="default" size="100%">Hutt, Evelyn&#xD;Ruscin, J Mark&#xD;Corbett, Kitty&#xD;Radcliff, Tiffany A&#xD;Kramer, Andrew M&#xD;Williams, Elizabeth M&#xD;Liebrecht, Debra&#xD;Klenke, William&#xD;Hartmann, Sheryl&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Am Geriatr Soc. 2006 Nov;54(11):1694-700. doi: 10.1111/j.1532-5415.2006.00937.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2006.00937.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">45</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mylotte, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA. Mylotte@buffalo.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nursing home-acquired pneumonia: update on treatment options</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs Aging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">377-90</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Community-Acquired Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1170-229X (Print)&#xD;1170-229x</style></isbn><abstract><style face="normal" font="default" size="100%">The management of nursing home-acquired pneumonia (NHAP) continues to be debatable because of the lack of clinical trials and controversy regarding its aetiology. The controversy regarding aetiology stems, in part, from studies that utilised sputum cultures for the diagnosis of NHAP without assessing the quality of the samples. These studies found a high proportion of Gram-negative aerobic bacilli in cultures as well as Staphylococcus aureus. However, in studies that have assessed the reliability of sputum samples, Gram-negative bacilli and S. aureus were isolated infrequently and Streptococcus pneumoniae and Haemophilus influenzae isolated most commonly. Since Gram-negative aerobic bacilli and S. aureus frequently cause hospital-acquired pneumonia, some authors have considered NHAP to be a variant of this group. Many other studies, however, have considered NHAP as part of the community-acquired pneumonia category. Depending on which categorisation is used for NHAP, the treatment recommendations have varied. There are several factors to consider in the management of NHAP in addition to choice of antibacterial: hospitalisation decision, initial route of administration of antibacterials for treatment in the nursing home, timing of switch from a parenteral to an oral agent and the duration of therapy. These factors, which have not been addressed in published guidelines, are discussed in this review. Recent guidelines recommend a fluoroquinolone (gatifloxacin, levofloxacin or moxifloxacin) or amoxicillin/clavulanic acid plus a macrolide for initial treatment of NHAP in the nursing home. For treatment in the hospital, a parenteral fluoroquinolone (as listed above) or a second- or third-generation cephalosporin plus a macrolide is recommended. A recent guideline for the treatment of healthcare-associated pneumonia (that includes NHAP) recommended an antipseudomonal cephalosporin or a carbapenem or an antipseudomonal penicillin/beta-lactamase inhibitor plus ciprofloxacin plus vancomycin or linezolid for treatment of NHAP based on findings in residents with severe pneumonia who required mechanical ventilation. However, this recommendation does not apply to the majority of residents who are hospitalised with pneumonia and not intubated. Other factors to consider when choosing an empiric regimen include recent antibacterial therapy and prior colonisation with a resistant organism, e.g. methicillin-resistant S. aureus. Recently, a group of studies by investigators in The Netherlands have focused on the concept of withholding antibacterial therapy in nursing home residents with pneumonia who have advanced dementia. These studies are reviewed in some detail because this is an approach to the management of NHAP that is uncommon but deserves more consideration given the terminal status of these people. Future studies of NHAP should focus on development of rapid (molecular) methods to identify aetiological agents, determination of the optimum antimicrobial regimen and duration of therapy, and identification of criteria that can assist physicians and families in making the decision to withhold antimicrobial therapy in residents with advanced dementia and pneumonia.</style></abstract><notes><style face="normal" font="default" size="100%">Mylotte, Joseph M&#xD;Journal Article&#xD;Review&#xD;New Zealand&#xD;Drugs Aging. 2006;23(5):377-90. doi: 10.2165/00002512-200623050-00002.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00002512-200623050-00002</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klapwijk, M. S.</style></author><author><style face="normal" font="default" size="100%">Caljouw, M. A. A.</style></author><author><style face="normal" font="default" size="100%">Van Soest-Poortvliet, M. C.</style></author><author><style face="normal" font="default" size="100%">Van Der Steen, J. T.</style></author><author><style face="normal" font="default" size="100%">Achterberg, W. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.S. Klapwijk, Department of Public Heath and Primary Care, Leiden University Medical Center, Leiden, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Observations of symptoms of dying and treatment in the last days before death in dementia patients in long-term care facilities</style></title><secondary-title><style face="normal" font="default" size="100%">European Geriatric Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Geriatric Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S207</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><keywords><keyword><style face="normal" font="default" size="100%">morphine</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen 15</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">European Union</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrics</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">comfort</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">symptomatology</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">rehydration</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dying</style></keyword><keyword><style face="normal" font="default" size="100%">examination</style></keyword><keyword><style face="normal" font="default" size="100%">pain assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-7649</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction.- Little is known about symptoms of dying and treatment of demented patients in long-term care facilities. Although dementia at the end of life is increasingly being studied, we lack observational data on dying patients. We observed symptoms of dying in patients with dementia in the last days before death. Methods.- When the elderly care physicians in two Dutch nursing homes expected death within one week, symptoms of (dis)comfort, pain and suffering were observed twice daily. The Pain Assessment in Advanced Dementia (PAINAD; range 0-10), Discomfort Scale - Dementia of Alzheimer Type (DS-DAT; range 0-27), End-Of- Life in Dementia-Comfort Assessment in Dying (EOLD-CAD; range 14-42) and Mini-Suffering State Examination (MSSE; range 0-9), were used. Also data regarding medical treatment were collected. Results.- Twenty-four patients (median age 91; 23 females) were observed several times (mean 4.3 observations [SD 2.6]), until they died. Most (n = 15) died from dehydration/cachexia and passed away quietly (n = 22). The mean PAINAD score was 1.0 (SD 1.7), DSDAT 7.0 (SD 2.1), EOLD-CAD 35.1 (SD 1.7), and MSSE 2.0 (SD 1.7). All participants received morphine, few antibiotics (n = 6) or rehydration (n = 1). No difference in symptomatology was found between the causes of death. Conclusion.- People with advanced dementia showed low levels of discomfort, suffering and number of symptoms in their last days of life, even for people dying from dehydration/cachexia. This relative &apos;good&apos; death was accompanied by active comfort treatment (morphine) and withholding of active and invasive curative treatment. The use of observation tools may help physicians to make treatment decisions.</style></abstract><notes><style face="normal" font="default" size="100%">L71182558&#xD;2013-10-07</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71182558&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.eurger.2013.07.690</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.eurger.2013.07.690</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paladino, J. A.</style></author><author><style face="normal" font="default" size="100%">Eubanks, D. A.</style></author><author><style face="normal" font="default" size="100%">Adelman, M. H.</style></author><author><style face="normal" font="default" size="100%">Schentag, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.A. Paladino, CPL Associates, LLC, 3980 Sheridan Drive, Buffalo, NY 14226, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">651-657</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">cefepime</style></keyword><keyword><style face="normal" font="default" size="100%">cefprozil</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">cefuroxime</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">levofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine clearance</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">glucose blood level</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">injection site discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">kidney dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity analysis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614&#xD;1532-5415</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To compare once-daily intramuscular cefepime with ceftriaxone controls. DESIGN: Double-blind study. SETTING: Six skilled nursing facilities. PARTICIPANTS: Residents aged 60 and older with nursing home-acquired pneumonia. INTERVENTION: Cultures were obtained, and patients were randomized to cefepime or ceftriaxone 1 g intramuscularly every 24 hours. MEASUREMENTS: Clinical success: cure or improvement. Cure was defined as complete resolution of all symptoms and signs of pneumonia or a return to the patient&apos;s baseline state. Improvement was defined as clear improvement but incomplete resolution of all pretherapy symptoms or signs or incomplete return to the patient&apos;s usual baseline status. Safety and pharmacoeconomics were also assessed. RESULTS: Sixty-nine patients were randomized; 61 were evaluable: (32 to cefepime, 29 ceftriaxone). Patients were predominately female (76%). They had a mean age±standard deviation of 85±6, with a mean 5.8±1.9 comorbidities; they had age-appropriate renal dysfunction, with a mean estimated creatinine clearance of 35±7 mL/min. Clinical success occurred in 78% of cefepime- and 66% of ceftriaxone-treated patients (P=.39). Fifty-seven patients (93%) were switched to oral antibiotics after 3 days. Antibiotic-related adverse events occurred in 5% of patients. Seven patients (11.5%) were hospitalized. The overall mortality rate was 8%. Mean antibiotic costs were $117±40 for cefepime- and $215±68 for ceftriaxone-treated patients (P&lt;.001). Cost-effectiveness analysis of total costs showed that cefepime would cost $597 and ceftriaxone $1,709 per expected successfully treated patient. One- and two-way sensitivity analyses using a generic price for ceftriaxone and improving its comparative efficacy revealed that the results were robust. CONCLUSIONS: Once-daily cefepime was a cost-effective alternative to ceftriaxone for the treatment of elderly nursing home residents who developed pneumonia and did not require hospitalization. © 2007, The American Geriatrics Society.</style></abstract><notes><style face="normal" font="default" size="100%">L46668971&#xD;2007-05-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L46668971&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1532-5415.2007.01152.x</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Elan(United States)&#xD;Hoffmann La Roche(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">17493183</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2007.01152.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orcel, B.</style></author><author><style face="normal" font="default" size="100%">Delclaux, B.</style></author><author><style face="normal" font="default" size="100%">Baud, M.</style></author><author><style face="normal" font="default" size="100%">Derenne, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Respir J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">446-52</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchitis/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0903-1936 (Print)&#xD;0903-1936</style></isbn><abstract><style face="normal" font="default" size="100%">Acute bronchitis is a major source of morbidity in elderly patients. The purpose of this study was to assess the preventive effects of oral immunisation with a bacterial extract. Three hundred and fifty four patients with chronic bronchitis, living in institutions for the elderly (aged &gt; 65 yrs), were included in a randomized, placebo-controlled, double-blind study. The purpose of the study was to assess preventive effects of OM-85 BV (an immunostimulating agent consisting of lyophilized fractions of eight of the most common pathogens isolated in respiratory tract infections) against acute lower respiratory tract infections. Two hundred and ninety patients completed the study (143 taking placebo and 147 taking OM-85 BV). There was a 28% reduction in the number of lower respiratory tract infections in the patients treated with OM-85 BV; this was entirely due to 40% reduction in the number of episodes of acute bronchitis (p &lt; 0.01), with no difference in the number of episodes of pneumonia and bronchopneumonia. A larger number of patients in the OM-85 BV group were free of acute bronchitis throughout the 6 month study period (96 vs 69) and there was a 28% reduction in the number of antibiotic prescriptions in the OM-85 BV treated group. These results suggest that OM-85 BV has a protective effect against acute bronchitis in elderly patients living in institutions.</style></abstract><notes><style face="normal" font="default" size="100%">Orcel, B&#xD;Delclaux, B&#xD;Baud, M&#xD;Derenne, J P&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;England&#xD;Eur Respir J. 1994 Mar;7(3):446-52. doi: 10.1183/09031936.94.07030446.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1183/09031936.94.07030446</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamashita, H.</style></author><author><style face="normal" font="default" size="100%">Tomita, K.</style></author><author><style face="normal" font="default" size="100%">Ueda, Y.</style></author><author><style face="normal" font="default" size="100%">Koshobu, T.</style></author><author><style face="normal" font="default" size="100%">Yamagata, S.</style></author><author><style face="normal" font="default" size="100%">Tohda, Y.</style></author><author><style face="normal" font="default" size="100%">Shimizu, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. Yamashita, Department of Respiratory Medicine, Yonago Medical Centre, Yonago, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outcome of failed empirical antibiotic therapy on the mortality of elderly patients with hospitalized pneumonia: A propensity score-based analysis</style></title><secondary-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">42</style></volume><keywords><keyword><style face="normal" font="default" size="100%">lactam</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">propensity score</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">European</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">proportional hazards model</style></keyword><keyword><style face="normal" font="default" size="100%">outcome variable</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">hazard ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">congestive heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0903-1936</style></isbn><abstract><style face="normal" font="default" size="100%">One of the major problems in analyzing covariates on prognosis of pneumonia is confounding by indication for a choice of antibiotic treatment. We assessed the outcome of unsuccessful empirical antibiotic therapy on the mortality of elderly patients (≥75 years old) with pneumonia, including community-acquired pneumonia (CAP) and nursing home-associated pneumonia (NHAP). We analyzed data collected prospectively in 4 medical hospitals at Sanin area in Japan from 2005 to 2011. Empirical therapy was considered as failure if initial treatment did not decrease white blood cells and/or fever within 3 days. The main outcome variables were in-hospital mortality. Adjusted analyses were performed by Cox proportional hazards regression with propensity score weighting. Of the 303 patients (205 CAP and 98 NHAP), 65 (21%) died due to pneumonia during hospitalization. After adjustment for propensity score of treatment weighting, it demonstrated that failure of initial treatment, congestive heart failure, the severity of CURB-65 score, and disuse of b-lactam/b-lactam inhibitor (BLBLI) combinations were independently associated with prognosis of pneumonia, with hazard ratios of 9.28 (95% confidence interval [CI], 5.07 to 17.0), 3.09 (95% CI, 1.44 to 6.63),1.93 (95% CI, 1.03 to 3.60), and 1.80 (95% CI, 1.01 to 3.19), respectively. By using the propensity score analysis, this study confirmed that choice of antibiotics was an important factor for prognosis of elderly patients with pneumonia.</style></abstract><notes><style face="normal" font="default" size="100%">L71843738&#xD;2015-04-20</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71843738&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://erj.ersjournals.com/content/42/Suppl_57/P4378.full.pdf+html?sid=3356b069-f4e4-4010-a6aa-4be8ac42e897</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">93</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thakar, C. V.</style></author><author><style face="normal" font="default" size="100%">Quate-Operacz, M.</style></author><author><style face="normal" font="default" size="100%">Leonard, A. C.</style></author><author><style face="normal" font="default" size="100%">Eckman, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.V. Thakar, Cincinnati VA Medical Center, University of Cincinnati, Cincinnati, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outcomes of Hemodialysis Patients in a Long-term Care Hospital Setting: A Single-Center Study</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Kidney Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">300-306</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">aminoglycoside</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin receptor antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">contrast medium</style></keyword><keyword><style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxymethylglutaryl coenzyme A reductase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">acute kidney tubule necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">African American</style></keyword><keyword><style face="normal" font="default" size="100%">ageism</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">convalescence</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">European American</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">hospice care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital discharge</style></keyword><keyword><style face="normal" font="default" size="100%">hospital readmission</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">kidney injury</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">race difference</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0272-6386</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Long-term care hospitals (LTCHs) provide intermediary care after an acute-care hospitalization and usually furnish care to patients with complex medical problems. Outcomes of hemodialysis patients admitted to LTCHs, which includes patients with either end-stage renal disease (ESRD) or acute kidney injury (AKI) requiring dialysis therapy, are not known. Study Design: Observational study. Setting &amp; Participants: All consecutive hemodialysis patients admitted to an LTCH. Predictors: Demographic characteristics, comorbid and laboratory variables, ESRD, and AKI status during LTCH stay. Outcomes: Disposition from LTCHs was classified as discharge to home, nursing home, death in LTCH or hospice care, and re-admission to the hospital. In patients with AKI, renal recovery was defined as discontinuation of dialysis therapy before meeting disposition outcomes. Results: 96 of 206 (46.6%) patients had ESRD, whereas 110 of 206 (53.3%) developed AKI requiring dialysis therapy during the acute-care hospitalization. 63 of 206 (31%) were discharged to home, 11 of 206 (5.4%) died or transferred to hospice, 81 of 206 (40%) went to a nursing home, and 49 of 206 (24%) were re-admitted to a hospital; mortality after re-admission was 32%. Older age (OR, 0.96; 95% CI, 0.93-0.98), diabetes mellitus (OR, 0.45; 95% CI, 0.23-0.94), number of re-admissions to the hospital (OR, 0.38; 95% CI, 0.18-0.78), aminoglycoside use (OR, 0.16; 95% CI, 0.04-0.64), and duration of hospitalization before LTCH admission (OR, 0.96; 95% CI, 0.94-0.99) were associated with lower odds of discharge to home. Of 110 patients with AKI requiring dialysis therapy, 30% (33 patients) discontinued dialysis therapy, whereas 70% were deemed to have ESRD on discharge. Limitations: Retrospective observational study. Conclusions: Most dialysis patients at LTCHs are either re-admitted to acute-care hospitals or require nursing home placement. Only 30% of patients with AKI recover sufficiently to discontinue dialysis therapy, whereas 70% are deemed to have ESRD.</style></abstract><notes><style face="normal" font="default" size="100%">L50733218&#xD;2009-12-15&#xD;2010-02-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L50733218&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1053/j.ajkd.2009.08.021</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20006413</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1053/j.ajkd.2009.08.021</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sin, D. D.</style></author><author><style face="normal" font="default" size="100%">Tu, J. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sunnybrook and Women&apos;s College Health Science Centre, University of Toronto, Toronto, Canada. don.sin@ualberta.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Can Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Can Respir J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">466-71</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases, Obstructive/*drug therapy/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Ontario/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1198-2241 (Print)&#xD;1198-2241</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the association between outpatient use of oral antibiotics and 30-day all-cause mortality following hospitalization in a group of elderly chronic obstructive pulmonary disease (COPD) patients. DESIGN: A population-based retrospective cohort study. SETTING: Ontario, Canada. POPULATION STUDIED: All 26,301 patients, 65 years of age or older, who were hospitalized for COPD between 1992 and 1996 in Ontario. METHODS: All elderly patients admitted at least once with a most responsible diagnosis of COPD using the Canadian Institute for Health Information database were identified. They were then linked to the Ontario Drug Benefit database to determine the use of antibiotics within 30 days of the index hospitalization and to the Ontario registered persons database to determine the 30-day mortality following their index hospitalization. RESULTS: Outpatient use of antibiotics within 30 days before the index hospitalization was associated with a significant reduction in the 30-day mortality following hospitalization (odds ratio [OR] 0.83, 95% CI 0.75 to 0.92). Use of macrolides had the lowest relative odds for mortality (OR 0.58, 95% CI 0.47 to 0.73), while use of fluoroquinolones had the highest relative odds (OR 0.98, 95% CI 0.84 to 1.15). CONCLUSIONS: Use of antibiotics before hospitalization was associated with a significant reduction in the risk of short term mortality among a group of elderly COPD patients who eventually required hospitalization for their disease. These findings support the early use of antibiotics in COPD patients who experience an acute exacerbation.</style></abstract><notes><style face="normal" font="default" size="100%">Sin, D D&#xD;Tu, J V&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Egypt&#xD;Can Respir J. 2000 Nov-Dec;7(6):466-71. doi: 10.1155/2000/417298.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2000/417298</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickson, M.</style></author><author><style face="normal" font="default" size="100%">Kozma, C.</style></author><author><style face="normal" font="default" size="100%">Benson, C.</style></author><author><style face="normal" font="default" size="100%">Bin Ng, D.</style></author><author><style face="normal" font="default" size="100%">Schein, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Dickson, University of South Carolina, Columbia, SC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pain management strategies of osteoarthritis patients in a medicaid population: 30 months of treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Pain Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pain Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">271</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">narcotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">nonsteroid antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">osteoarthritis</style></keyword><keyword><style face="normal" font="default" size="100%">medicaid</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">substance abuse</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">drug utilization</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">analgesia</style></keyword><keyword><style face="normal" font="default" size="100%">sleep</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">analysis of variance</style></keyword><keyword><style face="normal" font="default" size="100%">gender</style></keyword><keyword><style face="normal" font="default" size="100%">African American</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">1526-2375</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Common problems in the management of osteoarthritis (OA) pain include inadequate pain relief, insufficient duration of relief, sleep loss, and consequences that arise from these problems. The purpose of this study was to examine OA treatment patterns including medication use and cost. Methods: A longitudinal retrospective cohort study was implemented using South Carolina Medicaid data from January 2001-June 2005. Patients were selected in 2001 and 2002 and followed for 10 quarters from study initiation. Study included continuously eligible patients who were 18 years of age or older, had at least two OA diagnoses in a year, and in the follow-up period had at least one pain-related prescription, had no evidence of cancer, organ transplant, HIV/ AIDS, and no nursing home use. Mean utilization and cost were estimated, in a mixed model analysis of variance, for all nine therapeutic categories of study drugs and covariates for age, gender, and time (Q1-Q10) including interactions. Results: Study patients (n = 3,113) were older (mean age = 62.0 years), mostly female (83.4%), and typically African-American (57.4%). The most common comorbidities were hypertension and myocardial infarct. Obesity, drug, alcohol and substance abuse also were common. Results show substantial shifts in drug therapy over time. For example, 13.8% had no drug use in Q1 but by Q10 prevalence had risen to 54.0%. Similarly, 13.8% used narcotics in Q1 and 18.5% were users in Q10. Drug utilization models showed declining NSAID and COX-2 use, while all other drug use, except antidepressants, increased. Utilization by women was generally higher than men with the exception of narcotic use. Conclusions: Two prominent patterns of OA treatment over the study period were discontinuation of drug therapy, and an increasing number of patients using narcotic therapy. Whether the change in utilization is due to mismanagement or episodic drug therapy is not known.</style></abstract><notes><style face="normal" font="default" size="100%">L70205024&#xD;2010-07-20</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L70205024&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1526-4637.2008.00537.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1526-4637.2008.00537.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossio, R.</style></author><author><style face="normal" font="default" size="100%">Arcudi, S.</style></author><author><style face="normal" font="default" size="100%">Peyvandi, F.</style></author><author><style face="normal" font="default" size="100%">Piconi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Rossio, Dipartimento delle Units, Multispecialistiche e dei Trapianti – Area Ematologica, Fondazione IRCCS, Ca’ Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, Milano, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">86-89</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylsalicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">amiodarone</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">atorvastatin</style></keyword><keyword><style face="normal" font="default" size="100%">bisoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">clopidogrel</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">esomeprazole</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">insulin</style></keyword><keyword><style face="normal" font="default" size="100%">levothyroxine</style></keyword><keyword><style face="normal" font="default" size="100%">ramipril</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">continuous infusion</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">diabetic patient</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">frail elderly</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypoglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">0946-1965</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: Trimethoprim-sulfamethoxazole (co-trimoxazole) is a commonly used broad-spectrum antibiotic, but it can be associated with potentially serious adverse effects, often not recognized by clinicians. This is a relevant problem in elderly patients, who are particularly susceptible to adverse drug reactions. Moreover, multiple medications taken by older people increase the risk for adverse drug reactions and drug-drug interactions. Case report: We report the case of an 85-year-old man with diabetes mellitus who attended the emergency room with severe hypoglycemia that persisted despite multiple intravenous bolus doses and continuous infusion of glucose. He needed hospital admission to stabilize glycemia. The patient, a nursing home resident, was being treated with co-trimoxazole for an uncomplicated urinary tract infection, but was also taking multiple additional drugs for his co-morbidities. After co-trimoxazole was discontinued, plasma glucose levels slowly stabilized within the normal range. A diagnosis of prolonged and refractory hypoglycemia induced mainly by the antimicrobial agent was made, with additional contribution from multiple other drugs. No further episodes of hypoglycemia occurred during the next 6 months of follow-up. Conclusion: This case study illustrates once more the critical importance of prescription appropriateness in elderly patients with multiple morbidities in terms of type and dosage of drugs, in order to avoid serious adverse reactions.</style></abstract><notes><style face="normal" font="default" size="100%">L620313400&#xD;2018-02-01&#xD;2018-02-08</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L620313400&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.5414/CP203084</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">29191263</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.5414/CP203084</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gogol, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt, D.</style></author><author><style face="normal" font="default" size="100%">Dettmer-Flügge, A.</style></author><author><style face="normal" font="default" size="100%">Vaske, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Geriatrie, Krankenhaus Lindenbrunn, Lindenbrunn 1, 31863, Coppenbrügge, Deutschland. gogol@krankenhaus-lindenbrunn.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Pneumonia in the elderly: results of quality improvement program for a geriatric department in Lower Saxony 2006-2009]</style></title><secondary-title><style face="normal" font="default" size="100%">Z Gerontol Geriatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Z Gerontol Geriatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">235-9</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Community-Acquired Infections/*diagnosis/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Geriatric Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Departments/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*National Health Programs</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Bacterial/*diagnosis/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality Assurance, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0948-6704</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Is the time to diagnosis and to start antibiotic therapy a major factor contributing to the outcome in geriatric patients? METHODS: In 2006, a program for documentation and improvement for diagnostic and therapeutic procedures in patients with community-acquired pneumonia was introduced in German hospitals. The analyses were performed centrally by an independent board. SETTING: Tertiary geriatric department with 70 beds for acute care and rehabilitation in a hospital, also including a department of neurology and neurological rehabilitation. RESULTS: In Lower Saxony (LS), 81,853 patients were treated between 2006-2009 in our geriatric department (GD). In LS, 55.3% of the population was male, while 45.2% of the patients in the GD were male (p=0.063). Throughout an age of 79 years, the distribution was equal; however in the age groups 80-89 years (LS vs GD: 32.3 vs 47.6%) and &gt;90 years (LS vs GD: 10.2 vs 15.5%, p&lt;0.001) there were a higher proportion of male patients in the GD. The proportion of male nursing home patients was 46.8% vs 24.3%, hospital or rehabilitation unit 6.2% vs 40.5%, and status of confinement to bed was 47% vs 35.1% (LS vs GD, p&lt;0.001). Delirium caused by pneumonia occurred in 24.4% vs 9.3% and a status of chronic delirium (dementia) was assessed by 75.6% vs. 90.7% of all cases (LS vs GD, p=0.021). The distribution about the risk classes 1/2/3 of the CRB-65 score was 14.9/76.9/8.2% in LS and 3.6/89.3/7.1% in the GD (p=0.011). The time to starting antibiotics (no therapy, &lt;4, 4-8, and &gt;8 h) was 2.2/83.0/7.6/7.2% in LS and 15.4/47.4/10.3/26.9% in GD patients (p&lt;0.001). Overall mortality rates did not differ significantly (LS 14.6% vs GD 11.9%, p=0.53). CONCLUSIONS: Patients in the GD were older and more functionally dependent. The distribution of the risk index CRB-65 shows that these patients were at higher risk, were more often cognitively impaired (not caused by pneumonia), and time to starting antibiotics was longer. However, none of these differences had an influence on total mortality. The results are limited by the number of patients, potential differences of the treatment groups, and the quality of data in general as a result of a quality improvement program.</style></abstract><notes><style face="normal" font="default" size="100%">1435-1269&#xD;Gogol, M&#xD;Schmidt, D&#xD;Dettmer-Flügge, A&#xD;Vaske, B&#xD;English Abstract&#xD;Journal Article&#xD;Germany&#xD;Z Gerontol Geriatr. 2011 Aug;44(4):235-9. doi: 10.1007/s00391-011-0217-y.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00391-011-0217-y</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rauh, S. P.</style></author><author><style face="normal" font="default" size="100%">Heymans, M. W.</style></author><author><style face="normal" font="default" size="100%">Mehr, D. R.</style></author><author><style face="normal" font="default" size="100%">Kruse, R. L.</style></author><author><style face="normal" font="default" size="100%">Lane, P.</style></author><author><style face="normal" font="default" size="100%">Kowall, N. W.</style></author><author><style face="normal" font="default" size="100%">Volicer, L.</style></author><author><style face="normal" font="default" size="100%">van der Steen, J. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands.&#xD;Department of Family and Community Medicine, School of Medicine, University of Missouri, Columbia, Missouri, USA.&#xD;E.N. Rogers Memorial Veterans Hospital, Geriatric Research Education Clinical Center, Bedford, Massachusetts, USA.&#xD;VA Boston Healthcare System, Department of Veterans Affairs and Boston University Alzheimer Disease Center at BU School of Medicine, Boston, Massachusetts, USA.&#xD;School of Aging Studies, University of South Florida, Tampa, Florida, USA.&#xD;Leiden University Medical Center, Department of Public Health and Primary Care, Leiden, The Netherlands Radboud University Medical Center, Department of Primary and Community Care, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting mortality in patients treated differently: updating and external validation of a prediction model for nursing home residents with dementia and lower respiratory infections</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e011380</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment/methods</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*geriatric medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2044-6055</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate whether a model that was previously developed to predict 14-day mortality for nursing home residents with dementia and lower respiratory tract infection who received antibiotics could be applied to residents who were not treated with antibiotics. Specifically, in this same data set, to update the model using recalibration methods; and subsequently examine the historical, geographical, methodological and spectrum transportability through external validation of the updated model. DESIGN: 1 cohort study was used to develop the prediction model, and 4 cohort studies from 2 countries were used for the external validation of the model. SETTING: Nursing homes in the Netherlands and the USA. PARTICIPANTS: 157 untreated residents were included in the development of the model; 239 untreated residents were included in the external validation cohorts. OUTCOME: Model performance was evaluated by assessing discrimination: area under the receiver operating characteristic curves; and calibration: Hosmer and Lemeshow goodness-of-fit statistics and calibration graphs. Further, reclassification tables allowed for a comparison of patient classifications between models. RESULTS: The original prediction model applied to the untreated residents, who were sicker, showed excellent discrimination but poor calibration, underestimating mortality. Adjusting the intercept improved calibration. Recalibrating the slope did not substantially improve the performance of the model. Applying the updated model to the other 4 data sets resulted in acceptable discrimination. Calibration was inadequate only in one data set that differed substantially from the other data sets in case-mix. Adjusting the intercept for this population again improved calibration. CONCLUSIONS: The discriminative performance of the model seems robust for differences between settings. To improve calibration, we recommend adjusting the intercept when applying the model in settings where different mortality rates are expected. An impact study may evaluate the usefulness of the two prediction models for treated and untreated residents and whether it supports decision-making in clinical practice.</style></abstract><notes><style face="normal" font="default" size="100%">2044-6055&#xD;Rauh, Simone P&#xD;Orcid: 0000-0003-3627-6925&#xD;Heymans, Martijn W&#xD;Mehr, David R&#xD;Kruse, Robin L&#xD;Lane, Patricia&#xD;Kowall, Neil W&#xD;Volicer, Ladislav&#xD;van der Steen, Jenny T&#xD;P30 AG013846/AG/NIA NIH HHS/United States&#xD;R01 HS008551/HS/AHRQ HHS/United States&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Validation Study&#xD;BMJ Open. 2016 Aug 30;6(8):e011380. doi: 10.1136/bmjopen-2016-011380.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5013486</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjopen-2016-011380</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silber, J. H.</style></author><author><style face="normal" font="default" size="100%">Rosenbaum, P. R.</style></author><author><style face="normal" font="default" size="100%">Trudeau, M. E.</style></author><author><style face="normal" font="default" size="100%">Chen, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Lorch, S. A.</style></author><author><style face="normal" font="default" size="100%">Kelz, R. R.</style></author><author><style face="normal" font="default" size="100%">Mosher, R. E.</style></author><author><style face="normal" font="default" size="100%">Even-Shoshan, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Outcomes Research, Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA. silberj@wharton.upenn.deu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preoperative antibiotics and mortality in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Surg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-14</style></pages><volume><style face="normal" font="default" size="100%">242</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibiotic Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Geriatric Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Mortality/*trends</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Orthopedic Procedures/methods/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Preoperative Care</style></keyword><keyword><style face="normal" font="default" size="100%">Probability</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Surgical Procedures, Operative/methods/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Surgical Wound Infection/mortality/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-4932 (Print)&#xD;0003-4932</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE AND BACKGROUND: It is generally thought that the use of preoperative antibiotics reduces the risk of postoperative infection, yet few studies have described the association between preoperative antibiotics and the risk of dying. The objective of this study was to determine whether preoperative antibiotics are associated with a reduced risk of death. METHODS: We performed a multivariate matched, population-based, case-control study of death following surgery on 1362 Pennsylvania Medicare patients between 65 and 85 years of age undergoing general and orthopedic surgery. Cases (681 deaths within 60 days from hospital admission) were randomly selected throughout Pennsylvania using claims from 1995 and 1996. Models were developed to scan Medicare claims, looking for controls who did not die and who were the closest matches to the previously selected cases based on preoperative characteristics. Cases and their controls were identified, and charts were abstracted to define antibiotic use and obtain baseline severity adjustment data. RESULTS: For general surgery, the odds of dying within 60 days were less than half in those treated with preoperative antibiotics within 2 hours of incision as compared with those without such treatment: (odds ratio = 0.44; 95% confidence interval, 0.32-0.60), P &lt; 0.0001). For orthopedic surgery, no significant mortality reduction was observed (OR = 0.85; 95% confidence interval, 0.54-1.32; P &lt; 0.464). INTERPRETATION: Preoperative antibiotics are associated with a substantially lower 60-day mortality rate in elderly patients undergoing general surgery. In patients who appear to be comparable, the risk of death was half as large among those who received preoperative antibiotics.</style></abstract><notes><style face="normal" font="default" size="100%">1528-1140&#xD;Silber, Jeffrey H&#xD;Rosenbaum, Paul R&#xD;Trudeau, Martha E&#xD;Chen, Wei&#xD;Zhang, Xuemei&#xD;Lorch, Scott A&#xD;Kelz, Rachel Rapaport&#xD;Mosher, Rachel E&#xD;Even-Shoshan, Orit&#xD;HS-R01-9460/HS/AHRQ HHS/United States&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Ann Surg. 2005 Jul;242(1):107-14. doi: 10.1097/01.sla.0000167850.49819.ea.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC1357711</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.sla.0000167850.49819.ea</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Whitley, R. J.</style></author><author><style face="normal" font="default" size="100%">Monto, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Alabama at Birmingham, Birmingham, AL, 35233-1711, USA. rwhitley@peds.uab.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S133-8</style></pages><volume><style face="normal" font="default" size="100%">194 Suppl 2</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunocompromised Host/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza Vaccines/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Leukemia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Oseltamivir/administration &amp; dosage/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Infectious/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Zanamivir/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-1899 (Print)&#xD;0022-1899</style></isbn><abstract><style face="normal" font="default" size="100%">The pediatric population experiences preventable hospitalizations and serves as a reservoir for influenza and its transmission to other children as well as adults. As a consequence, the Advisory Committee on Immunization Practices has recommended initiating influenza immunization of children as young as 6 months of age through 23 months of age and, recently, up to 5 years of age. However, immunization of older children has not yet become a priority of the US Public Health Service. As a consequence, the importance of antiviral agents, particularly neuraminidase (NA) inhibitors, cannot be overemphasized. From an epidemiological perspective, influenza resulted in higher childhood mortality than did Bordetella pertussis infection in 2003-2004. During that season, 153 children died of influenza, and two-thirds were &lt;5 years of age. Importantly, nearly 50% of these children were previously healthy, with no underlying illness. Currently, 2 NA inhibitors are approved for the treatment of influenza in children. Zanamivir is approved for children &gt;7 years of age, and oseltamivir is approved for children &gt;1 year of age. Arguably, the younger children are at particular risk for influenza complications and hospitalization. In placebo-controlled studies in children &gt;1 year of age, oseltamivir therapy accelerated resolution of clinical illness and defervescence and decreased both the incidence of otitis media and the concomitant use of antibiotics. However, oseltamivir is not currently approved for children &lt;1 year of age. Three clinical toxicology studies identified neurotoxicity in newborn rats administered this medication. In these preclinical toxicology studies, the dose of oseltamivir exceeded that which would be used in humans. In addition, the metabolism of oseltamivir is different in rats than in humans. A key component of influenza therapy is the possibility for development of resistance. Although in studies performed in North America, resistance was not a frequent event, it has been documented in Japanese children treated with this medication; the adequacy of the dose used has been questioned. Children represent only one unique study population among others. Individuals who are at increased risk for influenza infection include the elderly, the immunocompromised, and pregnant women. Collectively, antiviral medications must be evaluated in populations in which they have not yet been assessed. The development of additional antiviral drugs is an important recommendation for the future, so that antiviral resistance can be circumvented. Similarly, availability of drugs for children &lt;1 year of age is mandatory.</style></abstract><notes><style face="normal" font="default" size="100%">Whitley, Richard J&#xD;Monto, Arnold S&#xD;Journal Article&#xD;United States&#xD;J Infect Dis. 2006 Nov 1;194 Suppl 2:S133-8. doi: 10.1086/507548.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/507548</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hugonot, R.</style></author><author><style face="normal" font="default" size="100%">Gutierrez, L. M.</style></author><author><style face="normal" font="default" size="100%">Hugonot, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hôpital Necker-Enfants malades, Paris.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Preventive action of an immunomodulator on respiratory infections in elderly subjects]</style></title><secondary-title><style face="normal" font="default" size="100%">Presse Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Presse Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1445-9</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">28</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Proteins/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/*drug therapy/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1988</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0755-4982 (Print)&#xD;0755-4982</style></isbn><abstract><style face="normal" font="default" size="100%">Three hundred and fourteen elderly subjects admitted to chronic medical centers were given either RU 41740 (n = 155) or a placebo (n = 159) at the rate of one course per month during three months. RU 41740 was administered in doses of 2 mg per day during 8 days in the first course and 1 mg per day during 8 days in the second and third courses. The subjects were followed up and regularly examined every three months for one year. The incidence of acute infectious episodes was evaluated in both groups. Compared to those patients who received the placebo, the number of subjects without infection was significantly higher in the treated group during the 0-6 months and the 0-9 months periods and during the 12 months of observation. The number of infectious episodes was reduced during the 0-3 months and 0-9 months periods and throughout the 12 months of the trial. The mean duration of pulmonary infections that occurred during the 0-6 and 0-9 months periods was reduced. Finally, there was a significant decrease in the duration of antibiotic therapy during the 0-3, 0-6, 0-9 months periods and during the 12 months of observation. The drug was well tolerated. This study showed that RU 41740 is effective in protecting elderly and therefore fragile subjects against respiratory infections.</style></abstract><notes><style face="normal" font="default" size="100%">Hugonot, R&#xD;Gutierrez, L M&#xD;Hugonot, L&#xD;Clinical Trial&#xD;Controlled Clinical Trial&#xD;English Abstract&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;France&#xD;Presse Med. 1988 Jul 27;17(28):1445-9.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takahashi, H.</style></author><author><style face="normal" font="default" size="100%">Oyama, N.</style></author><author><style face="normal" font="default" size="100%">Tanaka, I.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, M.</style></author><author><style face="normal" font="default" size="100%">Hirano, K.</style></author><author><style face="normal" font="default" size="100%">Shimada, C.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.&#xD;Department of Dermatology, JCHO Fukui Katsuyama General Hospital, Fukui, Japan.&#xD;Department of Nursing, JCHO Fukui Katsuyama General Hospital, Fukui, Japan.&#xD;Department of Clinical Examination, JCHO Fukui Katsuyama General Hospital, Fukui, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventive effects of topical washing with miconazole nitrate-containing soap to diaper candidiasis in hospitalized elderly patients: A prospective, double-blind, placebo-controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Dermatol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">760-766</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antifungal Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Candida/*drug effects/isolation &amp; purification/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Candidiasis, Cutaneous/epidemiology/microbiology/pathology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Diaper Rash/epidemiology/microbiology/pathology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">Hyphae/drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Miconazole/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Soaps/chemistry/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Spores, Fungal/drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">diaper dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">miconazole nitrate</style></keyword><keyword><style face="normal" font="default" size="100%">microscopic examination</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">washing soap</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0385-2407</style></isbn><abstract><style face="normal" font="default" size="100%">The objective of the present randomized, double-blind trial was to evaluate the efficacy and safety of daily washing with miconazole nitrate-containing soap for candidiasis at diaper-covered sites in elderly subjects under long-term inpatient care. To confirm the onset and disappearance of candidiasis, we microscopically evaluated the existence of the pseudohyphae and/or blastoconidia of Candida spp. We enrolled 75 elderly patients who wore diapers all day in the hospital or nursing home. Patients were randomly assigned to receive treatment with either miconazole soap or miconazole-free placebo soap, and 28 patients in the miconazole group and 27 patients in the placebo group were followed for 4 weeks. Although washing with miconazole soap did not affect the frequency of pseudohyphae/blastoconidia-positive patients, it significantly inhibited the positive conversion of pseudohyphae/blastoconidia compared with the placebo group. As a result, the frequency of patients positive for pseudohyphae/blastoconidia was significantly lower in the miconazole group than in the control group at 4 weeks (17.9% vs 44.4%). Clinically apparent diaper candidiasis did not develop in either group. Washing with miconazole soap was a significant independent factor for reducing the cases positive for pseudohyphae/blastoconidia, while diarrhea and heart failure were significant factors associated with an increase in the positive rate at the end-point. Severe adverse effects were not found in any patients. Thus, washing with miconazole soap is well-tolerated and can inhibit the positive conversion of Candida in patients wearing diapers. Therefore, maintenance of genital hygiene using this soap may prophylactically decrease the overall prevalence of patients with diaper candidiasis.</style></abstract><notes><style face="normal" font="default" size="100%">1346-8138&#xD;Takahashi, Hidenori&#xD;Orcid: 0000-0001-5555-4842&#xD;Oyama, Noritaka&#xD;Tanaka, Izumi&#xD;Hasegawa, Michiko&#xD;Hirano, Kaori&#xD;Shimada, Chieko&#xD;Hasegawa, Minoru&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England&#xD;J Dermatol. 2017 Jul;44(7):760-766. doi: 10.1111/1346-8138.13781. Epub 2017 Feb 22.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1346-8138.13781</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Hylwka, T.</style></author><author><style face="normal" font="default" size="100%">Smieja, M.</style></author><author><style face="normal" font="default" size="100%">Surrette, M.</style></author><author><style face="normal" font="default" size="100%">Bowdish, D. M. E.</style></author><author><style face="normal" font="default" size="100%">Loeb, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Loeb, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1346-1352</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">ear disease</style></keyword><keyword><style face="normal" font="default" size="100%">epistaxis</style></keyword><keyword><style face="normal" font="default" size="100%">eye disease</style></keyword><keyword><style face="normal" font="default" size="100%">feasibility study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hematuria</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">microcapsule</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">musculoskeletal disease</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nose disease</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">problem behavior</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">real time polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">throat disease</style></keyword><keyword><style face="normal" font="default" size="100%">very elderly</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1532-5415&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: To assess the feasibility of conducting a large clinical trial to evaluate the effectiveness of probiotics to reduce influenza and other respiratory virus infections in residents of long-term and chronic care facilities (LTCFs). Design: Randomized, double-blind, placebo-controlled pilot trial. Setting: Fourteen nursing homes in Hamilton and surrounding region, Ontario, Canada. Participants: Nursing home residents aged 65 and older (N=209). Those who were taking immunosuppressives (steroids or other immunosuppressives) or had a hematological malignancy, structural heart disease, or gastroesophageal or intestinal injury and others at high risk of an endovascular infection were excluded. Intervention: Participants were randomized to receive study probiotics—2 capsules of Lactobacillus rhamnosus GG (estimated 10 billion colony forming units of L. rhamnosus GG per capsule) or placebo (calcium carbonate) daily for 6 months. Measurements: Laboratory-confirmed respiratory viral infections. Results: One hundred ninety-six individuals were included in the analysis: 100 in the probiotics group and 96 in the placebo group. Laboratory-confirmed respiratory viral infections were observed in 14 (15.0%) residents in the probiotic group and 21 (22.9%) in the placebo group (hazard ratio=0.65, 95% confidence interval=0.32–1.31). Conclusion: A larger trial is warranted to determine whether probiotics reduce influenza and other respiratory virus infections in residents of LTCFs.</style></abstract><notes><style face="normal" font="default" size="100%">L622319056&#xD;2018-05-30&#xD;2018-08-08</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L622319056&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/jgs.15396</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">29741754</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jgs.15396</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">83</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Streitn, J. E.</style></author><author><style face="normal" font="default" size="100%">Porsteinsson, A. P.</style></author><author><style face="normal" font="default" size="100%">Breder, C. D.</style></author><author><style face="normal" font="default" size="100%">Swanink, R.</style></author><author><style face="normal" font="default" size="100%">Marcus, R.</style></author><author><style face="normal" font="default" size="100%">McQuade, R.</style></author><author><style face="normal" font="default" size="100%">Carson, W. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. E. Streitn, Section on Geriatric Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104-3309</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with alzheimer disease</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-550</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antipyretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">anxiolytic agent</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">nootropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">temazepam</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone</style></keyword><keyword><style face="normal" font="default" size="100%">zolpidem</style></keyword><keyword><style face="normal" font="default" size="100%">accidental injury</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Global Impression scale</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug screening</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">ecchymosis</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">psychological rating scale</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">faintness</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">1064-7481&#xD;1545-7214</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the efficacy and safety of aripiprazole treatment for psychotic symptoms associated with Alzheimer disease (AD). Methods: In this parallel group, randomized, double-blind, placebo-controlled, flexible-dose trial, institutionalized subjects with AD and psychotic symptoms were randomized to aripiprazole (n = 131) or placebo (n = 125) for 10 weeks. The aripiprazole starting dose was 2 mg/day, and could be titrated to higher doses (5, 10, and 15 mg/day) based on efficacy and tolerability. Results: No significant differences in mean change [2 X SD] from baseline between aripiprazole (mean dose ∼9 mg/day at endpoint; range = 0.7-15.0 mg) and placebo were detected in the coprimary efficacy endpoints of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) Psychosis score (aripiprazole, -4.53 [9.23]&apos;, placebo, -4.62 [9.56]; F = 0.02, df = 1, 222, p = 0.883 [ANCOVAJ) and Clinical Global Impression (CGI)-Severity score (aripiprazole, -0.57 [1.63]; placebo, -0.43 [1.65]; F = 1.67, df = 1, 220, p = 0.198 [ANCOVAJ) at endpoint. However, improvements in several secondary efficacy measures (NPI-NH Total, Brief Psychiatric Rating Scale Total, CGI - improvement, Cohen-Mansfield Agitation Inventory and Cornell Depression Scale scores) indicated that aripiprazole may confer clinical benefits beyond the primary outcome measures. Treatment-emergent adverse events (AEs) were similar in both groups, except for somnolence (aripiprazole, 14%; placebo, 4%). Somnolence with aripiprazole was of mild or moderate intensity, and not associated with accidental injury. Incidence of AEs related to extrapyramidal symptoms was low with aripiprazole (5%) and placebo (4%). Conclusions: In nursing home residents with AD and psychosis, aripiprazole did not confer specific benefits for the treatment of psychotic symptoms; but psychological and behavioral symptoms, including agitation, anxiety, and depression, were improved with aripiprazole, with a low risk of AEs. © 2008 American Association for Geriatric Psychiatry.</style></abstract><notes><style face="normal" font="default" size="100%">L354797055&#xD;2009-07-21</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354797055&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/JGP.0b013e318165db77</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18591574</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/JGP.0b013e318165db77</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faccin, J. E. G.</style></author><author><style face="normal" font="default" size="100%">Tokach, M. D.</style></author><author><style face="normal" font="default" size="100%">Allerson, M. W.</style></author><author><style face="normal" font="default" size="100%">Woodworth, J. C.</style></author><author><style face="normal" font="default" size="100%">DeRouchey, J. M.</style></author><author><style face="normal" font="default" size="100%">Dritz, S. S.</style></author><author><style face="normal" font="default" size="100%">Bortolozzo, F. P.</style></author><author><style face="normal" font="default" size="100%">Goodband, R. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Medicina Animal/Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.&#xD;Department of Animal Sciences and Industry, College of Agriculture, Kansas State University, Manhattan, KS.&#xD;Holden Farms, Inc., Northfield, MN.&#xD;PIC/Genus, Hendersonville, TN.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship between weaning age and antibiotic usage on pig growth performance and mortality</style></title><secondary-title><style face="normal" font="default" size="100%">J Anim Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Anim Sci</style></full-title></periodical><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Animal Feed/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Eating</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Weaning</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic use</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic-free</style></keyword><keyword><style face="normal" font="default" size="100%">growth</style></keyword><keyword><style face="normal" font="default" size="100%">weaning age</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0021-8812 (Print)&#xD;0021-8812</style></isbn><abstract><style face="normal" font="default" size="100%">A total of 2,184 pigs (DNA 600 × PIC L42) were used to evaluate the effects of weaning age and antibiotic (AB) use on pig performance from weaning to marketing in a commercial production system. Experimental treatments were arranged in a 3 × 2 factorial with main effects of weaning age (18.5, 21.5, or 24.5 d of age) and with the use of ABs or an antibiotic-free (NAE) program. At birth, pigs were ear tagged, and the date of birth and sex recorded. Pigs were weaned from a 4,000-sow farm over four consecutive weeks. Four weaning batches (one per week) of 546 pigs were used. Each weaning batch had one-third of pigs of each weaning age. Pigs were placed in pens by weaning age and then randomly assigned to an AB or NAE program. There were 14 replicate pens per treatment and 26 pigs per pen (13 barrows and 13 gilts). Pigs allocated to the AB program were fed a diet containing 441 mg/kg chlortetracycline (CTC) from day 8 to 21 postweaning. They were also administered 22 mg/kg of body weight (BW) of CTC via drinking water for five consecutive days after a porcine respiratory and reproductive syndrome outbreak during week 7 after weaning. In the first 42 d postweaning, increasing weaning age improved (linear, P &lt; 0.001) BW at day 42, average daily gain (ADG), and average daily feed intake (ADFI). From weaning to 197 d of age, increasing weaning age increased (linear, P &lt; 0.001) ADG and ADFI. Pigs on the AB program had greater (P = 0.031) ADG and ADFI compared with NAE pigs. An interaction (linear, P = 0.005) was observed for feed efficiency (G:F). When ABs were provided, increasing weaning age did not result in any change in G:F; however, in the NAE program, increasing weaning age increased G:F. Pigs on the AB program had lower (P &lt; 0.001) total losses (mortality and removals) than those on the NAE program. Increasing weaning age marginally (linear, P = 0.097) decreased total losses. Increasing weaning age decreased (quadratic, P &lt; 0.001) the number of pigs treated with an injectable AB but the AB program did not (P = 0.238). The weight sold (at 197 d of age) per pig weaned was increased (linear, P = 0.050) by increasing weaning age and by using AB in feed and water (P = 0.019). In summary, increasing weaning age linearly improved most of the pig performance criteria and relatively the short-term use of ABs reduced mortality and removals with both factors contributing to increased weight sold per pig weaned.</style></abstract><notes><style face="normal" font="default" size="100%">1525-3163&#xD;Faccin, Jamil E G&#xD;Tokach, Mike D&#xD;Allerson, Matthew W&#xD;Woodworth, Jason C&#xD;DeRouchey, Joel M&#xD;Dritz, Steve S&#xD;Bortolozzo, Fernando P&#xD;Goodband, Robert D&#xD;Journal Article&#xD;Randomized Controlled Trial, Veterinary&#xD;J Anim Sci. 2020 Dec 1;98(12):skaa363. doi: 10.1093/jas/skaa363.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7755175</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jas/skaa363</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Malin, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.-P. Malin, Neurologische Klinik und Poliklinik, Ruhr-Universitat, BG Krankenanstalten Bergmannsheil, Gilsingstr. 14, 4630 Bochum 1, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">A retrospective and an observational study with acyclovir</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical Virology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Virology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">102-105</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aciclovir</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference paper</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">postherpetic neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Varicella zoster virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year></dates><isbn><style face="normal" font="default" size="100%">0146-6615</style></isbn><abstract><style face="normal" font="default" size="100%">Retrospective analysis: This open controlled non-randomized study was carried out to investigate the influence of intravenous acyclovir (ACV) on the incidence of post-herpetic neuralgia (PHN). Twelve women and 11 men (mean age 52 years, range 19-89) received ACV 5 mg/kg every 8 hours for 10 days (I). Twenty-seven untreated patients (mean age 62 years, range 20-89) were taken as a control group (II). Six to 24 months after the onset of herpes zoster (shingles) the patients were reexamined. The analysis revealed a significantly lower incidence of both general pain and severe pain (P &gt; 0.05, χ2 = 5.55 and 4.39) for (I) compared to (II). For 21 patients who were treated for a period of 10 days, the significance level was 1% (χ2 = 7.82 and 8.62). Observational study: Fifteen thousand eight hundred and thirty-one non-hospitalized patients with hingles (mean age 55.2 years) received oral ACV (800 mg five times daily) for 7 days. At the onset of therapy, 15,420 patients (97.6%) reported pain (severe 42.6%, moderate 43.1%, mild 14.3%). The pain during treatment was documented by the patients (n = 5,728) in a diary and transferred to a scoring system (0 = none, 1 = mild, 2 = moderate, 3 = severe). From day 1 to day 7 there was a decrease in the pain score level from 2.3 to 0.9. Three months after the onset of herpes zoster, 2,519 of 14,858 patients (16.95%) reported pain; 311 patients (2.1%) complained of continuous pain, typical for PHN. The conclusion is that the incidence of PHN can be reduced if ACV is given for 7-10 days.</style></abstract><notes><style face="normal" font="default" size="100%">L23290493&#xD;1993-10-17</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L23290493&amp;from=export</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">8245873</style></custom5></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weed, H. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. G. Weed, Ohio State University College of Medicine, Columbus, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Review: Enhanced oral hygiene prevents respiratory infection in elderly people in hospitals and nursing homes</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">80</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">chlorhexidine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">hospital care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intervention study</style></keyword><keyword><style face="normal" font="default" size="100%">medical research</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">mouth hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">1356-5524&#xD;1473-6810</style></isbn><notes><style face="normal" font="default" size="100%">L354743784&#xD;2009-07-13</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354743784&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/ebm.14.3.80</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/ebm.14.3.80</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wintermeyer, S. M.</style></author><author><style face="normal" font="default" size="100%">Nahata, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.C. Nahata, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rimantadine: A clinical perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">299-310</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">amantadine</style></keyword><keyword><style face="normal" font="default" size="100%">paracetamol</style></keyword><keyword><style face="normal" font="default" size="100%">rimantadine</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral activity</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year></dates><isbn><style face="normal" font="default" size="100%">1060-0280</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To provide a review of rimantadine, including its antiviral activity, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage and administration. Information on influenza A virus and clinical features of influenza disease are presented. Comparative data on rimantadine and amantadine are described. DATA SOURCES: A MEDLINE search restricted to English-language literature published from 1966 through 1994 and an extensive review of journals was conducted. DATA EXTRACTION: The data on antiviral activity, pharmacokinetics, adverse effects, and drug interactions were obtained from various articles on rimantadine in open and controlled studies. Controlled double-blind studies were evaluated to assess the efficacy of rimantadine in prophylaxis and treatment of influenza A infection. DATA SYNTHESIS: Over 90% of a rimantadine dose was absorbed in 3-6 hours in healthy adults. Steady-state plasma concentrations have ranged from 0.10 to 2.60 μg/mL at doses of 3 mg/kg/d in infants to 100 mg twice daily in the elderly. Nasal fluid concentrations of rimantadine at steady-state were 1.5 times higher than plasma concentrations, which may explain the effectiveness of rimantadine despite a low plasma concentration. Over 75% of a rimantadine dose was metabolized in the liver, and the parent compound and metabolites were almost completely eliminated by the kidneys. The elimination half-life ranged from 24.8 to 36.5 hours, which allows once-daily dosing. Dosage adjustment is recommended for patients with severe renal impairment (creatinine clearance ≤ 0.17 mL/s), severe hepatic dysfunction, or elderly nursing home patients. Drug-resistant swains of influenza A virus to rimantadine occurred in several studies with children and/or adults. Clinical significance of drug-resistant strains has not been established. Rimantadine appeared to be effective in 85-90% of individuals for prevention of influenza A illness and in 50-65% for prevention of influenza A infection. Rimantadine reduced the time to a 50% reduction in symptoms by 1-3 days versus placebo. Differences in symptom reduction between rimantadine and placebo after the first 3 days of treatment was not generally clinically significant. The most common adverse effects of rimantadine administration were associated with the central nervous system (CNS) and the gastrointestinal (GI) tract. CNS- related adverse effects occurred in 3.2% of children younger than 10 years of age and 8.4% of adults. In elderly patients, the incidence of CNS-related adverse effects ranged from 4.9% at 100 mg/d to 12.5% at 200 mg/d. GI adverse effects occurred in 8.4% of children younger than 10 years of age. 3.1% of adults, and 2.9% at 100 mg/d and 17.0% at 200 mg/d in the elderly. CONCLUSIONS: Rimantadine offers some desirable features for the treatment and prophylaxis of influenza A infection. It appears to be an attractive choice in elderly patients with a history of CNS adverse effects from amantadine and in patients with mild or moderate renal impairment. Although approved for twice-daily dosing, rimantadine has a pharmacokinetic profile that would allow once-daily dosing. It is effective for prophylaxis (not postexposure prophylaxis) and treatment of influenza A virus. It also has a low incidence of adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">L25099666&#xD;1995-04-12</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L25099666&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/106002809502900312</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">7606077</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/106002809502900312</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sоkоvа, E. А</style></author><author><style face="normal" font="default" size="100%">Arkhipov, V. V.</style></author><author><style face="normal" font="default" size="100%">Demidova, O. A.</style></author><author><style face="normal" font="default" size="100%">Mazerkina, I. A.</style></author><author><style face="normal" font="default" size="100%">Alexandrova, T. V.</style></author><author><style face="normal" font="default" size="100%">Zhuravleva, M. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Е.А. Sоkоvа, Scientific Centre for Expert Evaluation of Medicinal Products, 8/2 Petrovsky Blvd, Moscow, Russian Federation</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors and characteristics of adverse reactions associated with the use of beta-lactam antibiotics in older patients</style></title><secondary-title><style face="normal" font="default" size="100%">Safety and Risk of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Safety and Risk of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">128-135</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrics</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nephrotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">scientific literature</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">cefaclor</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">2619-1164&#xD;2312-7821</style></isbn><abstract><style face="normal" font="default" size="100%">The frequency of adverse drug reactions (ADRs) in older patients is approximately 11.0%, according to scientific literature. Antibiotics are the third largest group (19.5%) of medicinal products in terms of ADR frequency in geriatric patients. Beta-lactam antibiotics are the empiric treatment of choice for older outpatients and inpatients with community-acquired pneumonia. The mortality in this group of patients accounts for 85% of the overall mortality from community-acquired pneumonia. The aim of the study was to analyse scientific data on risk factors and characteristics of adverse drug reactions associated with the use of beta-lactam antibiotics in older patients. Specificity of ADRs to beta-lactam antibiotics in this group of patients is due to age-related changes in pharmacokinetics and pharmacodynamics as well as polymorbidity and polypharmacy. The analysis of scientific literature demonstrated that there have not been so many pharmacoepidemiological studies in this group of patients, and their results have been inconsistent. The frequency, causes, and clinical manifestations of ADRs in geriatric patients are diverse and differ considerably from those in younger patients. Of the most widely used antibiotics, ceftriaxone and cefaclor exhibited a statistically lower risk of ADRs in older patients than in younger patients. At the same time, ceftriaxone was associated with a relatively higher frequency of serious ADRs in older patients as compared to younger patients, whereas the frequency of serious ADRs was lower with cefaclor. The likelihood of nephrotoxic, neurotoxic, and hepatotoxic ADRs associated with the use of beta-lactam antibiotics is becoming more and more obvious but it is still underestimated in clinical and geriatric practice. Safety monitoring, therapeutic drug monitoring with due consideration of ADR risk factors in older patients, and inclusion of older patients in clinical trials of antimicrobial drugs, would improve efficacy and safety of antibiotic treatment.</style></abstract><notes><style face="normal" font="default" size="100%">L2015218463&#xD;2021-11-12</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2015218463&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.30895/2312-7821-2021-9-3-128-135</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.30895/2312-7821-2021-9-3-128-135</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mantripragada, K.</style></author><author><style face="normal" font="default" size="100%">Castillo, J. J.</style></author><author><style face="normal" font="default" size="100%">Olszewski, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Mantripragada, Department of Medicine, Alpert Medical School, Brown University, Providence, RI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for early death after immunochemotherapy in older patients with diffuse large B-Cell Lymphoma (DLBCL)</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3914</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">23</style></number><keywords><keyword><style face="normal" font="default" size="100%">rituximab</style></keyword><keyword><style face="normal" font="default" size="100%">anthracycline</style></keyword><keyword><style face="normal" font="default" size="100%">growth factor</style></keyword><keyword><style face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style face="normal" font="default" size="100%">vincristine</style></keyword><keyword><style face="normal" font="default" size="100%">cyclophosphamide</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">large cell lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">hematology</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">medicare</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">endoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">poverty</style></keyword><keyword><style face="normal" font="default" size="100%">primary central nervous system lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">medicaid</style></keyword><keyword><style face="normal" font="default" size="100%">logistic regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">autopsy</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">kidney disease</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">febrile neutropenia</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">granulocyte</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">walking aid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">0006-4971</style></isbn><abstract><style face="normal" font="default" size="100%">Background: DLBCL is a curable malignancy for a majority of patients &gt;65 years old, but they are at higher risk of toxicities and potential early death after chemotherapy. We evaluated risk factors for death and other severe adverse events during the first month of rituximab-based immunochemotherapy among Medicare beneficiaries with DLBCL, using Medicare claims linked to the Surveillance, Epidemiology and End Results (SEER-Medicare) database. Methods: We selected patients aged ≥65 years, diagnosed with DLBCL between 2003 and 2012, excluding cases diagnosed by autopsy, with incomplete Medicare claims, primary central nervous system lymphoma, or first chemotherapy in the inpatient setting. Eligible patients initiated an outpatient regimen containing rituximab, cyclophosphamide, vincristine, with doxorubicin (R-CHOP-like), or a version without anthracycline. The primary outcome was defined as death within 30 days from the start of chemotherapy. Secondary outcomes included: admission to a hospital, critical care unit or a nursing home, and a cardiac event within this 30-day window. Risk factors were studied in multivariable logistic regression models adjusting for age, sex, race, Medicaid (poverty) status, DLBCL stage, B symptoms, and receipt of anthracycline. We stepwise-selected validated indicators of performance status and comorbidities (based on Medicare claims from the preceding year) which showed strongest associations with the outcomes, using Bonferroni correction. Results are expressed as odds ratios (OR) with 95% confidence intervals (CI). Results: We identified 6,425 patients with median age of 76 years, of whom 49% were women, 88% white non-Hispanic, 44% had stage III/IV lymphoma, and 84% received R-CHOP-like regimen. Cumulative incidence of death was 2.1% at day 30, and 12.3% at day 180 after chemotherapy. Prophylactic granulocyte growth factor was administered to 63% of patients during the first treatment cycle. In a multivariable model, the risk of early death was significantly higher for patients older than 75 years (OR vs. 65-70 years, 2.07, CI 1.04-4.14) or ≥80 years (OR, 3.22, CI, 1.66-6.24), and those with B-symptoms (OR, 1.90, CI, 1.13-3.20), but there was no significant difference by sex, race, stage, poverty status or anthracycline use. The risk was also associated with chronic kidney disease (OR, 3.37, CI, 2.07-5.46), poor performance status (OR, 2.08, CI, 1.22-3.54), prior use of walking AIDS (OR, 2.26, CI, 1.38-3.71), prior hospitalization (OR, 1.68, CI, 1.14-2.47), or a history of upper endoscopy (OR, 1.73, CI, 1.19-2.51). The risk of early death was only 1.1% for patients with &lt;2 of those factors (79% of cases) while it was 7.2% for those with ≥4 factors (6.8% of cases). The risk of other outcomes within 30 days of chemotherapy was: 24% for hospitalization (8% with a diagnosis of febrile neutropenia), 11% for a cardiac event, 8% for critical care, and 3% for nursing home admission. The median time to hospitalization was 9 days (interquartile range, 7 to 14). The risk of early hospitalization was associated with increasing age, female sex (OR, 1.14, CI, 1.01-1.28), B symptoms (OR, 1.49, CI, 1.27-1.74), stage IV lymphoma (OR, 1.20, CI, 1.02-1.40), prior myocardial infarction (OR, 2.56, CI, 1.57-4.18), renal disease (OR, 1.66, CI, 1.31-2.11), prior hospitalization (OR, 1.50, CI, 1.32-1.69) or a history of upper endoscopy (OR, 1.20, CI, 1.05-1.38). Conclusions: Among older DLBCL patients who receive contemporary rituximab-based chemotherapy, 1 in 50 die during the first month of treatment, and 1 in 4 are hospitalized. Easily identifiable factors can distinguish groups at highest risk of early death, who may benefit from preventive strategies such as the prephase treatment (Pfreundschuh, Blood 2010), or from novel, personalized therapeutic approaches. Despite national guidelines, prophylactic granulocytic growth factors are not administered to over 1/3 of patients, indicating an opportunity to lower the risk of adverse events. Withholding doxorubicin was not associated with a lower risk of arly death or hospitalization.</style></abstract><notes><style face="normal" font="default" size="100%">L72174604&#xD;2016-02-08</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L72174604&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://www.bloodjournal.org/content/126/23/3914</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pawar, A.</style></author><author><style face="normal" font="default" size="100%">Desai, R.</style></author><author><style face="normal" font="default" size="100%">Gautam, N.</style></author><author><style face="normal" font="default" size="100%">Kim, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Pawar, Brigham and Women &apos; s hospital, Boston, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of serious infections in tofacitinib versus other biologic drug initiators in patients with rheumatoid arthritis: A multi-database cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Arthritis and Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arthritis and Rheumatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5011-5013</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><keywords><keyword><style face="normal" font="default" size="100%">abatacept</style></keyword><keyword><style face="normal" font="default" size="100%">adalimumab</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">biological product</style></keyword><keyword><style face="normal" font="default" size="100%">certolizumab pegol</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">disease modifying antirheumatic drug</style></keyword><keyword><style face="normal" font="default" size="100%">etanercept</style></keyword><keyword><style face="normal" font="default" size="100%">golimumab</style></keyword><keyword><style face="normal" font="default" size="100%">infliximab</style></keyword><keyword><style face="normal" font="default" size="100%">methotrexate</style></keyword><keyword><style face="normal" font="default" size="100%">rituximab</style></keyword><keyword><style face="normal" font="default" size="100%">tocilizumab</style></keyword><keyword><style face="normal" font="default" size="100%">tofacitinib</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">health care utilization</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">malignant neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">medicare</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">opportunistic infection</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">probability</style></keyword><keyword><style face="normal" font="default" size="100%">propensity score</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatoid arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">secondary analysis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2326-5205</style></isbn><abstract><style face="normal" font="default" size="100%">Background/Purpose : It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk of SI across these DMARDs in a real-world setting. We aimed to compare incidence rate (IR) of serious bacterial, viral or opportunistic infection in rheumatoid arthritis (RA) patients initiating tofacitinib (TOF) (common exposure) versus other biologic DMARDs: abatacept (ABA), adalimumab (ADA), certolizumab (CER), etanercept (ETA), golimumab (GOL), infliximab (INF) or tocilizumab (TCZ). Methods : We analyzed data from 3 U.S. healthcare claims databases: Medicare (2012-2015), Optum (2012-09/2017) and MarketScan (2012-2017). RA patients aged≥18 years who initiated TOF or other biologic DMARD without any prior use of biologics or JAK inhibitors were identified. We excluded patients with recent infection, malignancy or rituximab use. The primary outcome was a composite endpoint of incident SI that included bacterial, viral or opportunistic infection based on the inpatient principal diagnosis code. Secondary outcomes were specific subtypes of SIs. We adjusted for &gt;70 potential confounders including demographics, prior DMARD and antibiotic use, comorbidities, other medications, and healthcare utilization factors in each database through propensity score (PS)-based inverse probability treatment weighting. For the as-treated analysis, follow-up time started the day after cohort entry until the earliest of: treatment discontinuation, switching to any biologic other than index therapy, nursing home admission, death, disenrollment, or the end of study period. For each drug-comparison, weighted Cox proportional hazards models estimated the HRs and 95% CIs. The estimates from 3 databases were combined using an inverse variance-weighted, fixed-effects meta-analysis. Results : A total of 123,960 biologic initiators were identified across 3 databases, of which 5,531 (4.5%) were TOF initiators. Mean age was 72 years in Medicare, 54 in Optum and 52 in MarketScan. During the 180-day baseline period, 64-71% patients used methotrexate and 68-73% used corticosteroids. After PS-weighting, all covariates were well balanced. The median follow-up time (days) in the as-treated analysis ranged from 164 (Optum) to 182 (Market-Scan). A total of 2,958 SI events occurred. In the TOF group, the crude IR for SIs per 100 person-years ranged from 2.80 (MarketScan) to 7.89 (Medicare). Adjusted HRs showed higher risk of composite SIs in TOF compared to ABA (HR 1.20, 95% CI 1.09-1.31), ETA (1.27, 1.14-1.42), GOL (1.35, 1.29-1.40) and TCZ (1.46, 1.31-1.63), but similar risk compared to ADA, CER and INF. Serious bacterial infection risk was higher in TOF than ABA, CER, ETA and GOL. Secondary analyses showed consistent findings ( Table 1 ). Conclusion : This large multi-database cohort study of RA patients found a higher risk for the composite endpoint of SIs requiring hospitalization after initiating TOF versus ABA, ETA, GOL and TCZ as their first biologic or targeted synthetic DMARD therapy. The risk of serious bacterial infection, pneumonia, herpes zoster, and skin and soft tissue infections was also higher in TOF initiators versus several other biologics.</style></abstract><notes><style face="normal" font="default" size="100%">L633057922&#xD;2020-10-14</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L633057922&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/art.41108</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/art.41108</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silagy, C. A.</style></author><author><style face="normal" font="default" size="100%">Campion, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.A. Silagy, Inst. of Pub. Hlth./Hlth. Svcs. Res., Monash Medical Centre, Locked Bag 29, Clayton, Vic. 3168, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of zanamivir in the treatment of influenza A and B viral infections - A review of efficacy and safety</style></title><secondary-title><style face="normal" font="default" size="100%">Today&apos;s Therapeutic Trends</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Today&apos;s Therapeutic Trends</style></full-title></periodical><pages><style face="normal" font="default" size="100%">345-357</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">amantadine</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">rimantadine</style></keyword><keyword><style face="normal" font="default" size="100%">sialidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">zanamivir</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced disease</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza B virus</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">relenza</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><isbn><style face="normal" font="default" size="100%">0741-2320</style></isbn><abstract><style face="normal" font="default" size="100%">Influenza is a serious respiratory illness associated with significant morbidity and mortality in such high-risk patients as the elderly, infants, and those with respiratory conditions or immunocompromise. The effectiveness of annual immunizations with inactivated influenza virus ranges from 30% to 75% of inoculated patients depending upon age, but is considerably lower in elderly nursing home patients. A new antiviral agent, zanamivir (Relenza®), is a potent and specific neuroaminidase inhibitor active against both influenza A and B virus, while other antiviral agents (amantadine and rimantadine) have demonstrated efficacy only against influenza A. In pooled analysis from extensive clinical trials using inhalation therapy, zanamivir reduced the overall duration of illness by an average of 1 day in febrile patients, but by 2.5-3 days in those with severe infection, ≥50 years of age, and others at increased risk of developing complications of influenza. The incidence of reported side effects is similar in placebo- and zanamivir- treated patients, and to date no naturally-occurring influenza A or B virus isolate has been identified which is resistant to zanamivir.</style></abstract><notes><style face="normal" font="default" size="100%">L30003022&#xD;2000-01-06</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L30003022&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">relenza</style></custom1></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monto, A. S.</style></author><author><style face="normal" font="default" size="100%">Ohmit, S. E.</style></author><author><style face="normal" font="default" size="100%">Hornbuckle, K.</style></author><author><style face="normal" font="default" size="100%">Pearce, C. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Public Health, University of Michigan, Ann Arbor 48109, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2224-8</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Rimantadine/*adverse effects/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">The safety and efficacy of rimantadine for long-term prophylaxis of influenza A (H3N2) infection were evaluated among elderly residents in 10 nursing homes. Within each nursing home, participating residents were randomly assigned to receive placebo or rimantadine at 100 or 200 mg/day. Residents were evaluated daily for symptoms and significant health events as possible side effects, as well as for influenza-like illness. The study medications were administered to 328 residents for up to 8 weeks, with no statistically significant differences in the frequencies of gastrointestinal or central nervous system symptoms between the groups. However, residents in the active medication groups were more likely to withdraw from the study and to experience various health events including death; some but not all of these differences were statistically significant. Efficacy evaluations were carried out on the 68 vaccinated residents in the two nursing homes with demonstrated influenza virus activity. Rimantadine appeared to provide an additional protective effect beyond vaccination in reducing the risk of clinical and laboratory-confirmed influenza-like illness; however, the efficacy estimates were never statistically significant. The efficacies of the 100- and 200-mg/day dosages were generally similar. When data for the 100- and 200-mg/day dosage groups were combined and compared with data for the group receiving placebo, the efficacy of rimantadine in reducing the risk of clinical influenza-like illness was estimated to be 58 percent (P = 0.079). The results suggest the relative safety and clinical efficacy of using rimantadine for influenza prophylaxis among vaccinated elderly individuals and support the recommendation for a dosage reduction to 100 mg/day in this population.</style></abstract><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Monto, A S&#xD;Ohmit, S E&#xD;Hornbuckle, K&#xD;Pearce, C L&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Antimicrob Agents Chemother. 1995 Oct;39(10):2224-8. doi: 10.1128/AAC.39.10.2224.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC162919</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.39.10.2224</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Camilleri, M.</style></author><author><style face="normal" font="default" size="100%">Beyens, G.</style></author><author><style face="normal" font="default" size="100%">Kerstens, R.</style></author><author><style face="normal" font="default" size="100%">Robinson, P.</style></author><author><style face="normal" font="default" size="100%">Vandeplassche, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Camilleri, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN 55905, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety assessment of prucalopride in elderly patients with constipation: A double-blind, placebo-controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">Neurogastroenterology and Motility</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurogastroenterology and Motility</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1256-1263+e117</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT00627692</style></keyword><keyword><style face="normal" font="default" size="100%">amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">cefotaxime</style></keyword><keyword><style face="normal" font="default" size="100%">digoxin</style></keyword><keyword><style face="normal" font="default" size="100%">enalapril</style></keyword><keyword><style face="normal" font="default" size="100%">loperamide</style></keyword><keyword><style face="normal" font="default" size="100%">mebhydrolin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">prucalopride</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bronchitis</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">colitis</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">diverticulitis</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose escalation</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiogram</style></keyword><keyword><style face="normal" font="default" size="100%">falling</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">heart supraventricular arrhythmia</style></keyword><keyword><style face="normal" font="default" size="100%">heart ventricle arrhythmia</style></keyword><keyword><style face="normal" font="default" size="100%">heart ventricle tachycardia</style></keyword><keyword><style face="normal" font="default" size="100%">Holter monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">melena</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">QT interval</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory failure</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">time to maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vital sign</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">1350-1925&#xD;1365-2982</style></isbn><abstract><style face="normal" font="default" size="100%">Chronic constipation is common among nursing home residents. The aim of this study was to evaluate safety, tolerability and pharmacokinetics of the selective 5HT4 receptor agonist prucalopride in elderly, chronically constipated patients in nursing homes. A multicentre, phase II, randomized, double-blind dose-escalation study in 89 elderly constipated nursing home residents treated with placebo, 0.5, 1 or 2 mg prucalopride once daily for 28 days was analysed. Adverse events, vital signs, ECG, Holter monitor and pharmacokinetics were assessed (Clinicaltrials.gov identifier: NCT00627692). Patients&apos; mean age was 83 years; 88% had a history of cardiovascular diseases. Most frequent adverse events, at least possibly related to prucalopride, were diarrhoea and abdominal pain. Relative to placebo, there were no differences in vital signs, ECG corrected QT interval, ECG morphology parameters, or incidence of supraventricular or ventricular arrhythmias on Holter monitoring. Plasma prucalopride concentrations increased proportionally with administered dose. Prucalopride up to 2 mg once daily for 4 weeks was safe and well-tolerated by constipated elderly patients, with no differences vs placebo in ECG or a range of Holter-monitoring parameters. © 2009 Blackwell Publishing Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L355825101&#xD;2010-01-25</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L355825101&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1365-2982.2009.01398.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">19751247</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2982.2009.01398.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, M.</style></author><author><style face="normal" font="default" size="100%">Yoshikawa, T. T.</style></author><author><style face="normal" font="default" size="100%">Bridge, J.</style></author><author><style face="normal" font="default" size="100%">Schlaifer, A.</style></author><author><style face="normal" font="default" size="100%">Osterweil, D.</style></author><author><style face="normal" font="default" size="100%">Reid, D.</style></author><author><style face="normal" font="default" size="100%">Norman, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, West Los Angeles, California.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Salmonella outbreak in a nursing home</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">531-4</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/economics/*epidemiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Feces/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Los Angeles</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Staff</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Salmonella Food Poisoning/economics/*epidemiology/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1990</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">We performed a retrospective review of an outbreak of Salmonella gastroenteritis that occurred in a community nursing home in 1987. Forty-four of 199 residents had a diarrheal illness; Salmonella heidelberg was isolated from the stool in 19 cases. Although the distribution of cases suggested a common source for the outbreak, no common source of infection could be demonstrated, despite extensive investigation. The clinical presentation of symptomatic individuals ranged from mild diarrhea to a severe gastrointestinal illness, and 26% of symptomatic, culture-positive patients required hospitalization. The median duration of pathogen excretion during convalescence in untreated residents was six weeks, but six patients who were treated with antibiotics shed S. heidelberg for a median duration of 14.5 weeks. We conclude that (1) the clinical spectrum of Salmonella gastroenteritis in nursing-home patients is variable, ranging from mild to severe illness; and (2) nursing-home Salmonella outbreaks impose a high economic burden because of expense of epidemiologic investigation, prolonged isolation measures, hospitalization for severely ill residents, and potential institutional closure.</style></abstract><notes><style face="normal" font="default" size="100%">Choi, M&#xD;Yoshikawa, T T&#xD;Bridge, J&#xD;Schlaifer, A&#xD;Osterweil, D&#xD;Reid, D&#xD;Norman, D C&#xD;Journal Article&#xD;United States&#xD;J Am Geriatr Soc. 1990 May;38(5):531-4. doi: 10.1111/j.1532-5415.1990.tb02403.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.1990.tb02403.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mayne, S.</style></author><author><style face="normal" font="default" size="100%">Bowden, A.</style></author><author><style face="normal" font="default" size="100%">Sundvall, P. D.</style></author><author><style face="normal" font="default" size="100%">Gunnarsson, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cairns Clinical School, College of Medicine and Dentistry, James Cook University, PO Box 902, Cairns, Queensland, 4870, Australia. sean.mayne@my.jcu.edu.au.&#xD;Cairns Clinical School, College of Medicine and Dentistry, James Cook University, PO Box 902, Cairns, Queensland, 4870, Australia.&#xD;Cairns Hospital, Queensland Health, Cairns, Queensland, Australia.&#xD;Research and Development Unit, Primary Health Care in Southern Älvsborg County, Sven Eriksonsplatsen 4, SE-503 38, Borås, Sweden.&#xD;Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The scientific evidence for a potential link between confusion and urinary tract infection in the elderly is still confusing - a systematic literature review</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Geriatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Geriatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Delirium/*diagnosis/drug therapy/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine/*methods/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/*diagnosis/drug therapy/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">*Confusion</style></keyword><keyword><style face="normal" font="default" size="100%">*Delirium</style></keyword><keyword><style face="normal" font="default" size="100%">*Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">*Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Ethics Committee was not sought as this was a systematic review of the published</style></keyword><keyword><style face="normal" font="default" size="100%">literature. CONSENT FOR PUBLICATION: N/A COMPETING INTERESTS: Authors PDS and RG</style></keyword><keyword><style face="normal" font="default" size="100%">have previous publications cited in this systematic literature review. PUBLISHER’S</style></keyword><keyword><style face="normal" font="default" size="100%">NOTE: Springer Nature remains neutral with regard to jurisdictional claims in</style></keyword><keyword><style face="normal" font="default" size="100%">published maps and institutional affiliations.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2318</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Non-specific symptoms, such as confusion, are often suspected to be caused by urinary tract infection (UTI) and continues to be the most common reason for suspecting a UTI despite many other potential causes. This leads to significant overdiagnosis of UTI, inappropriate antibiotic use and potential harmful outcomes. This problem is particularly prevalent in nursing home settings. METHODS: A systematic review of the literature was conducted assessing the association between confusion and UTI in the elderly. PubMed, Scopus and PsychInfo were searched with the following terms: confusion, delirium, altered mental status, acute confusional state, urinary tract infection, urine infection, urinary infection and bacteriuria. Inclusion criteria and methods were specified in advance and documented in the protocol, which was published with PROSPERO (registration ID: CRD42015025804). Quality assessment was conducted independently by two authors. Data were extracted using a standardised extraction tool and a qualitative synthesis of evidence was made. RESULTS: One thousand seven hunderd two original records were identified, of which 22 were included in the final analysis. The quality of these included studies varied, with frequent poor case definitions for UTI or confusion contributing to large variation in results and limiting their validity. Eight studies defined confusion using valid criteria; however, no studies defined UTI in accordance with established criteria. As no study used an acceptable definition of confusion and UTI, an association could not be reliably established. Only one study had acceptable definitions of confusion and bacteriuria, reporting an association with the relative risk being 1.4 (95% CI 1.0-1.7, p = 0.034). CONCLUSIONS: Current evidence appears insufficient to accurately determine if UTI and confusion are associated, with estimates varying widely. This was often attributable to poor case definitions for UTI or confusion, or inadequate control of confounding factors. Future well-designed studies, using validated criteria for UTI and confusion are required to examine the relationship between UTI and acute confusion in the elderly. The optimal solution to clarify this clinical issue would be a randomized controlled trial comparing the effect of antibiotics versus placebo in patients with new onset or worsening confusion and presence of bacteriuria while lacking specific urinary tract symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">1471-2318&#xD;Mayne, Sean&#xD;Orcid: 0000-0002-9895-3058&#xD;Bowden, Alexander&#xD;Sundvall, Pär-Daniel&#xD;Gunnarsson, Ronny&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;BMC Geriatr. 2019 Feb 4;19(1):32. doi: 10.1186/s12877-019-1049-7.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6360770</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12877-019-1049-7</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>193</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuil, S. D.</style></author><author><style face="normal" font="default" size="100%">Hidad, S.</style></author><author><style face="normal" font="default" size="100%">Fischer, J. C.</style></author><author><style face="normal" font="default" size="100%">Harting, J.</style></author><author><style face="normal" font="default" size="100%">Hertogh, Cmpm</style></author><author><style face="normal" font="default" size="100%">Prins, J. M.</style></author><author><style face="normal" font="default" size="100%">de Jong, M. D.</style></author><author><style face="normal" font="default" size="100%">van Leth, F.</style></author><author><style face="normal" font="default" size="100%">Schneeberger, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology, Amsterdam Infection &amp; Immunity Institute, Meibergdreef 9, Amsterdam, The Netherlands.&#xD;Amsterdam UMC, University of Amsterdam, Department of Clinical Chemistry, Meibergdreef 9, Amsterdam, The Netherlands.&#xD;Amsterdam UMC, University of Amsterdam, Department of Public Health, Amsterdam Public Health research institute, Meibergdreef 9, Amsterdam, The Netherlands.&#xD;Amsterdam UMC, VU University Medical Center, Department of General Practice and Elderly Care Medicine, Amsterdam Public Health, University Network of Organizations for Elderly Care, Amsterdam, The Netherlands.&#xD;Amsterdam UMC, University of Amsterdam, Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection &amp; Immunity Institute, Amsterdam, The Netherlands.&#xD;Amsterdam UMC, University of Amsterdam, Department of Global Health, Amsterdam, The Netherlands.&#xD;Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sensitivity of C-reactive protein and procalcitonin measured by Point-of-Care tests to diagnose urinary tract infections in nursing home residents: a cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">C-reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">Point-of-care test</style></keyword><keyword><style face="normal" font="default" size="100%">Procalcitonin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnosing urinary tract infections (UTI) in nursing home residents is complex, as specific urinary symptoms are often absent and asymptomatic bacteriuria (ASB) is prevalent. The aim of this study was to assess the sensitivity of blood C-reactive protein (CRP) and procalcitonin (PCT) measured by Point-of-Care tests (PoCT) to diagnose UTI in this setting. METHODS: Elderly residents (≥ 65 years old) with a suspected UTI were recruited from psychogeriatric, somatic, or rehabilitation wards, in the thirteen participating nursing homes. CRP and PCT were tested simultaneously in the same study participants. To assess the sensitivities, a stringent definition of &apos;true&apos; UTI was used including the presence of symptoms, urinary leucocytes, positive urine culture and symptom resolution during antibiotic treatment covering isolated uropathogen(s). The original sample size was 440 suspected UTI episodes, to detect a clinically relevant sensitivity of at least 65%, calculated for the matched analysis approach comparing both PoCT. RESULTS: After enrolment of 302 episodes (68.6% of the planned sample size) an unplanned and funder-mandated interim analysis was done, resulting in premature discontinuation of the study for futility. For 247 of 266 eligible episodes all mandatory items required for the &apos;true&apos; UTI definition (92.9%) were available. In total, 49 episodes fulfilled our stringent UTI definition (19.8%). The sensitivities of CRP (cut-off 6.5 mg/L) and PCT (cut-off 0.025 ng/mL) were 52.3% (36.7-67.5%, 95%-CI) and 37.0% (23.2-52.5%, 95%-CI) respectively. CONCLUSION: Our results indicate that CRP and PCT are not suitable to distinguish UTI and ASB in nursing home residents.Trial registration Netherlands Trial Registry NL6293.</style></abstract><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Kuil, S D&#xD;Hidad, S&#xD;Fischer, J C&#xD;Harting, J&#xD;Hertogh, C M P M&#xD;Prins, J M&#xD;de Jong, M D&#xD;van Leth, F&#xD;Schneeberger, C&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 2020 Nov 11:ciaa1709. doi: 10.1093/cid/ciaa1709.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciaa1709</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author><author><style face="normal" font="default" size="100%">Barnett, J. B.</style></author><author><style face="normal" font="default" size="100%">Dallal, G. E.</style></author><author><style face="normal" font="default" size="100%">Fine, B. C.</style></author><author><style face="normal" font="default" size="100%">Jacques, P. F.</style></author><author><style face="normal" font="default" size="100%">Leka, L. S.</style></author><author><style face="normal" font="default" size="100%">Hamer, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nutritional Immunology Laboratory, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. simin.meydani@tufts.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum zinc and pneumonia in nursing home elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1167-73</style></pages><volume><style face="normal" font="default" size="100%">86</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Boston/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*blood/drug therapy/*epidemiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin E/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9165 (Print)&#xD;0002-9165</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Zinc plays an important role in immune function. The association between serum zinc and pneumonia in the elderly has not been studied. OBJECTIVE: The objective was to determine whether serum zinc concentrations in nursing home elderly are associated with the incidence and duration of pneumonia, total and duration of antibiotic use, and pneumonia-associated and all-cause mortality. DESIGN: This observational study was conducted in residents from 33 nursing homes in Boston, MA, who participated in a 1-y randomized, double-blind, and placebo-controlled vitamin E supplementation trial; all were given daily doses of 50% of the recommended dietary allowance of essential vitamins and minerals, including zinc. Participants with baseline (n = 578) or final (n = 420) serum zinc concentrations were categorized as having low (&lt;70 microg/dL) or normal (&gt;or=70 microg/dL) serum zinc concentrations. Outcome measures included the incidence and number of days with pneumonia, number of new antibiotic prescriptions, days of antibiotic use, death due to pneumonia, and all-cause mortality. RESULTS: Compared with subjects with low zinc concentrations, subjects with normal final serum zinc concentrations had a lower incidence of pneumonia, fewer (by almost 50%) new antibiotic prescriptions, a shorter duration of pneumonia, and fewer days of antibiotic use (3.9 d compared with 2.6 d) (P &lt;or= 0.004 for all). Normal baseline serum zinc concentrations were associated with a reduction in all-cause mortality (P = 0.049). CONCLUSION: Normal serum zinc concentrations in nursing home elderly are associated with a decreased incidence and duration of pneumonia, a decreased number of new antibiotic prescriptions, and a decrease in the days of antibiotic use. Zinc supplementation to maintain normal serum zinc concentrations in the elderly may help reduce the incidence of pneumonia and associated morbidity.</style></abstract><notes><style face="normal" font="default" size="100%">Meydani, Simin N&#xD;Barnett, Junaidah B&#xD;Dallal, Gerard E&#xD;Fine, Basil C&#xD;Jacques, Paul F&#xD;Leka, Lynette S&#xD;Hamer, Davidson H&#xD;P01 AG004390/AG/NIA NIH HHS/United States&#xD;P01 AG004390-24/AG/NIA NIH HHS/United States&#xD;R01 AG013975-05/AG/NIA NIH HHS/United States&#xD;1R01-AG13975/AG/NIA NIH HHS/United States&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Am J Clin Nutr. 2007 Oct;86(4):1167-73. doi: 10.1093/ajcn/86.4.1167.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2323679</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS44687</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ajcn/86.4.1167</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singanayagam, A.</style></author><author><style face="normal" font="default" size="100%">Chalmers, J. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.D. Chalmers, Tayside Respiratory Research Group, University of Dundee, Dundee, DD1 9SY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet Respiratory Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Lancet Respiratory Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">653-662</style></pages><volume><style face="normal" font="default" size="100%">1</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">aminoglycoside antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">aminopenicillin</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">beta lactam antibiotic</style></keyword><keyword><style face="normal" font="default" size="100%">cefotaxime</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">cephalosporin</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">clarithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">gentamicin</style></keyword><keyword><style face="normal" font="default" size="100%">levofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">macrolide</style></keyword><keyword><style face="normal" font="default" size="100%">moxifloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin G</style></keyword><keyword><style face="normal" font="default" size="100%">piperacillin</style></keyword><keyword><style face="normal" font="default" size="100%">quinoline derived antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">roxithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">tazobactam</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium identification</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical practice</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Coxiella burnetii</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacteriaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophilus influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">health care delivery</style></keyword><keyword><style face="normal" font="default" size="100%">health care planning</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">inappropriate prescribing</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">low risk population</style></keyword><keyword><style face="normal" font="default" size="100%">medical society</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Moraxella catarrhalis</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Mycoplasma pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia Severity Index</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">process development</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">receiver operating characteristic</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">severity assessment score</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2213-2600</style></isbn><abstract><style face="normal" font="default" size="100%">Severity assessment scores were first developed to predict the 30 day mortality in community acquired pneumonia; however, several guidelines have extended their use to guide empirical antibiotic prescription decisions. This approach has theoretical advantages because a decrease in broad-spectrum antibiotic treatment in low-risk patients might reduce antibiotic-related side-effects, and to give broad-spectrum therapy to patients at higher risk of death is intuitive. However, evidence in support of this approach is not clear. In particular, the British Thoracic Society guidelines suggest withholding a macrolide from patients with low CURB 65 scores, despite evidence that these patients have a higher frequency of atypical pathogens than do those with a higher severity of pneumonia. Severity scores do not perform well in some groups and might overestimate disease severity in elderly people, leading to inappropriate broad-spectrum treatment to those at high risk of complications such as Clostridium difficile infection. In this Review, we discuss the evidence for antibiotic prescribing guided by severity score and suggest that more evidence of effect and implementation is needed before this approach can be universally adopted. © 2013 Elsevier Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L52651649&#xD;2013-07-01&#xD;2013-10-29</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L52651649&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S2213-2600(13)70084-5</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24461668</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S2213-2600(13)70084-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandven, P.</style></author><author><style face="normal" font="default" size="100%">Qvist, H.</style></author><author><style face="normal" font="default" size="100%">Skovlund, E.</style></author><author><style face="normal" font="default" size="100%">Giercksky, K. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Bacteriology, Norwegian Institute of Public Health, Oslo. per.sandven@folkehelsa.no</style></auth-address><titles><title><style face="normal" font="default" size="100%">Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations</style></title><secondary-title><style face="normal" font="default" size="100%">Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Crit Care Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-7</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antifungal Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Candidiasis/*complications/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluconazole/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Perforation/*microbiology/mortality/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Intraoperative Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Norway/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Peritonitis/epidemiology/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications/epidemiology/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Rupture</style></keyword><keyword><style face="normal" font="default" size="100%">Stomach Diseases/*microbiology/mortality/surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0090-3493 (Print)&#xD;0090-3493</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Determine the significance of recovering yeasts from intraoperative specimens from the abdominal cavity and to evaluate the effect of a single intraoperative dose of fluconazole on clinical outcome in patients with intra-abdominal perforations. DESIGN: Prospective, randomized, double-blind study. SETTING: Multicenter study from 13 hospitals in Norway. PATIENTS: One hundred nine patients with intra-abdominal perforations. INTERVENTIONS: Patients were randomized to receive either a single 400-mg fluconazole dose or placebo during the operation. MEASUREMENTS AND MAIN RESULTS: An intra-abdominal specimen for microbiological culture was obtained at the time of the operation. The primary response variable in the study was death. Secondary response variables were three parameters indicating a complicated postoperative period: mechanical ventilation for &gt; or = 5 days, intensive care treatment for &gt; or = 10 days, and use of a central venous catheter for &gt; or = 10 days. Yeasts were recovered from a intraoperative intra-abdominal specimen from only 1 (3.5%) of 28 patients with perforated appendicitis and from 32 (39.5%) of 81 nonappendicitis patients. Excluding the appendicitis patients, the yeast recovery rate was high both for patients hospitalized at the time of the perforation (45%) and for nonhospitalized patients (32%). The overall mortality was 11% (12 patients). Single-dose intraoperative fluconazole prophylaxis did not reach a statistically significant effect on mortality (4 of 53 patients in the fluconazole group and 8 of 56 patients in the placebo group died [p = .059]). The only two explanatory variables significantly related to death were a intraoperative finding of yeast from an intra-abdominal specimen and the occurrence of a spontaneous perforation in a patient already hospitalized for nonsurgical cancer treatment. Detection of yeast was also a significant explanatory variable for a prolonged period of mechanical ventilation, intensive care treatment, and prolonged use of a central venous catheter. CONCLUSIONS: Single-dose intraoperative fluconazole prophylaxis did not have a statistically significant effect on overall mortality (odds ratio = 0.21; 95% confidence interval, 0.04-1.06; p = .059) in patients with intra-abdominal perforation. The recovery rate of yeast from intraoperative specimens from the abdominal cavity was high (&gt;30%) and was associated with death and a complicated postoperative course.</style></abstract><notes><style face="normal" font="default" size="100%">Sandven, Per&#xD;Qvist, Hanne&#xD;Skovlund, Eva&#xD;Giercksky, Karl E&#xD;NORGAS Group and the Norwegian Yeast Study Group&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;United States&#xD;Crit Care Med. 2002 Mar;30(3):541-7. doi: 10.1097/00003246-200203000-00008.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00003246-200203000-00008</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Givens, J. L.</style></author><author><style face="normal" font="default" size="100%">Jones, R. N.</style></author><author><style face="normal" font="default" size="100%">Shaffer, M. L.</style></author><author><style face="normal" font="default" size="100%">Kiely, D. K.</style></author><author><style face="normal" font="default" size="100%">Mitchell, S. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. JaneGivens@hrca.harvard.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Survival and comfort after treatment of pneumonia in advanced dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Intern Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1102-7</style></pages><volume><style face="normal" font="default" size="100%">170</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Activities of Daily Living</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/*complications/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Routes</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Massachusetts/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/complications/*drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-9926 (Print)&#xD;0003-9926</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pneumonia is common among patients with advanced dementia, especially toward the end of life. Whether antimicrobial treatment improves survival or comfort is not well understood. The objective of this study was to examine the effect of antimicrobial treatment for suspected pneumonia on survival and comfort in patients with advanced dementia. METHODS: From 2003 to 2009, data were prospectively collected from 323 nursing home residents with advanced dementia in 22 facilities in the area of Boston, Massachusetts. Each resident was followed up for as long as 18 months or until death. All suspected pneumonia episodes were ascertained, and antimicrobial treatment for each episode was categorized as none, oral only, intramuscular only, or intravenous (or hospitalization). Multivariable methods were used to adjust for differences among episodes in each treatment group. The main outcome measures were survival and comfort (scored according to the Symptom Management at End-of-Life in Dementia scale) after suspected pneumonia episodes. RESULTS: Residents experienced 225 suspected pneumonia episodes, which were treated with antimicrobial agents as follows: none, 8.9%; oral only, 55.1%, intramuscular, 15.6%, and intravenous (or hospitalization), 20.4%. After multivariable adjustment, all antimicrobial treatments improved survival after pneumonia compared with no treatment: oral (adjusted hazard ratio [AHR], 0.20; 95% confidence interval [CI], 0.10-0.37), intramuscular (AHR, 0.26; 95% CI, 0.12-0.57), and intravenous (or hospitalization) (AHR, 0.20; 95% CI, 0.09-0.42). After multivariable adjustment, residents receiving any form of antimicrobial treatment for pneumonia had lower scores on the Symptom Management at End-of-Life in Dementia scale (worse comfort) compared with untreated residents. CONCLUSION: Antimicrobial treatment of suspected pneumonia episodes is associated with prolonged survival but not with improved comfort in nursing home residents with advanced dementia.</style></abstract><notes><style face="normal" font="default" size="100%">1538-3679&#xD;Givens, Jane L&#xD;Jones, Richard N&#xD;Shaffer, Michele L&#xD;Kiely, Dan K&#xD;Mitchell, Susan L&#xD;R01 AG024091/AG/NIA NIH HHS/United States&#xD;K24 AG033640-02/AG/NIA NIH HHS/United States&#xD;K24AG033640/AG/NIA NIH HHS/United States&#xD;K24 AG033640/AG/NIA NIH HHS/United States&#xD;R01 AG024091-05/AG/NIA NIH HHS/United States&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Arch Intern Med. 2010 Jul 12;170(13):1102-7. doi: 10.1001/archinternmed.2010.181.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2914628</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS221582</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinternmed.2010.181</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giamarellou, H.</style></author><author><style face="normal" font="default" size="100%">Dontas, A. S.</style></author><author><style face="normal" font="default" size="100%">Petrikkos, G.</style></author><author><style face="normal" font="default" size="100%">Gnardellis, C.</style></author><author><style face="normal" font="default" size="100%">Zorbas, P.</style></author><author><style face="normal" font="default" size="100%">Philippou, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Athens University School of Medicine, Attikon University General Hospital, Athens, Greece. hgiama@ath.forthnet.gr</style></auth-address><titles><title><style face="normal" font="default" size="100%">Survival of elderly bacteriuric subjects following long-term quinolone therapy</style></title><secondary-title><style face="normal" font="default" size="100%">J Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">185-92</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/*drug therapy/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Greece/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Ofloxacin/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Pulse Therapy, Drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1120-009X (Print)&#xD;1120-009x</style></isbn><abstract><style face="normal" font="default" size="100%">This study aimed to determine whether long-term oral fluoroquinolone administration exerts a significant positive effect on mobility and mortality in elderly subjects with asymptomatic bacteriuria. 132 institutionalized patients were divided into 4 groups: groups A and B were treated with ofloxacin while groups C and D were positive and negative control groups. At 3 months following treatment discontinuation 57%, 53% and 26% of patients in groups A, B and C respectively had negative urine cultures and all subjects were alive. After 3 years, positive cultures were 41.7%, 54.5% and 42.9% respectively for uncatheterized subjects per group vs. 13.3% for group D. In groups A, B, and C 20%, 15% and 29% of survivors respectively had permanent bladder catheters vs. 11.5% of survivors of group D. Survival in groups A, B and C, combined or per group did not differ significantly from group D, although it was shorter. &quot;Pulse&quot; antibiotic administration tended to perform better, in terms of clearing infection and maintaining continence. At 3 years, bacteriuria recurred and the need for bladder catheterization was doubled. Mortality increased independently of treatment. More elderly bacteriuric subjects should be studied to evaluate mobility and mortality issues.</style></abstract><notes><style face="normal" font="default" size="100%">Giamarellou, H&#xD;Dontas, A S&#xD;Petrikkos, G&#xD;Gnardellis, C&#xD;Zorbas, P&#xD;Philippou, P&#xD;Controlled Clinical Trial&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Chemother. 2007 Apr;19(2):185-92. doi: 10.1179/joc.2007.19.2.185.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1179/joc.2007.19.2.185</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boscia, J. A.</style></author><author><style face="normal" font="default" size="100%">Kobasa, W. D.</style></author><author><style face="normal" font="default" size="100%">Knight, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Infectious Diseases, The Medical College of Pennsylvania, Philadelphia, PA 19129</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1067-1071</style></pages><volume><style face="normal" font="default" size="100%">257</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefaclor</style></keyword><keyword><style face="normal" font="default" size="100%">trimethoprim</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">drug comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">drug sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus mirabilis</style></keyword><keyword><style face="normal" font="default" size="100%">sex difference</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus epidermidis</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1987</style></year></dates><isbn><style face="normal" font="default" size="100%">0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">This prospective randomized study was undertaken to determine the efficacy of antimicrobial therapy compared with no therapy for bacteriuria in elderly ambulatory nonhospitalized women. Sixty-one women (mean age, 85.8 years) with bacteriuria were in the no therapy control group and 63 women (mean age, 85.8 years) with bacteriuria were in the therapy group; none had symptoms of urinary tract infection. One short course of antimicrobial therapy achieved a cure rate of 68.3% (43 of 63 women cured) two weeks after treatment. During the six-month follow-up period, ten (16.4%) of 61 women in the no therapy group and five (7.9%) of 63 women in the therapy group developed symptomatic urinary tract infection. At the time of six-month follow-up, 19 (34.5%) of 55 women in the no therapy group and 35 (63.6%) of 55 women in the therapy group did not have bacteriuria. We conclude that for asymptomatic bacteriuria in elderly ambulatory nonhospitalized women, short-course antimicrobial therapy is effective at two-week follow-up and that antimicrobial therapy can eliminate bacteriuria in most of these women for at least a six-month period.</style></abstract><notes><style face="normal" font="default" size="100%">L17031496&#xD;1987-05-07</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L17031496&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1001/jama.257.8.1067</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">3806896</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.257.8.1067</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kane-Gill, S. L.</style></author><author><style face="normal" font="default" size="100%">Wong, A.</style></author><author><style face="normal" font="default" size="100%">Culley, C. M.</style></author><author><style face="normal" font="default" size="100%">Perera, S.</style></author><author><style face="normal" font="default" size="100%">Reynolds, M. D.</style></author><author><style face="normal" font="default" size="100%">Handler, S. M.</style></author><author><style face="normal" font="default" size="100%">Kellum, J. A.</style></author><author><style face="normal" font="default" size="100%">Aspinall, M. B.</style></author><author><style face="normal" font="default" size="100%">Pellett, M. E.</style></author><author><style face="normal" font="default" size="100%">Long, K. E.</style></author><author><style face="normal" font="default" size="100%">Nace, D. A.</style></author><author><style face="normal" font="default" size="100%">Boyce, R. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.L. Kane-Gill, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States&#xD;S.L. Kane-Gill, Department of Pharmacy, UPMC, Pittsburgh, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transforming the Medication Regimen Review Process Using Telemedicine to Prevent Adverse Events</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">530-538</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">laboratory device</style></keyword><keyword><style face="normal" font="default" size="100%">TheraDoc</style></keyword><keyword><style face="normal" font="default" size="100%">cefuroxime</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical decision making</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">data analysis software</style></keyword><keyword><style face="normal" font="default" size="100%">descriptive research</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital discharge</style></keyword><keyword><style face="normal" font="default" size="100%">hospital readmission</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">interpersonal communication</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical documentation</style></keyword><keyword><style face="normal" font="default" size="100%">medication therapy management</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacist</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">quality improvement study</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity analysis</style></keyword><keyword><style face="normal" font="default" size="100%">suburban area</style></keyword><keyword><style face="normal" font="default" size="100%">telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">transitional care</style></keyword><keyword><style face="normal" font="default" size="100%">treatment withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">urban area</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">1532-5415&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">Background/Objectives: Federally-mandated consultant pharmacist-conducted retrospective medication regimen reviews (MRRs) are designed to improve medication safety in nursing homes (NH). However, MRRs are potentially ineffective. A new model of care that improves access to and efficiency of consultant pharmacists is needed. The objective of this study was to determine the impact of pharmacist-led telemedicine services on reducing high-risk medication adverse drug events (ADEs) for NH residents using medication reconciliation and prospective MRR on admission plus ongoing clinical decision support alerts throughout the residents’ stay. Design: Quality improvement study using a stepped-wedge design comparing the novel service to usual care in a one-year evaluation from November 2016 to October 2017. Setting: Four NHs (two urban, two suburban) in Southwestern Pennsylvania. Participants: All residents in the four NHs were screened. There were 2,127 residents admitted having 652 alerts in the active period. Intervention: Upon admission, pharmacists conducted medication reconciliation and prospective MRR for residents and also used telemedicine for communication with cognitively-intact residents. Post-admission, pharmacists received clinical decision support alerts to conduct targeted concurrent MRRs and telemedicine. Measurement: Main outcome was incidence of high-risk medication, alert-specific ADEs. Secondary outcomes included all-cause hospitalization, 30-day readmission rates, and consultant pharmacists&apos; recommendations. Results: Consultant pharmacists provided 769 recommendations. The intervention group had a 92% lower incidence of alert-specific ADEs than usual care (9 vs 31; 0.14 vs 0.61/1,000-resident-days; adjusted incident rate ratio (AIRR) = 0.08 (95% confidence interval (CI) = 0.01–0.40]; P =.002). All-cause hospitalization was similar between groups (149 vs 138; 2.33 vs 2.70/1,000-resident-days; AIRR = 1.06 (95% CI = 0.72–1.58); P =.75), as were 30-day readmissions (110 vs 102; 1.72 vs 2.00/1,000-resident-days; AIRR = 1.21 (95% CI = 0.76–1.93); P =.42). Conclusions: This is the first evaluation of the impact of pharmacist-led patient-centered telemedicine services to manage high-risk medications during transitional care and throughout the resident&apos;s NH stay, supporting a new model of patient care.</style></abstract><notes><style face="normal" font="default" size="100%">L2007417514&#xD;2020-12-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2007417514&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/jgs.16946</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">TheraDoc(Premier,United States)</style></custom3><custom4><style face="normal" font="default" size="100%">Premier(United States)</style></custom4><custom5><style face="normal" font="default" size="100%">33233016</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jgs.16946</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>198</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leppik, I. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">I.E. Leppik, MINCEP Epilepsy Care, 7500 Western Avenue, Golden Valley, MN 55427, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of epilepsy in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Current Treatment Options in Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Treatment Options in Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">239-245</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent</style></keyword><keyword><style face="normal" font="default" size="100%">antidiabetic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antihypertensive agent</style></keyword><keyword><style face="normal" font="default" size="100%">antineoplastic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antirheumatic agent</style></keyword><keyword><style face="normal" font="default" size="100%">barbituric acid derivative</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">dextropropoxyphene</style></keyword><keyword><style face="normal" font="default" size="100%">diltiazem</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">etiracetam</style></keyword><keyword><style face="normal" font="default" size="100%">felbamate</style></keyword><keyword><style face="normal" font="default" size="100%">fosphenytoin sodium</style></keyword><keyword><style face="normal" font="default" size="100%">gabapentin</style></keyword><keyword><style face="normal" font="default" size="100%">Hypericum perforatum extract</style></keyword><keyword><style face="normal" font="default" size="100%">lamotrigine</style></keyword><keyword><style face="normal" font="default" size="100%">oxcarbazepine</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">pregabalin</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate</style></keyword><keyword><style face="normal" font="default" size="100%">tricyclic antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">verapamil</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin</style></keyword><keyword><style face="normal" font="default" size="100%">zonisamide</style></keyword><keyword><style face="normal" font="default" size="100%">age distribution</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">agranulocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">aplastic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">blurred vision</style></keyword><keyword><style face="normal" font="default" size="100%">bone turnover</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical competence</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diplopia</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug choice</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug protein binding</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">food drug interaction</style></keyword><keyword><style face="normal" font="default" size="100%">fracture</style></keyword><keyword><style face="normal" font="default" size="100%">gait disorder</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">gingiva hyperplasia</style></keyword><keyword><style face="normal" font="default" size="100%">grapefruit juice</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypocalcemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyponatremia</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">osteolysis</style></keyword><keyword><style face="normal" font="default" size="100%">osteoporosis</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">postmarketing surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">secondary hyperparathyroidism</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">seizure</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocyte function</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">1092-8480</style></isbn><abstract><style face="normal" font="default" size="100%">The elderly are the most rapidly growing segment of the population, and the incidence of epilepsy in persons over 65 is higher than in any other age group. In nursing homes, its incidence is even higher than in community-dwelling persons of similar ages. About 10% of nursing home residents are being treated with antiepileptic drugs (AEDs), with an &quot;epilepsy/seizure&quot; indication reported for about 7.7% of this use. Almost all elderly patients are being treated with AEDs introduced before 1978 - phenytoin, carbamazepine, valproate, and barbiturates. However, age-related changes in protein binding, decreases in hepatic and renal clearance, alterations in gastrointestinal absorption, and interactions with drugs used for other conditions make the choice of the best AED difficult. AEDs that do not interact with other drugs, are not metabolized by the liver, and are readily absorbed may offer benefits for the elderly. To complicate matters, the elderly are not a homogeneous population. Today there are many AEDs to choose from, and some of the newer AEDs have more favorable characteristics than the older ones. Choice of an AED should be made on an individual basis, considering the cost of the drug, the cost of consequences of drug-drug interactions, and expenses associated with acute and chronic adverse effects. In other words, clinical skills rather than formulaic approaches are needed to match detailed knowledge of each patient&apos;s characteristics with the properties of the various AEDs. © Springer Science+Business Media, LLC 2008.</style></abstract><notes><style face="normal" font="default" size="100%">L354099666&#xD;2009-02-02</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354099666&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s11940-008-0026-9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11940-008-0026-9</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wood, G. C.</style></author><author><style face="normal" font="default" size="100%">Underwood, E. L.</style></author><author><style face="normal" font="default" size="100%">Croce, M. A.</style></author><author><style face="normal" font="default" size="100%">Swanson, J. M.</style></author><author><style face="normal" font="default" size="100%">Fabian, T. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G. C. Wood, Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1665-1668</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">amikacin</style></keyword><keyword><style face="normal" font="default" size="100%">cefepime</style></keyword><keyword><style face="normal" font="default" size="100%">cilastatin plus imipenem</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">colistin</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">imipenem</style></keyword><keyword><style face="normal" font="default" size="100%">minocycline</style></keyword><keyword><style face="normal" font="default" size="100%">timentin</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">Achromobacter xylosoxidans</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">anastomosis</style></keyword><keyword><style face="normal" font="default" size="100%">APACHE</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolation</style></keyword><keyword><style face="normal" font="default" size="100%">body temperature</style></keyword><keyword><style face="normal" font="default" size="100%">brain hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">disk diffusion</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency health service</style></keyword><keyword><style face="normal" font="default" size="100%">eradication therapy</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Glasgow coma scale</style></keyword><keyword><style face="normal" font="default" size="100%">head injury</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human cell</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">lung lavage</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas infection</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent infection</style></keyword><keyword><style face="normal" font="default" size="100%">skull fracture</style></keyword><keyword><style face="normal" font="default" size="100%">Stenotrophomonas maltophilia</style></keyword><keyword><style face="normal" font="default" size="100%">subarachnoid hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">tracheostomy</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment response</style></keyword><keyword><style face="normal" font="default" size="100%">ventilator associated pneumonia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1060-0280</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To report a case of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia (VAP) that was successfully treated with doxycycline and aerosolized colistin. CASE SUMMARY: A 28-year-old male was admitted with a severe head injury and required mechanical ventilation. The patient developed S. maltophiliaVAP on hospital day 17, which was cured after 7 days of treatment with high-dose intravenous trimethoprim/sulfamethoxazole (TMP/SMX). However, on day 34, the patient developed recurrent S. maltophiliaVAP that did not respond clinically or demonstrate eradication on follow-up culture after 10 days of TMP/SMX. At that time, TMP/SMX was discontinued and treatment was initiated with intravenous doxycycline and aerosolized colistin. The VAP episode was cured after 14 days of treatment with doxycycline/aerosolized colistin. DISCUSSION: S. maltophiliais an emerging cause of VAP in some centers. This organism is associated with high mortality rates and has few treatment options because it is intrinsically resistant to most drug classes. Recent data suggest that doxycycline and aerosolized colistin each are effective in treatment of other multidrug-resistant organisms, such as Pseudomonas aeruginosaand Acinetobacter baumannii. However, this is the first report describing the use of this antibiotic regimen for S. maltophilia. High-dose TMP/SMX is considered to be the drug of choice primarily based on excellent in vitro activity. Few data exist on how to treat patients who fail therapy with TMP/SMX or cannot receive that drug because of resistance, allergy, or adverse events. Thus, it is important to report alternative methods for treating this infection. CONCLUSIONS: The positive clinical response to doxycycline and aerosolized colistin seen in the patient described here suggests that this combination may be an alternative treatment in patients who fail initial treatment or cannot receive standard therapies.</style></abstract><notes><style face="normal" font="default" size="100%">L359716209&#xD;2010-10-15&#xD;2010-10-28</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L359716209&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1345/aph.1P217</style></url><url><style face="normal" font="default" size="100%">http://www.theannals.com/cgi/reprint/44/10/1665</style></url></related-urls></urls><custom4><style face="normal" font="default" size="100%">Baxter(United States)</style></custom4><custom5><style face="normal" font="default" size="100%">20736426</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1345/aph.1P217</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zevallos, M.</style></author><author><style face="normal" font="default" size="100%">Justman, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Bronx-Lebanon Hospital Center, 1650 Grand Concourse, Bronx, NY 10457, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tuberculosis in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Geriatr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Geriatr Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">121-38</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antitubercular Agents/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Isoniazid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Tuberculin Test</style></keyword><keyword><style face="normal" font="default" size="100%">Tuberculosis/*diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tuberculosis, Lymph Node/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tuberculosis, Pleural/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0749-0690 (Print)&#xD;0749-0690</style></isbn><abstract><style face="normal" font="default" size="100%">As the result of the strengthening of TB-control programs nationwide, a decline in the overall number of reported TB cases in the United States has been observed within the last 10 years. Despite these declines in absolute numbers, the elderly continue to account for a disproportionate share of the cases. The high number of cases diagnosed at autopsy among the elderly suggests that this condition often remains unrecognized, possibly due to the subtle clinical manifestations in this age group. Evidence suggests that, compared with their community-dwelling counterparts, the institutionalized elderly are at a greater risk for re-activation of latent TB and for the acquisition of new TB infection. More studies are needed to make final conclusions. New guidelines for the treatment of LTBI emphasize targeted TST among persons at high risk for development of active TB and no longer use age as an exclusionary condition. All nursing home residents must therefore be regularly screened for LTBI and treated if necessary. Even though elderly persons are at greater risk for hepatic toxicity from TB treatment, the poor outcome of untreated TB in this age group warrants more aggressive treatment of this condition.</style></abstract><notes><style face="normal" font="default" size="100%">Zevallos, Mabel&#xD;Justman, Jessica E&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Clin Geriatr Med. 2003 Feb;19(1):121-38. doi: 10.1016/s0749-0690(02)00057-5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0749-0690(02)00057-5</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">94</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomas, D. R.</style></author><author><style face="normal" font="default" size="100%">Cote, T. R.</style></author><author><style face="normal" font="default" size="100%">Lawhorne, L.</style></author><author><style face="normal" font="default" size="100%">Levenson, S. A.</style></author><author><style face="normal" font="default" size="100%">Rubenstein, L. Z.</style></author><author><style face="normal" font="default" size="100%">Smith, D. A.</style></author><author><style face="normal" font="default" size="100%">Stefanacci, R. G.</style></author><author><style face="normal" font="default" size="100%">Tangalos, E. G.</style></author><author><style face="normal" font="default" size="100%">Morley, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.R. Thomas, Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, MO, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Understanding Clinical Dehydration and Its Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Directors Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">292-301</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">chlorpromazine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">hyaluronidase</style></keyword><keyword><style face="normal" font="default" size="100%">hydrocortisone</style></keyword><keyword><style face="normal" font="default" size="100%">recombinant hyaluronidase</style></keyword><keyword><style face="normal" font="default" size="100%">infusion fluid</style></keyword><keyword><style face="normal" font="default" size="100%">insulin</style></keyword><keyword><style face="normal" font="default" size="100%">metoclopramide</style></keyword><keyword><style face="normal" font="default" size="100%">morphine</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen</style></keyword><keyword><style face="normal" font="default" size="100%">opiate derivative</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">potassium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">Ringer solution</style></keyword><keyword><style face="normal" font="default" size="100%">sodium</style></keyword><keyword><style face="normal" font="default" size="100%">sodium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">streptomycin</style></keyword><keyword><style face="normal" font="default" size="100%">theophylline</style></keyword><keyword><style face="normal" font="default" size="100%">urea</style></keyword><keyword><style face="normal" font="default" size="100%">body water</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">dehydration</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">ecchymosis</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">frail elderly</style></keyword><keyword><style face="normal" font="default" size="100%">glomerulus filtration rate</style></keyword><keyword><style face="normal" font="default" size="100%">heart failure</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperosmolality</style></keyword><keyword><style face="normal" font="default" size="100%">hypervolemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyponatremia</style></keyword><keyword><style face="normal" font="default" size="100%">inappropriate vasopressin secretion</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">injection site bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">injection site infection</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">palliative therapy</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">plasma osmolarity</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">rehydration</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract disease</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">skin edema</style></keyword><keyword><style face="normal" font="default" size="100%">skin irritation</style></keyword><keyword><style face="normal" font="default" size="100%">sodium blood level</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous tissue</style></keyword><keyword><style face="normal" font="default" size="100%">thirst</style></keyword><keyword><style face="normal" font="default" size="100%">urea nitrogen blood level</style></keyword><keyword><style face="normal" font="default" size="100%">water analysis</style></keyword><keyword><style face="normal" font="default" size="100%">water deprivation</style></keyword><keyword><style face="normal" font="default" size="100%">water loading (test)</style></keyword><keyword><style face="normal" font="default" size="100%">water loss</style></keyword><keyword><style face="normal" font="default" size="100%">water metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">hylenex</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">1538-9375&#xD;1525-8610</style></isbn><abstract><style face="normal" font="default" size="100%">Dehydration in clinical practice, as opposed to a physiological definition, refers to the loss of body water, with or without salt, at a rate greater than the body can replace it. We argue that the clinical definition for dehydration, ie, loss of total body water, addresses the medical needs of the patient most effectively. There are 2 types of dehydration, namely water loss dehydration (hyperosmolar, due either to increased sodium or glucose) and salt and water loss dehydration (hyponatremia). The diagnosis requires an appraisal of the patient and laboratory testing, clinical assessment, and knowledge of the patient&apos;s history. Long-term care facilities are reluctant to have practitioners make a diagnosis, in part because dehydration is a sentinel event thought to reflect poor care. Facilities should have an interdisciplinary educational focus on the prevention of dehydration in view of the poor outcomes associated with its development. We also argue that dehydration is rarely due to neglect from formal or informal caregivers, but rather results from a combination of physiological and disease processes. With the availability of recombinant hyaluronidase, subcutaneous infusion of fluids (hypodermoclysis) provides a better opportunity to treat mild to moderate dehydration in the nursing home and at home. © 2008 American Medical Directors Association.</style></abstract><notes><style face="normal" font="default" size="100%">L351756273&#xD;2008-06-16</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L351756273&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jamda.2008.03.006</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">hylenex</style></custom1><custom5><style face="normal" font="default" size="100%">18519109</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jamda.2008.03.006</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ijaz, M.</style></author><author><style face="normal" font="default" size="100%">Sakam, S.</style></author><author><style face="normal" font="default" size="100%">Ashraf, U.</style></author><author><style face="normal" font="default" size="100%">Marquez, J. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Ijaz, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Bronx Lebanon Hospital Center, Bronx, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unusual presentation of recurrent pyogenic bilateral psoas abscess causing bilateral pulmonary embolism by iliac vein compression</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Case Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Case Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">606-610</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">D dimer</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">heparin</style></keyword><keyword><style face="normal" font="default" size="100%">piperacillin plus tazobactam</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">breathing rate</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">computed tomographic angiography</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">deep vein thrombosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">flank pain</style></keyword><keyword><style face="normal" font="default" size="100%">Gram positive cocci</style></keyword><keyword><style face="normal" font="default" size="100%">Gram staining</style></keyword><keyword><style face="normal" font="default" size="100%">heart rate</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">iliac vein compression</style></keyword><keyword><style face="normal" font="default" size="100%">leg swelling</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">lung embolism</style></keyword><keyword><style face="normal" font="default" size="100%">lung infarction</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen saturation</style></keyword><keyword><style face="normal" font="default" size="100%">psoas abscess</style></keyword><keyword><style face="normal" font="default" size="100%">pyogenic psoas abscess</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent infection</style></keyword><keyword><style face="normal" font="default" size="100%">sinus tachycardia</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus mitis</style></keyword><keyword><style face="normal" font="default" size="100%">vein occlusion</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1941-5923</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: Unusual presentation Background: Psoas abscesses are a known cause of back pain, but they have not been reported as a cause of acute lower extremity thromboses and bilateral pulmonary emboli. We report a patient with bilateral psoas abscesses causing extensive pulmonary emboli through compression of the iliac vein. Case Report: A 47-year-old man presented with bilateral leg swelling over 4 weeks. Physical examination revealed a thin male with bilateral leg swelling, extending to the thigh on his left side. He had hemoglobin of 10.5 g/dl, leukocytosis of 16 000/ml, and an elevated D-dimer. A computed tomography (CT) angiogram of his chest showed extensive bilateral pulmonary emboli and infarcts. He remained febrile with vague flank pain, prompting a CT of his abdomen and pelvis that showed large, multiloculated, septated, bilateral psoas abscesses with compression of the left femoral vein by the left psoas abscess and a thrombus distal to the occlusion. Two liters of pus was drained from the left psoas abscess by CT-guidance, and although the Gram staining showed Gram-positive cocci in clusters, cultures from the abscess and blood were negative. A repeat CT showed resolution of the abscesses, and the drain was removed. He was discharged to a nursing home to complete a course of intravenous antibiotics and anticoagulation. Conclusions: Although the infectious complications of psoas abscesses have been described in the literature, the mechanical complications of bilateral psoas abscesses are lacking. It is important to assess for complete resolution of psoas abscesses through follow-up imaging to prevent venous thromboembolic events.</style></abstract><notes><style face="normal" font="default" size="100%">L605960137&#xD;2015-09-18&#xD;2017-05-04</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L605960137&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.12659/AJCR.894206</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">26356406</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.12659/AJCR.894206</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolle, L. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Health Sciences Centre, Winnipeg, Ontario, Canada. lnicolle@hsc.mb.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in long-term-care facility residents</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">757-61</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homes for the Aged/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">*Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/epidemiology/microbiology/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary tract infection is the most frequent bacterial infection in residents of long-term-care facilities. Most infections are asymptomatic, with a remarkable prevalence of asymptomatic bacteriuria of 15%-50% among all residents. The major reasons for this high prevalence are chronic comorbid illnesses with neurogenic bladder and interventions to manage incontinence. Prospective, randomized, comparative trials of therapy and no therapy for asymptomatic bacteriuria among nursing home residents have repeatedly documented that antimicrobial treatment had no benefits. However, there is substantial diagnostic uncertainty in determining whether an individual with a positive urine culture has symptomatic or asymptomatic infection when there is clinical deterioration and there are no localized findings. In the noncatheterized resident, urinary infection is an infrequent source of fever but may not be definitively excluded. The use of antimicrobials for treatment of urinary infection is part of the larger concern about appropriate antimicrobial use in long-term-care facilities and the impacts of the selective pressure of antimicrobials on colonization and infection with resistant organisms.</style></abstract><notes><style face="normal" font="default" size="100%">Nicolle, L E&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 2000 Sep;31(3):757-61. doi: 10.1086/313996. Epub 2000 Oct 4.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/313996</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Regal, R. E.</style></author><author><style face="normal" font="default" size="100%">Pham, C. Q.</style></author><author><style face="normal" font="default" size="100%">Bostwick, T. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Adult Internal Medicine and Infectious Diseases, University of Michigan Hospitals and College of Pharmacy, Ann Arbor, 48109-0008, USA. reregal@umich.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in extended care facilities: preventive management strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Consult Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Consult Pharm</style></full-title></periodical><pages><style face="normal" font="default" size="100%">400-9</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Catheters, Indwelling/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Skilled Nursing Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/drug therapy/etiology/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0888-5109 (Print)&#xD;0888-5109</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To provide health care professionals with an overview of interventions that may be done to reduce the incidence of urinary tract infections (UTIs) in elderly patients, especially those residing in extended care facilities. DATA SOURCES: A Medline search of the English literature was performed from 1980 to January 2006 to find literature relevant to urinary tract prophylaxis. Further references were hand-searched from relevant sources. STUDY SELECTION: When assessing the effectiveness of various clinical interventions for reducing the incidence of UTIs in the elderly, preference was given to more recent, double-blind, placebo-controlled randomized studies, but studies of less robust design also were included in the discussions when the former were lacking. DATA EXTRACTION: Where possible, recent publications were favored over older studies. References were all reviewed by the authors and chosen to present key citations. DATA SYNTHESIS: Data selection was prioritized to address specific subtopics. CONCLUSION: Though still frequent in occurrence and quite costly in terms of morbidity, mortality, and cost to the health care system, numerous measures may be taken to ameliorate the incidence of UTIs in elderly, institutionalized residents. First and foremost, establishing and adhering to good infection-control practices by health care givers and minimizing the use of indwelling catheters are essential. Adequate staffing and training are germane to this effort. Reasonably well-designed clinical studies also give credence to the use of topical estrogens and lactobacillus &quot;probiotics&quot; for female subgroups and cranberry juice for a wider array of patients. Vitamin C is of no proven benefit. With regard to antibiotics, with the relative paucity of data available for this patient population, concerns for resistance proliferation must be balanced against perceived gains in UTI reduction.</style></abstract><notes><style face="normal" font="default" size="100%">Regal, Randolph E&#xD;Pham, Co Q D&#xD;Bostwick, Thomas R&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Consult Pharm. 2006 May;21(5):400-9. doi: 10.4140/tcp.n.2006.400.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4140/tcp.n.2006.400</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yeh, S. S.</style></author><author><style face="normal" font="default" size="100%">Lovitt, S.</style></author><author><style face="normal" font="default" size="100%">Schuster, M. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.-S. Yeh, Northport VAMC, Geriatric division, BOX 111, 79 Middleville road, Northport, NY 11768, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Nutrition, Health and Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Nutrition, Health and Aging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">448-454</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 6</style></keyword><keyword><style face="normal" font="default" size="100%">megestrol acetate</style></keyword><keyword><style face="normal" font="default" size="100%">transthyretin</style></keyword><keyword><style face="normal" font="default" size="100%">protein p75</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor receptor</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">appetite</style></keyword><keyword><style face="normal" font="default" size="100%">aspiration pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">body composition</style></keyword><keyword><style face="normal" font="default" size="100%">body weight</style></keyword><keyword><style face="normal" font="default" size="100%">cachexia</style></keyword><keyword><style face="normal" font="default" size="100%">caloric intake</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">colon cancer</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">hip fracture</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">Paget bone disease</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword><keyword><style face="normal" font="default" size="100%">wellbeing</style></keyword><keyword><style face="normal" font="default" size="100%">megace</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">1279-7707</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of this review is to assess the efficacy and safety of megestrol acetate (MA) in geriatric cachexia. The paper presented here reviews a previously published study of MA use in 69 patients in a randomized double blind placebo-controlled trial. This paper will also address the underlying pathogenesis of cachexia (specifically, the role of cytokines) along with the use of MA, its mechanism of action and its side effects. Objective: To compare the effects of MA oral suspension (O.S.), 800 mg/day, versus placebo on weight in geriatric nursing home patients with weight loss or low body weight. Design: Twelve weeks, randomized, double-blind, placebo-controlled trial with a 13-week follow-up period. Patients: Northport VAMC Nursing home patients with weight loss of * 5% of usual body weight over the past 3 months, or body weight 20% below their ideal body weight. Interventions: Patients were randomly assigned to receive placebo or MA 800 mg/d for 12 weeks and were then followed for 13 weeks off treatment and mortality 4 years post treatment. Measurements: Primary outcome- weight and appetite change. Secondary outcome-sense of well being, enjoyment of life, change in depression scale, laboratory nutrition parameters, energy intake counts, body composition, and adverse events. Results: At 12 weeks there were no significant differences in weight gain between treatment groups, while MA-treated patients reported significantly greater improvement in appetite, enjoyment of life, and well being. At week 25 (3 months after treatment), 61.9% of MA-treated patients had gained * 1.82 kg (4 lbs) compared to 21.7% of placebo patients. There was no difference in survival between MA and placebo groups. Considering possible confounders, higher initial IL-6, initial TNFR-p75 levels, and final neutrophil percentage were associated with elevated mortality, whereas higher initial pre-albumin, initial albumin, final pre-albumin, final albumin and final weight gain were associated with decreased death. © The Journal of Nutrition, Health &amp; Aging.</style></abstract><notes><style face="normal" font="default" size="100%">L354799430&#xD;2009-08-03</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L354799430&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s12603-009-0082-1</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">megace(Bristol Myers Squibb,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Bristol Myers Squibb(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">19390752</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12603-009-0082-1</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Myint, M. W. W.</style></author><author><style face="normal" font="default" size="100%">Kng, C.</style></author><author><style face="normal" font="default" size="100%">Wong, C. P.</style></author><author><style face="normal" font="default" size="100%">Mak, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.W.W. Myint, Department of Geriatrics, Ruttonjee Hospital, Hong Kong, Hong Kong</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of amantadine as prophylaxis for influenza A in a subvented care and attention home in Hong Kong</style></title><secondary-title><style face="normal" font="default" size="100%">Hong Kong Practitioner</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hong Kong Practitioner</style></full-title></periodical><pages><style face="normal" font="default" size="100%">534-543</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">amantadine</style></keyword><keyword><style face="normal" font="default" size="100%">rimantadine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">epidemic</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">home care</style></keyword><keyword><style face="normal" font="default" size="100%">Hong Kong</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">risk benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">1027-3948</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To document the tolerability and adverse effect profile of amantadine as prophylaxis for Influenza A in a group of elderly subjects in Hong Kong. Design: Retrospective cohort study. Subjects: Outbreak prophylaxis was prescribed to all 199 elderly residents present in a Government Subvented Care and Attention Home in Hong Kong during a documented outbreak of Influenza A. Main outcome measure: The incidence and type of adverse effects suffered were analysed, as well as risk factors for adverse reactions requiring drug withdrawal. Results: Twenty-four percent of the elderly residents were found to suffer from side effects resulting in withdrawal of the medication and of these subjects, 15% required hospitalization. A history of dementia and taking more than 5 concurrent medications were found to be significantly associated with discontinuation of amantadine. Conclusion: This study outlines our experience of using amantadine as mass prophylaxis of Influenza A in the Chinese elderly. A relatively high rate of adverse reactions and rate of withdrawal are noted. Further controlled trials are required to calculate the risk-benefit ratio and to provide much needed local guidelines on the use of this drug in managing future nursing home outbreaks.</style></abstract><notes><style face="normal" font="default" size="100%">L29001316&#xD;1999-01-20</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L29001316&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phillips, S. L.</style></author><author><style face="normal" font="default" size="100%">Branaman-Phillips, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Veterans Home of California, Yountville.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1071-4</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cefoperazone/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Ceftriaxone/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intramuscular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*drug therapy/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare the efficacy and safety of intramuscular cefoperazone and intramuscular ceftriaxone in the treatment of nursing home-acquired pneumonia in the nursing home setting. DESIGN: A randomized clinical trial. SETTING: Skilled nursing wards at the Veterans Home of California. PATIENTS: 104 residents of skilled nursing wards, aged 65 years or older. INTERVENTIONS: Intramuscular administration of either cefoperazone or ceftriaxone. MEASUREMENTS: The variables analyzed for baseline comparability were demographics (age, sex), clinical variables (duration in nursing home; presence of sputum, fever, cough, or leukocyte count), and clinical symptoms and signs. Efficacy was assessed by days of therapy, final maximum temperature, and clinical and bacteriological response. RESULTS: Fifty residents received cefoperazone, 1 gm every 12 hours, intramuscularly. Fifty-four residents received ceftriaxone, 1 gm every 24 hours, intramuscularly. The total duration of treatment was scheduled for 10 days. Clinical cure was seen in 45 (90%) of the cefoperazone treatment group and 51 (94%) of the ceftriaxone treatment group, with a mean duration of therapy of 10.30 and 9.90 days, respectively. Satisfactory sputum specimens were collected in 71% of the treated residents; the most common isolate was Streptococcus pneumoniae, followed by Haemophilus influenzae and Staphylococcus aureus, respectively. The overall mortality was 4.5% at long-term follow-up. Both agents were well tolerated and no therapy was discontinued due to intramuscular pain or abnormal laboratory values. CONCLUSIONS: Intramuscular cefoperazone and intramuscular ceftriaxone are safe and effective in the treatment of nursing home-acquired pneumonia. The clinical outcomes in both treatment groups support their use within this select population without the need for transferring the patient to an acute care hospital. Clinical studies are needed to evaluate the impact of such therapy on the control of health care expenditures within the nursing home facility.</style></abstract><notes><style face="normal" font="default" size="100%">Phillips, S L&#xD;Branaman-Phillips, J&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Geriatr Soc. 1993 Oct;41(10):1071-4. doi: 10.1111/j.1532-5415.1993.tb06454.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.1993.tb06454.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bowles, S. K.</style></author><author><style face="normal" font="default" size="100%">Lee, W.</style></author><author><style face="normal" font="default" size="100%">Simor, A. E.</style></author><author><style face="normal" font="default" size="100%">Vearncombe, M.</style></author><author><style face="normal" font="default" size="100%">Loeb, M.</style></author><author><style face="normal" font="default" size="100%">Tamblyn, S.</style></author><author><style face="normal" font="default" size="100%">Fearon, M.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">McGeer, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Sunnybrook and Women&apos;s College Health Sciences Centre, Toronto, Ontario.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">608-16</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acetamides/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amantadine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza Vaccines/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*drug therapy/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Ontario/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oseltamivir</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To describe the experience of Ontario long-term care facilities that used oseltamivir during influenza outbreaks in 1999/2000. DESIGN: Case series. SETTING: Ten Ontario long-term care facilities for older people and their residents. PARTICIPANTS: Older residents of long-term care facilities. INTERVENTION: Oseltamivir for treatment or prophylaxis during 11 influenza outbreaks in 1999/2000. MEASUREMENTS: Control of outbreaks; pneumonia, hospitalization, and death complicating acute influenza. RESULTS: All outbreaks were due to influenza A//H3N2/Sydney/05/97. One facility elected to use oseltamivir for treatment and amantadine for prophylaxis. The remaining nine facilities (10 outbreaks) recommended oseltamivir for treatment and prophylaxis (after amantadine failure in five and as primary prophylaxis in five). Use of oseltamivir was associated with termination of the outbreak in all eight evaluable outbreaks. Overall, 178/185 (96%) case-residents met the case definition of influenza and had complete data for evaluation. Of these, 63 (35%) were treated with antibiotics, 37 (21%) were diagnosed with pneumonia, 19 (11%) were hospitalized, and 16 (9%) died. Compared with residents receiving no therapy or who became ill while taking amantadine, residents who received oseltamivir within 48 hours of the onset of symptoms were less likely to be prescribed antibiotics, to be hospitalized, or to die (P &lt;.05 for each outcome). These differences persisted and remained statistically significant when corrected for influenza immunization status. A total of 730 residents received oseltamivir prophylaxis for a median of 9 days (range 5-12). Of these, side effects were identified in 30 (4.1%), the most common being diarrhea (12 residents, 1.6%), cough (5, 0.7%), confusion (4, 0.5%) and nausea (4, 0.5%). CONCLUSIONS: Oseltamivir is safe and appears to be effective when used as treatment or prophylaxis to control outbreaks of influenza in older nursing home residents.</style></abstract><notes><style face="normal" font="default" size="100%">Bowles, Susan K&#xD;Lee, Wayne&#xD;Simor, Andrew E&#xD;Vearncombe, Mary&#xD;Loeb, Mark&#xD;Tamblyn, Susan&#xD;Fearon, Margaret&#xD;Li, Yan&#xD;McGeer, Allison&#xD;Oseltamivir Compassionate Use Program Group&#xD;Journal Article&#xD;United States&#xD;J Am Geriatr Soc. 2002 Apr;50(4):608-16. doi: 10.1046/j.1532-5415.2002.50153.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1532-5415.2002.50153.x</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Breitenbucher, R. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Minnesota School of Medicine.</style></auth-address><titles><title><style face="normal" font="default" size="100%">UTI: managing the most common nursing home infection</style></title><secondary-title><style face="normal" font="default" size="100%">Geriatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Geriatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">68-70, 75</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Activities of Daily Living</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cefoperazone/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Ciprofloxacin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/drug therapy/*epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Catheterization/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/drug therapy/*epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1990</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0016-867X (Print)&#xD;0016-867x</style></isbn><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are the most common type of infection in nursing homes. Asymptomatic bacteriuria, the most common form, requires no treatment. Symptomatic UTI requires treatment, but symptoms (acute deterioration in functional ability or mental status) may be nonspecific. Complicated UTI is more common in nursing home residents than in other populations. Immobility and the use of bedpans instead of commodes contribute to decreased bladder emptying and an increased potential for UTI. Poor perineal hygiene in many females in nursing homes also increases the potential for UTI. For this reason, obtaining urine for culture by catheterization rather than voided specimen should be the norm for female nursing home patients.</style></abstract><notes><style face="normal" font="default" size="100%">Breitenbucher, R B&#xD;Journal Article&#xD;United States&#xD;Geriatrics. 1990 May;45(5):68-70, 75.</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gavazzi, G.</style></author><author><style face="normal" font="default" size="100%">Maggi, S.</style></author><author><style face="normal" font="default" size="100%">Flamaing, J.</style></author><author><style face="normal" font="default" size="100%">Gaillat, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G. Gavazzi, University of Grenoble Alpes, Grenoble, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vaccine for seniors: Present and future</style></title><secondary-title><style face="normal" font="default" size="100%">European Geriatric Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Geriatric Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S173-S174</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumococcus vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">varicella zoster vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">antivirus agent</style></keyword><keyword><style face="normal" font="default" size="100%">polysaccharide vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumococcus polysaccharide</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">inactivated vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant</style></keyword><keyword><style face="normal" font="default" size="100%">subunit vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">European Union</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrics</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">France</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">Varicella zoster virus</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">pneumococcal infection</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">serotype</style></keyword><keyword><style face="normal" font="default" size="100%">whole cell</style></keyword><keyword><style face="normal" font="default" size="100%">experimental medicine</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrician</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">gerontology</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">disability</style></keyword><keyword><style face="normal" font="default" size="100%">immunological memory</style></keyword><keyword><style face="normal" font="default" size="100%">plague</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza virus</style></keyword><keyword><style face="normal" font="default" size="100%">herd</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">Cochrane Library</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">herd immunity</style></keyword><keyword><style face="normal" font="default" size="100%">protection</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">university</style></keyword><keyword><style face="normal" font="default" size="100%">community</style></keyword><keyword><style face="normal" font="default" size="100%">season</style></keyword><keyword><style face="normal" font="default" size="100%">postherpetic neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">medical decision making</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">senescence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-7649</style></isbn><abstract><style face="normal" font="default" size="100%">Prof Joahn Flamaing (Belgium) Prof Stefania Maggi (Italy), Dr Jacques Gaillat (France), and Prof G. Gavazzi (France) on behalf of vaccine group of EUGMS. Introduction: As individuals age, and disability increases, prevalence and incidence of most of infectious diseases increase; several infection are preventable by vaccination. However, if vaccinations for children are well accepted and firmly organised in many countries, vaccination for elderly shows lower interests. Indeed it seems that immune senescence leads to decreased efficacy that may decrease the interest in vaccination in the oldest population. Yet, there is a requirement to better know which infection may be efficiently prevented by vaccine in elderly population. We then propose on behalf of vaccine study group of EUGMS a symposium regarding controversies of known and already used vaccines (health care workers/) but also news and future available vaccines. Prof Joahn Flamaing (Belgium) Prof Stefania Maggi (Italy), Prof G Gavazzi (France) and Dr Jacques Gaillat (France) will present the 4 following topics: - Pneumococcal vaccine: What to do after CAPITA? (JF) - Flu vaccine in elderly population: What to do after the Cochrane review? (SM) - Health care workers flu vaccine: What to do after the Cochrane review? (GG) - Recent and future vaccine: Zoster vaccine as an exemple (JG) Outlines: Pneumococcal vaccine, What to do after CAPITA? (Prof Joahn Flamaing, Division of Gerontology and Geriatrics, dept. Clinical and Experimental Medicine, KU Leuven, Belgium): Streptococcus pneumoniae is the most important bacterial cause of pneumonia. Children, immunocompromised individuals, persons with comorbid disease and the older population are susceptible to pneumococcal disease. Pneumococcal infections are treated with antimicrobials. For decades the 23-valent pneumococcal polysaccharide vaccines (PPV23) was the only vaccine available for the prevention of pneumococcal disease in adults. PPV23 prevents invasive pneumococcal disease (IPD) in healthy adults, but there is no hard evidence that non-invasive disease is prevented, nor that it prevents IPD in high-risk populations and the elderly. The pneumococcal conjugate vaccines (PCV7 and subsequently PCV13) have demonstrated a high efficacy in preventing both IPD and non-IPD in children. Moreover, prevention of IPD occurred in the adult and older population by vaccinating children (herd effect). PCV13 is now available for the prevention of IPD and pneumonia in adults. In contrast to the PPV23 PCV13 induces a boostable immunological memory and also protects against pneumococcal pneumonia (CAPITA trial). The pneumococcal serotype epidemiology, influenced by direct and indirect effects of pneumococcal vaccination must guide the choice of pneumococcal vaccine strategies. Until new vaccines (protein and/or whole cell vaccines) become available, combining the advantages of the PCV13 with the broad coverage of PPV23 can be preferred. This lecture gives the audience insight in the complex interaction between pneumococcal serotype epidemiology and pneumococcal vaccination. The attendees will be able to value pneumococcal vaccination guidelines and to adopt pneumococcal vaccination strategies with more knowledge. Flu vaccine in elderly population: What to do after the Cochrane review? Prof Stefania Maggi, Institute of Neuroscience, National Research Council, Italy): Influenza vaccination of elderly individuals is recommended worldwide as people aged 65 and older are at a higher risk of complications, hospitalizations and deaths from influenza. Trivalent inactivated vaccines are the most commonly used influenza vaccines and their public health safety profile appears to be acceptable. We will present the evidence from experimental and non-experimental studies carried out in older individuals, taking into account the biases affecting observational studies. We will discuss: 1. The recommendations by Jefferson (Cochrane review, 2010) that an adequately powered publicly-funded, placebo-controlled RCT needs to be conducted over several in luenza seasons, and 2. The interventions to increase influenza vaccination rates of those 60 years and older in the community, recommended in the review by Lorenzetti (Cochrane review, 2014) Health care workers flu vaccine: What to do after the Cochrane review? (Prof G. Gavazzi, Department of geriatric Medicine, University of Grenoble-Alpes, and University hospital of Grenoble, France): As Flu vaccine in elderly population is less effective than in younger population, and as flu is one of the first cause of death, directly and indirectly, the idea of protection of the most susceptible elderly population (Nursing home, Hospitalized population) vaccinating health care workers against flu has been proposed for decades (so called “herd immunity”). Although several studies demonstrated its interest particularly in nursing home, a recent Cochrane review (Thomas RE, et al. Cochrane Database Syst Rev 2013) stated to the inefficiency of HCW vaccination to prevent flu in elderly population living in long-term care facilities. Data eist also in other facilities and need further analysis. In the present lecture, we will discuss the limitations of published data and the latest statement of the Cochrane review in this field. In order to be able to participate to the implementations of flu vaccine programs we will also provide factors associated with acceptance and refusal of flu vaccine by Health care workers. Recent and future vaccine: Zoster vaccine as an example (Dr Jacques Gaillat, Division of Infectious Diseases, Hospital of Annecy- Genevois, France): Behind the two killers, influenza virus and Streptococcus pneumoniae, Herpes zoster virus (HZV) is probably the third plague for the elderly. The burden of disease is important with an annual HZ incidence throughout Europe, varying by country from 2.0 to 4.6/1 000 person-years with no clearly observed geographic trend. Shingles are not commonly life threatening but they can be complicated. Postherpetic neuralgia (PHN), the most common complication of herpes zoster, may have a serious impact on quality of life and functional ability, particularly in the elderly. The risk of zoster itself and the risk of post zoster pain increase with age, sharply after 50 years. The social and economical consequences are also a reason of concern. Antiviral drugs prescribed early improve the acute phase of infection but there impact on the reduction of post zoster pain is a subject of debate. Shingles developed as a result of reactivation of latent chickenpox virus (VZV). In this context a prophylactic vaccine against VZV represents a promising clinical approach to limit the debilitating complications of herpes zoster, including PHN. Two kinds of vaccines have emerged, one with an attenuated live varicella virus, already licensed in Europe and the US (Zostavax®), and a candidate Herpes Zoster subunit (HZ/su) vaccine (GSK).It combines gE, a protein found on the HZ virus, with an adjuvant system, AS01. In this presentation we will review the burden of illness, the vaccine efficacy and safety and cost-effectiveness of vaccination. Conclusions: Though different levels of evidences, flu vaccine are still recommended and need to be better implemented in elderly population, and in health care workers providing care for elderly population; there are requirements for modifications of pneumococcal vaccine and zoster vaccine outlines in many countries. The educational goals of the symposium are: (1) to enhance knowledge regarding recent studies about vaccinations in elderly population, (2) to give the audience the opportunity to better challenge with controversial data, (3) to better adapt the implementation of available vaccines in target populations, (4) to encourage geriatricians participating in Public health advisory board for vaccine.</style></abstract><notes><style face="normal" font="default" size="100%">L72037631&#xD;2015-10-17</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L72037631&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wendt, C.</style></author><author><style face="normal" font="default" size="100%">Schinke, S.</style></author><author><style face="normal" font="default" size="100%">Württemberger, M.</style></author><author><style face="normal" font="default" size="100%">Oberdorfer, K.</style></author><author><style face="normal" font="default" size="100%">Bock-Hensley, O.</style></author><author><style face="normal" font="default" size="100%">von Baum, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hygiene-Institut, University of Heidelberg, 69 120 Heidelberg, Germany. constanze_wendt@med.uni-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1036-43</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Local/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Baths</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier State/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorhexidine/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Mupirocin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/*drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Whole-body washing with antiseptic solution has been widely used as part of eradication treatment for colonization with methicillin-resistant Staphylococcus aureus (MRSA), but evidence for the effectiveness of this measure is limited. OBJECTIVE: To study the efficacy of whole-body washing with chlorhexidine for the control of MRSA. DESIGN: Randomized, placebo-controlled, double-blinded clinical trial. SETTING: University Hospital of Heidelberg and surrounding nursing homes. PATIENTS: MRSA carriers who were not treated concurrently with antibiotics effective against MRSA were eligible for the study. INTERVENTION: Five days of whole-body washing with either 4% chlorhexidine solution (treatment group) or with a placebo solution. All patients received mupirocin nasal ointment and chlorhexidine mouth rinse. The outcome was evaluated 3, 4, 5, 9, and 30 days after treatment with swab samples taken from several body sites. RESULTS: Of 114 patients enrolled in the study (56 in the treatment group and 58 in the placebo group), 11 did not finish treatment (8 from the treatment group and 3 from the placebo group [P=.02]). At baseline, the groups did not differ with regard to age, sex, underlying condition, site of MRSA colonization, or history of MRSA eradication treatment. Eleven patients were MRSA-free 30 days after treatment (4 from the treatment group and 7 from the placebo group [P=.47]). Only groin-area colonization was significantly better eradicated by the use of chlorhexidine. The best predictor for total eradication was a low number of body sites positive for MRSA. Adverse effects were significantly more frequent in the treatment group than in the placebo group (any symptom, 71% vs 33%) but were reversible in most cases. CONCLUSION: Whole-body washing can reduce skin colonization, but it appears necessary to extend eradication measures to the gastrointestinal tract, wounds, and/or other colonized body sites if complete eradication is the goal.</style></abstract><notes><style face="normal" font="default" size="100%">Wendt, C&#xD;Schinke, S&#xD;Württemberger, M&#xD;Oberdorfer, K&#xD;Bock-Hensley, O&#xD;von Baum, H&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2007 Sep;28(9):1036-43. doi: 10.1086/519929. Epub 2007 Jul 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/519929</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carrion, A. F.</style></author><author><style face="normal" font="default" size="100%">Martin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.F. Carrion, Department of Medicine, Miller School of Medicine, University of Miami, 1201 NW 16th Street, Miami, FL 33125, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Viral hepatitis in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">691-697</style></pages><volume><style face="normal" font="default" size="100%">107</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">adefovir</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">entecavir</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis A vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B(e) antigen</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G antibody</style></keyword><keyword><style face="normal" font="default" size="100%">lamivudine</style></keyword><keyword><style face="normal" font="default" size="100%">peginterferon</style></keyword><keyword><style face="normal" font="default" size="100%">peginterferon alpha2b</style></keyword><keyword><style face="normal" font="default" size="100%">ribavirin</style></keyword><keyword><style face="normal" font="default" size="100%">rituximab</style></keyword><keyword><style face="normal" font="default" size="100%">telbivudine</style></keyword><keyword><style face="normal" font="default" size="100%">tenofovir</style></keyword><keyword><style face="normal" font="default" size="100%">virus DNA</style></keyword><keyword><style face="normal" font="default" size="100%">acute disease</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">ascites</style></keyword><keyword><style face="normal" font="default" size="100%">blood donor</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">cancer chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">cholestasis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis A</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis A virus</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis C</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis E</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunization</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressive treatment</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">leukopenia</style></keyword><keyword><style face="normal" font="default" size="100%">liver cell carcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">liver transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">public health service</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">seroprevalence</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">virus hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">virus reactivation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9270&#xD;1572-0241</style></isbn><abstract><style face="normal" font="default" size="100%">As life expectancy continues to rise, elderly adults represent a rapidly growing proportion of the population. The likelihood of complications of acute and chronic liver disease and overall mortality are higher in elderly populations. Several physiological changes associated with aging, greater prevalence of co-morbid conditions, and cumulative exposure to hepatotropic viruses and environmental hepatotoxins may contribute to worse outcomes of viral hepatitis in the elderly. Although pharmacotherapy for hepatitis B and C continues to evolve, the efficacy, tolerability, and side effects of these agents have not been studied extensively in elderly adults. Immunization against hepatitis A and B in naïve elderly adults is an important public health intervention that needs to be revised and broadened. © 2012 by the American College of Gastroenterology.</style></abstract><notes><style face="normal" font="default" size="100%">L51839193&#xD;2012-02-02&#xD;2012-05-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L51839193&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1038/ajg.2012.7</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">22290404</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/ajg.2012.7</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">30</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author><author><style face="normal" font="default" size="100%">Han, S. N.</style></author><author><style face="normal" font="default" size="100%">Hamer, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.N. Meydani, Nutritional Immunology Laboratory, J. M. USDA Hum. Nutr. Res. Ctr. A., Tufts University, 711 Washington Street, Boston, MA 02111, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin E and respiratory infection in the elderly</style></title></titles><pages><style face="normal" font="default" size="100%">214-222</style></pages><volume><style face="normal" font="default" size="100%">1031</style></volume><number><style face="normal" font="default" size="100%">(Meydani S.N., simin.meydani@tufts.edu; Han S.N.; Hamer D.H.) J. M. USDA Hum. Nutr. Res. Ctr. A., Tufts University, Boston, MA 02111, United States</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">gamma interferon</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 2</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin E2</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">conference paper</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunostimulation</style></keyword><keyword><style face="normal" font="default" size="100%">infection rate</style></keyword><keyword><style face="normal" font="default" size="100%">infection resistance</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin intake</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">0077-8923</style></isbn><abstract><style face="normal" font="default" size="100%">Respiratory infections are prevalent in the elderly, resulting in increased morbidity, mortality, and utilization of health care services. Contributing to the increased incidence of infection with age is the well-described decline in immune response, which has been correlated with patterns of illness in the elderly. For example, there are higher morbidity and mortality from cancer, pneumonia, and post-operative complications in those who have diminished, delayed-type hypersensitivity skin test responses. Nutritional status is an important determinant of immune function. We have shown in double-blind, placebo-controlled trials that vitamin E supplementation significantly improved immune response, including DTH and response to vaccines. Furthermore, subjects receiving vitamin E in the 6-month trial had a 30% lower incidence of infectious diseases. That study, however, was not powered to demonstrate statistical significance, and the infections were self-reported. To overcome these limitations, we conducted a double-blind, placebo-controlled trial to determine the effect of one-year supplementation with 200 IU/day vitamin E on the incidence and duration of respiratory infections in 617 elderly nursing home residents. The results of this clinical trial show that vitamin E supplementation significantly reduces the incidence rate of common colds and the number of subjects who acquire a cold among elderly nursing home residents. A nonsignificant reduction in the duration of colds was also observed. Because of the high rate and more severe morbidity associated with common colds in this age group, these findings have important implications for the well being of the elderly as well as for the economic burden associated with their care. © 2004 New York Academy of Sciences.</style></abstract><notes><style face="normal" font="default" size="100%">L40361756&#xD;2005-03-29</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L40361756&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1196/annals.1331.021</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15753147</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1196/annals.1331.021</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author><author><style face="normal" font="default" size="100%">Leka, L. S.</style></author><author><style face="normal" font="default" size="100%">Fine, B. C.</style></author><author><style face="normal" font="default" size="100%">Dallal, G. E.</style></author><author><style face="normal" font="default" size="100%">Keusch, G. T.</style></author><author><style face="normal" font="default" size="100%">Singh, M. F.</style></author><author><style face="normal" font="default" size="100%">Hamer, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Mass 02111, USA. simin.meydani@tufts.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">828-36</style></pages><volume><style face="normal" font="default" size="100%">292</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Common Cold/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Homes for the Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/*epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin E/*administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0098-7484 (Print)&#xD;0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">CONTEXT: Respiratory tract infections are prevalent in elderly individuals, resulting in increased morbidity, mortality, and use of health care services. Vitamin E supplementation has been shown to improve immune response in elderly persons. However, the clinical importance of these findings has not been determined. OBJECTIVE: To determine the effect of 1 year of vitamin E supplementation on respiratory tract infections in elderly nursing home residents. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial was conducted from April 1998 to August 2001 at 33 long-term care facilities in the Boston, Mass, area. A total of 617 persons aged at least 65 years and who met the study&apos;s eligibility criteria were enrolled; 451 (73%) completed the study. INTERVENTION: Vitamin E (200 IU) or placebo capsule administered daily; all participants received a capsule containing half the recommended daily allowance of essential vitamins and minerals. MAIN OUTCOME MEASURES: Incidence of respiratory tract infections, number of persons and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions for respiratory tract infections among all participants randomized and those who completed the study. RESULTS: Vitamin E had no significant effect on incidence or number of days with infection for all, upper, or lower respiratory tract infections. However, fewer participants receiving vitamin E acquired 1 or more respiratory tract infections (60% vs 68%; risk ratio [RR], 0.88; 95% confidence interval [CI], 0.76-1.00; P =.048 for all participants; and 65% vs 74%; RR, 0.88; 95% CI, 0.75-0.99; P =.04 for completing participants), or upper respiratory tract infections (44% vs 52%; RR, 0.84; 95% CI, 0.69-1.00; P =.05 for all participants; and 50% vs 62%; RR, 0.81; 95% CI, 0.66-0.96; P =.01 for completing participants). When common colds were analyzed in a post hoc subgroup analysis, the vitamin E group had a lower incidence of common cold (0.67 vs 0.81 per person-year; RR, 0.83; 95% CI, 0.68-1.01; P =.06 for all participants; and 0.66 vs 0.83 per person-year; RR, 0.80; 95% CI, 0.64-0.98; P =.04 for completing participants) and fewer participants in the vitamin E group acquired 1 or more colds (40% vs 48%; RR, 0.83; 95% CI, 0.67-1.00; P =.05 for all participants; and 46% vs 57%; RR, 0.80; 95% CI, 0.64-0.96; P =.02 for completing participants). Vitamin E had no significant effect on antibiotic use. CONCLUSIONS: Supplementation with 200 IU per day of vitamin E did not have a statistically significant effect on lower respiratory tract infections in elderly nursing home residents. However, we observed a protective effect of vitamin E supplementation on upper respiratory tract infections, particularly the common cold, that merits further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">1538-3598&#xD;Meydani, Simin Nikbin&#xD;Leka, Lynette S&#xD;Fine, Basil C&#xD;Dallal, Gerard E&#xD;Keusch, Gerald T&#xD;Singh, Maria Fiatarone&#xD;Hamer, Davidson H&#xD;R01 AG013975-05/AG/NIA NIH HHS/United States&#xD;1R01-AG13975/AG/NIA NIH HHS/United States&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;JAMA. 2004 Aug 18;292(7):828-36. doi: 10.1001/jama.292.7.828.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2377357</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS47500</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.292.7.828</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Vitamin E supplementation in elderly care home residents may have a protective effect against the common cold</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Healthcare and Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Healthcare and Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">50-51</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric care</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">protection</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">residential care</style></keyword><keyword><style face="normal" font="default" size="100%">residential home</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">1744-2249</style></isbn><abstract><style face="normal" font="default" size="100%">Question: Do vitamin E supplements reduce respiratory tract infections in elderly care home residents? Study design: Randomised, double-blind, placebo controlled trial. Main results: At approximately 1 year, there were no significant differences between groups in incidence or number of days of respiratory tract infection. However, fewer people taking Vitamin E group had one or more respiratory tract infections compared with placebo (p = 0.48). A post-hoc subgroup analysis showed that people taking vitamin E had a lower incidence of common cold. Vitamin E had no significant effect on antibiotic use (see Results table). Authors&apos; conclusions: Supplementing the diet of elderly nursing home residents with 200 IU of vitamin E daily did not significantly reduce the incidence of lower respiratory tract infection. However, it did have a protective effect against the common cold and other upper respiratory tract infections. © 2005 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L40267922&#xD;2005-03-07</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L40267922&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ehbc.2004.11.022</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ehbc.2004.11.022</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aga, V. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V.M. Aga, Geriatric Psychiatrist, Layton Aging and Alzheimer&apos;s Disease Center, Oregon Health and Science University (OHSU), Mail Code CR131, 3181 S.W. Sam Jackson Park Road, Portland, OR, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">When and How to Treat Agitation in Alzheimer&apos;s Disease Dementia With Citalopram and Escitalopram</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1099-1107</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">aripiprazole</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">escitalopram</style></keyword><keyword><style face="normal" font="default" size="100%">memantine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">akathisia</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bedtime dosage</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular mortality</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiogram</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Food and Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">high school student</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">kidney function</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">Mini Mental State Examination</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimaging</style></keyword><keyword><style face="normal" font="default" size="100%">neurologist</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">posterior cingulate</style></keyword><keyword><style face="normal" font="default" size="100%">PR interval</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">QRS interval</style></keyword><keyword><style face="normal" font="default" size="100%">QTc interval</style></keyword><keyword><style face="normal" font="default" size="100%">restlessness</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">short term memory</style></keyword><keyword><style face="normal" font="default" size="100%">sinus rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">verbal hostility</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1545-7214&#xD;1064-7481</style></isbn><abstract><style face="normal" font="default" size="100%">Agitation is a common neuropsychiatric symptom (NPS) in the early and middle stages of Alzheimer&apos;s disease (AD) dementia, which is difficult to treat and causes much distress. The U.S. Food and Drug Administration (U.S. FDA) issued black box warnings against the use of antipsychotics in dementia in 2005 and 2008 due to the increased risk of morbidity and mortality, resulting in the reduction in antipsychotic use for treating dementia-related NPS and spurring the quest for safer and more effective pharmacological options. The data favoring the use of citalopram for treating agitation in AD dementia is particularly compelling, and this may be a class effect for all selective serotonin reuptake inhibitors. However, concerns about the cardiac side-effects of citalopram have limited its widespread use for this indication. In this article, available efficacy and safety data for the use of citalopram and escitalopram in treating agitation in AD dementia is reviewed, using a composite case to illustrate key points. Practical recommendations are made to facilitate the use of these medications in routine clinical practice, risk mitigation strategies are discussed and salient issues for future clinical research are emphasized.</style></abstract><notes><style face="normal" font="default" size="100%">L2002233832&#xD;2019-07-11&#xD;2019-09-12</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002233832&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jagp.2019.04.016</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31288974</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jagp.2019.04.016</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">79</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, K.</style></author><author><style face="normal" font="default" size="100%">Alluri, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Singh, Baystate Medical Center, Springfield, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">When Occam&apos;s razor fails: Linezolid induced lactic acidosis in a patient with severe aortic atherosclerotic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S468</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><keywords><keyword><style face="normal" font="default" size="100%">linezolid</style></keyword><keyword><style face="normal" font="default" size="100%">bicarbonate</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">lactic acidosis</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">implantable cardiac monitor</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">abdomen</style></keyword><keyword><style face="normal" font="default" size="100%">wound</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">colitis</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">stomach paresis</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocyte</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">vacuum</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">Gram positive bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">skin structure</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">Food and Drug Administration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE 1: Linezolid induced lactic acidosis was first reported in 2003, and till date there are only few case reports about the same. Linezolid is often used for prolonged duration and thus it is important to keep this side effect in mind. CASE: 65 yo M with a complicated PMH which included uncontrolled Diabetes, with numerous prior complicated diabetic infections on Linezolid since the past 6 weeks. He had severe PVD, CKD, CAD s/p CABG along with severe diabetic gastroparesis. He presented with vague complaints of nausea, vomiting and lethargy for 3 days. He clearly denied any abdominal pain. He denied any constipation or diarrhea. He resided in a nursing home and review of their records did not reveal any episodes of hypotension. He was in NSR and his abdomen was soft and non-tender. He had a wound vacuum on, and the wound itself was healthy. His labs revealed a lactate of 6,with anAG of 20 and bicarbonate of 21.Hewas also pancytopenic and his platelet andWBC counts were normal 2 months back. A CAT scan was done of the abdomen which did not reveal any evidence of colitis. Considering his overall picture, it was thought to be type B Lactic acidosis secondary to Linezolid. On review of his records, there were no new medications except Linezolid. Patient&apos;s lactic acidosis and thrombocytopenia both resolved within 5 days of stopping Linezolid DISCUSSION: There are limited choices for oral antibiotic therapy in disease caused by resistant gram positive organisms. This is what has made Linezolid an attractive option when IV access is not feasible or when the duration of treatment is long. Linezolid is currently FDA approved for the treatment of Vancomycin resistant Enterococcus, nosocomial pneumonia caused by Staphylococcus and Streptococcus, complicated skin and skin structure infections and community acquired pneumonias. The mechanism by which this drug causes lactic acidosis has not completely been elucidated. Mitochondrial toxicity has been proposed as a causative mechanism. There have also been mortalities reported due to this adverse effect. There is no proven therapy to treat Linezolid induced Lactic Acidosis. In addition to cessation of the drug, thiamine has been used in treatment (potential benefits without harm). A review of the literature reveals that the majority of episodes occurred in older patients and those getting prolonged therapy, and resolution of lactate levels varied from 2 days to 2 weeks. This case and others described in the literature demonstrate importance of continuous monitoring of medication related adverse effects and those factors which might predict which patients are at higher risk.</style></abstract><notes><style face="normal" font="default" size="100%">L71495866&#xD;2014-06-17</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L71495866&amp;from=export</style></url></related-urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">118</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">WHO Guidelines Approved by the Guidelines Review Committee</style></title><secondary-title><style face="normal" font="default" size="100%">WHO Guideline on Mass Drug Administration of Azithromycin to Children under Five Years of Age to Promote Child Survival</style></secondary-title></titles><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><notes><style face="normal" font="default" size="100%">Review&#xD;Book&#xD;NBK561641 [bookaccession]</style></notes><urls></urls></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reeve, E.</style></author><author><style face="normal" font="default" size="100%">Jordan, V.</style></author><author><style face="normal" font="default" size="100%">Thompson, W.</style></author><author><style face="normal" font="default" size="100%">Sawan, M.</style></author><author><style face="normal" font="default" size="100%">Todd, A.</style></author><author><style face="normal" font="default" size="100%">Gammie, T. M.</style></author><author><style face="normal" font="default" size="100%">Hopper, I.</style></author><author><style face="normal" font="default" size="100%">Hilmer, S. N.</style></author><author><style face="normal" font="default" size="100%">Gnjidic, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Reeve, Quality Use of Medicines and Pharmacy Research Centre, UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, Australia&#xD;E. Reeve, College of Pharmacy, Dalhousie University, Halifax, Canada&#xD;E. Reeve, Geriatric Medicine Research, Nova Scotia Health Authority and Dalhousie University, Halifax, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Withdrawal of antihypertensive drugs in older people</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2020</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT00219063</style></keyword><keyword><style face="normal" font="default" size="100%">NCT00785512</style></keyword><keyword><style face="normal" font="default" size="100%">amiloride plus hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin receptor antagonist</style></keyword><keyword><style face="normal" font="default" size="100%">antihypertensive agent</style></keyword><keyword><style face="normal" font="default" size="100%">beta adrenergic receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">chlortalidone</style></keyword><keyword><style face="normal" font="default" size="100%">clopamide</style></keyword><keyword><style face="normal" font="default" size="100%">cyclopenthiazide plus potassium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">furosemide</style></keyword><keyword><style face="normal" font="default" size="100%">hydralazine</style></keyword><keyword><style face="normal" font="default" size="100%">hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">methyldopa</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">renin inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">reserpine</style></keyword><keyword><style face="normal" font="default" size="100%">spironolactone</style></keyword><keyword><style face="normal" font="default" size="100%">thiazide diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">triamterene</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">antihypertensive therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular mortality</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">combination drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">diastolic blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">falling</style></keyword><keyword><style face="normal" font="default" size="100%">fatality</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">primary prevention</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">sexual dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">systolic blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1469-493X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Hypertension is an important risk factor for subsequent cardiovascular events, including ischaemic and haemorrhagic stroke, myocardial infarction, heart failure, chronic kidney disease, cognitive decline and premature death. Overall, the use of antihypertensive medications has led to reduction in cardiovascular disease, morbidity rates and mortality rates. However, the use of antihypertensive medications is also associated with harms, especially in older people, including the development of adverse drug reactions, drug-drug interactions and can contribute to increasing medication-related burden. As such, discontinuation of antihypertensives may be considered and appropriate in some older people. Objectives: To investigate whether withdrawal of antihypertensive medications is feasible, and evaluate the effects of withdrawal of antihypertensive medications on mortality, cardiovascular outcomes, hypertension and quality of life in older people. Search methods: The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to April 2019: the Cochrane Hypertension Specialised Register, CENTRAL (2019, Issue 3), Ovid MEDLINE, Ovid Embase, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also conducted reference checking, citation searches and, when appropriate, contacted study authors to identify any additional studies. The searches had no language restrictions. Selection criteria: We included randomised controlled trials (RCTs) of withdrawal versus continuation of antihypertensive medications used for hypertension or primary prevention of cardiovascular disease in older adults (defined as 50 years and over). Participants were eligible if they lived in the community, residential aged care facilities, or were based in hospital settings. We sought to include trials looking at the complete withdrawal of the antihypertensive medication, and those focusing on a dose reduction of the antihypertensive medicine. Data collection and analysis: We compared the intervention of discontinuing or reducing antihypertensive medication to usual treatment using mean differences (MD) and 95% confidence intervals (95% CIs) for continuous variables and we used Peto odds ratios (ORs) and 95% CI for binary variables. Our primary outcomes included: mortality, myocardial infarction, development of adverse drug reactions or adverse drug withdrawal reactions. Secondary outcomes included: blood pressure, hospitalisation, stroke, success of withdrawing from antihypertensives, quality of life, and falls. Two authors independently, and in duplicate, conducted all stages of study selection, data extraction and quality assessment. Main results: Six RCTs met the inclusion criteria and were included in the review (1073 participants). Study duration and follow-up ranged from 4 weeks to 56 weeks. Meta-analysis of studies showed that, in the discontinuation group compared to continuation, the odds for all-cause mortality were 2.08 (95% CI 0.79 to 5.46; low certainty of evidence), for myocardial infarction 1.86 (95% CI 0.19 to 17.98; very low certainty of evidence) and for stroke 1.44 (95% CI 0.25 to 8.35; low certainty of evidence). Blood pressure was higher in the discontinuation group than the continuation group (systolic blood pressure: MD = 9.75 mmHg, 95% CI 7.33 to 12.18; and diastolic blood pressure: MD = 3.5 mmHg, 95% CI 1.82 to 5.18; low certainty of evidence). For the development of adverse events, meta-analysis was not possible; antihypertensive discontinuation did not appear to increase the risk of adverse events and may lead to resolution of adverse drug reactions, although eligible studies had limited reporting of adverse effects of drug withdrawal (very low certainty of evidence). One study reported hospitalisation with an odds ratio of 0.83 for discontinuation compared to continuation (95% CI 0.33 to 2.10; low certainty of evidence). No studies were identified which reported falls. Between 10.5% and 33.3% of participants in the discontin ation group compared to 9% to 15% in the continuation group experienced raised blood pressure or other clinical criteria (as pre-defined by the studies) that would require restarting of therapy/removal from the study. The sources of bias included selective reporting (reporting bias), lack of blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and lack of blinding of participants and personnel (performance bias). Authors&apos; conclusions: There is no evidence of an effect of discontinuing compared with continuing antihypertensives used for hypertension or primary prevention of cardiovascular disease in older adults on all-cause mortality and myocardial infarction. The evidence was low to very low certainty mainly due to small studies and low event rates. These limitations mean that we cannot make any firm conclusions about the effect of deprescribing antihypertensives on these outcomes. Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio for use of antihypertensive medications, such as those with frailty, older age groups and those taking polypharmacy, and measure clinically important outcomes such as falls, quality of life and adverse drug events.</style></abstract><notes><style face="normal" font="default" size="100%">L632067289&#xD;2020-07-24&#xD;2020-10-26</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L632067289&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/14651858.CD012572.pub2</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32519776</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD012572.pub2</style></electronic-resource-num></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eiland, L. S.</style></author><author><style face="normal" font="default" size="100%">Eiland, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L.S. Eiland, UAB/Division of Pediatrics, 301 Governors Drive, Huntsville, AL 35801, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zanamivir for the prevention of influenza in adults and children age 5 years and older</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutics and Clinical Risk Management</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutics and Clinical Risk Management</style></full-title></periodical><pages><style face="normal" font="default" size="100%">461-465</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">influenza vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">rimantadine</style></keyword><keyword><style face="normal" font="default" size="100%">zanamivir</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchospasm</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug delivery system</style></keyword><keyword><style face="normal" font="default" size="100%">drug dosage form comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">flu like syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal pain</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza B virus</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nose disease</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">sore throat</style></keyword><keyword><style face="normal" font="default" size="100%">throat irritation</style></keyword><keyword><style face="normal" font="default" size="100%">tonsil disease</style></keyword><keyword><style face="normal" font="default" size="100%">diskhaler</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1176-6336</style></isbn><abstract><style face="normal" font="default" size="100%">On a yearly basis there are 3-5 million severe cases and 250,000-500,000 deaths worldwide attributed to influenza. Four antiviral medications are currently available on the market; however, resistance has resulted in the armamentarium being shrunk to two remaining active treatment options for influenza. These two neuraminidase inhibitors, oseltamivir and zanamivir, are recommended for the treatment and prophylaxis of influenza A and B in children and adults. Zanamivir, which is the focus of this review, is an inhaled antiviral that has shown benefit in the community, household, and nursing home population for post-exposure prophylaxis. Zanamivir protection rates range from 67%-84% in clinical trials of adults and children. Although the influenza vaccine remains the best modality to combat the disease, zanamivir may also assist in decreasing morbidity associated with influenza A and B. © 2007 Dove Medical Press Limited. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L47214986&#xD;2007-10-01</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L47214986&amp;from=export</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">diskhaler(Glaxo Wellcome,United Kingdom)</style></custom3><custom4><style face="normal" font="default" size="100%">Glaxo Wellcome(United Kingdom)</style></custom4></record><record><database name="Full text missing 4.enl" path="/Users/s5068337/Downloads/Full text missing 4.enl">Full text missing 4.enl</database><source-app name="EndNote" version="20.2">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="fw59wwttoserv4ezxth5vtvjtzvvfezp2pxt">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gravenstein, S.</style></author><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Loeschel, E.</style></author><author><style face="normal" font="default" size="100%">Webster, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eastern Virginia Medical School, Norfolk, Virginia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Saf</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1113-25</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">15</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Antiviral Agents/administration &amp; dosage/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Guanidines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza, Human/*complications/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Product Surveillance, Postmarketing</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sialic Acids/administration &amp; dosage/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Zanamivir</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">0114-5916 (Print)&#xD;0114-5916</style></isbn><abstract><style face="normal" font="default" size="100%">Post-marketing experience shows zanamivir to be well tolerated in the general population for the treatment and prophylaxis of influenza type A and B infections. Individuals at high-risk of influenza have potentially more to gain from zanamivir therapy. We assessed safety and tolerability findings from treatment and prophylaxis studies in over 982 high-risk subjects. Eight treatment studies involving high-risk subjects have been conducted with zanamivir 10 mg twice daily for 5 days. The incidence and pattern of adverse events was similar in zanamivir and placebo recipients. Lower respiratory adverse events reported by recipients receiving zanamivir occurred at similar or lower frequencies to those receiving placebo. In one treatment study involving 525 patients with asthma or chronic obstructive pulmonary disease, zanamivir recipients had a small but significantly increased mean morning peak expiratory flow rate (PEFR) and evening PEFR compared with placebo during the treatment period (days 1 to 5). Eight prophylaxis studies have been conducted, five in family or community settings and three in nursing homes. Data from these studies demonstrate that zanamivir is well tolerated for prophylaxis. In nursing home studies, where 90% of participants were high risk, the pattern and incidence of adverse events were similar to that reported in otherwise healthy individuals, and similar to both placebo and rimantadine, a comparator in one study. In treatment and prophylaxis studies the incidence and pattern of adverse events in participants &gt; or =65 years or with chronic underlying respiratory disorders was similar for zanamivir or placebo recipients. Overall, zanamivir was well tolerated and study drug discontinuations were low. A small number of deaths have been reported in studies of high-risk elderly individuals, but none were considered to be related to zanamivir. Thus clinical studies have demonstrated that zanamivir has a comparable safety profile in high-risk and otherwise healthy recipients. Approximately 1.72 million treatment courses of zanamivir were prescribed up to the end of January 2001. Many spontaneous adverse event reports received since marketing, a third of these from non-healthcare professionals, reflect the underlying condition being treated. However, a number of events have resulted in changes to the zanamivir prescribing information, including rare reports of bronchospasm, dyspnoea, rash, urticaria and allergic type reactions including facial and oropharyngeal oedema. The reported safety profile of zanamivir, for treatment and prophylaxis of high risk subjects with influenza type A and B infections supports its continued use in these individuals who are likely to benefit most.</style></abstract><notes><style face="normal" font="default" size="100%">Gravenstein, S&#xD;Johnston, S L&#xD;Loeschel, E&#xD;Webster, A&#xD;Journal Article&#xD;Review&#xD;New Zealand&#xD;Drug Saf. 2001;24(15):1113-25. doi: 10.2165/00002018-200124150-00003.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00002018-200124150-00003</style></electronic-resource-num></record></records></xml>